


REVIEW OPEN ACCESS

Ethnomedicinal Uses, Phytochemistry, Pharmacological Activities, and Toxicology of the Subfamily Gomphrenoideae (Amaranthaceae): A Comprehensive Review

Dayanna Isabel Araque Gelves¹  | Giulia Cristina de Andreoli Souza¹ | Alvaro Jose Hernandez Tasco² | Marcos José Salvador¹

¹Department of Plant Biology, University of Campinas (UNICAMP), São Paulo, Brazil | ²Department of Industrial Microbiology, Universidad de Santander (UDES), Bucaramanga, Colombia

Correspondence: Dayanna Isabel Araque Gelves (dayannaisabel96@gmail.com) | Marcos José Salvador (marcosjs@unicamp.br)

Received: 12 February 2025 | **Revised:** 2 April 2025 | **Accepted:** 23 April 2025

Funding: This work was only possible due to the support of the Coordination for the Improvement of Higher Education Personnel-Brazil (CAPES) Process no. 88887.513201/2020-00 and Financing Code 001. It also had the support of the São Paulo State Research Support Foundation (FAPESP, Processes no. 06/06079-4, 15/03726-8, 21/09693-5, and 2017/03598-5), from the National Council for Scientific and Technological Development (CNPq, Process no. 306603/2022-5, and 427859/2018-2), and from the Fund for Support to Teaching, Research, and Extension-UNICAMP (FAPEX-UNICAMP) for financial support and scholarships.

Keywords: bioactivity | gomphrenoideae | phytochemistry | toxicology | traditional use

Abbreviations: %A, percentage of cell apoptosis; %I, percentage of inhibition; %L, percentage of lethality; %R, percentage of reduction; %S, percentage of scavenging effect; %St, percentage of stimulation; %V, percentage of viability; %ILS, percentage increase in life span; %TAC, total antioxidant activity; [], concentration; =, same; †, increase or higher or superior; ‡, decrease or reduction or reduced; ←, regression or reverse; 1K1C1, kidney 1 clip; 2K1C2, kidneys 1 clip; AAE, ascorbic acid equivalents; ABTS, 2,2-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid); AcE, acetone extract; ACE, angiotensin-converting enzyme; ACh, acetylcholine; AChE, acetylcholinesterase; AF, aqueous fraction; AgNPs, silver nanoparticles; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AO/BE, acridine orange and ethidium bromide; AO/PI, acridine orange and propidium iodide; aPTT, activated partial thromboplastin; AqE, aqueous extract; AST, aspartate aminotransferase; AuNPs, gold nanoparticles; B-16, melanoma cells; B16-F10, murine melanoma; Bax Bcl-2, associated X protein; BCG, bacillus Calmette–Guérin; BChE, butyrylcholinesterase; Bcl-2, B-cell lymphoma; BE, butanolic extract; BHT, butylated hydroxytoluene; BrdU, 5-bromo-2'-deoxyuridine; BSA, bovine serum albumin; BT, total bilirubin; BthTX-I, bothropstoxin I; BthTX-II, bothropstoxin II; BuF, butanolic fraction; BUN, blood urea nitrogen; BW, body weight; Ca, calcium; CAA, cellular antioxidant activity; CAM, chloramphenicol; CAT, catalase; CB, conjugated bilirubin; CC₅₀, 50% cytotoxic concentration; CCB, calcium channel blocking; CCh, carbachol; Cdc2, cell division cycle protein 2 homolog; CF, chloroform fraction; CFA, Freund's complete adjuvant; CK-MB, creatine kinase; ClE, chloroform extract; CM, chorioallantoic membrane; COX-1, cyclooxygenase-1; COX-2, cyclooxygenase-2; CREB, cAMP response element-binding protein; CRP, C reactive protein; Cur, curcumin; D, time of death of worms; DAPI, 40,60-diamidino-2-phenylindole; DBP, diastolic blood pressure; DCFH-DA, 6-carboxy-2',7'-dichlorodihydrofluorescein diacetate; DCM, dichloromethane; DF, dichloromethane fraction; DOX, hydroxydaunomycin hydrochloride (doxorubicin); DPPH, 1,1-diphenyl-2-picrylhydrazyl; EAC, Ehrlich's ascites carcinoma; EaE, ethyl acetate extract; EB, extract of betacyanins; EC₅₀, values of the antiglycosidase activity: Sample concentration required to achieve 50% antiglycosidase activity; EC₅₀, values of the anti-inflammatory activity: Sample concentration providing 50% of inhibition in the production of NO; EC₅₀, values of the antioxidant activity: Sample concentration providing 50% of the antioxidant activity or 0.5 of absorbance in the reducing power; ED₅₀, 50% inhibition of growth; EE, ethanolic extracts; Ehr Ca, Ehrlich's carcinoma; ELISA, enzyme-linked immunosorbent assay; EqE100, concentrations of the extract that stimulated the cell proliferation equivalent 100 pM 17β-estradiol; ESR, erythrocyte sedimentation rate; FD, fraction of DCM; FEA, fraction of ethyl acetate; FEaMc, fraction of ethyl acetate: methylene chloride; FEaMcM, fraction of ethyl acetate: methylene chloride; FETAc, fraction of ethanol: acetone; FF, flavonoid fraction; FH, fraction of hexane; FHa, fraction of hydroalcohol; FMW, fraction of methanol: water; FnB, fraction of *n*-butanol; FnH, fraction of hexane; FST, forced swimming test; FTC, ferric thiocyanate; G1, phase cell growth; GC, glucocorticoids; GI₅₀, value of hepatoprotective activity: sample concentration providing 50% of inhibition of the net cell growth; GLB, glibenclamide; HaE, hydroalcoholic extract; Hb, hemoglobin; HBV, hepatitis b virus; HCMV, human cytomegalovirus; HCT-8, human colon carcinoma; HCTZ, hydrochlorothiazide; HDE, hydrophilic extracts; HDL-C, high-density lipoprotein cholesterol; HE, hydromethanolic extracts; HeE, hexanic extracts; HepG2, human hepatocellular carcinoma cells; HF, 20-hydroxyecdysone-enriched fraction; HG, high glucose; HL60, human leukemia cell; HSV-1, herpes simplex virus Type 1; HSV-2, herpes simplex virus Type 2; IC, inhibitory concentration; IDF, international diabetes federation; IL-6, interleukin-6; IMD, index of mucosal damage; J774, cancerous macrophage cell lines from BALB/C mouse; KB cell, tumor line was derived from a human epidermal carcinoma of the nasopharynx; Km, substrate concentration that yields a half-maximal velocity; LA, LDH activity; LC₅₀, lethal concentration 50; LC₉₀, lethal concentration 90; LD₅₀, lethal media dose; LDH, lactate dehydrogenase; MABP, mean arterial blood pressure; MAP, mean arterial pressure; MBC, minimal bactericidal concentration; MCF-7, human breast cancer cell line; MCW, made with cold water; MDA, malondialdehyde; MDA-MB-435, melanoma; ME, methanolic extracts; MFC, minimal fungicidal concentrations; MHW, made with hot water; MI-, microorganisms not irradiated with laser irradiation; MI+, microorganisms irradiated with laser irradiation; MIC, minimum inhibitory concentration; MO, microorganism; MPO, myeloperoxidase; MWMT, Morris water maze task; NA, not applicable; NAG, *N*-acetylglucosaminidase; ND, not detected; Nd, not determined; NDNS, numerical data not shown; NE, no effect; *n*HE, *n*-hexane extracts; NO, nitric oxide; NORT, Novel Object Recognition Test; NP-SG, non-protein sulfhydryl groups; NT, nitrotyrosine; OGTT, oral glucose tolerance test; OSTT, oral starch tolerance test; OVX, ovariectomized; P, times of paralysis; PARP, poly (ADP-ribose) polymerase; PBMN, peripheral blood mononuclear cells; PCs, human prostate cancer cell line; PCNA, proliferating cell nuclear antigen; PE, phenylephrine; PEE, petroleum ether extracts; PEF, petroleum ether fraction; PFC, plaque forming cells; PGE2, prostaglandin E2; Phe, phenylephrine; PLP2, porcine liver primary cells; PMNLs, polymorphonuclear leukocytes; PT, preventive therapy; PTP1B, protein tyrosine phosphatase 1B; PTT, prothrombin time; PTZ, pentylenetetrazole; qRT-PCR, Quantitative Reverse-Transcription PCR; RBCs, red blood cells; ROS, reactive oxygen species; RTE, relative Trolox equivalent; RT-PCR, real-time quantitative polymerase chain reaction; RW, relative weight; S180, sarcoma 180; SBP, systolic blood pressure; SC₅₀, scavenging concentration; SEM, scanning electron microscope; SF-295, glioblastoma; SGOT, serum glutamic oxaloacetate transaminase; SGPT, serum glutamic pyruvate transaminase; SIs, selectivity indices; SK-N-SH, human neuroblastoma cell line; SNP, sodium nitroprusside; SOD, superoxide dismutase; SPF, sun protection factor; SRB, sulforhodamine B; SRC, spontaneous rhythmic contraction; STZ, streptozotocin; T, trace of inhibition; TAA, total antibacterial activity; TC, the cure; TE, mmol Trolox equivalents; TEAC, Trolox equivalent antioxidant capacity; TNBS, trinitrobenzenesulphonic acid; TNF-α, tumor necrosis factor alpha; TP, total protein; TST, tail suspension test; UNa, urine sodium; *V*_{max}, maximum velocity; WBCs, white blood cells; WST-1, water-soluble tetrazolium salt; ZI, zone of inhibition; ZnONPs, zinc oxide nanoparticles; ΔΨ_m, mitochondrial membrane potential.

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2025 The Author(s). *Chemistry & Biodiversity* published by Wiley-VHCA AG.

ABSTRACT

The subfamily Gomphrenoideae is composed of about 480 accepted species, many of which have been historically used as medicinal plants, reason why they have been studied in terms of chemical profile, biological activity, and safety. This review consolidates the advances in research on this subfamily over the past 47 years, emphasizing its promising biotechnological potential and justifying the development of research in species that remain unstudied; additionally, it presents new perspectives based on the current knowledge, including the study of in vitro cultures and co-cultures of the members of this subfamily as a sustainable approach to standardizing their chemical profiles and, consequently, enhancing their biotechnological potential. The information was collected from scientific databases such as Wiley Online Library, PubMed, Springer Link, Scielo, and Nature Research for 4 years. Verification of the scientific names and affiliations of the plants was carried out using the databases Global Biodiversity Information Facility (www.gbif.org), Plants of the World Online (www.plantsoftheworldonline.org), and The Plant List (www.theplantlist.org). To date, 512 chemical compounds have been reported for this subfamily, evidencing a wide diversity of chemical structures. It was also shown that the extracts, fractions, isolated pure compounds, and nanoparticles of this subfamily present antimicrobial, antioxidant, anticancer, anti-inflammatory, antidiabetic, and antihyperglycemic activity, among others. Likewise, it is evident that the members of this subfamily do not present toxicity.

1 | Introduction

Amaranthaceae is an important family of plants and includes species of economic interest; many are marketed as ornamental plants or to be used as food or healthcare based on traditional medicinal knowledge. However, several species are also known as invasive or parasitic plants and are even listed among the worst weeds. Amaranthaceae is placed in the order Caryophyllales Juss. ex Bercht. & J. Presl. and comprises about 163–195 genera and approximately 2215–3805 species, according to The Plant List database (www.theplantlist.org), including those formerly treated as the family Chenopodiaceae [1–9].

The Amaranthaceae family has recently become the subject of intensive systematics research. Results of the molecular genetic studies suggest that the traditional classification based on morphological and anatomical characters often did not reflect phylogenetic relationships. The family Amaranthaceae (in their narrow circumscription) is classified into two subfamilies, Amaranthoideae and Gomphrenoideae, and contains about 65 genera and 900 species [1, 7].

The subfamily Gomphrenoideae comprises about 480 accepted species distributed in 15 genera (Scheme 1) (GBIF), with the majority of its members being annual and perennial herbs, with some shrubs or small trees and climbing plants that have adapted to salty soils, arid environments, and human settlements [4, 6, 8].

Members of the Gomphrenoideae subfamily are widely used in traditional medicine in Asia, America, and Africa, making them a focus of interest for researchers. Scientists seek to verify their medicinal properties through studies of the chemical and pharmacological profile, with the goal of finding new chemical compounds that could lead to the development of new, more efficient, and safer drugs.


This article provides a comprehensive review that consolidates all available information on members of this subfamily. A wide range of topics are covered, including traditional uses, reported phytochemical profiles, biological activities of interest, and safety

and/or toxicity of the extracts studied up until April 2024. Additionally, it concludes with a comparison of traditional uses and activities verified under laboratory conditions and perspectives and research directions.


This review aims to highlight the biotechnological potential of the members of this subfamily, proposing them as a promising source of bioactive molecules. It also emphasizes the importance of studying the relationship among traditional uses, chemical profiles, biological activities, and safety; additionally, it seeks to demonstrate the effect of biotic and abiotic factors on the chemical profile, among which it can mention location, climatic conditions, available nutrients, exposure to UV light, interaction with other living beings, and even the plant genotype; this highlights the need for new research strategies that allow for controlled growth conditions, enabling the optimization and standardization of metabolite production in plants. As a sustainable alternative, the use of in vitro plant tissue cultures is suggested.

2 | Methodology

To gather relevant literature, a comprehensive search was conducted using widely recognized scientific libraries. The search focused on keywords such as names of accepted genera or their synonyms, and the literature search was limited to sources in English. Chemical structures were drawn using ChemSketch, and their names, structures, and classifications were confirmed via the PubChem and ChemSpider websites. The information was summarized in different sections in the form of tables and figures for a better understanding. Scheme 2 outlines the methodology and work plan followed to develop this review. All plant names were consulted in “Global Biodiversity Information Facility” (www.gbif.org), “Plants of the World Online” (www.plantsoftheworldonline.org), “The Plant List” (www.theplantlist.org), “The World Flora Online” (<http://www.worldfloraonline.org>), MPNS (<http://mpns.kew.org>), on July 14, 2023 and May 20, 2024.



SCHEME 1 | Members of the subfamily Gomphrenoideae. The subfamily Gomphrenoideae has 15 accepted genera and additionally has the genus *Pseudogomphrena* R.E.Fr. and *Lithophila* Sw. that are synonyms of the genus *Gomphrena* L.; *Woehleria* Griseb. and *Irinella* suess that are synonymous with *Iresine*; and *Gossypianthus* Hook. that is synonymous with *Guilleminea* Kunth. In terms of species, this subfamily has 480.




SCHEME 2 | Methodology and work plan. The literature review was conducted in several stages, including a comprehensive bibliographic search, article structuring, table and chemical structure design, and concluding with a critical analysis.

3 | Traditional Medicinal Uses

Ethnomedicine plays a significant role in both research and society, with 80% of the population relying on traditional medicine for healthcare. The evidence of the pharmaceutical potential of commonly used plants has increased since 2013. By 2020, the WHO indicated that over 20 000 species of plants are utilized in medicine, with 13 000 plants having been studied. Furthermore, various sources indicate that 25%–50% of modern medicine is based on compounds derived from plants [10–15].

Currently, many drug development studies are based on traditional medicine, among which can be cited aspirin, atropine, curare alkaloids, ephedrine, cortisone, digoxin, morphine, penicillin, and tubocurarine [11, 15, 16].

In Africa, America, Asia, Europe, and Antarctica, different members of this subfamily have been used to treat a wide variety of conditions, including chronic diseases, infectious diseases, skin diseases, respiratory issues, gastrointestinal disorders and sexually transmitted diseases, urinary disorders, malaria, diabetes,



SCHEME 3 | Medicinal plants as a source of molecules of interest. Plants utilized in traditional medicine are excellent candidates for bioprospecting studies; their choice should be based on the objective of the research and uses in traditional medicine, and previous reports, if any. Once the plant material is chosen, it is important to determine the most suitable solvents for extraction. Following this, analyses of chemical profile and biological activity should be conducted. Additionally, it may be beneficial to consider other factors such as drug delivery systems and polytherapy.

cancer, hypertension, burns, wounds, snake bites, and scorpion stings, among others. The main uses of some of the members of this subfamily are summarized in Table 1. It is important to note that some plants listed in Table 1 are included in Ayurveda, Unani, Siddha, Homeopathy, Chinese Pharmacopoeia, and “Zhonghua Bencao.”

It is noteworthy that among the 15 genera of this subfamily, the traditional use of only eight (8) has been documented in the literature, accounting for 53.33%. Most of these plants have been used to treat infections, inflammation, pain and gastrointestinal, respiratory, and skin diseases. In this regard, conducting multidisciplinary research to verify whether these plants really have the potential to treat these conditions, as shown in Scheme 3. To date, only some species belonging to the subfamily have been studied in terms of chemical profile and biotechnological potential, as described in detail in the following sections.

4 | Phytochemistry

Medicinal plants produce secondary metabolites or phytochemicals, which are responsible for their biological and pharmacological activity [12, 85, 88].

The production, quality, and quantity of phytochemical compounds are influenced by the biotic and abiotic factors present in the environment. Consequently, the phytochemical profile of a plant can vary significantly based on the location and growing conditions.

Furthermore, the concentration of secondary metabolites differs among the different parts of the plant, with the leaves typically exhibiting the highest concentration of phytochemicals [16, 129, 130].

Different natural products and their derivatives have been studied, revealing therapeutic potential for various diseases with fewer side effects than synthetic drugs [14, 131]. In this context, 109

compounds identified within this subfamily have been evaluated for various biological activities, demonstrating significant activity in most instances. Notably, phenolic compounds are the most widely studied, with antimicrobial activity being the most assessed.

In the case of this subfamily until 2024, 512 compounds have been reported, including phenolic compounds, terpenoids, alkaloids, lipid compounds, and other minor compounds, demonstrating the wide chemical diversity present in the members of this subfamily.

A comprehensive review of the bioactive secondary metabolites isolated from Gomphrenoideae, including their sources, structures, and biological properties, is presented below and summarized in Tables 2–6 and Figure 1. The structures of compounds 63, 286, 287, and 334 are not provided, as there is no available literature presenting them, nor sufficient information to determine them.

Currently, only 8.22% of the members of Gomphrenoideae have a documented phytochemical profile. Notably, *Gomphrena globosa* L. has been found to contain 107 compounds, representing 20.94% of the total compounds reported in Gomphrenoideae, including phenolic compounds, terpenoids, alkaloids, lipid compounds, carboxylic acids, and tocopherols. Similarly, *Alternanthera brasiliana* (L.) Kuntze exhibits a remarkable phytochemical profile with 91 secondary metabolites, including phenolic compounds, terpenoids, alkaloids, lipid compounds, tocopherols, vitamins, among other compounds. In contrast, for other species, fewer than 10 chemical compounds have been reported, examples include *Alternanthera paronychioides* A.St.-Hil. (24, 149), *Alternanthera repens* (Synm. *Alternanthera caracasana* Kunth) (159, 239–242), *Gomphrena boliviana* Moq. (6, 7, 9, 10, 17, 54), *Gomphrena claussenii* Moq. (13, 19, 20, 23–24, 66, 96), *Gomphrena macrocephala* A.St.-Hil. (243–247), *Gomphrena marginata* Seub. (494), *Gomphrena martiana* Gillies ex Moq. (6–7, 9–10, 17–18, 38, 53–54), *Pfaffia townsendii* Pedersen (67, 106), and *Tidestromia oblongifolia* (S. Watson) Standl. (Synm. *Tidestromia suffruticosa*

TABLE 1 | Uses in traditional medicine for major species of the Gomphrenoideae subfamily.

Accepted names	Vernacular names and/or synonyms	Geographical location	Medicinal part	Medicinal condition treated	References
<i>Alternanthera bettzickiana</i>	Baptist plant, border plant, joyweed, Matiti ya ba temoins de Jéhovah, nanthara, and red calico plant	Pakistan, South America, Thailand	Whole plant, leaves	Treatment of arthritis, gastrointestinal discomfort, menstrual pain, prevention of dementia, and its use as a mild laxative. Additionally, it is characterized by having anti-Alzheimer's, anti-inflammatory, antimicrobial, antioxidant, antipyretic, blood purifying, cytotoxic, diuretic, healing, hemolytic, and mutagenic properties. It is also used to promote lactation (as a galactagogue) and to provide nourishment	[17–21]
<i>Alternanthera brasiliana</i>	Brazilian joyweed, Carrapichinho, Doril, Novalgina, Lancetilla macho, Penicillin, Perpétua, Perpétua do mato, perpetuate of the bush, Tetracycline, Terramycin	Australia, Central America (e.g., Belize, Guatemala, Honduras, Nicaragua), French Guiana, French Guiana, India, North America (Mexico, United States), South America (e.g., Argentina, Bolivia, Brazil, Colombia, Ecuador, Guyana, Peru, Suriname, Venezuela)	Leaves, whole plant	Treatment of asthma, bronchitis, cancer, cough, cold, diarrhea, discharge, fever, flu, headache, infections, inflammation, influenza, skin injuries, and wound healing. It is also used as an abortifacient, analgesic, antinociceptive, anticonvulsant, antitumoral, antiviral, anxiolytic, cholagogue, diuretic, galactagogue, and immunomodulator	[22–32]
<i>Alternanthera caracasana</i> HBK	Tianguis, tianguistumina, tianguispepetla, tialpetate	Mexico	Stems, leaves, flowers, and roots	Treatment of dysentery, diarrhea, fever, and other conditions	[33]
<i>Alternanthera flavescens</i>	Lancetilla hembra			Treatment of fever and wound healing	[31]
<i>Alternanthera littoralis</i> P. Beauv.	<i>Alternanthera maritima</i> (Mart.) St. Hil.	Brazil		Treatment of infectious and inflammatory diseases	[8, 34]
<i>Alternanthera paronychioides</i>		Central and South America		Treatment of hyperuricemia, gout, rheumatic arthritis, nephritis, cystitis, uremia, diabetes, and systemic neuralgia	[35]
<i>Alternanthera philoxeroides</i>	Alligator weed, haicha shak, Phak Pet	Australia, Asia (e.g., Bangladesh, China, India), South America		Treatment of acute brain fever, anemia, diabetes, diarrhea, dysentery, encephalitis, hazy vision, herpes zoster, inflammation, influenza, malaria, measles, night blindness, pain, postnatal complaints, postnatal depression, puerperal fever, and viral infectious diseases. It is also used as an antipyretic, diuretic, and dressing for wounds and ulcers	[36–42]

(Continues)

TABLE 1 | (Continued)

Accepted names	Vernacular names and/or synonyms	Geographical location	Medicinal part	Medicinal condition treated	References
<i>Alternanthera porrigens</i>	Sanguinaria, Moradilla, Lancetilla	Peru	Whole plant	Cleansing the womb after childbirth	[43]
<i>Alternanthera pungens</i>	Kakishak and Motsweetswe	Bangladesh, Limpopo Province	Tuber and whole plant	Treatment of mouth ulcers, cough, fever, gonorrhoea (drop), kidney problems, and malaria	[16, 44, 45]
<i>Alternanthera repens</i>	Tianquis, tianquiz, or tianguispepetla	Mexico		Treatment of gastrointestinal ailments, such as diarrhoea, inflammation, and stomach ache, as well as for the treatment of typhus fever. It is also used as diaphoretic, diuretic, and astringent agent	[46, 47]
<i>Alternanthera sessilis</i>	<i>Alternanthera triandra</i> , <i>Alternanthera repens</i> , Abisrana, amaranth, Angelica, Bhiringi jhar, Brede chevrette, bunga-bunga, Carpet weed, Chanchi, Chanchi shak, Daun tolod, Dwarf copperleaf, Gandai, Gudrisag, Hong Tian Wu, Haicha, Honagone, Honugonesoppu, Hong Tian Wu, Horng-tyan-wu, Kachari, keremek, keremak merah, kermak putih, Lian zi cao, Lilonchi, Lupo, Matyakshika, Matikanduri, Matsyaksi, Minannani, Mukunuwenna, Phak ped khao, Phak pet daeng, Ponnagantikura, ponnankannikkirai, ponnandan, ponnanganni, ponnannani, pudoh, rumpu aoh, red sessile joyweed, Sachi-shak, serapat, Sessile Joy weed, water Dwarf Copperleaf	Africa, Argentina, Australia, Bangladesh, Bhutan, Brazil, Cameroon, Chad, China (e.g. Huanjiang), Ecuador, Egypt, Gambia, India, Indonesia, Iran, Kenya, Malaysia, Micronesia, Nepal, New Zealand, Nigeria, Pakistan, Philippines, Saudi Arabia, Singapore, Solomon Islands, Sri Lanka, Taiwan, Uganda, United States, Zambia, and Zaire	Whole plant, leaves, roots, and shoots	Treatment of anemia, aphthous ulcer, asthma, blood dysentery, bone fractures, bronchitis, burning sensations, chickenpox, cough, cuts, diabetes, diarrhoea, dysentery, dyspepsia, eczema, eye diseases, fever, flatulence, gonorrhoea, hemorrhoids, headache, helminthiasis, hepatitis, hernia, hypertension, indigestion, kidney diseases, leucorrhoea, liver and spleen diseases, low sperm count, lung diseases, malaria, measles, menstrual disorder, nausea, neuralgia, night blindness, ophthalmia, post-natal depression, pruritis, rheumatism, severe pain, skin diseases, splenomegaly, sprains, tight chest, ulcers, venereal disease, vertigo, vomiting, vomiting blood, and wound healing. It is also used as an abortifacient, analgesic, anti-inflammatory, antioxidant, antidote to snakebite and scorpion sting, antimicrobial, for bleeding control, as a cholagogue, diuretic, galactagogue, and for refreshing of eyes and body. Additionally, it is used as a poultice for boils, to relieve neuritis, and to remove tiredness, laziness, and sleepiness	[38, 48–65]

(Continues)

TABLE 1 | (Continued)

Accepted names	Vernacular names and/or synonyms	Geographical location	Medicinal part	Medicinal condition treated	References
<i>Alternanthera tenella</i>	Anador, Enxuga, Joyweed, melhoral, Meracilina, pépetua do mato, and quebra panela	Australia, India, and South America (e.g., Brazil)	Leaves and roots	Treatment of bronchitis, bruises, cough, diabetes, diarrhea, dysentery, fevers, flatulence, genital inflammation, headache, inflammation, infections, itches, nausea, pain, swelling, vomiting, and wounds. It is also used as a diuretic	[29, 66–70]
<i>Blutaparon portulacoides</i>	Capotiraguá, pirrixiu, or breço-de-praia	Brazil		Treatment of leukorrhoea and vulvovaginitis	[71]
<i>Froelichia</i>	Cottonweed, snake-cotton, and roadside weed	From the southern extremes of Canada to Northern Argentina and Uruguay	NA	To date, no traditional uses have been reported	[72]
<i>Froelichia floridana</i> (Nuttall)	Florida snake-cotton and plains snake-cotton	North America, West Indies of the Caribbean, and Australia	NA	To date, no traditional uses have been reported	[72]
<i>Gomphrena</i>	Bachelor Button, Globe Amaranth	Americas (particularly in South America), Antarctica, and Indo-Malaysia		Treatment of asthma, infant flu, body wounds, bronchial disorders, cooling, cough, diarrhea, fever, gastrointestinal and respiratory disorders, high cholesterol, infectious diseases, jaundice, kidney disorders, liver disease, malaria, oliguria, throat disorders, and urinary problems. It is also utilized as an analgesic, tonic, and carminative	[2, 3, 73]
<i>Gomphrena arborescens</i> L.	Paratudo, Paratudinho, Perpétua raiz do padre	Brazil	Leaves, flowers, and tuberous roots	Treatment of colitis, fevers, intermittent fevers, malaria, mental fatigue, and weakness. It is also utilized as an antidiarrheal, antithermal, antitoxic, aromatic, emmenagogue, eupeptic, protector, and tonic	[74]
<i>Gomphrena boliviana</i>		Argentina	Leaves and roots	Treatment of gastrointestinal disorders, infections, stomachache, and traumatic injuries	[75]

(Continues)

TABLE 1 | (Continued)

Accepted names	Vernacular names and/or synonyms	Geographical location	Medicinal part	Medicinal condition treated	References
<i>Gomphrena celosioides</i>	<i>Gomphrena serrata</i> , <i>Gomphrena decumbens</i> , adukowé, amegantaxe, bachelor's button, brava, perducilla, perpétua, pkaa Toum Hou, prostrate globe-amaranth, soft khaki weed, and white-eye	Americas (Argentina, Benin, Brazil, Paraguay, and Uruguay), Africa, Australia, Cambodia, East and West Vietnam, India, Indo-Malaysia, Nigeria, Togo, and Zimbabwe	Leaves, roots, whole plant	Treatment of asthma, bronchitis, wound healing, coughs, cold, dermatological problems, diabetes, diarrhea, dysmenorrhea, fever, gastrointestinal diseases, hay fever, hypertension, kidney infections, jaundice, kidney stones, lithiasis problems, liver diseases (e.g., viral hepatitis A and C, liver damage), malaria, renal disorders, respiratory diseases, sexually transmitted diseases, skin infections/diseases/problems, infectious diseases, urinary tract disorders, vulvovaginitis, and worms. It is also used as an abortive, analgesic, antifungal, antibiotic, diuretic, immunostimulant, and tonic/carminative	[3, 76–92]
<i>Gomphrena globosa</i>	Bachelor button, Botamphul, Globe amaranth, Meilingper, Perpétua, Perpétuas-roxas, Qianrihong, Trochiek Toun Say, and White bachelor button	Argentina, Bangladesh, Belize, Bolivia, Brazil, Cambodia, Canada, China (Huanjiang), Colombia, Costa Rica, Ecuador, French Guiana, Guatemala, Guyana, Honduras, India, Mexico, Panama, Peru, Portugal, South Africa, Suriname, United States, Trinidad, Tobago, Venezuela	Leaves, inflores- cence, flowers, rhizome, and whole plant	Treatment of bronchial asthma, bronchitis, cough, diabetes, diarrhea, gallstones, gangrenous wounds, giddiness, hemorrhage, headache, heat and indigestion, hemoptysis, hoarseness, hypertension, indigestion, jaundice, kidney and prostate problems, oliguria, reproductive problems, respiratory diseases, urinary retention, tuberculosis, urinary system conditions, uterine infection, and whooping cough. It is also used as an antimicrobial, antioxidant, and expectorant	[3, 25, 29, 44, 79, 93–98]
<i>Gomphrena macrocephala</i>		Brazil	Roots	It is used as a stimulant and a tonic	[99]
<i>Gomphrena martiana</i>	Solo and yerba de pollo	South America (e.g., Argentina)	Leaves and roots	Treatment of liver, kidney, urinary tract, and gastrointestinal disorders; infections; stomachache; and traumatic injuries. It is also used as a diuretic and blood purifier	[75, 100]
<i>Gomphrena virgata</i>	Cangussu-branco	Brazil		Treatment of pain, inflammation, and infection. It is also used as an anti-lethargic	[101]
<i>Guilleminea densa</i>	Sanguinaria			Treatment of gastric ulcers and menstrual cramps. It is also used as an antihemorrhagic	[102]
<i>Iresine angustifolia</i>	Hierba del arlomo	Mexico		Treatment of insect bites	[103]

(Continues)

TABLE 1 | (Continued)

Accepted names	Vernacular names and/or synonyms	Geographical location	Medicinal part	Medicinal condition treated	References
<i>Iresine diffusa</i>	<i>Iresine celosia</i> , <i>Iresine celosoides</i> , herb of the Mayas, Paja Blanca, and Sangrinaría	Central and South America (e.g., Mexico, Peru), the West Indies, and the Southeastern United States	Whole plant	Treatment of anorexia, cancer, fever, inflammation, malaria, menstrual symptoms in adolescents, mouth sores, oral infections, prostate and urethra ailments, rash, skin problems, swelling, and typhoid fever	[43, 104, 105]
<i>Iresine herbstii</i> Hook	Bloodleaf, cimora senorita, chicken gizzard, beefsteak plant, herbst's bloodleaf, Mussurú, and Phak phaeo daeng	The entire world	Whole plant, aerial part, leaves, and stem	Treatment of anemia, broken bones, cancer, candidiasis, burns, eczema, wound healing, inflammatory bowel diseases, peptic ulcer, pimples, and sores. It is also used as antipyretic, skin depurative, and tonic	[106, 107, 58, 59, 108–111]
<i>Pfafﬂia glomerata</i>	Acõnito, Brazil ginseng, corango sempre-viva, dipyrone, fáfia, paratudo, and novalgina	Brazil and Ecuador	Roots	Treatment of cancer, cholesterol, diabetes, flu, gastritis, impotence, inflammatory disorders, memory lapses, local pain, palpitations, rheumatism, stomach problems, and stress. It is also used as antioxidants, aphrodisiac, stimulant, tonic, and for wound healing. As well as it is utilized for restoring vital functions, increasing physical strength and mental equilibrium, and protecting the gastric mucosa from injury	[25, 112–119]
<i>Pfafﬂia paniculata</i>	<i>Hebanthe eriantha</i> , <i>Hebanthe paniculata</i> , <i>Gomphrena paniculata</i> , <i>Gomphrena eriantha</i> , <i>Iresine erianthos</i> , <i>Iresine paniculata</i> , <i>Iresine tenuis</i> , <i>Pfafﬂia eriantha</i> , <i>Pfafﬂia virgata</i> , <i>Xeraea paniculata</i> , Brazilian ginseng, paratudo, suma	Brazil, Ecuador, Panama, Peru, and Venezuela	Roots	Treatment of arthritis, diabetes, cancer, rheumatism, and ulcers. It is also used as an analgesic, anti-inflammatory, antistress, antitumor, aphrodisiac, invigorating, memory booster, and tonic	[120–126]
<i>Pfafﬂia townsendii</i>	Brazilian ginseng	Brazil		It is used as an anti-inflammatory, tonic, analgesic, and antidiabetic agent	[127]
<i>Tidestromia oblongifolia</i>		United States, Mexico		Treatment of headache and foot pain	[128]

TABLE 2 | Phenolic compounds isolated from the Gomphrenoideae subfamily.

No.	Compound	Species	Parts of plant	References
Flavonoids				
Flavan3-ols				
1	Catechin	<i>Alternanthera bettzickiana</i>	Aerial parts	[19]
		<i>Alternanthera philoxeroides</i>	Whole plant	[132]
		<i>Alternanthera sessilis</i>	Whole plant	[57, 133]
		<i>Gomphrena celosioides</i> Mart.	Aerial parts	[81]
		<i>Gomphrena perennis</i>	Aerial parts	[134]
2	Epigallocatechin	<i>Alternanthera sessilis</i>	—	[57]
Flavones				
3	Apigenin	<i>Alternanthera brasiliiana</i>	Leaves	[26]
		<i>Alternanthera sessilis</i>	Leaves	[55, 57]
4	Demethyltorosaflavone B	<i>Alternanthera philoxeroides</i>	Aerial parts	[38]
5	Demethyltorosaflavone D	<i>Alternanthera philoxeroides</i>	Aerial parts and whole plant	[38, 135, 136]
6	5,7-Dihydroxy-3,6-dimethoxyflavone	<i>Gomphrena boliviana</i>	Whole plant	[75]
		<i>Gomphrena martiana</i>	Whole plant	[75, 100, 137]
7	5,7-Dihydroxy-6-methoxyflavone (oroxilin A)	<i>Gomphrena boliviana</i>	Whole plant	[75]
		<i>Gomphrena martiana</i>	Whole plant	[75, 137]
8	Dimethoxy-flavone	<i>Gomphrena celosioides</i> Mart.	Aerial parts	[81]
9	5,6-Dimethoxy-7-hydroxyflavone (baicalein 5,6-dimethyl ether)	<i>Gomphrena boliviana</i>	Whole plant	[75]
		<i>Gomphrena martiana</i>	Whole plant	[75, 137]
10	3,5-Dimethoxy-6,7-methylenedioxyflavone	<i>Gomphrena boliviana</i>	Whole plant	[75]
		<i>Gomphrena martiana</i>	Whole plant	[75, 137]
11	Diosmetin	<i>Froelichia floridana</i>	Whole plants	[72]
12	Isoorientin	<i>Alternanthera sessilis</i>	Leaves	[137]
13	Isorhamnetin	<i>Alternanthera maritima</i>	Aerial parts	[138]
		<i>Gomphrena agrestis</i>	Roots and leaves	[139]
		<i>Gomphrena clausenii</i>	Whole plant	[137]
		<i>Gomphrena globosa</i>	Inflorescence	[94, 98]

(Continues)

TABLE 2 | (Continued)

No.	Compound	Species	Parts of plant	References
14	Isovitexin	<i>Alternanthera maritima</i>	Aerial parts	[137]
		<i>Alternanthera sessilis</i>	Whole plant	[140]
		<i>Gomphrena perennis</i>	Aerial parts	[134]
15	Luteolin	<i>Alternanthera brasiliana</i>	Leaves	[26]
		<i>Gomphrena agrestis</i>	Roots and leaves	[139]
16	Orientin	<i>Alternanthera brasiliana</i>	Leaves	[26]
		<i>Alternanthera sessilis</i>	Leaves	[137]
17	3,5,6,7-Tetramethoxyflavone	<i>Gomphrena boliviana</i>	Whole plant	[75]
		<i>Gomphrena martiana</i>	Whole plant	[75, 137]
Flavonol				
18	Galangin triOMe	<i>Gomphrena martiana</i>	Whole plant	[137]
19	Gomphrenol	<i>Blutaparon portulacoides</i>	Stems	[71]
		<i>Gomphrena celosioides</i> Mart.	—	[84]
		<i>Gomphrena clausenii</i>	Whole plant	[137]
		<i>Gomphrena globosa</i>	Leaves	[137]
20	Kaempferol	<i>Alternanthera brasiliana</i>	Leaves, stems, and whole plant	[23, 28]
		<i>Alternanthera maritima</i>	Aerial parts	[34, 137]
		<i>Alternanthera philoxeroides</i>	Leaves	[38, 141]
		<i>Alternanthera tenella</i> Colla	Leaves, stems, and whole plant	[28, 142, 143]
		<i>Gomphrena agrestis</i>	Roots and leaves	[139]
		<i>Gomphrena clausenii</i>	Whole plant	[137]
		<i>Gomphrena globosa</i>	Inflorescence and leaves	[94, 98, 136, 144]
		<i>Iresine angustifolia</i>	Whole plant	[103]
21	Kaempferol monosulfate	<i>Alternanthera sessilis</i>	Stems	[56]
22	Myricetin	<i>Alternanthera sessilis</i>	—	[55]
23	Patuletin	<i>Gomphrena clausenii</i>	Whole plant	[137]
24	Quercetin	<i>Alternanthera bettzickiana</i>	Aerial parts	[19]

(Continues)

TABLE 2 | (Continued)

No.	Compound	Species	Parts of plant	References
		<i>Alternanthera brasiliiana</i>	Leaves, stems, and whole plant	[23, 26, 28]
		<i>Alternanthera maritima</i>	Aerial parts	[34, 137, 138, 145]
		<i>Alternanthera paronychioides</i>	—	[35]
		<i>Alternanthera philoxeroides</i>	Leaves	[42, 136]
		<i>Alternanthera sessilis</i>	Leaves and whole plant	[55, 133, 137]
		<i>Alternanthera tenella</i> Colla	Leaves, stems, and whole plant	[28, 142, 143]
		<i>Gomphrena agrestis</i>	Roots and leaves	[139]
		<i>Gomphrena celosioides</i>	Roots	[146]
		<i>Gomphrena clausenii</i>	Whole plant	[137]
		<i>Gomphrena globosa</i>	Inflorescence and leaves	[94, 98, 137]
		<i>Iresine angustifolia</i>	Whole plant	[103]
25	Quercetin 3-methyl ether (3-methoxy quercetin)	<i>Alternanthera maritima</i>	Aerial parts	[138, 145]
		<i>Alternanthera tenella</i> Colla	Whole plant	[142]
26	Quercetin-3-O-methyl ester	<i>Alternanthera maritima</i>	Aerial parts	[34]
27	3,5,3',4'-Tetrahydroxy-6,7-methylenedioxy flavone	<i>Gomphrena globosa</i>	Inflorescence	[94, 98]
Isoflavone				
28	Daidzein	<i>Alternanthera sessilis</i>	Stem	[56, 57]
29	Daidzin	<i>Froelichia floridana</i>	Whole plants	[72]
30	2',5-Dimethoxy-6,7-methylenedioxyisoflavanone (tlatlancuayin)	<i>Iresine celosioides</i>	Whole plant	[137]
		<i>Iresine herbstii</i>	Aerial parts	[111, 147]
31	Irisonone B	<i>Blutaparon portulacoides</i>	Aerial parts	[148]
		<i>Gomphrena celosioides</i> Mart.	Aerial parts	[81]
32	2',2,5-Trimethoxy-6,7-methylenedioxyisoflavanone	<i>Iresine herbstii</i>	Aerial parts	[111]
Aurone				
33	(<i>E</i>)-3'- <i>O</i> - β -D-glucopyranosyl-4,5,6,4'-tetrahydroxy-7,2'-dimethoxyaurone	<i>Gomphrena agrestis</i>	Whole plant	[2]
Flavonoid glycosides				
Flavone glycosides				
34	Acacetin 8-C-[α -L-rhamnopyranosyl-(1 \rightarrow 2)- β -D-glucopyranoside]	<i>Alternanthera maritima</i>	Aerial parts	[34, 138, 145]

(Continues)

TABLE 2 | (Continued)

No.	Compound	Species	Parts of plant	References
		<i>Alternanthera tenella</i> Colla	Whole plant	[142, 143]
35	Alternanthin	<i>Alternanthera philoxeroides</i>	Aerial parts, stems, leaves, and whole plant	[36, 38, 135, 137]
36	Alternanthin B	<i>Alternanthera philoxeroides</i>	Aerial parts and whole plant	[36, 38, 135, 136]
37	Apigenin-6,8-di-C- β -D-glucopyranoside	<i>Alternanthera sessilis</i>	Stems and whole plant	[56, 149]
38	Chrysin 7-O-glucuronide	<i>Gomphrena martiana</i>	Whole plant	[137]
39	Chrysoeriol-6-C- β -D-boivinopyranoside	<i>Alternanthera philoxeroides</i>	—	[40]
40	Chrysoeriol-6-C- β -D-Boivinopyranosyl-4'-O- β -D-glucopyranoside	<i>Alternanthera philoxeroides</i>	—	[40]
41	Chrysoeriol 7-O-rhamnoside or chrysoeriol 7-rhamnoside	<i>Alternanthera philoxeroides</i>	Whole plant and aerial parts	[38, 135, 136]
42	Glucopyranosyl-vitexin	<i>Alternanthera tenella</i> Colla	Leaves and stems	[28]
43	2''-O- β -D-glucopyranosyl-vitexin	<i>Alternanthera maritima</i>	Aerial parts	[34, 138, 145]
		<i>Alternanthera tenella</i> Colla	Whole plant	[142, 143]
44	Isorhamnetin 3-O- α -L-rhamnosyl-(1 \rightarrow 6)- β -D-galactopyranoside	<i>Alternanthera maritima</i>	Aerial parts	[34, 138]
45	Isorhamnetin 3-O- α -L-rhamnosyl-(1 \rightarrow 6)- β -D-glucopyranoside	<i>Alternanthera maritima</i>	Aerial parts	[34]
46	Isorhamnetin-3-hexoside	<i>Gomphrena globosa</i> <i>Gomphrena</i> sp.	Inflorescence Flower	[73, 94, 98] [73]
47	Isorhamnetin-3-(pentosyl)hexoside	<i>Gomphrena globosa</i>	Inflorescence	[94, 98]
48	Isorhamnetin-3-(6-rhamnosyl)hexoside	<i>Gomphrena globosa</i>	Inflorescence	[94, 98]
49	Isorhamnetin 3-O-[α -rhamnopyranosyl-(1 \rightarrow 6)- β -D-glucopyranoside]	<i>Alternanthera maritima</i>	Aerial parts	[138]
		<i>Gomphrena celosioides</i>	Aerial parts	[92]
50	Isorhamnetin 3-O- α -L-rhamnosyl-(1 \rightarrow 6)- β -D-glucopyranoside	<i>Alternanthera maritima</i>	Aerial parts	[145]
		<i>Gomphrena globosa</i> L.	Flower	[144]
51	Isorhamnetin-3-O- β -D-apiofuranosyl-(1 \rightarrow 2)- β -D-glucopyranoside	<i>Gomphrena globosa</i> L.	Flower	[144]
52	Isorhamnetin 3-O-glucoside	<i>Gomphrena globosa</i> var. <i>albiflora</i> <i>Gomphrena</i> sp.	Flower Flower	[73, 150] [73]
53	Isorhamnetin 3-O-robinobioside	<i>Alternanthera maritima</i>	Aerial parts	[137]
		<i>Gomphrena martiana</i>	Whole plant	[137]

(Continues)

TABLE 2 | (Continued)

No.	Compound	Species	Parts of plant	References
54	Isorhamnetin 3-O- β -robinobioside	<i>Gomphrena boliviana</i>	Whole plant	[75]
		<i>Gomphrena martiana</i>	Whole plant	[75]
55	Isorhamnetin 3-O-rutinoside	<i>Alternanthera brasiliiana</i>	Leaves and stems	[28]
		<i>Alternanthera maritima</i>	Aerial parts	[137]
		<i>Alternanthera tenella</i> Colla	Leaves and stems	[28]
		<i>Gomphrena agrestis</i>	Roots and leaves	[139]
		<i>Gomphrena globosa</i>	Flower	[150]
56	Isorhamnetin-O-glucuronyl-deoxyhexosyl-hexoside	<i>Gomphrena haageana</i> K.	Flower	[73]
57	Isorhamnetin-O-glucuronyl-hexoside	<i>Gomphrena haageana</i> K.	Flower	[73]
58	Luteolin-6-C- β -D-boivinopyranoside	<i>Alternanthera philoxeroides</i>	—	[40]
59	Luteolin-6-C- β -D-boivinopyranosyl-3'-O- β -D-glucopyranoside	<i>Alternanthera philoxeroides</i>	—	[40]
60	Luteolin-6-C- β -D-boivinopyranosyl-4'-O- β -D-glucopyranoside	<i>Alternanthera philoxeroides</i>	—	[40]
61	Luteolin 8-C-E-propenoic acid	<i>Alternanthera philoxeroides</i>	Aerial parts	[38]
62	Luteolin-8-C-rhamnosylglucoside	<i>Alternanthera brasiliiana</i>	Aerial parts	[22]
63	Methoxy-trihydroxymethylenedioxyflavone O-glucuronyl-hexoside	<i>Gomphrena haageana</i> K.	Flower	[73]
64	Nepetin 3-O-rhamnoside	<i>Alternanthera philoxeroides</i>	Leaves	[137]
65	Patuletin O-deoxyhexosyl-hexoside	<i>Gomphrena haageana</i> K.	Flower	[73]
66	Patuletin 3-O-glucoside	<i>Gomphrena claussenii</i>	Whole plant	[137]
67	Patuletin 3-O- β -D-glucopyranoside	<i>Pfaffia townsendii</i>	Whole plant	[127]
68	Patuletin O-hexoside	<i>Gomphrena haageana</i> K.	Flower	[73]
69	2''-O-pentosyl-6-C-hexosyl-apigenin (2''-O-pentosyl-isovitexin)	<i>Alternanthera brasiliiana</i>	Leaves	[28]
		<i>Alternanthera tenella</i> Colla	Leaves and stems	[28]
70	2''-O-pentosyl-8-C-hexosyl-apigenin (2''-O-pentosyl-vitexin)	<i>Alternanthera brasiliiana</i>	Leaves and stems	[28]
		<i>Alternanthera tenella</i> Colla	Stems	[28]
71	Potentilin A	<i>Gomphrena globosa</i> L.	Flower	[144]

(Continues)

TABLE 2 | (Continued)

No.	Compound	Species	Parts of plant	References
72.	2''-O-Rhamnopyranosyl-vitexin	<i>Alternanthera brasiliiana</i>	Leaves	[28]
		<i>Alternanthera maritima</i>	Aerial part	[34, 138, 145]
		<i>Alternanthera tenella</i> Colla	Leaves and whole plant	[28, 143]
73	2''-O-rhamnosyl-6-C-glucosil methyluteolin	<i>Alternanthera brasiliiana</i>	Aerial parts	[22]
74	2''-O-rhamnosylvitexin	<i>Alternanthera brasiliiana</i>	Aerial parts	[22]
		<i>Alternanthera sessilis</i>	Stems	[56]
75	2''-O-Rhamnosylswertisin	<i>Alternanthera brasiliiana</i>	Aerial parts	[22]
76	3,5,3',4'-Tetrahydroxy-6,7-methylenedioxyflavone-3-O-deoxyhexosyl-hexoside	<i>Gomphrena haageana</i> K.	Flower	[73]
77	3,5,3',4'-tetrahydroxy-6,7-methylenedioxyflavone-3-hexoside	<i>Gomphrena globosa</i>	Inflorescence	[94, 98]
		<i>Gomphrena haageana</i> K.	Flower	[73]
78	7,3',4',5'-Tetrahydroxy-flavanone 7-O-glucoside	<i>Alternanthera sessilis</i>	Leaves	[137]
79	Torosafavone E	<i>Alternanthera philoxeroides</i>	Aerial parts and whole plant	[38, 145]
80	3,5,3'-Trihydroxy-4'-methoxy-6,7-methylenedioxyflavone	<i>Blutaparon portulacoides</i>	Aerial parts, stem, and whole plant	[71, 148, 151, 152]
81	3,5,3'-Trihydroxy-4'-methoxy-6,7-methylenedioxy-favone-glucosilated	<i>Blutaparon portulacoides</i>	Stems and whole plant	[71, 152]
82	3',4',7-Trihydroxy-6-methoxyflavone	<i>Iresine herbstii</i>	—	[111]
83	3,5,4'-Trihydroxy-6,7-methylenedioxyflavone-3-(6-acetyl)hexoside or Gomphrenol 3-O-(6-acetyl)hexoside	<i>Gomphrena globosa</i>	Inflorescence	[73, 94, 98, 150]
		<i>Gomphrena</i> sp.	Flower	[73]
84	3,5,4'-Trihydroxy-6,7-methylenedioxyflavone-3-hexoside or gomphrenol 3-O-hexoside	<i>Gomphrena globosa</i>	Inflorescence	[73, 94, 98, 150]
		<i>Gomphrena</i> sp	Flower	[73]
85	3,5,4'-trihydroxy-6,7-methylenedioxyflavone-3-(2-pentosyl) hexoside or gomphrenol 3-O-(2-pentosyl)-hexoside	<i>Gomphrena globosa</i>	Inflorescence	[73, 94, 98]
		<i>Gomphrena</i> sp.	Flower	[73]
86	3,5,4'-Trihydroxy-6,7-methylenedioxyflavone-3-(2-pentosyl, 6-acetyl)hexoside or gomphrenol 3-O-(2-pentosyl, 6-acetyl)-hexoside	<i>Gomphrena globosa</i>	Inflorescence	[73, 94, 98]

(Continues)

TABLE 2 | (Continued)

No.	Compound	Species	Parts of plant	References
		<i>Gomphrena</i> sp.	Flower	[73]
87	3,5,4'-Trihydroxy-6,7-methylenedioxyflavone-3-(6-rhamnosyl)hexoside	<i>Gomphrena globosa</i>	Inflorescence	[94, 98]
88	Vitexin	<i>Alternanthera brasiliiana</i>	Leaves and whole plant	[23, 26, 28]
		<i>Alternanthera maritima</i>	Aerial parts	[34, 137, 138]
		<i>Alternanthera tenella</i> Colla	Leaves, stems, and whole plant	[28, 142, 143]
89	2'' Vitexin-O-glucoside	<i>Alternanthera maritima</i>	Aerial parts	[137]
90	2'' Vitexin-O-rhamnoside	<i>Alternanthera maritima</i>	Aerial parts	[137]
Flavonol glycosides				
91	Gomphrenol-3-glucoside	<i>Blutaparon portulacoides</i>	Stems and whole plant	[71, 152]
92	Gomphrenol-3-O- β -D-glucopyranoside	<i>Gomphrena globosa</i> L.	Flower	[144]
93	Gomphrenol-3-O- β -D-glucopyranosyl-(1 \rightarrow 6)- β -D-glucopyranoside	<i>Gomphrena globosa</i> L.	Flower	[144]
94	Gomphrenol-3-O- β -D-xylopyranosyl-(1 \rightarrow 2)- β -D-glucopyranoside	<i>Gomphrena globosa</i> L.	Flower	[144]
95	3'-Hydroxygomphrenol-3-O- β -D-glucopyranoside	<i>Gomphrena globosa</i> L.	Flower	[144]
96	Kaempferol glucoside	<i>Alternanthera brasiliiana</i>	Leaves and stems	[28]
		<i>Alternanthera tenella</i> Colla	Leaves and stems	[28]
97	Kaempferol-3-(2-pentosyl)hexoside	<i>Gomphrena globosa</i>	Inflorescence	[94, 98]
98	Kaempferol-3-(2-pentosyl, 6-rhamnosyl)hexoside	<i>Gomphrena globosa</i>	Inflorescence	[94, 98]
99	Kaempferol-3-(6-rhamnosyl)hexoside	<i>Gomphrena globosa</i>	Inflorescence	[94, 98]
100	Kaempferol-3-O- α -L-rhamnopyranosyl-(1 \rightarrow 6)- β -dglucopyranoside	<i>Gomphrena globosa</i> L.	Flower	[144]
101	Kaempferol-3-O- β -dglucopyranoside	<i>Gomphrena globosa</i> L.	Flower	[144]
102	Kaempferol O-acetylhexoside	<i>Gomphrena globosa</i> var. <i>albiflora</i>	Flower	[73, 150]
		<i>Gomphrena</i> sp.	Flower	[73]
103	Kaempferol 3-O-glucoside	<i>Alternanthera philoxeroides</i>	Whole plant	[136]
		<i>Gomphrena clausenii</i>	Whole plant	[137]
		<i>Gomphrena globosa</i> var. <i>albiflora</i>	Flower	[73, 94, 98, 150, 153]
		<i>Gomphrena</i> sp.	Flower	[73]
		<i>Pfaffia glomerata</i>	Inflorescences	[154]

(Continues)

TABLE 2 | (Continued)

No.	Compound	Species	Parts of plant	References
104	Kaempferol <i>O</i> -glucuronide- <i>O</i> -hexoside	<i>Gomphrena globosa</i>	Flower	[150]
105	Kaempferol 3- <i>O</i> -(2-pentosyl)-hexoside	<i>Gomphrena globosa</i> var. <i>albiflora</i>	Flower	[73, 150]
		<i>Gomphrena</i> sp.	Flower	[73]
106	Kaempferol 3- <i>O</i> - β -D-(6- <i>O</i> - <i>p</i> - <i>E</i> -coumaroyl)-glucopyranoside (tiliroside) or kaempferol-3- <i>O</i> -(6- <i>p</i> -coumaroyl)-glucoside	<i>Froelichia floridana</i>	Whole plants	[72]
		<i>Gomphrena agrestis</i>	Whole plant	[2]
		<i>Pfaffia glomerata</i>	Inflorescences	[154]
		<i>Pfaffia townsendii</i>	Whole plant	[127]
107	Kaempferol-3- <i>O</i> -(6''- <i>O</i> -(<i>E</i>)- <i>p</i> -coumaroyl)- β -D-glucopyranoside	<i>Gomphrena globosa</i> L.	Flower	[144]
108	Kaempferol-3- <i>O</i> -(6''- <i>O</i> -(<i>Z</i>)- <i>p</i> -coumaroyl)- β -D-glucopyranoside	<i>Gomphrena globosa</i> L.	Flower	[144]
109	Kaempferol 3- <i>O</i> - β -D-(6''-feruloyl)glucopyranoside)	<i>Gomphrena globosa</i> L.	Flower	[144]
110	Kaempferol 3- <i>O</i> -(2-pentosyl, 6- <i>O</i> -rhamnosyl)-hexoside	<i>Gomphrena globosa</i> var. <i>albiflora</i>	Flower	[73, 150]
		<i>Gomphrena</i> sp.	Flower	[73]
111	Kaempferol-rhamnosyl-rhamnosyl- glycoside	<i>Alternanthera brasiliiana</i>	Leaves and stems	[28]
		<i>Alternanthera tenella</i> Colla	Stems	[28]
112	Kaempferol 3- <i>O</i> -(2-rhamnosyl)-hexoside	<i>Gomphrena globosa</i>	Flower	[150]
113	Kaempferol 3- <i>O</i> -(6-rhamnosyl)-hexoside	<i>Gomphrena globosa</i> var. <i>albiflora</i>	Flower	[73]
		<i>Gomphrena</i> sp.	Flower	[73]
114	Kaempferol <i>O</i> -rhamnosyl-pentoside	<i>Gomphrena globosa</i> var. <i>albiflora</i>	Flower	[73]
		<i>Gomphrena</i> sp.	Flower	[73]
115	Kaempferol 3- <i>O</i> -robinobioside	<i>Alternanthera brasiliiana</i>	—	[28]
116	Kaempferol rutinoside or kaempferol 3- <i>O</i> -rutinoside or kaempferol 3-rutinoside	<i>Alternanthera brasiliiana</i>	Leaves and stems	[28]
		<i>Alternanthera tenella</i> Colla	Leaves and stems	[28]
		<i>Gomphrena agrestis</i>	Roots and leaves	[139]
		<i>Gomphrena celosioides</i>	Aerial parts	[92]
		<i>Gomphrena globosa</i> var. <i>albiflora</i>	Flower	[73, 150, 153]
		<i>Gomphrena</i> sp.	Flower	[73]
117	Laricitin 3- <i>O</i> - β -D-glucopyranoside	<i>Froelichia floridana</i>	Whole plants	[72]
118	8,8'''-methylene bis(spinacetin 3- <i>O</i> -robinobioside)	<i>Blutaparon portulacoides</i>	Leaves	[155]
119	Quercetin-glucoside	<i>Alternanthera brasiliiana</i>	Leaves and stems	[28]

(Continues)

TABLE 2 | (Continued)

No.	Compound	Species	Parts of plant	References
		<i>Alternanthera tenella</i> Colla	Leaves and stems	[28]
120	Quercetin-3-hexoside	<i>Gomphrena globosa</i>	Inflorescence	[94, 98]
121	Quercetin-3-(pentosyl)hexoside	<i>Gomphrena globosa</i>	Inflorescence	[94, 98]
122	Quercetin-3-(2-pentosyl)hexoside	<i>Gomphrena globosa</i>	Inflorescence	[94, 98]
123	Quercetin-3-(2-pentosyl, 6-rhamnosyl)hexoside	<i>Gomphrena globosa</i>	Inflorescence	[94, 98]
124	Quercetin-3-(6-rhamnosyl)hexoside	<i>Gomphrena globosa</i>	Inflorescence	[94, 98]
125	Quercetin 3- <i>O</i> -(2-pentosyl, 6-rhamnosyl)-hexoside	<i>Gomphrena globosa</i> var. <i>albiflora</i>	Flower	[73]
		<i>Gomphrena</i> sp.	Flower	[73]
126	Quercetin 3- <i>O</i> -glucoside	<i>Gomphrena globosa</i> var. <i>albiflora</i>	Flower	[73, 150]
		<i>Gomphrena haageana</i> K.	Flower	[73]
		<i>Gomphrena</i> sp.	Flower	[73]
		<i>Pfaffia glomerata</i>	Inflorescences	[154]
127	Quercetin 3-OMe	<i>Alternanthera maritima</i>	Aerial parts	[137]
128	Quercetin 3- <i>O</i> -(6-pentosyl)-hexoside	<i>Gomphrena globosa</i> var. <i>albiflora</i>	Flower	[73, 150]
		<i>Gomphrena</i> sp.	Flower	[73]
129	Quercetin 3- <i>O</i> - α -L-rhamnosyl-(1 \rightarrow 6)- β -D-glucopyranoside	<i>Alternanthera maritima</i>	Aerial parts	[145]
130	Quercetin 3- <i>O</i> -rutinoside (rutin)	<i>Alternanthera brasiliiana</i>	Aerial parts and stems	[22, 28]
		<i>Alternanthera maritima</i>	Aerial parts	[34, 137, 138]
		<i>Alternanthera sessilis</i>	Leaves and whole plant	[55, 133]
		<i>Alternanthera tenella</i> Colla	Leaves and stems	[28]
		<i>Gomphrena globosa</i> var. <i>albiflora</i>	Flower	[73, 150, 153]
		<i>Gomphrena haageana</i> K.	Flower	[73]
		<i>Gomphrena</i> sp.	Flower	[73]
131	Quercetin- <i>O</i> -acetylhexoside	<i>Gomphrena</i> sp.	Flower	[73]
132	Quercetin <i>O</i> -glucuronide- <i>O</i> -hexoside	<i>Gomphrena globosa</i> var. <i>albiflora</i>	Flower	[73, 150]
		<i>Gomphrena</i> sp.	Flower	[73]
133	Spinacetin 3- <i>O</i> -robinobioside	<i>Blutaparon portulacoides</i>	Leave and whole plant	[152, 155]
Non-flavonoid phenolic compounds				
Benzoic acids				
134	Dihydroxybenzoic acid glucoside	<i>Alternanthera brasiliiana</i>	Leaves and stems	[28]

(Continues)

TABLE 2 | (Continued)

No.	Compound	Species	Parts of plant	References
		<i>Alternanthera tenella</i> Colla	Leaves and stems	[28]
135	3,4-Dimethoxybenzoic acid	<i>Gomphrena elegans</i> Mart.	Leaves	[156]
136	3,4-Dimethylbenzoic acid	<i>Gomphrena globosa</i>	—	[156]
137	Ethyl gallate	<i>Alternanthera sessilis</i>	—	[57]
138	Gallic acid	<i>Alternanthera bettzickiana</i>	Aerial parts	[19]
		<i>Alternanthera brasiliiana</i>	Leaves	[26]
		<i>Alternanthera philoxeroides</i>	Whole plant	[132]
		<i>Alternanthera sessilis</i>	—	[55]
		<i>Gomphrena agrestis</i>	Roots and leaves	[139]
		<i>Gomphrena globosa</i>	Flowers	[153]
		<i>Gomphrena perennis</i>	Aerial parts	[134]
		<i>Iresine angustifolia</i>	Whole plant	[103]
139	Gentisic acid	<i>Alternanthera brasiliiana</i>	Leaves and stems	[28]
		<i>Alternanthera tenella</i> Colla	Leaves and stems	[28]
140	4-Hydroxybenzoic acid or <i>p</i> -hydroxybenzoic acid	<i>Alternanthera brasiliiana</i>	Leaves and stems	[28]
		<i>Alternanthera philoxeroides</i>	Aerial parts	[38]
		<i>Alternanthera sessilis</i>	Stems	[55, 56, 57]
		<i>Alternanthera tenella</i> Colla	Leaves and stems	[28]
		<i>Gomphrena agrestis</i>	Roots and leaves	[139]
		<i>Gomphrena celosioides</i> Mart.	Aerial parts	[78, 157]
		<i>Gomphrena elegans</i> Mart.	Leaves	[156]
141	<i>p</i> -Methoxybenzoic acid	<i>Gomphrena elegans</i> Mart.	Leaves	[156]
142	Protocatechuic acid	<i>Alternanthera sessilis</i>	Stems	[56]
Hydroxycinnamic acids–phenolic acids				
143	Caffeic acid	<i>Alternanthera brasiliiana</i>	Leaves	[26]
		<i>Blutaparon portulacoides</i>	Stems and whole plant	[71, 152]
		<i>Gomphrena celosioides</i> Mart.	Aerial parts	[81]

(Continues)

TABLE 2 | (Continued)

No.	Compound	Species	Parts of plant	References
		<i>Gomphrena globosa</i>	Flowers	[153]
		<i>Iresine angustifolia</i>	Whole plant	[103]
144	Caffeoyl-glucose	<i>Gomphrena celosioides</i> Mart.	Aerial parts	[81]
145	Chlorogenic acid	<i>Alternanthera bettzickiana</i>	Aerial parts	[19]
		<i>Alternanthera brasiliiana</i>	Leaves and stems	[26, 28]
		<i>Alternanthera philoxeroides</i>	Leaves	[38, 141]
		<i>Alternanthera sessilis</i>	—	[57]
		<i>Iresine angustifolia</i>	Whole plant	[103]
146	Cinnamic acid	<i>Iresine angustifolia</i>	Whole plant	[103]
147	Coumaric acid	<i>Alternanthera brasiliiana</i>	Leaves and stems	[28]
		<i>Alternanthera tenella</i> Colla	Leaves and stems	[28]
148	<i>cis-p</i> -Coumaric acid	<i>Gomphrena globosa</i>	Flowers	
149	Ferulic acid or <i>trans</i> -ferulic acid	<i>Alternanthera brasiliiana</i>	Leaves and stems	[28]
		<i>Alternanthera paronychioides</i>	—	[35]
		<i>Alternanthera philoxeroides</i>	Leaves	[38, 141]
		<i>Alternanthera sessilis</i>	Leaves	[55, 57]
		<i>Alternanthera tenella</i> Colla	Leaves and stems	[28]
		<i>Blutaparon portulacoides</i>	Stems and whole plant	[71, 152]
		<i>Gomphrena celosioides</i> Mart.	Aerial parts	[81]
		<i>Gomphrena globosa</i>	Inflorescence	[94, 98, 150]
		<i>Iresine angustifolia</i>	Whole plant	[103]
150	<i>cis</i> -Ferulic acid	<i>Gomphrena globosa</i>	Flowers	[150]
151	<i>cis</i> -Ferulic acid hexoside	<i>Gomphrena globosa</i>	Flowers	[150]
152	<i>trans</i> -Ferulic acid hexoside	<i>Gomphrena globosa</i>	Flowers	[150]
153	Isoferulic acid	<i>Gomphrena elegans</i> Mart.	Leaves	
154	<i>p</i> -Coumaric acid or <i>trans-p</i> -coumaric acid	<i>Gomphrena agrestis</i>	Roots and leaves	[139]
		<i>Gomphrena globosa</i>	Inflorescence	[94, 98, 150]
		<i>Gomphrena perennis</i>	Aerial parts	[134]
		<i>Gomphrena haageana</i> K.	Flower	[73]
155	Sinapic acid	<i>Alternanthera bettzickiana</i>	Aerial parts	[19]
		<i>Iresine angustifolia</i>	Whole plant	[103]

(Continues)

TABLE 2 | (Continued)

No.	Compound	Species	Parts of plant	References
156	Vanillic acid	<i>Alternanthera philoxeroides</i>	Aerial parts and whole plant	[38, 132]
		<i>Alternanthera sessilis</i>	—	[57]
		<i>Blutaparon portulacoides</i>	Stems, roots, and whole plant	[71, 148, 152]
		<i>Gomphrena agrestis</i>	Roots and leaves	[139]
		<i>Gomphrena celosioides</i> Mart.	Aerial parts	[78, 81, 157]
		<i>Gomphrena elegans</i> Mart.	Leaves	[156]
Gallic acid derivatives				
157	Ellagic acid	<i>Alternanthera sessilis</i>	Whole plant	[133]
158	Syringic acid	<i>Alternanthera philoxeroides</i>	Leaves	[38, 141]
Coumarins				
159	7-Methoxycoumarin	<i>Alternanthera caracasana</i>	Aerial parts	[33]
Lignans				
160	Pinoresinol-4''-O- β -D-glucopyranoside	<i>Gomphrena celosioides</i>	Aerial parts	[92]
161	Tortoside A	<i>Gomphrena celosioides</i>	Aerial parts	[92]
Coumarinolignoids				
162	Cleomiscosin A	<i>Gomphrena celosioides</i> Mart.	Leaves	[84]
Phenylpropanoid				
163	3,4-Dihydroxyphenyl caffeate	<i>Froelichia floridana</i>	Whole plants	[72]
164	Safrole	<i>Alternanthera philoxeroides</i>	Leaves	[141]
Phenylpropanoid glycosides				
165	β -D-(1-O-acetyl-3,6-O- <i>p</i> -E-dicoumaroyl)-fructofuranosyl- α -D-(4'-O-acetyl-2'-O- <i>p</i> -E-coumaroyl)-glucopyranoside	<i>Froelichia floridana</i>	Whole plants	[72]
Sesquiterpene phenol				
166	Dictyoceratin C	<i>Gomphrena celosioides</i> Mart.	Leaves	[84]
Other phenolic compounds				
167	2-Ethyl-4,5-dimethylphenol	<i>Alternanthera sessilis</i>	Stems	[57]
168	Hydrangeifolin I	<i>Gomphrena celosioides</i>	Aerial parts	[92]
169	Hydroxytyrosol	<i>Alternanthera littoralis</i> P. Beauv.	Aerial parts	[8]
170	2-Phenylethyl β -primeveroside	<i>Gomphrena celosioides</i>	Aerial parts	[92]
171	2-Phenylethyl β -rutinoside	<i>Gomphrena celosioides</i>	Aerial parts	[92]

(Continues)
21 of 133

TABLE 2 | (Continued)

No.	Compound	Species	Parts of plant	References
172	Salicylic acid	<i>Alternanthera philoxeroides</i>	Leaves	[38, 141]
		<i>Gomphrena agrestis</i>	Roots and leaves	[139]
173	Tannic acid	<i>Alternanthera philoxeroides</i>	Whole plant	[132]

TABLE 3 | Terpenoids compounds isolated from the Gomphrenoideae subfamily.

No.	Compound	Species	Parts of plant	References
Monoterpenes				
174	Linalool	<i>Gomphrena virgata</i>	Whole plant	[101]
175	(-)-Loliolide	<i>Alternanthera brasiliiana</i>	Aerial parts	[22]
176	Myrcene	<i>Alternanthera philoxeroides</i>	Leaves	[141]
177	Neryl acetone	<i>Alternanthera brasiliiana</i>	Aerial parts	[22]
Monoterpene glycoside				
178	(+)-Angelicoidenol-2-O- β -D-glucopyranoside	<i>Pfaffia paniculata</i> Kuntze	Roots	[123]
Sesquiterpenes				
179	11,12 Acetonide of 11,12,13-trihydroxydrimene	<i>Tidestromia oblongifolia</i>	Aerial parts	[128]
180	α -Amorphene	<i>Gomphrena virgata</i>	Whole plant	[101]
181	Aromadendrene	<i>Gomphrena virgata</i>	Whole plant	[101]
182	δ -Cadinene	<i>Gomphrena virgata</i>	Whole plant	[101]
183	α -Cadinol	<i>Gomphrena virgata</i>	Whole plant	[101]
184	<i>cis</i> -Calamenene	<i>Gomphrena virgata</i>	Whole plant	[101]
185	β -Caryophyllene	<i>Gomphrena virgata</i>	Whole plant	[101]
186	β -Elemene	<i>Gomphrena virgata</i>	Whole plant	[101]
187	Ilimaquinone	<i>Gomphrena celosioides</i> Mart.	Leaves	[84]
188	α -Ionone	<i>Alternanthera sessilis</i>	Leaves	[63]
189	α -Muurolene	<i>Gomphrena virgata</i>	Whole plant	[101]
190	Neodactyloquinone	<i>Gomphrena celosioides</i> Mart.	Leaves	[84]
191	Nerolidol	<i>Gomphrena virgata</i>	Whole plant	[101]
192	Polygodial	<i>Tidestromia oblongifolia</i>	Aerial parts	[128]
193	β -Selinene	<i>Gomphrena virgata</i>	Whole plant	[101]
194	11,12,13-Trihydroxydrimene	<i>Tidestromia oblongifolia</i>	Aerial parts	[128]
195	3 β ,7 α ,14-Trihydroxy- Δ ^{8,9} -drimen-11,12-olide	<i>Iresine diffusa</i>	Aerial parts	[105]
196	3 β ,7 β ,14-Trihydroxy- Δ ^{8,9} -drimen-11,12-olide	<i>Iresine diffusa</i>	Aerial parts	[105]
197	6,10,14-Trimetil-2-pentadecanone or phytone	<i>Alternanthera sessilis</i>	Stems	[57]
		<i>Gomphrena virgata</i>	Whole plant	[101]
Diterpenoids				
198	Fitone	<i>Alternanthera brasiliiana</i>	Aerial parts	[22]
		<i>Alternanthera sessilis</i>	Leaf	[158]
199	Gibberellin	<i>Alternanthera sessilis</i>	Stems	[56]

(Continues)

TABLE 3 | (Continued)

No.	Compound	Species	Parts of plant	References
200	Jatropone	<i>Gomphrena elegans</i> Mart.	Leaves	[156]
201	Neophytadiene	<i>Alternanthera brasiliiana</i>	Aerial parts	[22]
		<i>Alternanthera sessilis</i>	Stems	[57, 158]
202	Phytol	<i>Alternanthera bettzickiana</i>	—	[19]
		<i>Alternanthera brasiliiana</i>	Aerial parts	[22]
		<i>Alternanthera philoxeroides</i>	—	[41]
		<i>Alternanthera sessilis</i>	Stems and leaves	[57, 158]
Triterpenes				
203	α -Amyrin	<i>Alternanthera brasiliiana</i>	Aerial parts and whole plant	[22, 23]
		<i>Alternanthera maritima</i>	Aerial parts	[138]
204	α -Amyrin acetate	<i>Alternanthera brasiliiana</i>	Whole plant	[23]
		<i>Alternanthera maritima</i>	Aerial parts	[138]
205	α -Amyrin-3-O- β -D-glucopyranoside	<i>Iresine diffusa</i>	Aerial parts	[105]
206	β -Amyrin	<i>Alternanthera brasiliiana</i>	Aerial parts and whole plant	[22, 23]
		<i>Alternanthera maritima</i>	Aerial parts	[138]
207	β -Amyrin-3-O- β -D-glucopyranoside	<i>Iresine diffusa</i>	Aerial parts	[105]
208	Azadirachtin	<i>Alternanthera sessilis</i>	Whole plant	[149]
209	Calenduloside E 6'-methyl ester	<i>Pfaffia paniculata</i> Kuntze	Roots	[123]
210	Epitaraxerol	<i>Gomphrena globosa</i>	—	[156]
211	Friedelin	<i>Alternanthera brasiliiana</i>	Whole plant	[23]
		<i>Alternanthera maritima</i>	Aerial parts	[138]
212	Glomeric acid	<i>Pfaffia glomerata</i>	Roots	[154]
		<i>Pfaffia paniculata</i>	—	[159]
213	Gypsogenic acid	<i>Pfaffia glomerata</i>	Roots	[115]
214	Handianol	<i>Alternanthera sessilis</i>	—	[64]
215	16 β -Hydroxyl-3-oxo-akebonoic acid	<i>Pfaffia glomerata</i>	Roots	[115]
216	16 β -Hydroxyl-3-oxo-akebonoic acid 28-O- β -D-glucopyranoside	<i>Pfaffia glomerata</i>	Roots	[115]
217	Lupeol	<i>Alternanthera sessilis</i>	Leaves	[62, 158]
218	Lupeol acetate	<i>Alternanthera brasiliiana</i>	Whole plant	[23]
		<i>Alternanthera maritima</i>	Aerial parts	[138]
219	Mesembryanthemoidigenic acid	<i>Pfaffia paniculata</i> Kuntze	Roots	[123]
220	24-Methylenecycloartanol	<i>Alternanthera philoxeroides</i>	—	[41]
		<i>Alternanthera sessilis</i>	—	[64]
221	Oleanolic acid	<i>Alternanthera philoxeroides</i>	—	[41]
		<i>Alternanthera sessilis</i>	—	[64]
		<i>Pfaffia glomerata</i>	Roots	[115, 160]
		<i>Pfaffia paniculata</i>	—	[159]
222	Oleanolic acid 28-O- β -D-glucopyranoside	<i>Pfaffia paniculata</i> Kuntze	Roots	[123]
223	Oleanonic acid	<i>Alternanthera philoxeroides</i>	Aerial parts	[38]
		<i>Pfaffia glomerata</i>	Inflorescences	[154]

(Continues)

TABLE 3 | (Continued)

No.	Compound	Species	Parts of plant	References
224	3-Oxo-akebonoic acid	<i>Pfaffia glomerata</i>	Roots	[115]
225	Pfaffianol A	<i>Pfaffia glomerata</i>	Roots	[161]
226	Pfaffic acid	<i>Hebanthe eriantha</i>	Roots	[122]
		<i>Hebanthe paniculata</i>	—	[121]
		<i>Pfaffia glomerata</i>	Roots	[112]
		<i>Pfaffia paniculata</i> Kuntze	Roots	[123, 125]
227	Pfaffine A	<i>Pfaffia paniculata</i> Kuntze	Roots	[123]
		<i>Pfaffia glomerata</i>	Roots and aerial parts	[162]
228	Pfaffine B	<i>Pfaffia paniculata</i> Kuntze	Roots and aerial parts	[4, 123]
229	Pfameric acid	<i>Pfaffia glomerata</i>	Roots	[154]
		<i>Pfaffia paniculata</i> Kuntze	Roots	[123]
230	Serratagenic acid	<i>Pfaffia glomerata</i>	Roots	[115]
231	Squalene	<i>Gomphrena agrestis</i>	Roots and leaves	[139]
		<i>Gomphrena elegans</i> Mart.	Leaves and stem	[156]
232	Taraxerone	<i>Gomphrena globosa</i>	—	[156]
233	Taraxerol	<i>Gomphrena globosa</i>	—	[156]
Triterpenoid saponins				
234	Akebonoic acid	<i>Pfaffia glomerata</i>	Roots	[161]
235	Boussingoside A ₂	<i>Pfaffia glomerata</i>	Aerial parts and roots	[4]
236	Calenduloside E	<i>Alternanthera philoxeroides</i>	Whole plant	[38, 41]
		<i>Pfaffia glomerata</i>	Roots	
237	Chikusetsusaponin IV	<i>Pfaffia glomerata</i>	Inflorescences	[154]
238	Chikusetsusaponin IVa	<i>Alternanthera philoxeroides</i>	Aerial parts and whole plant	[4, 41]
		<i>Pfaffia glomerata</i>	Roots	[115, 163]
239	2 α ,3 β -Dihydroxyurs-12,20(30)-diene-28-oic acid-3- α -L-arabinopyranosyl-(1 \rightarrow 2)-[β -D-xylopyranosyl-(1 \rightarrow 3)]- β -D-glucopyranosyl	<i>Alternanthera repens</i>	Aerial parts	[4]
240	2 α ,3 β -Dihydroxyurs-12,20(30)-diene-28-oic acid-3- β -D-glucopyranosyl-(1 \rightarrow 2)- α -L-arabinopyranosyl-(1 \rightarrow 2)-[β -D-xylopyranosyl-(1 \rightarrow 3)]- β -D-glucuronopuranside	<i>Alternanthera repens</i>	Aerial parts	[4]
241	2 α ,3 β -Dihydroxyurs-12,20(30)-diene-28-oic acid-3- β -D-quinovopyranosyl-(1 \rightarrow 2)- α -L-arabinopyranosyl-(1 \rightarrow 2)-[β -D-xylopyranosyl-(1 \rightarrow 3)]- β -D-glucopyranosyl	<i>Alternanthera repens</i>	Aerial parts	[4]
242	2 α ,3 β -Dihydroxyurs-12,20(30)-diene-28-oic acid-3- β -D-xylopyranosyl-(1 \rightarrow 3)- β -D-glucopyranosyl	<i>Alternanthera repens</i>	Aerial parts	[4]
243	11 α ,12 α -epoxy-3 β -[(O- β -D-galactopyranosyl-(1 \rightarrow 3)-O-[β -D-glucopyranosyl-(1 \rightarrow 2)]- β -D-glucuronopyranosyl)-oxy]olean-28,13-olide	<i>Gomphrena macrocephala</i>	Roots	[99]

(Continues)

TABLE 3 | (Continued)

No.	Compound	Species	Parts of plant	References
244	11 α ,12 α -Epoxy-3 β -[(<i>O</i> - β -D-glucuronopyranosyl)oxy]olean-28,13-olide	<i>Gomphrena macrocephala</i>	Roots	[99]
245	11 α ,12 α -Epoxy-3 β -[(<i>O</i> - β -D-glucuronopyranosyl)oxy]taraxer-14-en-28-oic acid β -D-glucopyranosyl ester	<i>Gomphrena macrocephala</i>	Roots	[99]
246	11 α ,12 α -Epoxy-3 β -hydroxyolean-28,13-olide	<i>Gomphrena macrocephala</i>	Roots	[99]
247	11 α ,12 α -Epoxy-3 β -hydroxytaraxer-14-en-28-oic acid	<i>Gomphrena macrocephala</i>	Roots	[99]
248	Ginsenoside R ₀	<i>Pfaffia glomerata</i>	Inflorescences	[154]
249	3 β - <i>O</i> -(β -D glucopyranosyluronic acid) 28- <i>O</i> - β -D-Glucopyranosyl oleanolic acid	<i>Alternanthera sessilis</i>	—	[64]
250	Gomphrenoside	<i>Gomphrena globosa</i>	Aerial parts	[4]
251	Oleanolic acid-3- β -D-glucopyranosyl	<i>Alternanthera philoxeroides</i>	Aerial parts	[4]
252	Oleanolic acid 3- <i>O</i> - β -D-glucuronopyranoside	<i>Alternanthera philoxeroides</i>	—	[39]
253	Pfaffiaglycoside A	<i>Pfaffia glomerata</i>	Aerial parts and roots	[4, 161]
254	Pfaffiaglycosides B	<i>Pfaffia glomerata</i>	Aerial parts and roots	[4, 161, 163]
255	Pfaffoside A	<i>Hebanthe eriantha</i> <i>Hebanthe paniculata</i> <i>Pfaffia glomerata</i> <i>Pfaffia paniculata</i>	Roots Roots Roots Roots	[126] [121] [112] [125]
256	Pfaffoside B	<i>Hebanthe eriantha</i> <i>Hebanthe paniculata</i> <i>Pfaffia glomerata</i> <i>Pfaffia paniculata</i>	Roots Roots Roots Roots	[126] [121] [112] [125]
257	Pfaffoside C	<i>Hebanthe eriantha</i> <i>Hebanthe paniculata</i> <i>Pfaffia glomerata</i> <i>Pfaffia paniculata</i>	Roots Roots Roots Roots	[126] [121] [161] [125]
258	Pfaffoside D	<i>Hebanthe eriantha</i> <i>Hebanthe paniculata</i> <i>Pfaffia glomerata</i> <i>Pfaffia paniculata</i>	Roots Roots Roots Roots	[126] [121] [112] [164]
259	Pfaffoside E	<i>Hebanthe eriantha</i> <i>Hebanthe paniculata</i> <i>Pfaffia glomerata</i> <i>Pfaffia paniculata</i>	Roots Roots Roots Roots	[126] [121] [112] [164]
260	Pfaffoside F	<i>Hebanthe eriantha</i> <i>Hebanthe paniculata</i> <i>Pfaffia glomerata</i> <i>Pfaffia paniculata</i>	Roots Roots Roots Roots	[126] [121] [112] [164]

(Continues)

TABLE 3 | (Continued)

No.	Compound	Species	Parts of plant	References
261	Philoxeroideside A	<i>Alternanthera philoxeroides</i>	Aerial parts	[37]
262	Philoxeroideside B	<i>Alternanthera philoxeroides</i>	Aerial parts	[37]
263	Philoxeroideside C	<i>Alternanthera philoxeroides</i>	Aerial parts	[37]
264	Philoxeroideside D	<i>Alternanthera philoxeroides</i>	Aerial parts	[37]
Carotenoids				
265	Astaxanthin	<i>Alternanthera sessilis</i>	Whole plant	[149]
266	β -Carotene	<i>Alternanthera sessilis</i>	—	[64]
267	Dihydroactinidiolide	<i>Alternanthera brasiliiana</i>	Aerial parts	[22]
		<i>Alternanthera sessilis</i>	Leaf	[158]
		<i>Gomphrena elegans</i> Mart.	Leaves	[156]
Drimene				
268	3 β ,14-Dihydroxy- $\Delta^{7,8}$ -drimen-11,12-acetonide	<i>Iresine diffusa</i>	Aerial parts	[105]

var. *oblongifolia* (S. Watson) Sanch.Pino & Flores Oliv.) (179, 192, 194, 391, 408, 410).

However, no studies have been conducted on the phytochemical profile of species within the genera *Froelichiella*, *Guilleminea*, *Hebanthodes*, *Pedersenina*, *Pseudoplantago*, *Quaternella*, and *Xerosiphon*, leaving them chemically unexplored.

Determining the chemical profile of a plant is crucial, as it allows for the deduction of its biological activity, safety, and toxicity. Additionally, it facilitates the study of how internal and external factors influence the production of secondary metabolites and, consequently, biological activity. Research has demonstrated that plants of the same species collected from different locations or at different times, as well as subspecies, can exhibit different phytochemical profiles.

In accordance with the above, it is also worth mentioning that in many cases, the compounds identified in the chemical profile of a plant are produced by its endophytic microorganisms or by the interaction plant-microorganisms. This association has become a new area of multidisciplinary research of high biotechnological interest.

It is important to emphasize that, to date, there are no studies that evaluate the effect of biotic and abiotic factors on the chemical profile of the members of this subfamily. Additionally, there are no reports on the endophytic communities present in these plants and their effect on the production of secondary metabolites.

4.1 | Phenolic Compounds

Phenolic compounds are the most numerous and ubiquitously distributed group of secondary plant metabolites [73]. This group includes all substances that contain phenolic functions linked to aromatic or aliphatic structures [187].

These compounds exhibit a broad range of biological effects mainly related to their antioxidant capacity due to the presence of hydrogen-donating hydroxyl groups [73, 77, 90, 188]. Previous studies have reported that these compounds inhibit cellular DNA mutagenicity and possess antimicrobial and anti-inflammatory activities [73, 85, 188].

To date, 173 phenolic compounds have been isolated from the Gomphrenoideae subfamily. In this review, these compounds have been classified into two categories: flavonoids and their glycosides (1–133) and non-flavonoid phenolic compounds (134–173), as detailed in Sections 4.1.1 and 4.1.2, Table 2, and Figure 1.

Some of these compounds have been subjected to in vivo and in vitro studies to evaluate their biological activity, aiming to propose them as potential therapeutic agents for various diseases.

In terms of antimicrobial activity, compounds 5,7-dihydroxy-3,6-dimethoxyflavone (6), oroxilin A (7), baicalein 5,6-dimethyl ether (9), 3,5-dimethoxy-6,7-methylenedioxyflavone (10), and 3,5,6,7-tetramethoxyflavone (17) were evaluated against *Mycobacterium phlei*, *Staphylococcus aureus* ATTC 12600, and *Enterococcus faecalis* ATCC 19433. All were more active against *M. phlei*, with compounds 6 and 7 presenting the highest activity, with an MIC of 15 μ g/mL [75]. Likewise, these compounds were evaluated against *Aspergillus niger*, *Candida albicans*, and *Saccharomyces cerevisiae* at concentrations of 125–4000 μ g/mL and showed MICs ranging from 250 to 1000 μ g/mL [75]. Compounds kaempferol (20), quercetin (24), quercetin 3-methyl ether (3-methoxy quercetin) (25), acacetin 8-C-[α -L-rhamnopyranosyl-(1 \rightarrow 2)- β -D-glucopyranoside (34), 2''-O- β -D-glucopyranosyl-vitexin (43), 2''-O-rhamnopyranosyl-vitexin (72), and vitexin (88) were assessed against 15 gram-positive and 4 gram-negative bacteria, 7 yeast, and 4 dermatophytes at concentrations of 50–500 μ g/mL. All these compounds showed activity against at least 3 microorganisms, with compound 24 showing the broadest spectrum, exhibiting activity against 19 of the 30 microorganisms evaluated [142].

TABLE 4 | Alkaloid compounds isolated from the Gomphrenoideae subfamily.

No.	Compound	Species	Parts of plant	References
Guanidine alkaloids				
269	Celosiadine A	<i>Iresine diffusa</i>	Aerial parts	[165]
270	Celosiadine B	<i>Iresine diffusa</i>	Aerial parts	[165]
Indole alkaloid				
271	Bruceolline F	<i>Gomphrena celosioides</i> Mart.	Leaves	[84]
272	β -Carboline	<i>Alternanthera philoxeroides</i>	Leaves	[42]
Pyridine alkaloids				
273	Trigonelline	<i>Iresine herbstii</i>	—	[111]
Alkaloids with phenethylamine nucleus				
274	Alternamide A (7,8-dihydroxy-1,2,4,5-tetrahydro-3H-1,5-ethano[c]azepin-3-one)	<i>Alternanthera littoralis</i> P. Beauv.	Aerial parts	[8]
275	Alternamide B (6,7-dihydroxy-3,4-dihydroquinoline-1-one)	<i>Alternanthera littoralis</i> P. Beauv.	Aerial parts	[8]
Betalains				
Amaranthin group (betacyanins)				
276	Amaranthine (previously named amaranthin)	<i>Alternanthera betzickiana</i>	Leaves	[166]
		<i>Alternanthera brasiliana</i>	Leaves	[27, 28]
		<i>Alternanthera ficoidea</i>	Leaves	[166]
		<i>Alternanthera tenella</i>	Leaves and stems	[28]
		<i>Gomphrena globosa</i>	Petals and inflorescences	[29, 166–168]
		<i>Iresine herbstii</i>	Leaves	[110, 111]
		<i>Iresine lindenii</i>	Leaves	[169]
277	Celosianin I	<i>Alternanthera betzickiana</i>	Leaves	[166]
278	Celosianin II or celosianin	<i>Alternanthera betzickiana</i>	Leaves	[166]
		<i>Gomphrena globosa</i>	Red petals and red flowers	[29, 167, 170]
		<i>Iresine herbstii</i>	Leaves	[110]
		<i>Iresine lindenii</i>	Leaves	[169]
279	17-Decarboxy-amaranthin	<i>Gomphrena globosa</i>	Red petals and red flowers	[29, 150, 167, 171]
280	17-Decarboxy-isoamaranthine	<i>Gomphrena globosa</i>	Red inflorescences	[29, 170]
281	2 ^{'''} -O-E-Feruloyl-iresinin or (2 ^{'''} -O-E-feruloyl)-iresinin I	<i>Iresine herbstii</i>	Leaves	[110, 169]

TABLE 4 | (Continued)

No.	Compound	Species	Parts of plant	References
		<i>Iresine lindenii</i>	Leaves	[169]
282	2 ^{'''} -O-E-Feruloyl-isoiresinin or (2 ^{'''} -O-E-Feruloyl)-isoiresinin I	<i>Iresine herbstii</i>	Leaves	[110]
		<i>Iresine lindenii</i>	Leaves	[169]
283	Iresin	<i>Iresine celosia</i>	Aerial parts	[104]
		<i>Iresine diffusa</i>	Aerial parts	[105]
284	Iresinin previously named iresinin I	<i>Alternanthera brasiliiana</i>	Leaves	[27]
		<i>Iresine herbstii</i>	Leaves	[110, 111, 166, 172]
		<i>Iresine lindenii</i>	Leaves	[169]
285	Iresinin II (=isoiresinine I)	<i>Iresine herbstii</i>	Leaves	[110, 111, 166]
		<i>Iresine lindenii</i>	Leaves	[169]
286	Iresinin III	<i>Iresine herbstii</i>	—	[111]
287	Iresinin IV	<i>Iresine herbstii</i>	—	[111]
288	Isoamaranthine (Isoamaranthin)	<i>Alternanthera betzickiana</i>	Leaves	[166]
		<i>Alternanthera brasiliiana</i>	Leaves	[27, 28]
		<i>Alternanthera ficoidea</i>	Leaves	[166]
		<i>Alternanthera tenella</i> Colla	Leaves and stems	[28]
		<i>Gomphrena globosa</i>	Red and orange petals	[29, 167]
		<i>Iresine herbstii</i>	Leaves	[110, 111, 166]
		<i>Iresine lindenii</i>	Leaves	[169]
289	Isocelosianin or isocelosianin II or (2 ^{''} -O-E-sinapoyl)-amaranthine or lindenin	<i>Alternanthera betzickiana</i>	Leaves	[166]
		<i>Gomphrena globosa</i>	Red petals and red flowers	[29, 170]
		<i>Iresine herbstii</i>	Leaves	[110]
		<i>Iresine lindenii</i>	Leaves	[169]
290	Sinapoyl-amaranthin	<i>Gomphrena globosa</i>	Red petals and red flowers	[29, 167, 170]
291	2 ^{'''} -O-E-sinapoyl-iresinin or (2 ^{'''} -O-E-sinapoyl)-iresinin I	<i>Iresine herbstii</i>	Leaves	[110]
		<i>Iresine lindenii</i>	Leaves	[169]
292	(2 ^{''} -O-E-Sinapoyl)-isoamaranthine or Isolindenin	<i>Iresine herbstii</i>	Leaves	[110]
		<i>Iresine lindenii</i>	Leaves	[169]
293	2 ^{'''} -O-E-sinapoyl-isoiresinin or (2 ^{'''} -O-E-sinapoyl)-isoiresinin I	<i>Iresine herbstii</i>	Leaves	[110]
		<i>Iresine lindenii</i>	Leaves	[169]
Betanin group (betacyanins)				
294	Betanidin	<i>Gomphrena globosa</i>	Red and purple petals	[29]

(Continues)

TABLE 4 | (Continued)

No.	Compound	Species	Parts of plant	References
295	Betanin	<i>Alternanthera betzickiana</i>	Leaves	[166]
		<i>Alternanthera brasiliana</i>	Leaves and stems	[27, 28]
		<i>Alternanthera ficoidea</i>	Leaves	[166]
		<i>Alternanthera tenella</i> Colla	Leaves and stems	[28]
		<i>Gomphrena globosa</i>	Red petals	[29, 167]
		<i>Iresine herbstii</i>	Leaves	[110]
		<i>Iresine lindenii</i>	Leaves	[169]
296	Isobetanidin	<i>Gomphrena globosa</i>	Purple petals	[29, 167]
297	Isobetanin	<i>Alternanthera betzickiana</i>	Leaves	[166]
		<i>Alternanthera brasiliana</i>	Leaves and stems	[28]
		<i>Alternanthera ficoidea</i>	Leaves	[166]
		<i>Alternanthera tenella</i> Colla	Leaves and stems	[28]
		<i>Gomphrena globosa</i>	Red petals	[29, 167]
		<i>Iresine herbstii</i>	Leaves	[110]
		<i>Iresine lindenii</i>	Leaves	[169]
Gomphrenin group (betacyanins)				
298	<i>cis</i> -Isomer of gomphrenin II	<i>Gomphrena globosa</i>	Purple flower	[167, 168, 173]
299	<i>cis</i> -Isomer of gomphrenin III	<i>Gomphrena globosa</i>	Pigmented floral parts from the inflorescences	[167, 168, 173, 174]
300	<i>cis</i> -Isomer of isogomphrenin II	<i>Gomphrena globosa</i>	Purple petals	[167]
301	<i>cis</i> -Isomer of isogomphrenin III	<i>Gomphrena globosa</i>	Purple petals	[167]
302	Gomphrenin	<i>Gomphrena celosioides</i>	—	[84]
		<i>Gomphrena globosa</i>	Flowers, bract, and bracteoles	[29, 175]
303	Gomphrenin I	<i>Gomphrena globosa</i>	Pigmented floral parts from the inflorescences	[94, 98, 166, 168, 173, 174, 176]
304	Gomphrenin II or globosin	<i>Gomphrena globosa</i>	Pigmented floral parts from the inflorescences	[94, 98, 150, 166–168, 173, 174, 176]
		<i>Iresine herbstii</i>	Leaves	[110]

(Continues)

TABLE 4 | (Continued)

No.	Compound	Species	Parts of plant	References
305	Gomphrenin III or basellin	<i>Gomphrena globosa</i>	Pigmented floral parts from the inflorescences	[94, 98, 150, 166–168, 173, 174, 176]
		<i>Iresine herbstii</i>	Leaves	[110]
		<i>Iresine lindenii</i>	Leaves	[169]
306	Gomphrenin IV	<i>Gomphrena globosa</i>	Inflorescences	[175]
307	Isogomphrenin	<i>Gomphrena globosa</i>	Flowers	[175]
308	Isogomphrenin I	<i>Gomphrena globosa</i>	Pigmented floral parts from the inflorescences	[94, 98, 166, 168, 173, 174, 176]
309	Isogomphrenin II or Isoglobosin	<i>Gomphrena globosa</i>	Inflorescence	[29, 94, 98, 150, 166–168, 176]
		<i>Iresine herbstii</i>	Leaves	[110]
310	Isogomphrenin III or isobasellin	<i>Gomphrena globosa</i>	Pigmented floral parts from the inflorescences, bract, and bracteoles	[29, 94, 98, 150, 166–168, 173, 174, 176–]
		<i>Iresine herbstii</i>	Leaves	[110]
		<i>Iresine lindenii</i>	Leaves	[169]
311	Isosinapoyl-gomphrenin I or isogandolin	<i>Gomphrena globosa</i>	Purple flowers	[173]
		<i>Iresine herbstii</i>	Leaves	[110]
312	Sinapoyl-gomphrenin I or gandolin	<i>Gomphrena globosa</i>	Inflorescence	[94, 98, 167, 168, 173]
		<i>Iresine herbstii</i>	Leaves	[110]
313	Sinapoyl-isogomphrenin I	<i>Gomphrena globosa</i>	Inflorescence	[94, 98, 167, 168]
Other betalains				
314	Hylocerenin	<i>Iresine herbstii</i>	Leaves	[110]
		<i>Iresine lindenii</i>	Leaves	[169]
315	Isohylocerenin	<i>Iresine lindenii</i>	Leaves	[169]
Betaxanthins				
316	Arginine-betaxanthin	<i>Gomphrena globosa</i>	Red petals	[29, 167]
317	Dopamine-betaxanthine	<i>Alternanthera brasiliana</i>	Leaves and stems	[28]
		<i>Alternanthera tenella</i> Colla	Leaves and stems	[28]
318	Glutamine-betaxanthin (vulgaxanthin I)	<i>Gomphrena globosa</i>	Red petals	[29, 167]
319	Histidine-betaxanthin (muscaarin VII)	<i>Gomphrena globosa</i>	Red petals	[29, 167]
320	Isoleucine-betaxanthin	<i>Gomphrena globosa</i>	Red petals	[29, 167]
321	Lysine-betaxanthin	<i>Gomphrena globosa</i>	Red petals	[29, 167]

(Continues)

TABLE 4 | (Continued)

No.	Compound	Species	Parts of plant	References
322	3-Methoxytyramine-betaxanthin	<i>Alternanthera brasiliiana</i>	Leaves and stems	[28]
		<i>Alternanthera tenella</i> Colla	Leaves and stems	[28]
323	Tryptophan-betaxanthin	<i>Gomphrena globosa</i>	Red petals	[29, 167]
Other alkaloids				
324	Alternamine A ((R)-1-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol)	<i>Alternanthera littoralis</i> P. Beauv.	Aerial parts	[8]
325	Alternamine B (4-(2-aminoethyl)benzene-1,2-diol-4-(2-aminoethyl)benzene-1,2-diol-b-D-glucopyranose)	<i>Alternanthera littoralis</i> P. Beauv.	Aerial parts	[8]
326	Aurantiamide	<i>Gomphrena celosioides</i> Mart.	Whole plant	[83–85, 89]
327	Aurantiamide acetate	<i>Gomphrena agrestis</i> <i>Gomphrena celosioides</i> Mart.	Whole plant Whole plant	[2] [83, 85, 89]
328	N-(3,4-dihydroxyphenethyl)formamide	<i>Alternanthera littoralis</i> P. Beauv.	Aerial parts	[8]
329	N-feruloyl-tyramine	<i>Iresine herbstii</i>	—	[111]
330	Pyrimidine-2,4 (1H, 3H)-dione (uracil)	<i>Gomphrena elegans</i> Mart.	Leaves, roots, and stem	[156]

Compounds (*E*)-3'-*O*- β -D-glucopyranosyl-4,5,6,4'-tetrahydroxy-7,2'-dimethoxyaurone (**33**) and kaempferol 3-*O*- β -D-(6-*O*-*p*-*E*-coumaroyl)-glucopyranoside (tiliroside) or kaempferol-3-*O*-(6-*p*-coumaroyl)-glucoside (**106**) were tested against 19 bacteria but only showed activity against four microorganisms in a concentration range of 0.02–0.5 mg/mL [2]. Compound 3,5,3'-trihydroxy-4'-methoxy-6,7-methylenedioxyflavone (**80**) was evaluated against 15 microorganisms and showed activity against 7 microorganisms, with the lowest MIC observed against *Streptococcus mutans* 11.22.1 (20 μ g/mL) and the highest in *S. aureus* ATCC 6538 (1250 μ g/mL) [151]. Compounds kaempferol (**20**), kaempferol-3-*O*-(6''-*O*-(*E*)-*p*-coumaroyl)- β -D-glucopyranoside (**107**), kaempferol-3-*O*-(6''-*O*-(*Z*)-*p*-coumaroyl)- β -D-glucopyranoside (**108**), and kaempferol 3-*O*- β -D-(6''-feruloyl)glucopyranoside (**109**) were evaluated against *Pseudomonas aeruginosa*. Among these, compound **20** showed the highest activity with an MIC of 0.008 mg/mL, which was lower than that of ceftriaxone sodium [144].

The compound vanillic acid (**156**) was evaluated against five (5) bacteria at a concentration of 0.2 mg/disc and showed activity against two (2) of these microorganisms [157]. The compound 7-methoxycoumarin (**159**), identified in *A. caracasana*, was evaluated in vitro for antimicrobial activity against *Bacillus subtilis*, *S. aureus* ATCC 12398, *Staphylococcus epidermidis*, *Sarcina lutea*,

and *Vibrio cholerae* No. 01 ATCC 35971, showing MIC between 0.5 and 0.75 mg/mL, highlighting that this compound demonstrated an MCB of 1 mg/mL against *V. cholerae* No. 01 ATCC 35971 [33].

Compounds chrysoeriol-6-C- β -D-boivinopyranoside (**39**), chrysoeriol-6-C- β -D-boivinopyranosyl-4'-*O*- β -D-glucopyranoside (**40**), luteolin-6-C- β -D-boivinopyranoside (**58**), luteolin-6-C- β -D-boivinopyranosyl-3'-*O*- β -D-glucopyranoside (**59**), and luteolin-6-C- β -D-boivinopyranosyl-4'-*O*- β -D-glucopyranoside (**60**) were evaluated for antiviral activity. It was evident that compounds **40**, **59**, and **60** blocked the secretion of HBsAg, as detailed in subsequent sections [40]. The compound (**80**) was evaluated as an antiparasitic against *Trypanosoma cruzi* and *Leishmania amazonensis* at concentrations between 4 and 500 μ g/mL, but they showed a low reduction in viability [151].

The results described show that the phenolic compounds exhibit antimicrobial activity at the laboratory level. Most were evaluated against bacteria, followed by yeasts, fungi, viruses, and, to a lesser extent, parasites, highlighting the potential of these compounds as a promising source of antimicrobials.

The isolated phenolic compounds of this subfamily have also been assessed for antioxidant activity. Compounds patuletin 3-*O*- β -D-glucopyranoside (**67**) and kaempferol-3-*O*-(6''-*O*-(*E*)-*p*-coumaroyl)- β -D-glucopyranoside (**106**), as well as a mixture of

TABLE 5 | Lipid compounds isolated from Gomphrenoideae subfamily.

No.	Compound	Species	Parts of plant	References
Fatty acids				
331	Arachidonic acid	<i>Alternanthera sessilis</i>	Whole plant	[149]
332	Butyl hexadecanoate	<i>Gomphrena elegans</i> Mart.	Leaves	[156]
333	Ethyl linolenate	<i>Gomphrena elegans</i> Mart.	Leaves, root, and stem	[156]
334	Ethyl linoleolate	<i>Gomphrena elegans</i> Mart.	Leaves, root, and stem	[156]
335	Ethyl palmitate or ethyl hexadecanoate	<i>Alternanthera brasiliiana</i>	Whole plant	[23]
		<i>Alternanthera sessilis</i>	Stems	[56]
		<i>Gomphrena elegans</i> Mart.	Leaves, root, and stem	[156]
336	Hexadecanoate	<i>Pfaffia glomerata</i>	Roots	[177]
		<i>Alternanthera sessilis</i>	Stems	[56]
		<i>Alternanthera brasiliiana</i>	Stems	[32]
337	(8E)-10-Hydroxy-8-octadecenoic acid	<i>Alternanthera brasiliiana</i>	Stems	[32]
338	(10E)-9-Hydroxy-10-octadecenoic acid	<i>Alternanthera brasiliiana</i>	Stems	[32]
339	(8E,12Z)-10-Hydroxy 8,12-octadecadienoic acid	<i>Alternanthera brasiliiana</i>	Stems	[32]
340	(9Z,11E)-13-Hydroxy-9,11-octadecadienoic acid	<i>Alternanthera brasiliiana</i>	Stems	[32]
341	(9Z,11E,15Z)-13-Hydroxy-9,11,15-octadecatrienoic acid	<i>Alternanthera brasiliiana</i>	Stems	[32]
342	(9Z,12Z,14E)-16-Hydroxy-9,12,14-octadecatrienoic acid	<i>Alternanthera brasiliiana</i>	Stems	[32]
343	(9Z,13E)-12-Hydroxy-9,13-octadecadienoic acid	<i>Alternanthera brasiliiana</i>	Stems	[32]
344	(9Z,13E,15Z)-12-Hydroxy-9,13,15-octadecatrienoic acid	<i>Alternanthera brasiliiana</i>	Stems	[32]
345	(10E,12E)-9-Hydroxy-10,12-Octadecadienoic acid	<i>Alternanthera brasiliiana</i>	Stems	[32]
346	(10E,12Z)-9-Hydroxy-10,12-octadecadienoic acid	<i>Alternanthera brasiliiana</i>	Stems	[32]
347	Linoleic acid	<i>Alternanthera bettzickiana</i>	—	[19]
		<i>Alternanthera brasiliiana</i>	Aerial parts	[22]
348	Linoleic acid ethyl ester	<i>Alternanthera brasiliiana</i>	Aerial parts	[22]
349	Methyl linoleate or linoleic acid methyl ester	<i>Alternanthera sessilis</i>	Stems	[56]
		<i>Gomphrena elegans</i> Mart.	Leaves and stem	[156]
350	Methyl linolenate	<i>Gomphrena elegans</i> Mart.	Leaves and stem	[156]
351	Methyl palmitate or methyl hexadecanoate	<i>Gomphrena celosioides</i>	Roots	[157]
		<i>Gomphrena elegans</i> Mart.	Leaves, stem	[156]
		<i>Alternanthera sessilis</i>	Leaves	[158]
352	Methyl stearate	<i>Gomphrena elegans</i> Mart.	—	[156]

(Continues)

TABLE 5 | (Continued)

No.	Compound	Species	Parts of plant	References
353	Miristic acid	<i>Alternanthera brasiliana</i>	Aerial parts	[22]
		<i>Gomphrena agrestis</i>	Roots and leaves	[139]
354	(9Z)-9-octadecenedioic acid	<i>Alternanthera brasiliana</i>	Stems	[32]
355	Oleic acid	<i>Alternanthera brasiliana</i>	Whole plant	[23]
356	(7E)-9-oxo-7-octadecenoic acid	<i>Alternanthera brasiliana</i>	Stems	[32]
357	(8E)-10-oxo-8-octadecenoic acid	<i>Alternanthera brasiliana</i>	Stems	[32]
358	(9E,11E)-13-oxo-9,11-octadecadienoic acid	<i>Alternanthera brasiliana</i>	Stems	[32]
359	(9Z,11E)-13-oxo-9,11-octadecadienoic acid	<i>Alternanthera brasiliana</i>	Stems	[32]
360	(10E,12E)-9-oxo-10,12-octadecadienoic acid	<i>Alternanthera brasiliana</i>	Stems	[32]
361	(10E,12Z)-9-oxo-10,12-octadecadienoic acid	<i>Alternanthera brasiliana</i>	Stems	[32]
362	Palmitic acid	<i>Alternanthera brasiliana</i>	Aerial parts and whole plant	[22, 23]
		<i>Alternanthera sessilis</i>	Stems, leaves, and whole plant	[57, 149, 158]
		<i>Gomphrena elegans</i> Mart.	Leaves	[156]
363	Stearic acid	<i>Alternanthera brasiliana</i>	Aerial parts and whole plant	[22, 23]
Fatty alcohol				
364	1-Hexadecanol	<i>Gomphrena elegans</i> Mart.	Leaves and stem	[156]
Fatty amide				
365	Erucamide	<i>Alternanthera brasiliana</i>	Aerial parts	[22]

these two, were evaluated using the DPPH and ORAC assays, both compound **67** and the mixture exhibited relevant activity [127]. Compounds quercetin (**24**), quercetin 3-methyl ether (3-methoxy quercetin) (**25**), acacetin 8-C-[α -L-rhamnopyranosyl-(1 \rightarrow 2)- β -D-glucopyranoside (**34**), 2''-O- β -D-glucopyranosyl-vitexin (**43**), isorhamnetin 3-O- α -L-rhamnosyl-(1 \rightarrow 6)- β -D-glucopyranoside (**50**), 2''-O-rhamnopyranosyl-vitexin (**72**), and quercetin 3-O- α -L-rhamnosyl-(1 \rightarrow 6)- β -D-glucopyranoside (**129**) were evaluated using chemiluminescent assays, showing activity, with compounds **24** and **25** exhibiting greater activity [145]. Similarly, compounds **34**, **43**, **70**, and **88** were evaluated using ORAC, demonstrating their antioxidant potential, where compound **88** showed the best activity with 0.96 relative TE [143]. Although there have been few studies focused on studying the antioxidant potential of the phenolic compounds identified and isolated from this subfamily, the research conducted to date demonstrates that they are a promising source of antioxidant compounds.

Regarding cytotoxic activity against cancer cell lines, the mixture of compounds 5,7-dihydroxy-3,6-dimethoxyflavone (**6**), oroxilin A (**7**), 3,5-dimethoxy-6,7-methylenedioxyflavone (**10**), and 3,5,6,7-tetramethoxyflavone (**17**) presented an ED₅₀: 27.5 μ g/mL against KB cell [100]. The compounds alternanthin (**35**) and alternanthin B (**36**) were evaluated against HeLa cells at concentrations of 10 and 30 μ g/mL, showing inhibition percentages between 8.9% and 55.9% [36]. Likewise, the mixture of flavonoids (**6**, **7**, **10**, and **17**) was evaluated in vivo, resulting in an increase in the survival of the mice and a reduction in the size of the tumor [100].

Furthermore, compounds quercetin (**24**), quercetin 3-methyl ether (3-methoxy quercetin) (**25**), acacetin 8-C-[α -L-rhamnopyranosyl-(1 \rightarrow 2)- β -D-glucopyranoside (**34**), 2''-O- β -D-glucopyranosyl-vitexin (**43**), isorhamnetin 3-O- α -L-rhamnosyl-(1 \rightarrow 6)- β -D-glucopyranoside (**50**), 2''-O-rhamnopyranosyl-vitexin (**72**), and quercetin 3-O- α -L-rhamnosyl-(1 \rightarrow 6)- β -D-glucopyranoside (**129**) were evaluated as immunomodulators, and it was evidenced that at 50 μ mol/L, they do not induce significant release of LDH and are not cytotoxic against PMNL [145].

For some compounds, the effect on the nervous system has been evaluated. Compounds demethyltorosaf flavone D (**5**), alternanthin (**35**), alternanthin B (**36**), chrysoeriol 7-O-rhamnoside or chrysoeriol 7-rhamnoside (**41**), and torosaf flavone E (**79**) were evaluated as antidepressants and antedementia agents. In the first case, the inhibition of MAO-A and MAO-B enzymes was evaluated, whereas in the second, the reduction in β -amyloid ($A\beta$) aggregation was assessed. The authors report that the compounds were able to inhibit MAO-A and MAO-B, as well as reduce the formation of the $A\beta$ -aggregation, highlighting that compound **36** presents the greatest inhibition of toxic $A\beta$ plaques [38, 135]. These results show that the phenolic compounds isolated from this family also have promising activity in the nervous system.

Additionally, the analgesic and anti-inflammatory activity in vivo was evaluated for compounds 2''-O- β -D-glucopyranosyl-vitexin (**43**) and 2''-O-rhamnopyranosyl-vitexin (**72**). In both cases, the compounds inhibited hyperalgesia, edema formation,

TABLE 6 | Other compounds isolated from the Gomphrenoideae subfamily.

No.	Compound	Species	Parts of plant	References
Phytoecdysones				
366	Ecdysone	<i>Pfaffia glomerata</i>	Inflorescences, roots, and aerial parts	[154, 162, 163]
		<i>Pfaffia paniculata</i>	Roots	[123]
367	β -Ecdysone or 1 α ,20R-dihydroxyecdysone or ecdysterone or 20-hydroxyecdysone	<i>Froelichia floridana</i>	Seeds and whole plant	[72]
		<i>Gomphrena celosioides</i>	Roots and aerial parts	[133]
		<i>Gomphrena virgata</i>	Roots	[101]
		<i>Pfaffia glomerata</i>	Inflorescences, stems, roots, and aerial parts	[154, 159, 161, 162, 179–184]
		<i>Pfaffia paniculata</i> Kuntze	Roots	[123]
Phytoecdysteroids				
368	Achyranthesterone A	<i>Froelichia floridana</i>	Whole plants	[72]
369	Blechnoside B	<i>Froelichia floridana</i>	Whole plants	[72]
370.	2-Dehydro-3-epi-20-hydroxyecdysone	<i>Froelichia floridana</i>	Seeds	[182]
371	2,22-Dideoxyecdysone 25-O- β -D-glucopyranoside	<i>Froelichia floridana</i>	Whole plants	[72]
372	2,22-Dideoxyecdysone 25-O- β -D-glucopyranosyl-(1 \rightarrow 2)- β -D-glucopyranoside	<i>Froelichia floridana</i>	Whole plants	[72]
373	(5 α)-2,22-Dideoxyecdysone 25-O- β -D-glucopyranosyl-(1 \rightarrow 2)- β -D-glucopyranoside	<i>Froelichia floridana</i>	Whole plants	[72]
374	2,22-Dideoxy-20-hydroxyecdysone 25-O- β -D-glucopyranoside	<i>Froelichia floridana</i>	Whole plants	[72]
375	2,22-dideoxy-5 β -hydroxyecdysone 25-O- β -D-glucopyranosyl-(1 \rightarrow 2)- β -D-glucopyranoside	<i>Froelichia floridana</i>	Whole plants	[72]
376	β -Glucopyranosil oleanolate	<i>Pfaffia paniculata</i>	—	[159]
377	22-Oxo-20-hydroxyecdysone	<i>Pfaffia glomerata</i>	Roots	[161]
378	Pfaffiaglycoside C	<i>Pfaffia glomerata</i>	Roots	[161]
379	Pfaffiaglycoside D	<i>Pfaffia glomerata</i>	Roots	[161]
380	Pfaffiaglycoside E	<i>Pfaffia glomerata</i>	Roots	[161]
381	Pterosterone	<i>Pfaffia glomerata</i>	Roots	[161]
		<i>Pfaffia paniculata</i> Kuntze	Roots	[123]
382	Rapisterone	<i>Pfaffia paniculata</i> Kuntze	Roots	[123]
383	Rubrosterone	<i>Pfaffia glomerata</i>	Roots, aerial parts, and roots	[154, 162]
		<i>Pfaffia paniculata</i>	—	[159]
384	Taxisterone	<i>Pfaffia glomerata</i>	Roots	[161]
385	2 β ,3 β ,14 α ,17 β -Tetrahydroxy-5 β -androst-7-en-6-one	<i>Pfaffia glomerata</i>	Roots	[161]
Phytosterols				
386	Campesterol	<i>Alternanthera brasiliana</i>	Whole plant	[23]

(Continues)

TABLE 6 | (Continued)

No.	Compound	Species	Parts of plant	References
		<i>Alternanthera maritima</i>	Aerial parts	[138]
		<i>Alternanthera sessilis</i>	—	[62]
		<i>Alternanthera tenella</i> Colla	Whole plant	[142]
		<i>Blutaparon portulacoides</i>	Aerial parts	[148]
		<i>Gomphrena celosioides</i> Mart.	Aerial Parts	[78, 157]
		<i>Gomphrena globosa</i>	—	[156]
		<i>Pfaffia glomerata</i>	Roots	[177]
387	Campesterol	<i>Gomphrena celosioides</i> Mart.	Aerial parts	[81]
388	Cycloeucalenol	<i>Alternanthera philoxeroides</i>	—	[41]
		<i>Alternanthera sessilis</i>	—	[64]
389	3- β -Hydroxystigmast-5-en-7-one	<i>Alternanthera philoxeroides</i>	—	[41]
390	Sitostenone or β -sitostenone	<i>Alternanthera brasiliiana</i>	Aerial parts	[22]
		<i>Gomphrena elegans</i> Mart.	Leaves	[156]
391	Sitosterol or β -sitosterol	<i>Alternanthera brasiliiana</i>	Whole plant and leaves	[23, 28]
		<i>Alternanthera maritima</i>	Aerial parts	[138]
		<i>Alternanthera philoxeroides</i>	—	[41]
		<i>Alternanthera sessilis</i>	—	[62]
		<i>Alternanthera tenella</i> Colla	Whole plant	[142]
		<i>Blutaparon portulacoides</i>	Aerial parts	[148]
		<i>Gomphrena agrestis</i>	Roots and leaves	[139]
		<i>Gomphrena celosioides</i> Mart.	Aerial parts	[78, 81, 157]
		<i>Gomphrena elegans</i> Mart.	Leaves, roots, and stem	[156]
		<i>Gomphrena globosa</i>	—	[156]
		<i>Hebanthe paniculata</i>	—	[121]
		<i>Iresine diffusa</i>	Aerial parts	[105]
		<i>Pfaffia glomerata</i>	Roots	[112, 177]
		<i>Pfaffia paniculata</i>	Roots	[183]
		<i>Tidestromia oblongifolia</i>	Aerial parts	[128]
392	β -Sitosteryl- β -O-D-glucopyranoside	<i>Iresine diffusa</i>	Aerial parts	[105]
393	γ -Sitosterol	<i>Alternanthera brasiliiana</i>	Aerial parts	[22]
394.	Sitosterol glycoside or 3-O- β -D-glucopyranosyl β -sitosterol	<i>Alternanthera brasiliiana</i>	—	[32]
		<i>Alternanthera tenella</i> Colla	Whole plant	[142]
395	Sitosteryl	<i>Blutaparon portulacoides</i>	Roots	[148, 151]
396	Spinasterol or α -spinasterol	<i>Alternanthera brasiliiana</i>	Leaves and whole plant	[23, 28]
		<i>Alternanthera maritima</i>	Aerial parts	[138]
		<i>Alternanthera philoxeroides</i>	—	[41]
		<i>Alternanthera tenella</i> Colla	Whole plant	[142]
		<i>Alternanthera sessilis</i>	—	[64]
		<i>Pfaffia glomerata</i>	Roots	[177]
397	Δ^7 -Spinasterol	<i>Pfaffia glomerata</i>	Roots	[177]
398	β -Spinasterol	<i>Alternanthera sessilis</i>	—	[64]

(Continues)

TABLE 6 | (Continued)

No.	Compound	Species	Parts of plant	References
399	Spinasteryl β -D-glucopyranoside	<i>Blutaparon portulacoides</i>	Roots	[148]
400	5 α -Stigmasta-7,22-dien-3 β -ol	<i>Gomphrena elegans</i> Mart.	Leaves, roots, and stem	[156]
401	5 α -Stigmasta-enol	<i>Alternanthera sessilis</i>	—	[64]
402	5 α -Stigmasta-7-enol	<i>Alternanthera sessilis</i>	—	[184]
403	Stigmasta 4,6,22 trien-3- α -ol	<i>Alternanthera brasiliiana</i>	Whole plant	[23]
404	Stigmasta 4,7,22 trien-3- β -ol	<i>Alternanthera brasiliiana</i>	Whole plant	[23]
405	Δ^7 -Stigmastenol	<i>Pfaffia glomerata</i>	Roots	[177]
406	Stigmast-7-en-3-ol	<i>Alternanthera brasiliiana</i>	Aerial parts	[22]
407	Stigmast-7en-3 β -ol	<i>Alternanthera brasiliiana</i> <i>Alternanthera maritima</i>	Whole plant Aerial parts	[23] [138]
408	Stigmast-22-en-3 β -ol	<i>Tidestromia oblongifolia</i>	Aerial parts	[128]
409	Stigmast-7-enyl	<i>Blutaparon portulacoides</i>	Roots	[148]
410	Stigmasterol	<i>Alternanthera brasiliiana</i> <i>Alternanthera maritima</i> <i>Alternanthera sessilis</i> <i>Alternanthera tenella</i> Colla <i>Blutaparon portulacoides</i> <i>Gomphrena agrestis</i> <i>Gomphrena celosioides</i> Mart. <i>Gomphrena globosa</i> <i>Hebanthe paniculata</i> <i>Iresine diffusa</i> <i>Pfaffia glomerata</i> <i>Pfaffia paniculata</i> <i>Tidestromia oblongifolia</i>	Leaves and whole plant Aerial parts — Whole plant Aerial parts Roots and leaves Aerial parts and roots — — Aerial parts Roots Roots Aerial parts	[23, 28] [138] [62] [142] [148] [139] [78, 81, 157] [156] [121] [105] [177] [183] [128]
411	Δ^7 -Stigmasterol	<i>Alternanthera tenella</i> Colla	Whole plant	[142]
412	Stigmasteryl 3- β -O-glucoside 6'-O-palmitate	<i>Blutaparon portulacoides</i>	Roots	[151]
Phytosteroids				
413	4,6 Cholestadien-3-beta-ol	<i>Alternanthera brasiliiana</i>	Whole plant	[23]
Saponins				
414	3-O- β -D-glucopyranosyl spinasterol	<i>Alternanthera tenella</i> Colla	Whole plant	[142]
415	3-O- β -D-glucopyranosyl stigmasterol	<i>Alternanthera tenella</i> Colla	Whole plant	[142]
416	3-O- β -D-glucopyranosyl Δ^7 -stigmasterol	<i>Alternanthera tenella</i> Colla	Whole plant	[142]
417	Stigmast-6-en-3-O- β -(D-glicopiranoside)	<i>Gomphrena celosioides</i>	Roots	[157]
Aliphatic alcohols				
418	Triacantanol	<i>Iresine diffusa</i>	Aerial parts	[105]
Aliphatic hydrocarbons				
419	cis-Jasmone	<i>Gomphrena virgata</i>	Whole plant	[101]
420	Docosane	<i>Pfaffia glomerata</i>	Roots	[177]

(Continues)

TABLE 6 | (Continued)

No.	Compound	Species	Parts of plant	References
421	Docosano	<i>Gomphrena elegans</i> Mart.	Roots and stem	[156]
422	Docoseno	<i>Gomphrena elegans</i> Mart.	Stem, root and leaves	[156]
423	Eicosene	<i>Gomphrena elegans</i> Mart.	Roots and stem	[156]
424	3-Eicosene	<i>Gomphrena elegans</i> Mart.	—	[156]
425	9-Eicosene	<i>Gomphrena elegans</i> Mart.	—	[156]
426	Heptacosane	<i>Gomphrena elegans</i> Mart.	Leaves	[156]
427	Heptadecane	<i>Gomphrena elegans</i> Mart.	Roots and stem	[156]
428	Hexacosane	<i>Pfaffia glomerata</i>	Roots	[177]
429	1-Hexacosene	<i>Gomphrena elegans</i> Mart.	Roots	[156]
430	Hexacosano	<i>Gomphrena elegans</i> Mart.	Roots	[156]
431	Hexadecane	<i>Gomphrena elegans</i> Mart.	Roots and stem	[156]
432	Nonadecane	<i>Gomphrena elegans</i> Mart.	Roots and stem	[156]
		<i>Pfaffia glomerata</i>	Roots	[177]
433	Octadecane	<i>Gomphrena elegans</i> Mart.	Roots and stem	[156]
		<i>Pfaffia glomerata</i>	Roots	[177]
434	1-Octadecene	<i>Gomphrena elegans</i> Mart.	Roots and stem	[156]
435	Pentacosane	<i>Pfaffia glomerata</i>	Roots	[177]
436	Pentacosano	<i>Gomphrena elegans</i> Mart.	Roots and stem	[156]
437	Pentadecane	<i>Gomphrena elegans</i> Mart.	Leaves and stem	[156]
438	Tetracosane	<i>Pfaffia glomerata</i>	Roots	[177]
439	Tetracosano	<i>Gomphrena elegans</i> Mart.	Roots and stem	[156]
440	7,11,15-Trimethyl-3-methylenehexadec-1-ene	<i>Gomphrena elegans</i> Mart.	Leaves and stem	[156]
Alkane				
441	Eicosane	<i>Pfaffia glomerata</i>	Roots	[177]
442	16-Hentriacontane	<i>Alternanthera sessilis</i>	—	[64]
443	Heptadecane	<i>Gomphrena virgata</i>	Whole plant	[101]
444	Pentadecane	<i>Gomphrena virgata</i>	Whole plant	[101]
445	Tetradecane	<i>Gomphrena virgata</i>	Whole plant	[101]
446	2,6,10-Trimethyldodecane	<i>Gomphrena virgata</i>	Whole plant	[101]
Carboxylic acid				
447	Citric acid	<i>Gomphrena agrestis</i>	Roots and leaves	[139]
		<i>Gomphrena globosa</i>	—	[97]
448	Fumaric acid	<i>Gomphrena agrestis</i>	Roots and leaves	[139]
		<i>Gomphrena globosa</i>	—	[97]
449	3-(4-Hydroxyphenyl) methylpropenoate	<i>Gomphrena celosioides</i>	Whole plant	[82]
450	Malic acid	<i>Gomphrena agrestis</i>	Roots and leaves	[139]
		<i>Gomphrena globosa</i>	—	[97]
451	Methylsalicylate	<i>Gomphrena virgata</i>	Whole plant	[101]
452	Oxalic acid	<i>Gomphrena globosa</i>	—	[97]
453	Quinic acid	<i>Gomphrena globosa</i>	Flowers	[153]

(Continues)

TABLE 6 | (Continued)

No.	Compound	Species	Parts of plant	References
Feruloyl tyramine				
454	<i>N-cis</i> -feruloyl tyramine	<i>Alternanthera philoxeroides</i>	Aerial parts	[36]
455	<i>N-trans</i> -feruloyl tyramine	<i>Alternanthera philoxeroides</i>	Aerial parts	[36]
456	<i>N-trans</i> -feruloyl-3,5-dimethoxytyramine	<i>Alternanthera philoxeroides</i>	Aerial parts	[36]
457	<i>N-trans</i> -feruloyl-3-methyl-dopamine	<i>Alternanthera philoxeroides</i>	Aerial parts	[36]
Heterocyclic compounds				
458	4 <i>H</i> -Pyran-4-one,2,3-dihydro-3,5-dihydroxy-6-methyl	<i>Alternanthera sessilis</i>	Whole plant	[149]
459	2-Methoxy-3-isopropylpyrazine	<i>Gomphrena virgata</i>	Whole plant	[101]
Hydrocarbon				
460	α -Copaene	<i>Gomphrena virgata</i>	Whole plant	[101]
461	Nonacosane	<i>Alternanthera sessilis</i>	—	[64]
		<i>Gomphrena elegans</i> Mart.	Leaves	[156]
462	Tricosano	<i>Gomphrena elegans</i> Mart.	Roots	[156]
Organic acid				
463	Gluconic acid	<i>Pfaffia glomerata</i>	Inflorescences and aerial parts	[154, 162]
Tocopherols				
464	α -Tocopherol	<i>Alternanthera bettzickiana</i>	Aerial parts	[19]
		<i>Alternanthera brasiliiana</i>	Aerial parts	[22]
		<i>Gomphrena agrestis</i>	Roots and leaves	[139]
		<i>Gomphrena globosa</i>	—	[97]
465	α -Tocopherol acetate	<i>Alternanthera brasiliiana</i>	Aerial parts	[22]
466	γ -Tocopherol	<i>Alternanthera bettzickiana</i>	Aerial parts	[19]
		<i>Gomphrena globosa</i>	—	[97]
467	δ -Tocopherol	<i>Gomphrena agrestis</i>	Roots and leaves	[139]
		<i>Gomphrena globosa</i>	—	[97]
Vitamins				
468	Riboflavin	<i>Alternanthera brasiliiana</i>	—	[185]
469	Niacin	<i>Alternanthera brasiliiana</i>	—	[185]
Other types of compounds				
470	Allantoin	<i>Hebanthe paniculata</i>	—	[121]
		<i>Pfaffia paniculata</i>	Roots	[183]
471	Benzophenone-4	<i>Alternanthera sessilis</i>	Stem	[56]
472	Butyrolactone	<i>Alternanthera sessilis</i>	Stems	[57]
473	Choline	<i>Alternanthera sessilis</i>	—	[64]
474	2-Decenal	<i>Alternanthera brasiliiana</i>	Whole plant	[23]
475	Diisobutyl Phthalate	<i>Gomphrena elegans</i> Mart.	Stem	[156]
476	7,9-di-ter-butyl-oxaspiro [4, 5] deca-6,9-dien-2,8-dione	<i>Gomphrena elegans</i> Mart.	Roots	[156]
477	2,4-Dihydroxy-2,5-dimethyl-3(2 <i>H</i>)-furan-3-one	<i>Alternanthera sessilis</i>	Stems	[57]

(Continues)

TABLE 6 | (Continued)

No.	Compound	Species	Parts of plant	References
478	11-(3-Ethenylcyclopentyl)undec-10-enoic acid, ethyl ester	<i>Alternanthera sessilis</i>	Stems	[57]
479	3-Ethyl-5-(2-ethylbutyl)-octadecane	<i>Gomphrena elegans</i> Mart.	Roots	[156]
480	Ethyl 9-octadecenoate	<i>Gomphrena elegans</i> Mart.	Leaves, root, and stem	[156]
481	Formic acid, 2-propenyl ester	<i>Alternanthera sessilis</i>	Stems	[57]
482	Furfural	<i>Alternanthera sessilis</i>	Stems	[57]
483	β -Glucopyranosyl oleanolate	<i>Pfaffia glomerata</i>	Roots	[154]
484	L-Glutamic acid	<i>Alternanthera sessilis</i>	Stems	[57]
485	Glutamine, L-	<i>Alternanthera sessilis</i>	Stems	[57]
486	Glycinebetaine	<i>Iresine herbstii</i>	—	[111]
487	Heneicosane	<i>Pfaffia glomerata</i>	Roots	[177]
488	1-Hexadecene	<i>Gomphrena elegans</i> Mart.	—	[156]
489	(<i>E</i>)-hexyl 2-methylbut-2-enoate	<i>Gomphrena virgata</i>	Whole plant	[101]
490	<i>p</i> -Hydroxycinnamoyl moiety	<i>Alternanthera sessilis</i>	Stems	[56]
491	Indole-3-carbaldehyde	<i>Alternanthera philoxeroides</i>	Aerial parts	[38]
492.	Inulin	<i>Pfaffia glomerata</i>	—	[186]
493	Laurenan-2-ona	<i>Gomphrena elegans</i> Mart.	Leaves	[156]
494	Levan	<i>Gomphrena marginata</i>	—	[186]
495	8-Methyl-1-decene	<i>Gomphrena elegans</i> Mart.	Stem	[156]
496	Methyl octadecanoate	<i>Gomphrena elegans</i> Mart.	Leaves	[156]
		<i>Alternanthera sessilis</i>	Leaves	[158]
497	Methyl 6-octadecenoate	<i>Gomphrena elegans</i> Mart.	Stem	[156]
498	Methyl 8-octadecenoate	<i>Gomphrena elegans</i> Mart.	Leaves	[156]
499	3-Methyl-5-propylnonane	<i>Alternanthera brasiliiana</i>	Aerial parts	[22]
500	Nonanal	<i>Gomphrena virgata</i>	Whole plant	[101]
501	<i>Z</i> -3,17-Octadecadien-1-ol acetate	<i>Alternanthera sessilis</i>	Stems	[57]
502	Palmitic acid ethyl ester	<i>Alternanthera brasiliiana</i>	Aerial parts	[22]
503	Pentanal	<i>Alternanthera sessilis</i>	Stems	[57]
504	Phaeophytin a	<i>Alternanthera philoxeroides</i>	—	[41]
505	Phenylacetaldehyde	<i>Alternanthera sessilis</i>	Stems	[57]
506	Pheophytin a'	<i>Alternanthera philoxeroides</i>	—	[41]
507	Sebacic acid, bis(2-ethylhexyl) ester	<i>Alternanthera sessilis</i>	Stems	[57]
508	6,10,14-Trimethyl-2-pentadecanone	<i>Gomphrena elegans</i> Mart.	Leaves and roots	[156]
509	(<i>5Z</i>)-2,6,10-Trimethyl-1,5,9-undecatriene	<i>Alternanthera brasiliiana</i>	Aerial parts	[22]
510	1,2,4-Trioxolane,3-phenyl-	<i>Alternanthera sessilis</i>	Stems	[57]
511	Uridine	<i>Gomphrena elegans</i> Mart.	Leaves	[156]
512	Umbellatosides B	<i>Gomphrena celosioides</i>	Aerial parts	[178]

and reduced leukocyte migration [34, 67]. Likewise, compounds patuletin 3-*O*- β -D-glucopyranoside (**67**) and tiliroside (**106**) were evaluated for anti-inflammatory activity in vivo, demonstrating a reduction in the edema formation and leukocyte migration [127]. These results show that phenolic compounds have potential as analgesic compounds.

Hypoglycemic activity was also evaluated in cleomiscosin A (**162**) and dictyoceratin C (**166**), but their activity was low [84].

Besides the above, it should be noted that some phenolic compounds such as caffeic acid (**132**) and ferulic acid (**137**), which have been isolated from members of this subfamily, can become

candidates for drugs with dual activity (anti-inflammatory and antimicrobial activity), which would provide an advantage from the pharmaco-economic point of view [71].

A total of 36 out of 173 phenolic compounds identified in this subfamily have been researched in terms of biological activity, showing promising effects such as antimicrobial, antiviral, antioxidant, anticancer, immunomodulatory, antidepressant, antimentia, analgesic, and anti-inflammatory. Compounds **43** and **72** are particularly noteworthy, as they have demonstrated antimicrobial, immunomodulatory, anti-inflammatory, and analgesic activity, highlighting their biotechnological potential.

4.1.1 | Flavonoids and Their Glycosides

Flavonoids are phenolic compounds commonly found in nature, known for their diverse biological activities. They exhibit antioxidant, analgesic, anti-inflammatory, anticancer, antipyretic, antiallergic, antidiabetes, antiulcer, antimicrobial, antiprotozoal, antiplatelet, antiatherogenic, antiestrogenic, cardioprotective, neuroprotective, hepatoprotective, and radioprotective activities [28, 77, 85, 90, 187–190].

Currently, 133 flavonoids (Table 2) have been reported in members of Gomphrenoideae (Table 2 and Figure 1), consisting of 57 flavone glycosides (**34–90**), 43 flavonol glycosides (**91–133**), 15 flavones (**3–17**), 10 flavonols (**18–27**), 5 iso-flavones (**28–32**), 2 flavan-3-ols (**1–2**), and an aurone (**33**). It should be noted that quercetin (**24**), kaempferol (**20**), and rutin (**130**) are the most commonly isolated flavonoids from these plants.

Some important aspects of the discovery of flavonoids are described below. In 1992, Pomilio reported the occurrence of an isorhamnetin glycoside (**54**) for the first time in *G. boliviana* Moq. [75]. Later, in 2003, Oliveira first reported the isolation of the symmetrically glycosylated methylene bioflavonoid 8,8''-methylene bis(spinacetin 3-O-robinobioside) (**118**) from the ethanol extract of *Blutaparon portulacoides* (A.St.-Hil.) Mears leaves. In 2004, Ferreira discovered a new hepta-substituted (*E*)-aurone glucoside (**33**) in the ethanol extract of *Gomphrena agrestis* Mart. [2]. In 2011, Valentová isolated a new isoflavone (**32**) from the aerial parts of *Iresine diffusa* f. *herbstii* (Hook.) Pedersen, characterized by the presence of a methoxy group in position two of the isoflavanone skeleton [111].

In 2011, Ferreres reported a tetrahydroxymethylenedioxyflavone derivative (**77**) for the first time *in natura* [94]. In 2014, Felipe reported the presence of flavonoids (**103**, **106**, **126**) in the inflorescences of *Pfaffia glomerata* (Spreng.) Pedersen for the first time [154]. In 2017, Deladino reported the isolation of pentosylvitexin (**70**) and pentosyl-isovitexin (**69**) in *A. brasiliana* and *Alternanthera tenella* (Synm. *Alternanthera sessilis* (L.) R.Br. ex DC. and *Alternanthera pungens* Kunth) for the first time [28].

Quercetin (**24**) has been reported in various species, including *Alternanthera bettzickiana* (Regel) G. Nicholson, *A. brasiliana*, *Alternanthera maritima* (Mart.) A.St.-Hil. (Synm. *Alternanthera littoralis* Beauv. ex Moq.), *A. paronychioides*, *Alternanthera philoxeroides* (Mart.) Griseb., *A. sessilis* (L.) R.Br. ex DC., *A.*

tenella Moq. (Synm. *A. sessilis* (L.) DC. and *Alternanthera ficoidea* (L.) P. Beauv.), *G. agrestis*, *Gomphrena celosioides* Mart., *G. clausenii*, *Gomphrena globosa*, and *Iresine angustifolia* Euphrasén. Quercetin is one of the most abundant flavonoids in the nature and is known for its therapeutic application in allergies, cancer, inflammation, obesity, arthritis, asthma, diabetes, prostate adenocarcinoma, immunity, and infections, as well as its gastroprotective and analgesic properties [189].

On the other hand, it is noteworthy that *G. globosa*, with 50 flavonoids (**13**, **19–20**, **24**, **27**, **46–48**, **50–52**, **55**, **71**, **77**, **83–87**, **92–95**, **97–105**, **107–110**, **112–114**, **116**, **120–126**, **128**, **130**, **132**), is the plant with the highest number of flavonoid-type compounds reported to date.

4.1.2 | Non-Flavonoid Phenolic Compounds

Currently, only 40 non-flavonoid phenolic compounds have been reported. These include 14 hydroxycinnamic acids (**143–156**), 9 benzoic acids (**134–142**), 2 derivatives of gallic acid (**157–158**), 2 lignans (**160–161**), 2 phenylpropanoids (**163–164**), a coumarin (**159**), a coumarinolignoid (**162**), a glycosylated phenylpropionate (**165**), a sesquiterpene phenol (**166**), and 7 other phenolic compounds (**167–173**) (Table 2 and Figure 1).

G. celosioides has the highest number of non-flavonoid phenolic constituents, with 12 compounds (**140**, **143–144**, **149**, **156**, **160–162**, **166**, **168**, **170–171**). Ferulic acid (**149**) is the most abundant non-flavonoid phenolic compound distributed among the species of Gomphrenoideae, having been reported in *A. brasiliana*, *A. paronychioides*, *A. philoxeroides*, *A. sessilis*, *A. tenella*, *B. portulacoides*, *G. celosioides* Mart., *G. globosa*, and *I. angustifolia*.





































4.2 | Terpenoids

Among the terpenes are found monoterpenes, triterpenes, sesquiterpenes, and triterpenoid saponins. These compounds exhibit different biological activities, including antioxidant, antimicrobial, antimalarial, anti-HIV, anti-inflammatory, antitumor, antimutagenic, anticancer, antipruritic, antidiabetic, antiatherosclerotic, antiallergic, cytotoxic, hemolytic, hypotensive, hepatoprotective, immunomodulatory, and nutraceutical activities, as well as inhibition of cardio-cerebral vascular diseases, playing an important role in the pharmaceutical industry [4, 9, 77, 131, 191].

To date, the production of 95 different terpenes in this subfamily has been reported (Table 3 and Figure 1), including 31 triterpenoid saponins (**234–264**), 31 triterpenes (**203–233**), 19 sesquiterpenes (**179–197**), 5 diterpenoids (**198–202**), 4 monoterpenes (**174–177**), 3 carotenoids (**265–267**), a glycoside monoterpene (**178**), and a drimene (**268**).

Phytol (**202**), oleanolic acid (**221**), pfaflacic acid (**226**), and pfaflacides A–F (**255–260**) are the most abundant terpenoid compounds distributed among the species of Gomphrenoideae.

In 1984, Nishimoto was the first to isolate the nortriterpene glucuronides called pfaflacides A–C (**255–257**) from the roots

Flavan3-ols**Flavones****Flavonol****Isoflavone****Aurone****Flavone glycosides****FIGURE 1** | Chemical compounds identified in the subfamily Gomphrenoideae.







FIGURE 1 | (Continued)




Benzoic acids




Hydroxycinnamic acids




Gallic acid derivatives




Coumarins




Lignans




Coumarinolignoids




Phenylpropanoid



Phenylpropanoid glycosides



Sesquiterpene phenol



Other phenolic compounds




FIGURE 1 | (Continued)




FIGURE 1 | (Continued)




FIGURE 1 | (Continued)




FIGURE 1 | (Continued)




FIGURE 1 | (Continued)




FIGURE 1 | (Continued)

Phytoecdysones

Phytoecdysteroids




FIGURE 1 | (Continued)




FIGURE 1 | (Continued)




FIGURE 1 | (Continued)

of *Pfaffia paniculata* (Mart.) Kuntze (Synm. *Hebanthe eriantha* (Poir.) Pedersen) [125]. That same year, Nakai reported the isolation of three additional nortriterpenoids, pfaffosides D–F (258–260), from the roots of *P. paniculata* [164]. In 2005, Rios identified three new drimenes (268, 195, 196) from the acetone extract of aerial parts of *I. diffusa* Humb. & Bonpl. ex Willd. [105]. In 2006, Kuroda reported for the first time the isolation of a taraxane glycoside (245) from a natural source, the roots of *G. macrocephala* [99].

In 2008, Chaudhary reported the presence of drimanes in the Amaranthaceae family for the first time, with the isolation of 11,12-acetonide of 11,12,13-trihydroxydrimene (179) and 11,12,13-trihydroxydrimene (194) from the acetone extract of the aerial parts of *T. oblongifolia* (S. Watson) Standl. (Synm. *T. suffruticosa* var. *oblongifolia* (S. Watson) Sanch.Pino & Flores Oliv.). Notably, this remains the only phytochemical study conducted on any *Tidestromia* species [128]. In 2010, 26 years after Nishimoto's discovery, Li reported the isolation of two new nortriterpenoids,

pfaffine A and B (**227–228**), from the root of *P. paniculata* [123]. In 2018, Han reported the isolation of three new norolean-type triterpenes (**215, 216, 224**) from the root of *P. glomerata* [115].

With 24 compounds (**212–213, 215–216, 221, 223–226, 229–230, 234–235, 237–238, 248, 253–260**), *P. glomerata* has the highest number of terpenoid compounds. It is worth noting that in 2014, Felipe was the first to report the presence of glomeric acid (**212**), oleanonic acid (**223**), pferamic acid (**229**), chikusetsusaponin IV (**237**), and ginsenoside R₀ (**248**) in this plant [154].

As mentioned, terpenes exhibit various pharmaceutical activities, which has led to research on compounds isolated from this subfamily. However, their antimicrobial activity (antiparasitic, antibacterial, and antifungal activity) was not extensively studied. To date, only pferamic acid (**226**) has been evaluated against *T. cruzi*, showing an IC₅₀ of 44.78 ± 7.83 µg/mL [177].

Antiviral activity has been assessed solely for chikusetsusaponin IVa (**238**) against 11 viruses, demonstrating efficacy against enveloped viruses (Table S1), and this compound was also evaluated in vivo in mice infected with HSV-2, revealing a reduction in viral titer, symptom alleviation, and increased survival (Table 10) [41].

The cytotoxicity of pferoside A (**255**), pferoside C (**257**), pferoside D (**258**), pferoside E (**259**), and pferoside F (**260**) was evaluated against B-16 cells, with inhibitory concentrations between 30 and 120 µg/mL as seen in Table S2 [125, 164]. Philoxeroideside A (**261**), philoxeroideside B (**262**), philoxeroideside C (**263**), and philoxeroideside D (**264**) were evaluated against HL60 and SK-N-SH cell lines, with IC₅₀ values ranging from 37.29 to 271.45 µg/mL. Compound **264** exhibited the highest activity, with IC₅₀ values of 45.93 and 37.29 µg/mL, respectively [37].

Additionally, compounds 11 α ,12 α -epoxy-3 β -[(*O*- β -D-galactopyranosyl-(1 → 3)-*O*-[β -D-glucopyranosyl-(1 → 2)]- β -D-glucuronopyranosyl)-oxy]olean-28,13-olide (**243**), 11 α ,12 α -epoxy-3 β -[(*O*- β -D-glucuronopyranosyl)oxy]olean-28,13-olide (**244**), 11 α ,12 α -epoxy-3 β -[(*O*- β -D-glucuronopyranosyl)oxy]taraxer-14-en-28-oic acid β -D-glucopyranosyl ester (**245**), 11 α ,12 α -epoxy-3 β -hydroxyolean-28,13-olide (**246**), and 11 α ,12 α -epoxy-3 β -hydroxytaraxer-14-en-28-oic acid (**247**) were evaluated against HSC-2, but only compounds **246** and **247** showed activity, with IC₅₀ values of 20 µM [99]. These results confirm the potential of most terpenoid-type compounds as anticancer agents.

Hypoglycemic activity was evaluated in ilimaquinone (**187**) and neodactyloquinone (**190**), showing different levels of activity, with the compound **187** showing the highest efficacy [84].

Pfaffianol A (**225**), boussingoside A₂ (**235**), pferaglycosides B (**254**), and pferoside C (**257**) were evaluated for their effects on melanogenesis inhibition. The results indicated that only compounds **225** and **257** had a significant effect, even greater than that of arbutin [161], as shown in Table 9.

The studies described above provide evidence of antiparasitic, antiviral, and cytotoxic activity against carcinogenic cell lines,

as well as hypoglycemic activity and antimelanosis properties in 21 out of the 95 compounds identified in this family. This suggests that the members of this subfamily serve as a reservoir of terpenoid compounds with pharmacological activity.

4.3 | Alkaloids

Alkaloids possess a wide range of biological activities, including inhibition of malignant cell growth and proliferation, as well as antioxidant, anti-inflammatory, antiviral, antibacterial, and immunomodulatory effects [77, 84, 151].

To date, 62 alkaloids have been isolated (Table 4 and Figure 1), including 48 betalains (**276–323**), 2 guanidine alkaloids (**269–270**), 2 indole alkaloids (**271–272**), 2 tricyclic alkaloids (**274–275**), a pyridine alkaloid (**273**), and other alkaloids (**324–330**). Among these, the betacyanins amaranthine (**276**), isoamaranthine (**288**), betanin (**295**), and isobetanin (**297**) are the most abundant alkaloids found in species of Gomphrenoideae, being reported all in *A. betzickiana*, *A. brasiliana*, *A. ficoidea* Griseb. (Synm. *A. littoralis* Beauv. ex Moq.), *A. tenella*, *G. globosa*, *I. herbstii*, and *Iresine lindenii* Van Houtte.

G. globosa has the highest number of alkaloid compounds, with 33 compounds (**276, 278–280, 288–290, 294–313, 316, 318–321, 323**).

In 2020, Killian reported the isolation of two new, unusual guanidine alkaloids (**269–270**) from the ethanol extract of aerial parts of *I. diffusa* [165], being the first time that this type of compound was isolated from a Gomphrenoideae species.

On the other hand, aurantiamide (**326**) has been found to possess antioxidant, anti-inflammatory, antiviral, antibacterial, and immunomodulating properties [84]. This compound has been reported in the extract of the whole plant *G. celosioides* [83–85, 89]. The presence of betalains in this subfamily is noteworthy, as these compounds are exclusively produced by plants belonging to the order Caryophyllales and have demonstrated significant biological activity.

Of the 62 identified alkaloids, 16 have been studied for their biological activity. For instance, the antimicrobial activity of compound aurantiamide acetate (**327**) was evaluated against 19 bacteria and 3 yeasts, showing activity against only 5 bacteria, as detailed in Table S1 [2]. In 2018, Spórna-Kucab evaluated extracts, seven fractions (mixtures of alkaloids), and individual alkaloid-type compounds for antimicrobial activity (bacteria and yeast). The study demonstrated that the isolated compounds exhibited better activity than the fractions, whereas the fractions showed better activity than the extracts. The compounds evaluated included *cis*-isomer of gomphrenin II (**298**), *cis*-isomer of gomphrenin III (**299**), *cis*-isomer of isogomphrenin II (**300**), *cis*-isomer of isogomphrenin III (**301**), gomphrenin II (**304**), gomphrenin III (**305**), isogomphrenin II (**309**), isogomphrenin III (**310**), isosinapoyl-gomphrenin I (**311**), and sinapoyl-isogomphrenin I (**313**) [173]. These findings are intriguing, as they suggest that the combination of these compounds may produce an antagonistic effect on antibacterial activity, which is not always the case. In many instances, fractions and extracts exhibit greater activity than isolated compounds due to compound synergism.

This research highlights the importance of studying extracts, fractions, and isolated compounds in the search for substances of biotechnological interest.

Additionally, antiparasitic and antioxidant activities were evaluated for compounds alternamide A (7,8-dihydroxy-1,2,4,5-tetrahydro-3H-1,5-ethano[c]azepin-3-one) (**274**), alternamide B (6,7-dihydroxy-3,4-dihydroquinoline-1-one) (**275**), alternamine A ((R)-1-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol) (**324**), and alternamine B (4-(2-aminoethyl)benzene-1,2-diol-4-(2-aminoethyl)benzene-1,2-diol- β -D-glucopyranose) (**325**). These compounds showed different degrees of activity, as detailed in Tables S1 and S2, with compound **324** exhibiting promising antiparasitic activity [8].

Regarding anticancer activity, only compounds celosiadine A (**269**) and celosiadine B (**270**) have been evaluated in vitro, showing activity against LNCaP but not PC3 cells. Hypoglycemic activity was evaluated in bruceoline F (**271**), but it showed no activity [84].

The studies evaluating the bioactivity of alkaloid compounds from this subfamily have confirmed their antimicrobial, antioxidant, anticancer, and hypoglycemic properties, demonstrating the potential of this subfamily as a source of biologically active compounds. However, there is still a vast area for investigation, as there have been limited studies to ascertain the biotechnological potential of the betalains identified in this subfamily.

4.3.1 | Betalains

Betalains are classified into betacyanins (red-violet) and betaxanthins (yellow) based on their structure. In plants, they serve protective functions against pathogens and various environmental conditions, aiding in plant propagation. Once isolated, betalains can be utilized as colorants and exhibit a wide range of biological activities, including antioxidants, anticancer, radioprotective, antilipidemic, antihypoglycemic, anti-inflammatory, and antimicrobial (antibacterial, antifungal, and antiviral) effects. They are also used in the treatment of hypertension, diabetes, anemia, thalassemia, high cholesterol levels, calcium deficiency disorders, and liver-related issues. Additionally, betalains demonstrate chemopreventive properties and have positive effects on metabolism, cardiovascular health, and gastrointestinal health in humans. Importantly, betalains are non-toxic and do not exhibit mutagenic or allergic reactions [29, 96, 130, 174].

To date, 48 types of betalains have been reported in this subfamily. These include 18 belonging to the amaranthin group (**276–293**), 16 to the gomphrenin group (**298–313**), 8 types of betaxanthine (**316–323**), 4 belonging to the betanin group (**294–297**), and 2 other betalains (**314–315**). Deladino's 2017 study indicates that it was the first report of amaranthine (**276**), isoamaranthine (**288**), betanin (**295**), and isobetanin (**297**) in *Alternanthera* species, although these compounds are commonly isolated from *Amaranthus* species [28]. However, it is important to note that these compounds were previously reported by Cai in *A. bettzickiana* and *A. ficoidea*, making Cai's study the first to report these compounds [166].

As mentioned above, *G. globosa* showed the broadest phytochemical profile in terms of betalains. It is also worth noting that 22 betalains (**276, 277, 281–282, 284–289, 291–293, 295, 297, 304–305, 309–312, 314**) have been reported in *I. herbstii* and 17 (**276, 278, 281–282, 284–285, 288–289, 291–293, 295, 297, 305, 310, 314–315**) have been reported in *I. lindenii*. Among the compounds isolated in this subfamily, Betanin (**295**) is known to combat oxidative stress and reduce tumors in the lung, skin, colon, liver, and esophageal in various animal models. It also shows activity against tumors in the prostate, breast, and pancreas in humans and inhibits the proliferation of various human cancer cell lines [130]. Additionally, gomphrenin (**302**) has been found to have chemopreventive activity, whereas celosianin (**278**) and iresin (**283**) exhibit antioxidant potential [130].

Spórna-Kucab in 2020 proposed new tribal names for some betalains. Among the proposed changes was renaming gomphrenina II (**304**) to globosin, gomphrenina III (**305**) to basellin (due to its presence in *Basella alba*), 2''-OE-sinapoyl-amaranthin (**289**) to lindenin (because of its presence in *I. lindenii*), sinapoyl-gomphrenin I (**312**) to gandolin (due to its presence in *Gandola nigra*), celosianin I (**277**) to argentinianin, and celosianin II (**278**) to celosianin [110].

4.4 | Compounds of Lipid Nature

Currently, 35 compounds have been reported in members of this subfamily. These include 33 fatty acids (**331–363**), a fatty alcohol (**364**), and a fatty amide (**365**) (Table 5 and Figure 1). *A. brasiliiana* has the largest spectrum of lipid compounds (**335, 337–348, 353–363, 365**).

Regarding the evaluation of biological activity, only the antimicrobial and antimelanosis activities have been evaluated as described below. Compounds (8E)-10-hydroxy-8-octadecenoic acid (**337**), (10E)-9-hydroxy-10-octadecenoic (**338**), (8E,12Z)-10-hydroxy 8,12-octadecadienoic acid (**339**), (9Z,11E)-13-hydroxy-9,11-octadecadienoic acid (**340**), (9Z,11E,15Z)-13-hydroxy-9,11,15-octadecatrienoic acid (**341**), (9Z,12Z,14E)-16-hydroxy-9,12,14-octadecatrienoic acid (**342**), (9Z,13E)-12-hydroxy-9,13-octadecadienoic acid (**343**), (9Z,13E,15Z)-12-hydroxy-9,13,15-octadecatrienoic acid (**344**), (10E,12E)-9-hydroxy-10,12-octadecadienoic acid (**345**), (10E,12Z)-9-hydroxy-10,12-octadecadienoic acid (**346**), (9Z)-9-octadecenedioic acid (**354**), (7E)-9-oxo-7-octadecenoic acid (**356**), (8E)-10-oxo-8-octadecenoic acid (**357**), (9E,11E)-13-oxo-9,11-octadecadienoic acid (**358**), (9Z,11E)-13-oxo-9,11-octadecadienoic acid (**359**), (10E,12E)-9-oxo-10,12-octadecadienoic acid (**360**), and (10E,12Z)-9-oxo-10,12-octadecadienoic (**361**) were evaluated against three bacteria, but only nine of them showed activity as detailed in Table S1 [32].

Of the 35 compounds identified, only 17 have been evaluated for biological activity, highlighting a significant research opportunity.

4.5 | Other Compounds

A total of 146 other compounds were reported, which consisted of 26 phytosterols (**386–412**), 22 aliphatic hydrocarbons (**419–440**),

20 phytoecdysteroids (368–385), 7 carboxylic acids (447–443), 6 alkanes (441–446), 4 saponins (414–417), 4 feruloyl tyramine derivatives (454–457), 4 tocopherols (464–467), 3 hydrocarbons (460–462), 2 phytoecdysones (366–367), 2 vitamins (468–469), 2 heterocyclic compounds (458–459), 1 phytosteroid (413), 1 aliphatic alcohol (418), 1 organic acid (463), and 43 compounds that were not classified (470–512) (Table 6 and Figure 1). With 30 compounds, *Gomphrena elegans* Mart. had the highest number of secondary metabolites of another type (421–427, 429–434, 436–437, 439–440, 461–462, 475–476, 479–480, 488, 493, 495–498, 508, 511), highlighting that 77.27% of aliphatic hydrocarbons were reported in *G. elegans* Mart. Additionally, it can be seen from Table 6 that feruloyl tyramine-type compounds were only reported in *A. philoxeroides*.

In 1998, Sarker was the first to report the phytoecdysteroid 2-dehydro-3-epi-20-hydroxyecdysone (370) in seeds of *Froelichia floridana* (Nutt.) Moq. [192]. Another important aspect was that Roriz, in 2014, reported tocopherols (464, 466, 467) for the first time in *G. globosa* [97].

The biological activity of these compounds has been studied little. Compounds Δ^7 -stigmaterol (411) and 3-*O*- β -D-glucopyranosyl Δ^7 -stigmaterol (416), and the following mixtures 411 and campesterol (386); spinasterol (396) and 411; 3-*O*- β -D-glucopyranosyl stigmaterol (415) and 416; sitosterol glycoside (394) and 3-*O*- β -D-glucopyranosyl spinasterol (414), were evaluated against bacteria, yeast, and fungi, showing activity to varying degrees, as detailed in Table S1 [142]. Likewise, the mixture of compounds sitosteryl (395) and stigmasteryl 3- β -*O*-glucoside 6'-*O*-palmitate (412) was evaluated for antimicrobial activity against 15 microorganisms but showed activity against 6 (Table S1) [151]. Compound stigmast-6-en-3-*O*- β -(D-glicopyranoside) (417) was evaluated against five microorganisms but only had activity against two of them (Table S1) [157]. On the other hand, the mixture of compounds 395 and 412 was evaluated against *T. cruzi* and *L. amazonensis* and showed activity (Table S1) [151]. Compound (449) was tested against six bacteria and showed activity against all of them, although the activity was lower than that of the extracts tested (Table S1) [82].

Additionally, compounds β -ecdysone (367), 22-oxo-20-hydroxyecdysone (377), pterosterone (381), taxisterone (384), and 2 β ,3 β ,14 α ,17 β -tetrahydroxy-5 β -androst-7-en-6-one (385) were evaluated as melanogenesis inhibitors, but none showed activity. Notably, terpenoid compounds were also assessed as melanogenesis inhibitors and demonstrated significant activity (see Table 9) [161]. Compounds (455), (456), and (457) were evaluated against HeLa cells, and two of them showed significant effects, as evidenced in Table S2 [36].

5 | Pharmacological Activities

To date, 162 articles have evaluated biological activity, both in vitro (108 articles) and in vivo (73 articles), of 30 species within the Gomphrenoideae subfamily. This research shows that only 6.10% of the members of this subfamily have been studied in terms of biological activity. Furthermore, of the 15 genera, only 6 have been studied. This indicates that the remaining genera, *Froelichia*,

Froelichiella, *Hebanthodes*, *Pederseniana*, *Pseudoplantago*, *Quaternella*, *Tidestromia*, and *Xerosiphon*, remain unexplored in terms of biological activity.

On the other hand, it should be noted that the pharmacological investigations of different extracts and isolated compounds from members of this subfamily confirm various biological activities. These include antioxidant, antimicrobial, anticancer, anti-inflammatory, antidiabetic, antihyperglycemic, antiarthritic, antihypertensive, analgesic, immunomodulatory, neuroprotective, cardioprotective, gastroprotective, hepatoprotective, diuretic, and wound-healing properties.


It is important to emphasize that when consolidating and analyzing the biological activity data of the isolated compounds, fractions, extracts, and extract-based nanoparticles, a notable variability becomes evident. In some cases, isolated compounds exhibit greater activity compared to extracts and fractions, whereas in others, the opposite occurs. This variability can be attributed to synergistic and antagonistic interactions between the compounds, as well as the specific concentrations of each compound present in the extract, which can influence the overall activity.

In this sense, the importance of conducting studies focused on examining extracts, fractions, isolated compounds, and compound mixtures is evident, as this could lead to the discovery of phytotherapeutics that are beneficial for the pharmaceutical industry and the community. Additionally, it is crucial to conduct studies that evaluate the potential of free extracts and drug delivery systems, such as nanoparticles, because the latter have shown that they can enhance the biological activity of the extract in many cases.


Another important observation, which is discussed in the following sections, is that extracts from the same species exhibited different results for the same biological activity. This variability can be attributed to the fact that the study plants were sourced from different geographical locations and times, resulting in distinct phytochemical profiles and consequently varying biological activities. These findings underscore the importance of conducting studies that consider different varieties of the same species, plants collected at different times and locations, and various environmental and stress conditions, as well as the use of in vitro systems and greenhouses to assess the stability of the phytochemical profile and biological activity. Such studies can help determine the optimal conditions for producing bioactive substances of interest.

The significance of the studies that lead to the discovery of new phytotherapeutic compounds lies in their lower cost, greater availability, reduced adverse effects, biodegradability, and environmental safety compared to synthetic drugs [14, 16, 129, 192].

An overview of the modern pharmacological studies conducted on different extracts and isolated compounds is described in the following subsections, Tables 7–10, and Schemes 4–7. In general, the reported studies used standardized and/or similar techniques and concentrations, allowing comparisons between the reported results, thus generating a more comprehensive analysis.



SCHEME 4 | Antimicrobial activity assays. The tests presented are used to evaluate bacteria, yeasts, and fungi. All tests are standardized in terms of culture medium, temperature, and incubation period, according to the evaluated microorganism. Each assay includes a negative control, positive control (bacteria: ampicillin, amoxicillin, bacitracin, chloramphenicol, ceftriaxone sodium, clarithromycin, ciprofloxacin, erythromycin, gentamicin, isoniazid, kanamycin, norfloxacin, streptomycin, streptomycin sulfate, and tetracycline; yeast: amphotericin B, chloramphenicol, ketoconazole, nystatin, and tioconazole; fungi: fluconazole, ketoconazole, tioconazole), and different concentrations of the tested agent (0.5–12 500 µg/mL).




SCHEME 5 | Antiparasitic activity assays. The tests presented are used to evaluate the antiparasitic potential. They are standardized in terms of culture medium, temperature, and incubation period according to the evaluated organism. The assay includes a negative control, a positive control (*Trypanosoma cruzi*: crystal violet and gentian violet; *Leishmania amazonensis*: amphotericin B), and different concentrations of the agent (1–4000 µg/mL).

5.1 | Antimicrobial Activity

Infections caused by fungi and bacteria are responsible for the development of serious diseases and over fifty thousand deaths per year [96]. Additionally, many microorganisms have developed resistance to existing drugs, posing a risk to pub-

lic health and presenting a challenge for the pharmaceutical and healthcare industries, with economic implications [11, 14, 89, 129, 223].

In addition to the development of drug resistance by microorganisms, developing and underdeveloped countries lack access



SCHEME 6 | Antioxidant activity assays. All tests are standardized and include negative control, positive control, and different concentrations of the test agent.

to medications to treat infections, leading to increased mortality rates. Therefore, the search for new broad-spectrum antimicrobials with low toxicity derived from natural sources is necessary [14, 89, 223].


To date, 46 articles have evaluated the antimicrobial activity of members of 5 genera of this subfamily. Twenty-seven articles report the presence or absence of antibacterial activity, evaluating a total of 98 bacterial strains; 14 articles discuss antifungal potential, evaluating 19 yeast strains and 8 fungal strains; 6 articles report on antiparasitic activity against *T. cruzi* and *L. amazonensis*; and 2 articles discuss antiviral potential of *A. philoxeroides*, evaluating its activity against 13 viruses. These studies examined the potential of approximately 46 extracts, 16 fractions, 6 mixtures of compounds, and 73 isolated compounds (6, 7, 9, 10, 17, 20, 24, 25, 33, 34, 39, 40, 43, 50, 51, 54, 58, 60, 70, 71, 72, 80, 88, 92, 93, 94, 95, 100, 101, 106, 107, 108, 109, 156, 159, 226, 238, 274, 275, 298, 299, 300, 301, 304, 305, 309, 310, 311, 313, 324, 325, 327, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 354, 356, 357, 358, 359, 360, 361, 411, 416, 417, 449). These studies cover only 3.54% of the Gomphrenoideae members (*A. bettzickiana*, *A. brasiliiana*, *A. caracasana* HBK, *A. dentata*, *A. littoralis* P. Beauv., *A. philoxeroides*, *A. pungens*, *A. repens*, *A. sessilis* (Linn.), *A. tenella* Colla, *B. portulacoides*, *G. agrestis*, *G. boliviana*, *G. celosioides*, *G. globosa*, *G. martiana*, *H. eriantha*, *I. herbstii*, *P. glomerata*, and *P. paniculata*). Schemes 4 and 5 summarize the main methodologies, and Table S1 presents the results obtained.

Kumar and his research group are currently the only ones who have studied the antibacterial activity of *Alternanthera dentata*, demonstrating that AgNPs of AqE of leaves are active against the four microorganisms evaluated [225]. Research by Zavala and collaborators showed that the ME of *A. repens* was not active against bacteria and yeasts [216].

Bhattacharjee and his research group are currently the only ones who have studied the antibacterial activity of *A. philoxeroides*. They demonstrated that fraction X of leaf ME exhibits remarkable activity, as it was able to inhibit *Escherichia coli* and *Micrococcus luteus* with relatively small MICs (11.23 ± 0.11 and 16.23 ± 0.23 $\mu\text{g/mL}$, respectively) and large ZI, when compared with the results obtained for the AuNPs of AqE from *A. bettzickiana*, the subfractions of FEaMc and extracts of *A. brasiliiana*, ME of *A. sessilis*, EE and PEE from *G. boliviana*, extracts from *G. celosioides*, AcE from *G. globosa*, compounds (20, 24, 25, 34, 43, 72, 88, 410, 411), and mixtures of compounds (411 and 386), (396 and 411), (415 and 416), (394 and 414) [26, 27, 32, 75, 82, 89, 142, 141, 173, 226].

A. sessilis was studied by four research groups, three of which used nanoparticles. Niraimathi et al. and Kabeerdass et al. demonstrated that the AgNPs of AqE of leaves are active against bacteria, especially gram-negative strains [60, 227]. Venkatraman and collaborators showed that the ZnONPs of leaves possess antibacterial activity and suggested that the mechanism of action involves membrane destruction, leading to metabolic dysfunction

Evaluation of *In Vitro* anticancer activity



SCHEME 7 | Anticancer activity assays.

and protein excretion by the bacteria [228]. Ullah and collaborators reported similar results, demonstrating that the ME of the whole plant presented activity against 10 of the 12 microorganisms evaluated [226].


G. celosioides was studied by five research groups. Moura's results for *E. coli* differed from those obtained by some authors; he reported that the EE of aerial parts and compounds **156** and **417** did not show activity against this strain. However, Dosumu and Omokhua-Uyi reported that this strain was sensitive to AcE, EaE, and compound **449** [82, 89, 151]. Another interesting discovery was made by Dosumu, who concludes that the higher activity observed in EaE was due to synergistic relationships between molecules [82]. However, this information cannot be extrapolated, because extracts sometimes present less activity due to antagonistic relationships between molecules, as observed in the study by Sporna-Kucab in *G. globosa* [173]. Additionally, Dosumu also reported that ME has antifungal activity similar to that of tioconazole [82]. This finding is particularly relevant because there are currently very few antifungal agents available on the market, highlighting the need for new broad-spectrum antifungals. In this context, Abalaka et al. also obtained interesting results, demonstrating that AuNPs of leaf extract exhibited activity similar to CAM and streptomycin [229].

Rahamouz Haghghi and Sharafi in 2024 published the first article of the antibacterial activity of *H. eriantha*, demonstrating that it was active against the five microorganisms evaluated, having the same effect as gentamicin on *S. aureus* [230].

Dipangar and Murugan obtained results similar to Bhattacharjee with AgNPs of AqE from leaves of *I. herbstii*, which inhibited three gram-negative bacteria and two gram-positive with MICs between 6.25 and 50 µg/mL [231].

A. brasiliensis was studied by six different researchers, two of whom studied both antibacterial and antifungal activity. In summary, Johann, Andraza, and Coutinho reported that the HeE and EE of the whole plant, the HaE of aerial parts, and the EE of leaves did not show relevant activity against the tested microorganisms [23, 26, 232]. Araújo obtained similar results when evaluating AqE of leaves, showing that the extract did not show activity against four microorganisms, had clinically irrelevant activity against four microorganisms, and showed activity only against *Mycobacterium smegmatis* (MIC: 15.6 µg/mL) and *C. albicans* (MIC: 31.2 µg/mL) [27]. These results are consistent with those obtained by Marchete in 2021, who indicated that the HaE of the leaves has weak activity against *P. aeruginosa*, *S. aureus* ATCC 25923, oxacillin-resistant *S. aureus*, and *E. coli* ATCC 25922 [193]. In contrast, Trapp reported that the FEaMc (1:1) and three sub-fractions showed activity against *B. subtilis* and *M. luteus*, and that compounds **340**, **341**, **342**, **344**, **346**, **354**, **358**, **359**, and **361** showed activity against *B. subtilis*, *M. luteus*, *E. coli*, and *P. aeruginosa* [32]. The difference in results could be attributed to the extraction methods used.

Dominguez et al. in 2022 published the only article that discusses the effect of glycolic extract of the roots of *P. paniculata* on mixed-species biofilms of *C. albicans* and *S. mutans*, *S. aureus*,



SCHEME 7 | (Continued)

or *P. aeruginosa*. Their main results reported biofilm inhibition to varying degrees [233].

Another important discovery was made by the research groups of Nagalingman and Andrezza, who concluded that the effect of the extract on microorganisms can be potentiated when used with drug delivery systems such as nanoparticles or in combination with other methods such as photosensitization [21, 23].

To date, the trypanocidal and leishmanicidal effects have been evaluated in *A. littoralis* Beauv. ex Moq., *B. portulacoides*, *G. agrestis*, and *P. glomerata*, all of which showed antiparasitic activity [2, 8, 117, 151, 177, 234]. The greatest activity was observed in compound **324** isolated from *A. littoralis*, with IC₅₀ values of 0.23 and 0.16 mM for *T. cruzi* and *L. amazonensis*, respectively. Additionally, it should be noted that compounds **226** and FH from the HaE of *P. glomerata* showed high activity against *T. cruzi*, with IC₅₀ values of 44.78 and 47.86 µg/mL, respectively [8, 177].

Antiviral activity has only been evaluated in vitro and in vivo for *A. philoxeroides*, and the results were promising, as that compound **238** showed in vitro activity against HSV-1, HSV-2, human cytomegalovirus, measles virus, and mumps virus. In a genital herpes model in mice (in vivo) caused by HSV-2, compound **238** was effective, indicating that this compound could be a candidate for an anti-herpes agent. Additionally, compounds **59**, **40**, and **60** significantly blocked the secretion of HBsAg in HepG2.2.15 cells [40, 41].

5.2 | Antioxidant Activity

Antioxidant compounds play a crucial role in protecting the human body against free radicals, including reactive oxygen species (ROS), which can lead to various pathological conditions. These conditions include Alzheimer's disease, anemia, arthritis, asthma, atherosclerosis, cancer, cataracts, liver cirrhosis, diabetes, neurological disorders, Parkinson's disease, cardiovascular diseases, hypertension, hypotension, ischemia, inflammation, Down syndrome, neurodegeneration, and the aging process. Therefore, antioxidant compounds are important in the treatment and prevention of these diseases [14, 77, 151, 224].

In recent years, there has been a growing interest in the antioxidant potential of plants. This interest persists despite the availability of synthetic drugs on the market, as concerns about their safety and toxicity continue to be significant.

To date, 32 articles have discussed the antioxidant potential of the Gomphrenoideae subfamily members, with 2 studies conducted using in vivo models. These studies described the antioxidant potential of 3.54% of the subfamily members (*A. bettzickiana*, *A. brasiliana*, *Alternanthera flavescens*, *A. littoralis* P. Beauv., *A. paronychioides*, *A. philoxeroides*, *A. pungens*, *A. sessilis* (Linn.), *A. tenella* Colla, *G. celosioides*, *G. globosa*, *Gomphrena haageana* K., *I. angustifolia*, *I. herbstii*, *P. glomerata*, *P. paniculata*, *P. townsendii*), evaluating 47 extracts, 22 fractions, and 14 compounds (**24**, **25**, **34**, **43**, **50**, **67**, **70**, **88**, **106**, **129**, **274–275**, **324**, **325**). Additionally,

two extracts contained in nanoparticles, a green leaf juice, a commercial preparation, and a flower infusion were assessed. Scheme 6 summarizes the main methodologies, and Table S2 summarizes the results obtained.

A. brasiliiana was evaluated by five different research groups. Pereira et al. evaluated the antioxidant potential of EE, BuF, DF, and FEA using the DPPH assay, but only FEA exhibited radical scavenging activity, which was dose-dependent [235]. Marchete et al. showed that the HaE of leaves has antioxidant activity, evidenced by an increase in the scavenging capacity of DPPH, FRAP, and ABTS free radicals [193]. Paliwal et al. obtained similar results to Marchete et al., showing that HaE of leaves had higher activity than CIE and ME of leaves [236].

The antioxidant potential of *A. philoxeroides* was evaluated by five different research groups. In general, fraction X of the ME of leaves showed better activity against DPPH and ABTS radicals compared to the HdE of the tender stem, shoots, and leaves, as well as the EE of the whole plant. The IC₅₀ values were 33.94 ± 3.45 µg/mL for DPPH and 60.76 ± 4.31 µg/mL for ABTS [132, 135, 136, 141, 237].

Two research groups demonstrated that the antioxidant potential of *A. pungens* was low [16, 238].

The antioxidant potential of *A. sessilis* was evaluated by eight different authors. The best results for DPPH activity were obtained with the FEA of the ME of leaves (EC₅₀: 10.81 ± 0.29 µg/mL), followed by the CF of the ME of callus (EC₅₀: 34.12 ± 0.67 µg/mL), ME of aerial parts (IC₅₀: 35.39 µg/mL), BuF of the ME of leaves (EC₅₀: 35.71 ± 1.24 µg/mL), AF of the ME leaves (EC₅₀: 35.96 ± 1.28 µg/mL), FEA of the ME of callus (EC₅₀: 43.87 ± 0.39 µg/mL), and BuF of the ME of callus (EC₅₀: 57.11 ± 0.13 µg/mL). The other extracts evaluated showed IC₅₀, EC₅₀, or SC₅₀ values greater than 80 µg/mL [49, 55, 57, 60, 195, 196, 238]. Additionally, Mohd Hazli and Muniandy evaluated the EE of the stem of *A. sessilis*, obtaining IC₅₀ values of >1000 µg/mL and 782 ± 29.9 µg/mL, respectively [55, 57]. Despite the similarity in the results, discrepancies were observed that could be due to differences in the growth conditions of each plant.

The ethanolic extract of *G. celosioides* has been studied in vitro and in vivo. According to the in vitro study, the EE of leaves eliminates the DPPH radicals more efficiently than Trolox. Additionally, in the in vivo rat model, it is capable of reducing TBARS levels and increasing the total antioxidant ability in serum [77, 194, 239].

The antioxidant potential of *G. globosa* has been studied by four research groups. The extracts, commercial preparations, and floral infusions demonstrated antioxidant activity in various assays, including DPPH, FRAP, TBARS, and radical scavenging activities involving O₂⁻ and NO. However, they exhibited high values in EC₅₀ and IC₅₀, in most cases exceeding 500 µg/mL [73, 98, 150, 153].

Dipankar and Murugan, in their study, evaluated the antioxidant potential of EE of *I. herbstii* and AgNPs synthesized using the AqE

of the leaves, concluding that the NPs potentially enhance the antioxidant activity of the extract [231].

Regarding *H. eriantha* (Poir.) Pedersen, it has been reported to have low antioxidant potential [215]. However, in that publication, the plant is cited as *P. paniculata*, which is a synonym of *H. eriantha* according to GBIF (<https://www.gbif.org/es/species/101306355>).

In 2018, Corrêa et al. conducted an analysis on various extracts and compounds derived from the whole plant of *P. townsendii* Pedersen. The study encompassed hexanoic and ethanolic extracts, as well as the hexane, dichloromethane, and hydroalcoholic phases. Additionally, the research included an examination of compounds **67** and **106**, both individually and in combination. The results demonstrated that the mixture of compounds **67** and **106** exhibited the highest DPPH radical scavenging activity, with an EC₅₀ value of 3.7 µg/mL. Individually, compound **67** showed significant activity with an EC₅₀ of 4.9 µg/mL, whereas compound **106** alone had an EC₅₀ of 83.2 ± 2 µg/mL. Remarkably, when compound **106** was combined with compound **67**, there was a 95.55% reduction in the EC₅₀ value, indicating an enhanced activity likely stemming from a synergistic interaction between the two compounds. Notably, the HeE and the hexane phase both displayed the lowest DPPH activity, with EC₅₀ values exceeding 200 µg/mL [127].

5.3 | Anticancer Activity

Cancer is one of the main causes of morbidity and mortality worldwide, characterized by irregular cell growth triggered by genetic or environment stimuli. Currently, chemotherapy remains a primary treatment option; however, it often leads to adverse effects, including the development of cancer cell lines resistant to multiple medications, leading to chemotherapy failure. Therefore, one strategy to combat cancer is the search for bioactive compounds with antiproliferative and antitumoral activities [131, 240].

Currently, 33 articles discuss the in vivo and in vitro anticancer potential of 28 extracts, 16 fractions, 5 NPs, and 22 isolated compounds (**35, 36, 243, 244, 245, 246, 247, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 269, 270, 455, 456, 457**), 3 mixtures of active molecules, and a paste of leaves and plant powder obtained from 3.13% of the members of Gomphrenoideae (*A. betzickiana*, *A. brasiliiana*, *A. flavescens*, *A. philoxeroides*, *A. sessilis*, *A. tenella*, *G. celosioides*, *G. elegans* mart., *G. globosa*, *G. macrocephala*, *G. martiana*, *H. erianthos* (Synm. *Hydrangea paniculata*, Synm. *P. paniculata*), *I. diffusa*, *I. herbstii*). Ten articles discuss their activity in vivo models, and 26 discuss their activity in vitro models. Scheme 7 summarizes the main methodologies, and Table 10 and Table S3 summarize the results obtained.

In vitro activity was evaluated across a range of cancer cell lines. These included four leukemia cell lines (HL60, MT-1, MT-2, MK-1); four colon cancer cell lines (Caco-2, HT-29, HCT-8, HCT116); three pancreatic cancer cell lines (Panc-1, MIA PaCa-2, Capan-1); two prostate cancer cell lines (PC3, Human LNCaP); two breast cancer cell lines (MCF-7 cell, MDA-MB-435); two cervical cancer

lines (HeLa, KB); two cholangiocarcinoma cells (KKU-100, KKU-213); two skin cancer cell lines (B16F10, B-16); one line of lung cancer (A549); one Ehrlich ascites carcinoma cell line (EAC cell); one liver cancer cell line (Hep-G2); one human neuroblastoma cell line (SK-N-SH); a cell line glioblastoma (SF-295); and one oral cavity carcinoma cell line (HSC-2 cells).

The ME of aerial parts of *A. brasiliiana* and *A. flavescens* Kunth. were evaluated against Caco-2 and HT-29 cell lines. In both cell lines, the extract of *A. brasiliiana* was more effective, with the lowest IC₅₀ values: 252.9 ± 5.7 µg/mL for Caco-2 and 160.3 ± 8.5 µg/mL for HT-29 [31]. Regarding HCT-8, it was evaluated only in *G. elegans*, and it was found that HeE from leaves caused the highest percentage of lethality (101.16%), followed by FnH (%L: 100), AqE, and FnB from leaves with 99.68% lethality, and CIE with %L of 79.08%. The other 12 extracts and 8 fractions showed a lethality percentage lower than 30% [156, 241]. The HCT11-6 cell line was evaluated only with the ME of roots of *H. paniculata*, which generated a decline in cell viability [230]. These findings suggest that these four plants exhibit cytotoxic activity against colon cancer cell lines.

The ME of the aerial parts of *A. brasiliiana* and *A. flavescens*, and the pfaffosidic fraction of *H. paniculata* (Syn. *H. eriantha* (Poir.) Pedersen), were evaluated against the Hep-G2 cell line. It was shown that both the extracts and the fraction exhibited activity against this cell line, with the pfaffosidic fraction presenting the highest activity, reducing more than 50% of the cells at a concentration of 100 µg/mL [31, 121].

Five compounds isolated from *A. philoxeroides*, AuNPs from the AqE of *A. sessilis* leaves, the EE from the whole *A. sessilis* plant, AgNPs of the AqE of *I. herbstii* leaves, and the ME of the whole *G. globosa* plant were evaluated against HeLa cells. The results indicated that compounds **455**, **456**, **457**, and **35** isolated from *A. philoxeroides* exhibited the highest activity against this cell line, followed by AgNPs of *I. herbstii*. On the other hand, the EE of *A. sessilis* showed low activity, and *G. globosa* showed no activity [37, 62, 231, 242].

The ME of the whole *G. globosa* plant was evaluated against leukemia cell lines MT-1, MT-2, and MK-1, and the isolated compounds from *A. philoxeroides* (**261–264**) were tested against HL60 cell line. The results showed that *G. globosa* exhibited no cytotoxic activity, whereas all the compounds from *A. philoxeroides* were active against the HL60 cell line. Compound **264** presented the highest activity with an IC₅₀ value of 45.93 µg/mL, whereas compound **263** had the lowest activity, with an IC₅₀ of 271.45 µg/mL [37, 243].

Only one study has evaluated the potential of this subfamily against pancreatic cancer cell lines, obtaining remarkable results. Overall, the ME, PEF, and CF of *A. sessilis* leaves at a concentration of 100 µg/mL reduced survival percentages to less than 2% in Panc-1 cells. Among these, CF presented the highest activity, and the authors also reported that it obtained IC₅₀ values of 13.08 ± 10.40 µg/mL for MIA PaCa-2 and 34.92 ± 2.20 µg/mL for Capan-1 [244].

The isolated compounds from *I. diffuse* (**269** and **270**) were tested against the PC3 and human LNCaP prostate cancer cell lines,

and the AgNPs from AqE of the leaves of *A. sessilis* were tested against the PC3 line. It was found that compounds **269** and **270** showed activity against LNCaP cells. In contrast, the AgNPs of *A. sessilis* showed remarkable activity inhibiting 94.11% of PC3 cells at 25 µg/mL [165, 245].

Currently, seven studies have been conducted to find compounds with cytotoxic activity against breast cancer cell lines. In summary, it was found that MCF-7 cells are sensitive to the AgNPs (IC₅₀: 3.043 µL/mL and 99% of inhibition at 25 µg/mL) and ZnONPs (IC₅₀: 210 µg/mL) of *A. sessilis*, but not to the AuNPs of this same plant. In this cell line, the AgNPs of *A. tenella* also showed activity with an IC₅₀ of 42.5 µg/mL. Additionally, the BE of *P. paniculata* showed cytotoxic activity [70, 124, 184, 228, 246]. Regarding the MDA-MB-435 cell line, different extracts and fractions of *G. elegans* Mart. were evaluated. It was shown that AqE and FnB at a concentration of 100 µg/mL generated a lethality percentage of 97.39, whereas HeE and FnH reached lethality percentages of 96.35. However, the other 13 extracts and 8 fractions at this same concentration obtained lethality percentages lower than 50% [155, 241].

Two studies have evaluated the cytotoxic potential against skin cancer cell lines. In this context, the compounds **255**, **256**, **257**, **258**, **259**, and **260**, isolated from *P. paniculata*, were tested against the B-16 cell line. Compound **260** presented the highest activity with an IC₅₀ of 30 µg/mL, and the compound with the lowest activity was **259**, with an IC₅₀ of 120 µg/mL [125, 164]. In contrast, the ME of the whole plant of *G. globosa* was inactive against B16F10 [247].

A total of 6 of the 10 in vivo studies aimed to find a bioactive substance for treating Ehrlich carcinoma. Remarkably, the EaE of the leaves of *A. brasiliiana*, the AqE of the aerial parts of *A. tenella* Colla, the BuF from *P. paniculata* root, and 20 and 60 mg/kg of the mixture of flavonoids (**6**, **7**, **10**, **17**) isolated from *G. martiana* increased the survival of mice with EAC. However, only the extract of *A. brasiliiana* and *A. tenella* reduced viable cells. Additionally, the mixture of flavonoids inhibited tumor formation by 32%, and the root powder of *P. paniculata* and the EaE of *A. brasiliiana* reduced the volume of EAC [66, 100, 185, 207]. It should also be noted that Pinello et al. [210] evaluated the anticancer potential of the ME of *P. paniculata* root, focusing on macrophage activity. They found that the ME increased peritoneal macrophages and phagocytosis, suggesting that the anticancer activity of *P. paniculata* may result from the stimulation of macrophages, natural killer cells, and cytotoxic T lymphocytes [210]. In conclusion, the extracts of *A. brasiliiana* and *A. tenella* have antitumor activity, the mixture of compounds has moderate cytotoxic activity, and the root powder and BuF of *P. paniculata* have an antineoplastic effect.

Da Silva et al. [208, 211] demonstrated that *P. paniculata* root powder has anti-hepatocarcinogenic properties, reducing liver lesions and adenoma in mice. The chemopreventive effect is attributed to the inhibition of cell proliferation and an increase in apoptotic processes [208, 211]. However, *A. sessilis* exhibited no activity against squamous cell adenocarcinoma of the stomach in mice [206].

5.4 | Analgesic and Antinociceptive Activity

Pain, a sensory perception, often represents the primary symptom in the diagnosis of various diseases. Considered a global public health issue, the search for treatments to alleviate or control pain is crucial. Among these treatments, the use of medicinal herbs and their compounds stands out [190, 191, 248, 249].

It should be noted that many medications commonly used to treat pain have unwanted side effects, including respiratory depression, drowsiness, decreased gastrointestinal motility, nausea, gastric ulcers, hepatotoxicity, and various disorders of the autonomic nervous and endocrine systems. Furthermore, many of them do not reduce pain in all treated individuals [191, 248, 249]. This highlights the need to search for new bioactive compounds with analgesic activity that lacks side effects.

Currently, 11 articles discuss the analgesic potential of eleven extracts and 2 isolated compounds from 7 members of the Gomphrenoideae subfamily. The results are described in Table 10. In the acetic acid-induced abdominal contractions assay, extracts from *A. brasiliiana*, *A. philoxeroides*, *A. sessilis*, *G. celosioides*, and *P. glomerata* all showed a reduction in the number of contractions. Notably, the AqE of *A. brasiliiana* and the ME of *A. sessilis* exhibited better activity than dipyrone and aspirin, respectively [30, 39, 87, 118, 133, 204, 205]. In the carrageenan-induced paw edema assay, the EE of *A. maritima* (Mart.) A.St.-Hil. (Synm. *A. littoralis* Beauv. ex Moq.), *A. tenella*, *B. portulacoides*, *G. celosioides*, and compounds **43** and **72** showed inhibition of mechanical hyperalgesia induced by carrageenan. Compound **43** achieved 100% inhibition of hyperalgesia [34, 67, 71, 78].

In the hot plate test, the EE of the whole plant of *A. sessilis* and the AqE of *G. celosioides* increased the reaction time, indicating an analgesic effect on the central nervous system. However, the HaE of the roots and rhizomes of *P. glomerata* showed no effect, indicating the absence of analgesic activity [87, 118, 133].

In the carrageenan-induced cold allodynia test, the EE of the whole plant of *A. tenella* Colla and the EE of the aerial parts of *G. celosioides* inhibited the response to cold, with the EE of the *A. tenella* showing the highest activity. However, compound **43** did not show any effect in this test. These same extracts and compound **43** were evaluated in the zymosan-induced articular inflammation assay, where all reduced mechanical hyperalgesia and inhibited edema [67, 78].

5.5 | Anti-Inflammatory Activity

Inflammatory diseases, such as asthma, rheumatoid arthritis, psoriasis, autoimmune diseases, and severe autoinflammatory diseases, develop due to the overproduction of pro-inflammatory mediators. For this reason, their inhibition has therapeutic value in the development of anti-inflammatory agents [73, 250].

Over time, GCs have been used to treat various inflammatory disorders characterized by their effectiveness, but their chronic use causes undesirable adverse effects, such as skin atrophy, inhibition of wound healing, osteoporosis, obesity, hyperglycemia, and glaucoma [71, 250].

It should be noted that the anti-inflammatory compounds caffeic acid, ferulic acid, vanillic acid, and catechin have been isolated from *G. celosioides* [78].

To date, 21 studies have been carried out to evaluate the anti-inflammatory activity of extracts, fractions, infusions, isolated compounds, and commercial preparations of 2.30% of the members of the Gomphrenoideae subfamily, with 7 studies conducted using in vitro models and fifteen using in vivo models. Tables 7 and 10 provide detailed information on these studies.

Regarding in vitro activity, extracts of *A. sessilis*, *G. celosioides*, *G. globosa*, and *Gomphrena haageana* Klotzsch have been shown to reduce NO levels [56, 73, 98, 194]. Additionally, the extract of *G. celosioides* and *A. sessilis* reduces COX-2 expression levels [56, 194]. The EE of *A. sessilis* also reduces the viability of RAW 264.7 cells, proinflammatory cytokines, and PGE₂, as well as prevents the activation of the NF- κ B pathway. However, none of the extracts of *G. celosioides* affect RAW 264.7 cell viability [194].

The in vivo anti-inflammatory activity was evaluated in most of the studies through edema or pleuritis induced by carrageenan. The results showed that the extracts of *A. maritima* [34], *A. tenella* Colla [213], *B. portulacoides* [71], *G. celosioides* [77, 87], *P. glomerata* [118, 119], and *P. townsendii* [127], as well as compound **72** isolated from *A. maritima* [34], and compounds **67** and **106** isolated from *P. townsendii* [127], exhibited inhibition of edema formation. The best activity was observed in compounds **67** and **106**, which at a concentration of 1 mg/kg, were able to inhibit edema by 75.4% \pm 4.0% and 73.00% \pm 4.0%, respectively [127]. This was followed by the activity of the HaE of *P. glomerata*, which showed an ID₅₀ of 20.4 mg/kg for the intraperitoneal dose and an ID₅₀ of 60.5 mg/kg for the oral dose [119]. The least efficient extract was that of *G. celosioides*, which, at a concentration of 400 mg/kg, only achieved a 39.62% inhibition of edema [87].

Regarding the anti-inflammatory activity in the carrageenan-induced pleuritis model, it was observed that the extracts of *A. tenella* Colla [67], *B. portulacoides* [71], *P. townsendii* [127], compound **72** isolated from *A. maritima* [34], and compounds **67** and **106** isolated from *P. townsendii* [127] reduced leukocyte migration to the pleura. Compound **72** showed the greatest inhibition at a concentration of 10 mg/kg (%I: 77) [34]. Compounds **67** and **106** also showed high activity, with an inhibition of 50.7% \pm 1.03% and 59.4% \pm 1.25%, respectively, at a concentration of 1 mg/kg [127]. In this test, it was also observed that compound **72** and the extract of *B. portulacoides* reduced protein extravasation [34, 71]. The EE of *A. maritima* [34] and *A. tenella* Colla [67], as well as compound **43** [67], reduced the number of leukocytes, with the extract of *A. maritima* showing the best activity (%I: 68) [34, 67]. Additionally, the AqE of *A. brasiliiana* reduced the number of lymphocytes, polymorphonuclear cells, and exudate [30]. These results suggest that both the extracts and the isolated compounds have anti-inflammatory activity.

It should be noted that the EE of leaves from *A. brasiliiana* also reduced the formalin-induced edematogenic process [26]. The EE of the whole plant of *A. tenella* Colla and compound **43** inhibited the formation of zymosan-induced edema [67]. The EE of *B. portulacoides* inhibited *Bothrops jararacussu* venom, BthTX-I, and BthTX-II-induced edema formation but did not

TABLE 7 | Anti-inflammatory activity of the Gomphrenoideae subfamily.

Species	Extract(s)/			Activity			References	
	Compounds	Assay method	Model	Dose	Positive control	Values		Analysis
<i>Alternanthera brasiliana</i>	HaE of leaves	ELISA IL-6	RAW 264.7 cells	10.0, 50.0, and 100.0 µg/mL	Gallic acid and quercetin	↓ Production of IL-6	↓ The production of IL-6 and TNF-α in a dose-dependent manner	[193]
		ELISA TNF-α	RAW 264.7 cells	10.0, 50.0, and 100.0 µg/mL	Gallic acid and quercetin	↓ Production of TNF-α	Significantly ↓ free radical (NO and O ₂ ⁻)	
	EE of stems	NO releasing	RAW 264.7 cells	10.0, 50.0, and 100.0 µg/mL	Gallic acid and quercetin	IC ₅₀ : 79.2 ± 5.7 µg/mL		[56]
		Inhibition of O ₂ ⁻ production	RAW 264.7 cells	10.0, 50.0, and 100.0 µg/mL	Gallic acid and quercetin	IC ₅₀ : 72.1 ± 6.0 µg/mL		
<i>Gomphirena celosoides</i>	Extract	Cell viability (MTT method)	RAW 264.7 cells	25, 50, 100, 200, 300, 400, and 500 µg/mL	—		500 µg/mL ↓ cell viability by 80%	[56]
		NO releasing	RAW 264.7 cells	50, 100, and 200 µg/mL	Dexamethasone		↓ NO levels in a dose-dependent manner	
	367	ELISA	RAW 264.7 cells	50, 100, and 200 µg/mL	Dexamethasone		Significantly suppresses the production of PGE ₂ , IL-6, IL-1β, and TNF-α	[195]
		Immunocytochemistry	RAW 264.7 cells	50, 100, and 200 µg/mL	Dexamethasone		Inhibit the translocation of the NF-κB subunit p65 to the nucleus	
512	Protein expression analysis	RAW 264.7 cells	50, 100, and 200 µg/mL	—		↓ The expression of iNOS and COX-2	[195]	
	NO releasing	RAW 264.7 cells	10 mg/mL	BSA		Prevents phosphorylation of IκBα and, consequently, activation of NF-κB p65		
20-Hydroxycyclosone-20,22-monoacetone	AqE of inflorescences	Determination of COX-2	RAW 264.7 cells	Uninformed	Celecoxib		%I: 31.1	[178]
		NO determination	RAW 264.7 cells	Uninformed	L-NMMA		%I: 59.4	
<i>Gomphirena globosa</i>	EB of inflorescences	Cell viability (MTT and LDH assays)	RAW 264.7 cells	Uninformed	Dexamethasone		NDNS	[98]
		NO determination	RAW 264.7 cells	Uninformed	Dexamethasone		IC ₅₀ : 19.55 ± 0.61 µM	
	Commercial preparation	Cell viability (MTT and LDH assays)	RAW 264.7 cells	Uninformed	Dexamethasone		IC ₅₀ : 97.35 ± 1.14 µM	[98]
		NO determination	RAW 264.7 cells	Uninformed	Dexamethasone		NDNS	
<i>Gomphirena globosa</i> var. <i>albiflora</i> (white amaranth)	HE of flowers	Cell viability (MTT and LDH assays)	RAW 264.7 cells	Uninformed	Dexamethasone		NDNS	[73]
		NO determination	RAW 264.7 cells	Uninformed	Dexamethasone		NDNS	
	HE of flowers	NO determination	RAW 264.7 cells	Uninformed	Dexamethasone		EC ₅₀ (µg/mL): 198 ± 5	[73]
		NO determination	RAW 264.7 cells	Uninformed	Dexamethasone		EC ₅₀ (µg/mL): 136 ± 4	
<i>Gomphirena sp.</i> (pink globe amaranth)	HE of flowers	NO determination	RAW 264.7 cells	Uninformed	Dexamethasone		EC ₅₀ (µg/mL): 133 ± 7	(Continues)
		NO determination	RAW 264.7 cells	Uninformed	Dexamethasone		EC ₅₀ (µg/mL): 133 ± 7	

(Continues)

TABLE 7 | (Continued)

Species	Extract(s)/ Compounds	Assay method	Model	Dose	Positive control	Values	Activity		References
							Analysis		
<i>Puffia glomerata</i>	FD of roots	NO determination	BMDM (bone marrow-derived macrophage)	250, 25, 2.5, and 0.25 µg/mL	—	NDNS	The highest concentrations evaluated (250 and 25 µg/mL) of the two fractions ↓	[162]	
	FD of aerial part					NDNS	NO production. Only the FD of roots at a concentration of 0.25 µg/mL was able to ↓ the NO production of cells stimulated with LPS		

Abbreviations: EE, ethanolic extracts; ELISA, enzyme-linked immunosorbent assay; FD, fraction of DCM; HaE, hydroalcoholic extract; HE, hydromethanolic extracts; IL-6, interleukin-6; LDH, lactate dehydrogenase; NDNS, numerical data not shown; TNF- α , tumor necrosis factor alpha.

affect leukocyte migration [214]. HaE from roots of *P. glomerata* reduced edema induced by bradykinin, substance P, histamine, serotonin, and LPS [119], and the ME of *P. paniculata* roots reduced colonic and intestinal inflammation, the latter being related to the modulation of the expression and production of MAPKs and mucin [120, 215].

5.6 | Antidiabetic Activity and Antihyperglycemic Activity

Diabetes is a disease that is spreading rapidly throughout the world, and every year the number of people suffering from this disease increases. In 2016, the WHO reported that 400 million people were affected by diabetic disorder, and in 2017, the IDF reported that 425 million people had diabetes mellitus. It is estimated that by 2045, the number of people with diabetes will rise to 629 million. Additionally, diabetes can lead to the development of other diseases, including cardiovascular, kidney, and eye diseases, as well as stroke and lower limb amputation [15, 204].

Currently, diabetes can be treated with insulin or hypoglycemic agents, but both can cause side effects such as hypoglycemia, weight gain, gastrointestinal upset, nausea, diarrhea, liver dysfunction, jaundice, and heart failure [15].

It should be noted that around 400 plant species and their metabolites are used to treat diabetes mellitus worldwide. The antioxidant potential of medicinal plants is a key factor in reducing the incidence of diabetic complications [15].

Currently, eight studies have evaluated the antidiabetic and/or antihyperglycemic potential of five extracts, fourteen fractions, five compounds, and a green juice, representing 0.83% of the members of the Gomphrenoideae subfamily (Tables 8 and 10).

In the in vitro studies, the inhibition of α -glucosidase was evaluated for fraction X of *A. philoxeroides*, the green leaf juice of *A. sessilis*, and eight fractions of the latter plant. The results demonstrated that all the evaluated substances had α -glucosidase inhibitory activity. The most potent activity was observed in fraction X of *A. philoxeroides* (IC_{50} : 52.41 ± 5.22 µg/mL), whereas the weakest activity was found in the FH of the ME of *A. sessilis* leaves (EC_{50} : 6.31 ± 1.70 mg/mL) [141, 195, 196]. It was also described that *A. paronychioides* has a preventive action on diabetic glucotoxicity [35], and among the five compounds isolated from *G. celosioides* (162, 166, 187, 190, 271), compound 190 showed a significant improvement in glucose uptake and the highest inhibitory effect on PTP1B, indicating its potential for use in the prevention and treatment of Type 2 diabetes [84].

As for the in vivo studies, they were generally analyzed using the OGTT. Notably, the ME of the entire *A. philoxeroides* plant [39], the ME of aerial parts of *A. sessilis* [204], and the FEA of the EE from the aerial parts of *A. sessilis* [212] reduced glucose levels in a manner comparable to GLB. It should also be noted that neither the green juice nor HF and FA of *A. sessilis* reduced glucose levels [195, 212].

TABLE 8 | Antidiabetic and antihyperglycemic activity of the Gomphrenoideae subfamily.

Species	Extract(s)/ Compounds	Assay method	Model	Dose	Positive control	Activity	References
<i>Alternanthera paronychioides</i>	ME	CAA assay	HepG2	Uninformed	—	EE presented the highest antioxidant activity (175.8 ± 1.7 µM QE/g)	[35]
<i>Alternanthera philoxeroides</i>	EE	CAA assay	HepG2	Uninformed	—	EE did not show a cytotoxic effect, on the contrary, inhibited 90% of the cytotoxicity induced by HG in HIT-T15 cells	EE inhibits: HG-induced ROS production, cell accumulation in sub-G1, cell apoptosis by up to 14%, activation and activity of caspases 3 and 9, cleavage of PARP EE ↑ ΔΨm and attenuates the ↑ in Bax/ Bcl-2 ratio EE ← PDX1 translocation in RIN-m5F cells and ↑ the level of insulin secretion
		MTT assay	HIT-T15	10–100 µg/mL	Ferulic acid and quercetin		
	Staining with PI and DAPI	RIN-m5F	20 and 50 µg/mL	Quercetin			
		HIT-T15	20 and 50 µg/mL	Quercetin			
	ΔΨm analysis	HIT-T15	50 µg/mL	Quercetin			
		HIT-T15	20 and 50 µg/mL	Quercetin			
	Western blot analysis	RIN-m5F	20 and 50 µg/mL	Quercetin			
		HIT-T15	20 and 50 µg/mL	Quercetin			
	AqE	ELISA	RIN-m5F	20 and 50 µg/mL	Quercetin		
			HepG2	Uninformed	—		
<i>Alternanthera philoxeroides</i>	Fraction X of ME of leaves	α-Glucosidase inhibition assay	—	20, 40, and 60 µg/mL	Luteolin	%I ₆₀ µg/mL: 58.2 and IC ₅₀ : 52.41 ± 5.22	[141]
		Prevention of Hb glycation	—	200 µL	—	—	NE
<i>Alternanthera sessilis</i>	Green leaf juice	α-Amylase inhibition assay	Pancreatic α-amylase	—	—	Potent α-glucosidase inhibitor	
		α-Glucosidase inhibition assay	Rat intestinal α-glucosidase	20 µL	—	IC ₅₀ : 0.22 ± 0.0 mg/mL acarbose equivalent	

(Continues)

TABLE 8 | (Continued)

Species	Extract(s)/ Compounds	Assay method	Model	Dose	Positive control	Activity	References
<i>Alternanthera sessilis</i>	FH of ME of leaves	α -Glucosidase inhibition assay	—	Uninformed	Acarbose EC ₅₀ : 6.31 ± 1.70 mg/mL	Callus fractions exhibited higher antiglucosidase activity than leaf fractions The FEA of leaves, and FH, CF, and FEA of callus showed an EC ₅₀ lower than acarbose. In contrast, the AF of leaves, and BuF and AF of callus exhibited glucosidase-stimulating activity	[196]
	CF of ME of leaves	α -Glucosidase inhibition assay	—	Uninformed	Acarbose EC ₅₀ : 4.89 ± 1.67 mg/mL	The FEA of leaves and callus have been identified	
	FEA of ME of leaves	α -Glucosidase inhibition assay	—	Uninformed	Acarbose EC ₅₀ : 0.55 mg/mL	As noncompetitive and competitive α -glucosidase inhibitors, respectively	
	BuF of ME of leaves	Lineweaver–Burk plot analysis α -Glucosidase inhibition assay	—	0, 550, and 825 μ g/mL Uninformed	Acarbose EC ₅₀ : 2.95 ± 0.31 mg/mL		
	AF of ME of leaves	α -Glucosidase inhibition assay	—	Uninformed	Acarbose EC ₅₀ : Nd		
	FH of ME of callus	α -Glucosidase inhibition assay	—	Uninformed	Acarbose EC ₅₀ : 0.67 ± 0.05 mg/mL		
	CF of ME of callus	α -Glucosidase inhibition assay	—	Uninformed	Acarbose EC ₅₀ : 0.90 ± 0.11 mg/mL		
	FEA of ME of callus	α -Glucosidase inhibition assay	—	Uninformed	Acarbose EC ₅₀ : 0.25 ± 0.01 mg/mL		
		Lineweaver–Burk plot analysis	—	0, 250, and 375 μ g/mL	Acarbose EC ₅₀ : 0.063 ± 0.009 for 375 μ g/mL		

(Continues)

TABLE 8 | (Continued)

Species	Extract(s)/ Compounds	Assay method	Model	Dose	Positive control	Activity	References
	BuF of ME of callus	α -Glucosidase inhibition assay	—	Uninformed	Acarbose	EC ₅₀ : Nd	
	AF of ME of callus	α -Glucosidase inhibition assay	—	Uninformed	Acarbose	EC ₅₀ : Nd	
<i>Gomphrena celosioides</i>	271	PTPIB inhibition assay	—	50 mM	Ursolic acid	40.21% \pm 1.69%	[84]
		Measuring glucose uptake	3T3-L1 adipocytes	20 μ M	Insulin	% 2-NBDG absorbance: \cong 125	
	162	PTPIB inhibition assay	—	50 mM	Ursolic acid	17.89% \pm 2.76%	
		Measuring glucose uptake	3T3-L1 adipocytes	20 μ M	Insulin	% 2-NBDG absorbance: \cong 118	
	166	PTPIB inhibition assay	—	50 mM	Ursolic acid	8.10% \pm 5.19%	
		Measuring glucose uptake	3T3-L1 adipocytes	20 μ M	Insulin	% 2-NBDG absorbance: 100	
	187	PTPIB inhibition assay	—	50 mM	Ursolic acid	28.64% \pm 8.01%	
		Measuring glucose uptake	3T3-L1 adipocytes	20 μ M	Insulin	% 2-NBDG absorbance: \cong 122	
	190	PTPIB inhibition assay	—	50 mM	Ursolic acid	80.39% \pm 6.88%	
		Measuring glucose uptake	3T3-L1 adipocytes	20 μ M	Insulin	% 2-NBDG absorbance: \cong 138	

Abbreviations: AF, aqueous fraction; CAA, cellular antioxidant activity; CF, chloroform fraction; DCFH-DA, 6-carboxy-2',7'-dichlorodihydrofluorescein diacetate; EE, ethanolic extracts; ELISA, enzyme-linked immunosorbent assay; FEA, fraction of ethyl acetate; FH, fraction of hexane; ME, methanolic extracts.

5.7 | Hepatoprotective Activity

The liver is responsible for regulating several important metabolic functions, and injury to this organ can disrupt these functions [251]. Liver damage typically involves oxidative stress and is characterized by a progressive evolution from steatosis to chronic hepatitis, fibrosis, and cirrhosis [252].

Currently, liver diseases are treated with corticosteroids, vaccines, and antivirals. However, these treatments often cause side effects, particularly with chronic or subchronic use. This highlights the necessity of finding new phytotherapeutic drugs that are both safe and more effective [252].

To date, only four in vivo studies on the hepatoprotective activity of members of this subfamily have been conducted (Table 10). The HaE from the leaves of *A. brasiliiana* L. [236], the ME from the entire *A. sessilis* plant [51], the AqE from the stems and leaves of *G. celosioides* [90], and AqE from *G. globosa* L. [218]. All studies showed an improvement in the antioxidant profile and a reduction in liver damage [51, 90].

5.8 | Other Activities

Other activities have been studied in members of the Gomphrenoideae subfamily, as shown in Tables 9 and 10. An analysis of some of these activities will be presented below.

5.8.1 | Neurological Activity

To date, 14 investigations have been carried out to evaluate the potential of fourteen extracts, 10 fractions, 6 compounds, and an infusion of aerial parts of 7 members of this subfamily. Among the isolated compounds of *A. philoxeroides* (5, 35, 36, 41, 79), compound 35 exhibited the highest inhibitory activity against MAO-A (IC_{50} : $0.00046 \pm 0.04 \mu\text{M}$), higher than that of Clorgyline. Compound 36 showed the highest inhibitory activity against MAO-B (IC_{50} : $0.00022 \pm 0.12 \mu\text{M}$) and inhibited the formation of toxic $A\beta$ plaques (%I: 81.96 ± 2.14), exhibiting greater activity than curcumin in the latter. It should be noted that all these compounds demonstrated greater inhibition of MAO-A and MAO-B than the EE of this plant. These results are significant because monoamine oxidases are enzymes related to cognitive dysfunction and depression. Therefore, it can be suggested that these flavonoids have antidepressant activity. Furthermore, these five flavonoids play an important role in the search for anti-Alzheimer's compounds, since preventing $A\beta$ aggregation is one of the objectives for the development of therapeutic strategies. In general, these flavone derivatives exhibit an antidementia effect [38, 135]. Additionally, the EE of the entire *A. philoxeroides* plant was evaluated in an in vivo model, showing that it improves recognition, spatial working, and reference memory in ovariectomized mice, indicating its potential to prevent senile dementia [135].

The inhibition of AChE and BChE was also evaluated in the EE of *A. philoxeroides*, but this extract did not exert a significant effect on these neurotransmitters [135]. A similar result was previously obtained by Silva and collaborators, who evaluated two extracts (AqE and EB) and a commercial preparation of inflorescences

of *G. globosa* L. and found that none of these substances were capable of inhibiting AChE [98].

Kim (2019) conducted an in vivo and in vitro study to determine whether the EE of the aerial parts of *Iresine celosia* L. (Syn. of *I. dif-fusa* Humb. & Bonpl. ex Willd.) had an anti-neuroinflammatory effect. In the in vitro study, the extract reduced cytokine levels and inflammatory mediators in the microglia, partly due to the inhibition of the MAPKs/NF- κ B signaling pathway. In the in vivo study, the researchers concluded that the EE improves behavioral dysfunctions caused by neuroinflammation in mice. These results suggest that the extract is a potential therapeutic agent for treating neuroinflammation associated with neurodegenerative diseases such as Parkinson's, Alzheimer's, and Huntington's [104].

The aqueous and methanol extracts of *I. herbstii* were shown to affect the CNS by interacting with dopamine and serotonin receptors, suggesting their potential for treating diseases such as Parkinson's and schizophrenia [108, 201]. Regarding *A. brasiliiana*, researchers found that the infusion of its aerial parts increases exploratory activity but has no effect on anxiety [30]. Meanwhile, the ME exhibited anxiolytic, sedative, and anticonvulsant effects [24]. In 2014, Mondal reported that the EE of *A. sessilis* has central stimulant activity [133]. It is also worth noting that *P. glomerata* was studied by three different research groups, which found that the EE of its roots and rhizomes did not have robust effects on depression and anxiety [219]. The HaE of the root exhibited stimulating effects, improved the acquisition and retention of behaviors, and partially reversed age-related memory deficits [116]. Finally, the HF of ME of root was found to reduce stress and depressive behaviors and protect against anxiety development, possibly by maintaining antioxidant defenses and reducing oxidative damage [114, 219].

5.8.2 | Gastrointestinal Activity

Eight articles are currently discussed the gastrointestinal activity of 14 extracts and 8 fractions of 5 members of the Gomphrenoideae subfamily. It has been reported that the aqueous, methanolic, and hexanolic extracts of *A. repens* (Syn. *A. sessilis* (L.) R.Br. ex DC. and *A. pungens* Kunth), as well as six fractions of the ME, exhibit spasmolytic activity according to in vitro studies [216]. The AqE, EE, and ME of this plant also demonstrate antidiarrheal activity in vivo models [46, 47, 216]. Similarly, Saquib and Janbaz reported that the EE of *A. sessilis* has spasmolytic activity based on in vitro study results [64]. Additionally, it was reported that ME from the leaves of *G. celosioides* has an antiulcerogenic effect (both preventive and curative), which is likely related to its antioxidant activity [88, 217]. The HaE of *Guilleminea densa* (Humb. & Bonpl. ex Schult.) Moq. leaves have been shown to have a gastroprotective effect. It can inhibit gastric lesions induced by indomethacin, ethanol, cold immobilization, or stress. Additionally, it increases gastric mucus, demonstrating an enhancing effect on the protective mucosal barrier. Finally, it inhibits the presence of ulcers, erosive gastritis, acute inflammation infiltration, and focal hemorrhage [102]. Freitas reported in 2004 that the AqE from roots and rhizomes of *P. glomerata* exerts a protective effect on the gastric mucosa [159].

TABLE 9 | Other activities of the Gomphrenoideae subfamily.

Species	Extract(s)/Compounds	Assay method	Model	Dose	Positive control	Activity		References
						Values	Analysis	
Activity in blood cells								
<i>Alternanthera bettzickiana</i>	AqE of leaves	Emmel test	Sickle cell blood	0, 5, 10, 15, and 20 µg/mL	Parahydroxybenzoic acid	% of normalization: 86 for 11 µg/mL	It has an antiskicking effect since the RBCs maintain a circular (biconcave) and normal shape	[18]
<i>Puffia paniculata</i>	Commercial capsule powder	Ektactometric studies	RBCs	0–0.5 mg/mL	—	↑ The deformity index indicates improvement in cellular hydration, which is independent of density. Also ↑ the mean corpuscular volume, Na ⁺ , and ↓ the mean cell hemoglobin []		[239]
<i>Puffia paniculata</i>	Extract of commercial powder	Hematological and RBC deformability measurement	RBCs	0.2 or 0.5 mg/mL	—	0.5 mg/mL ↑ the deformity of falciform cells		[240]
Activity related to the urinary system								
<i>Gomphrena celosoides</i>	367	Xanthine oxidase inhibitory activity	—	Uninformed	Allopurinol	IC ₅₀ : 81.04 ± 0.49 µM	The inhibitory action of xanthine oxidase was most evident in compound 512	[183]
	512			Uninformed	Allopurinol	IC ₅₀ : 33.78 ± 0.49 µM		
	20-Hydroxyecdysone-20,22-monoacetone			Uninformed	Allopurinol	IC ₅₀ : 101.15 ± 0.48 µM		
Anti-aging activities								
<i>Gomphrena globosa</i>	HaE of flowers	Determination of anti-elastase activity	Neutrophil elastase	100 and 250 µg/mL	SPCK	NDNS	Elastase and collagenase inhibitory activity were [] dependent	[156]
		Determination of anti-collagenase activity	Collagenase	100 and 250 µg/mL	1,10-Phenanthroline	%I ₂₅₀ µg/mL, about 40%	HaE has significant anti-collagenase properties	
Anti-allergy activity								
<i>Alternanthera sessilis</i>	EE of aerial parts	Measurement of LDH release	RBL-2H3 cells	25, 50, and 100 µg/mL	—	NE	↓ The release of β-hexosaminidase in a []-dependent manner	[24]
		β-Hexosaminidase secretion assay	RBL-2H3 cells sensitized with DNP-specific IgE	25, 50, and 100 µg/mL	—	NDNS	↓ Intracellular Ca ²⁺ levels	
		Ca ²⁺ measurement	RBL-2H3 cells sensitized with DNP-specific IgE	25, 50, and 100 µg/mL	—	NDNS	Suppresses the release of IL-6, TNF-α, IL-4, and IL-13	
		Measurement of IL-6, TNF-α, IL-13, and IL-4 (ELISA=)	RBL-2H3 cells sensitized with DNP-specific IgE	25, 50, and 100 µg/mL	—	NDNS	↓ Degradation of IκBα and nuclear translocation of p65 NF-κB	
		Western Blot Analysis	RBL-2H3 cells sensitized with DNP-specific IgE	25, 50, and 100 µg/mL	—	NDNS	Suppresses antigen-induced degranulation of RBL-2H3 cell	

(Continues)

TABLE 9 | (Continued)

Species	Extract(s)/Compounds	Assay method	Model	Dose	Positive control	Activity		References
						Values	Analysis	
Antiarthritic activity								
<i>Alternanthera bettzickiana</i>	EE of aerial parts	Egg albumin denaturation inhibition	—	50, 100, 200, 400, 800, 1600, 3200, and 6400 µg/mL	Diclofenac sodium	%I ₆₄₀₀ µg/mL: 94.23%	Dose-dependent activity	[19]
		Protein denaturation using BSA				%I ₆₄₀₀ µg/mL: 97.43 ± 0.70	The results of the EE were better than those of the standard drug	
Anticoagulant activity								
<i>Alternanthera philoxeroides</i>	ME of whole plant	PTT test	—	250, 500, and 1000 µg/mL	—	To 1000 µg/mL: 13.26	Showed significant anticoagulant activity of ME	[138]
	Tannic acid	aPTT tests	—	10 µg/mL	—	To 1000 µg/mL: 66.28	According to PT, vanillic acid exhibited the highest anticoagulant activity, whereas in aPTT, tannic acid had the highest activity	
	Gallic acid	PTT test	—	10 µg/mL	—	12.62		
		aPTT tests	—	10 µg/mL	—	57.54		
		PTT test	—	10 µg/mL	—	13.33		
		aPTT tests	—	10 µg/mL	—	56.26		
	Catechin	PTT test	—	10 µg/mL	—	11.71		
		aPTT tests	—	10 µg/mL	—	56.87		
	Vanillic acid	PTT test	—	10 µg/mL	—	15.91		
		aPTT tests	—	10 µg/mL	—	56.14		
Antidepressant activity								
<i>Alternanthera philoxeroides</i>	EE of whole plant	Estrogenic activity (cell-based assay)	MCF-7	1–100 µg/mL	17β-Estradiol	EqE ₁₀₀ = 1.68 µg/mL	1.68 µg/mL is equally effective as 100 pM of 17β-estradiol	[38]
Anti-diarrhea and/or anti-dysentery activity								

(Continues)

TABLE 9 | (Continued)

Species	Extract(s)/Compounds	Assay method	Model	Dose	Positive control	Activity		References
						Values	Analysis	
<i>Alternanthera repens</i>	AqE of leaves	[-]-response curves to CaCl ₂	Ileum of rats	0.56, 1.09, or 2.09 mg/mL	—	IC ₅₀ : 0.25 ± 0.03 mM at a [] of 0.56 mg/mL	AqE, ME, and F2 to F4 have a spasmodic effect on the CaCl ₂ -induced contractions, with ME showing the highest activity	[47]
		Relaxant effect on K ⁺ -C	Ileum of rats	0.56, 1.09, or 2.09 mg/mL	—	IC ₅₀ : 0.82 ± 0.01 mM at a [] of 0.56 mg/mL	ME, AqE, and F2 to F4 inhibit the stimulatory effect of KCl; therefore, their mechanism of action is CCB	
		Inhibition of dose-response curves to 5-HT	Ileum of rats	0.56, 1.09, or 2.09 mg/mL	—	IC ₅₀ : 7.19 ± 0.04 × 10 ⁻⁸ M at a [] of 0.56 mg/mL	All extracts and F2 to F4 inhibited 5-HT-induced ileum contractions, presenting a spasmodic effect	
		[-]-response curves to ACh	Ileum of rats	2.09 mg/mL	—	%I: 58.6		
	HeE of leaves	[-]-response curves to CaCl ₂	Ileum of rats	0.24, 0.47, or 0.91 mg/mL	—	IC ₅₀ : 72.68 ± 0.08 × 10 ⁻⁶ M		
		Relaxant effect on K ⁺ -C	Ileum of rats	0.24, 0.47, or 0.91 mg/mL	—	NE		
		Inhibition of dose-response curves to 5-HT	Ileum of rats	0.24, 0.47, or 0.91 mg/mL	—	IC ₅₀ : 5.44 ± 0.08 × 10 ⁻⁶ M at a [] of 0.24 mg/mL		
	ME of leaves	[-]-response curves to CaCl ₂	Ileum of rats	0.24, 0.47, or 0.91 mg/mL	—	IC ₅₀ : 0.18 ± 0.061 mM at a [] of 0.24 mg/mL		
		Relaxant effect on K ⁺ -C	Ileum of rats	0.24, 0.47, or 0.91 mg/mL	—	IC ₅₀ : 0.043 ± 0.001 mM at a [] of 0.24 mg/mL		
		Inhibition of dose-response curves to 5-HT	Ileum of rats	0.24, 0.47, or 0.91 mg/mL	—	IC ₅₀ : 2.24 ± 0.06 × 10 ⁻⁷ M at a [] of 0.24 mg/mL		
Six DF of ME	[-]-response curves to CaCl ₂	Ileum of rats	0.66 mg/mL	—	NDNS			
	Relaxant effect on K ⁺ -C	Ileum of rats	0.66 mg/mL	—	NDNS			
	Inhibition of dose-response curves to 5-HT	Ileum of rats	0.24, 0.47, or 0.91 mg/mL	—	NDNS			

(Continues)

TABLE 9 | (Continued)

Species	Extract(s)/Compounds	Assay method	Model	Dose	Positive control	Activity		References
						Values	Analysis	
<i>Alternanthera sessilis</i>	EE of whole plant	Relaxant and/or contractile	Jejunum of rabbit	Uninformed	Verapamil	EC ₅₀ : 0.26 mg/mL SRC EC ₅₀ : 0.08 mg/mL K ⁺ -SC	EE and DF relax SRC and K ⁺ -SC, but AF only has a spasmodic effect on CRS	[64]
	DF of EE	Evaluation of CCB	Jejunum of rabbit	0.1-0.3 mg/mL	Verapamil	EC ₅₀ : 0.02 mg/mL SRC	EE acts as CCB and generates the repolarization of the ΔV _{mem}	
		Relaxant and/or contractile	Jejunum of rabbit	Uninformed	Verapamil	EC ₅₀ : 0.04 mg/mL K ⁺ -SC	DF showed greater CCB activity than FA	
	AF of EE	Evaluation of CCB	Jejunum of rabbit	Uninformed	Verapamil	EC ₅₀ : 0.36 mg/mL SRC		
		Relaxant and/or contractile	Jejunum of rabbit	Uninformed	Verapamil	EC ₅₀ : NE		
		Evaluation of CCB	Jejunum of rabbit	Uninformed	Verapamil			
Antihypertensive effect								
<i>Alternanthera sessilis</i>	EE of whole plant	Vasorelaxant activity	Aorta of rabbit constricted by PE or K ⁺	Uninformed	Verapamil	EC ₅₀ (mg/mL): 2.03 and 0.34 for PE and K ⁺ induced contraction, respectively	DF exhibited the highest vasorelaxant effect	[64]
	DF of EE	Vasorelaxant activity	Aorta of rabbit constricted by PE or K ⁺	Uninformed	Verapamil	EC ₅₀ (mg/mL): 0.32 and 0.15 for PE and K ⁺ induced contraction, respectively	EE and DF reinforce the presence of the CCB mechanism	
An tiparasitic activity	AF of EE	Vasorelaxant activity	Aorta of rabbit constricted by PE or K ⁺	Uninformed	Verapamil	NE		D (min for 10 mg/mL)

(Continues)

TABLE 9 | (Continued)

Species	Extract(s)/Compounds	Assay method	Model	Dose	Positive control	Activity			References
						Values	Analysis		
<i>Gomphrena celosoides</i>	EaE of whole plant	Anthelmintic assay (P and D)	<i>F. gigantica</i>	10, 20, 30, 40, 50, 70, and 100 mg/mL	Piperazine citrate	20 ± 0.8	35 ± 0.5	ME was more potent in causing paralysis of <i>P. posthuma</i> than EaE and the positive control	[82]
			<i>T. solium</i>				40 ± 0.2	>60	
	ME of whole plant		<i>F. gigantica</i>	10, 20, 30, 40, 50, 70, and 100 mg/mL	Piperazine citrate	40 ± 0.5	40 ± 0.3		
			<i>P. posthuma</i>				8 ± 0.9	60 ± 0.5	
			<i>T. solium</i>			37 ± 0.3	42 ± 0.3		
Antitumor activity									
<i>Alternanthera pungens</i>	AqE of whole plant	Potato disc method	<i>A. tumefaciens</i>	10, 100, 1000, and 10 000 ppm	Vincristine	IC ₅₀ (ppm): 1800		Dose-dependent activity	[16]
			<i>A. tumefaciens</i>	10, 100, 1000, and 10 000 ppm	Vincristine	IC ₅₀ (ppm): 11			
			<i>A. tumefaciens</i>	10, 100, 1000, and 10 000 ppm	Vincristine	IC ₅₀ (ppm): 90			
Cardioprotective activity									
<i>Alternanthera philoxeroides</i>	ME of leaves	MTT assay	Rat cardiac H9c2 cells with DOX-induced apoptosis	10, 20, 40, 80, and 160 mg/mL	—	%V ₁₀ mg/mL: 38.43 ± 11.5		↑ Cell viability, indicating a protective effect against DOX-mediated cytotoxicity	[42]
						%V ₂₀ mg/mL: 66.33 ± 6.03			
						%V ₄₀ mg/mL: 79.00 ± 3.6			
						%V ₈₀ mg/mL: 84.33 ± 5.5			
						%V ₁₆₀ mg/mL: 83.16 ± 8.12			
						%A ₁₀ mg/mL: 51.18			
						%A ₂₀ mg/mL: 42.5		↓ The cell apoptosis induced by DOX	
						%A ₄₀ mg/mL: 33.18			
						%A ₈₀ mg/mL: 25.2			
						%A ₁₆₀ mg/mL: 23.46			

(Continues)

TABLE 9 | (Continued)

Species	Extract(s)/Compounds	Assay method	Model	Dose	Positive control	Activity		References
						Values	Analysis	
Endothelial activation								
<i>Alternanthera sessilis</i>	EE of whole plant	MTT assay	HAECs cells	25, 50, 100, 200, 400, and 800 µg/mL	—	6.25–200 µg/mL of EE does not affect the viability of HAECs		[153]
		FITC-dextran permeability assay	HAECs cells	25–200 µg/mL	Simvastatin	200 µg/mL of EE ↓ the ↑ permeability stimulated by TNF-α		
		sVCAM-1 production assay	HAECs cells	25, 50, 100, and 200 µg/mL	NAC	EE does not alter the secretion of sVCAM-1 induced by TNF-α		
		ROS quantitative assay	HAECs cells	25, 50, 100, and 200 µg/mL	—	200 µg/mL of EE suppresses the release of intracellular ROS stimulated by TNF-α		
						EE does not ↓ the elevated production of H ₂ O ₂ induced by TNF-α		
						EE ↑ SOD activity in a dose-dependent manner		
						EE enhances CAT activity in cells exposed to by H ₂ O ₂		
Hemolytic activity								
<i>Puffia glomerata</i>	FD of roots	Hemolysis assay	Blood from 6- to 8-week-old male C57BL/6 mice	250, 25, 2.5, and 0.25 µg/mL	Saponin from <i>Quillaja</i> sp.			[167]
	FD of aerial part						The two FDs did not cause hemolytic effects	

(Continues)

TABLE 9 | (Continued)

Species	Extract(s)/Compounds	Assay method	Model	Dose	Positive control	Activity		References
						Values	Analysis	
<i>Pfaffia glomerata</i>	225	Melano genesis assay	Murine B16 melanoma 4A5 cells RCB0557	0.1, 3, 10, 30, and 100 μ M	Arbutin	%I ₁₀₀ μ M: 80.0 \pm 2.5 IC ₅₀ : 44 μ M	Pfaffianol A (225) and pfaffoside C (257) substantially inhibited melanogenesis without cytotoxic effects, showing stronger effects than arbutin	[166]
		Viability assay	Murine B16 melanoma 4A5 cells RCB0557	0.1, 3, 10, 30, and 100 μ M	Arbutin	%I ₁₀ μ M: -1.2 \pm 1.6	The other compounds showed no effect	
	235	Melano genesis assay	Murine B16 melanoma 4A5 cells RCB0557	0.1, 3, 10, 30, and 100 μ M	Arbutin	%I ₁₀₀ μ M: 22.1 \pm 2.4		
	367	Melano genesis assay	Murine B16 melanoma 4A5 cells RCB0557	0.1, 3, 10, 30, and 100 μ M	Arbutin	%I ₁₀₀ μ M: -6.1 \pm 7.6		
	384	Melano genesis assay	Murine B16 melanoma 4A5 cells RCB0557	0.1, 3, 10, 30, and 100 μ M	Arbutin	%I ₃₀ μ M: 1.9 \pm 3.5		
	381	Melano genesis assay	Murine B16 melanoma 4A5 cells RCB0557	0.1, 3, 10, 30, and 100 μ M	Arbutin	%I ₁₀₀ μ M: -3.3 \pm 3.0		
	377	Melano genesis assay	Murine B16 melanoma 4A5 cells RCB0557	0.1, 3, 10, 30, and 100 μ M	Arbutin	%I ₃₀ μ M: 7.4 \pm 2.2		
	385	Melano genesis assay	Murine B16 melanoma 4A5 cells RCB0557	0.1, 3, 10, 30, and 100 μ M	Arbutin	%I ₁₀₀ μ M: 2.3 \pm 4.2		
	257	Melano genesis assay	Murine B16 melanoma 4A5 cells RCB0557	0.1, 3, 10, 30, and 100 μ M	Arbutin	%I ₁₀₀ μ M: 51.4 \pm 1.2 IC ₅₀ : 92 μ M		

(Continues)

TABLE 9 | (Continued)

Species	Extract(s)/Compounds	Assay method	Model	Dose	Positive control	Activity		References
						Values	Analysis	
Immunomodulatory activity								
<i>Alternanthera brasiliensis</i>	AqE of leaves	Proliferation assay	PBMN stimulated with PHA	0–200 µg/mL	—	Aqueous and ethanol extracts inhibit the proliferative response of lymphocytes to PHA		[242]
	EE of leaves	Proliferation assay	PBMN stimulated with PHA	0–200 µg/mL	—	10 µg/mL of FEA completely inhibits lymphocyte proliferation		
<i>Alternanthera maritima</i>	AqE of leaves	Proliferation assay	PBMN stimulated with PHA	0–200 µg/mL	—			
	EE of leaves	Proliferation assay	PBMN stimulated with PHA	0–200 µg/mL	—			
<i>Alternanthera tenella</i>	AqE of leaves	Proliferation assay	PBMN stimulated with PHA	0–200 µg/mL	—			
	EE of leaves	Proliferation assay	PBMN stimulated with PHA	0–200 µg/mL	—			
<i>Alternanthera maritima</i>	FEA of AqE of leaves	Proliferation assay	PBMN stimulated with PHA	0–200 µg/mL	—			
	EE of aerial parts	Cytotoxicity and LDH assay	PMNLs	100 µg/mL	Total cell lysis	%V: 78.50 ± 1.50 and LA (10 ⁴ 1000): 1.39 0 0.07	EE, BuF, and the seven isolated compounds do not induce significant LDH release, nor do they exhibit cytotoxicity against human PMNL	[149]
parts	BuF of EE of aerial	Cytotoxicity and LDH assay	PMNLs	100 µg/mL	Total cell lysis	%V: 82.00 ± 1.00 and LA (10 ⁴ 1000): 0.76 ± 0.17		
	25	Cytotoxicity and LDH assay	PMNLs	50 µmol/L	Total cell lysis	%V: 97.75 ± 0.35 and LA (10 ⁴ 1000): 5.22 ± 0.27		
	24	Cytotoxicity and LDH assay	PMNLs	50 µmol/L	Total cell lysis	%V: 91.25 ± 1.77 and LA (10 ⁴ 1000): 6.29 ± 3.20		

(Continues)

TABLE 9 | (Continued)

Species	Extract(s)/Compounds	Assay method	Model	Dose	Positive control	Activity		References
						Values	Analysis	
	129	Cytotoxicity and LDH assay	PMNLs	50 µmol/L	Total cell lysis	%V: 94.50 ± 0.71 and LA (1U*1000): 5.63 ± 1.01		
	50	Cytotoxicity and LDH assay	PMNLs	50 µmol/L	Total cell lysis	%V: 87.00 ± 2.83 and LA (1U*1000): 4.13 ± 1.46		
	43	Cytotoxicity and LDH assay	PMNLs	50 µmol/L	Total cell lysis	%V: 91.50 ± 3.54 and LA (1U*1000): 4.08 ± 1.93		
	72	Cytotoxicity and LDH assay	PMNLs	50 µmol/L	Total cell lysis	%V: 87.50 ± 0.71 and LA (1U*1000): 5.81 ± 1.64		
	34	Cytotoxicity and LDH assay	PMNLs	50 µmol/L	Total cell lysis	%V: 93.50 ± 1.41 and LA (1U*1000): 5.74 ± 2.27		
<i>Gomphrena celosoides</i>	Extract	Proliferation assay (MTT)	RAW 264.7	0–100 µg/mL	—	IC ₅₀ : >100	It has no cytotoxic effect against RAW 264.7 cells, nor does it enhance phagocytosis	[213]
		Phagocytosis assay	RAW 264.7	10 µg/mL	—	NDNS	Significantly inhibits TNF-α production	
		Measurement of TNF-α	RAW 264.7	10 µg/mL	—	%I: 32.5		
<i>Gomphrena virgata</i>	AqE of roots	Viability assay (trypan blue)	PBMN	1, 0.5, and 0.025 mg/mL	Cadmium chloride	%V1 mg/mL: 95.86 ± 7.12 (24 h) and %V1 mg/mL: 69.14 ± 26.69 (7 days)	c.	[101]
Insecticidal activity								
<i>Gomphrena elegans</i>	AqE, ClE, HeE, and ME of leaves	Insecticidal activity tests	Larvae of <i>Aedes aegypti</i>	10 mg/L	Bt	None of the extracts exhibited insecticidal activity.		[159]

(Continues)

TABLE 9 | (Continued)

Species	Extract(s)/Compounds	Assay method	Model	Dose	Positive control	Activity		References
						Values	Analysis	
Larvicidal activity								
<i>Alternanthera sessilis</i>	AgNPs of leaves	Mosquito culture and larvicidal bioassays	<i>Aedes aegypti</i>	Uninformed	Silver nitrate	LC ₅₀ : 7.2 (24 h), 4.63 (48 h), and 2.93 (72 h)	For the three larval models, both the AgNPs complex and the different extracts exhibited a dose-dependent effect. HeE stands out as having the greatest larvicidal effect compared to the others	[163]
			<i>Culex quinquefasciatus</i>			LC ₅₀ : 9.28 (24 h), 5.43 (48 h), and 2.82 (72 h)		
			<i>Anopheles stephensi</i>			LC ₅₀ : 12.92 (24 h), 3.29 (48 h), and 2.9 (72 h)		
	ME of leaves	Mosquito culture and larvicidal bioassays	<i>Aedes aegypti</i>	Uninformed	Silver nitrate	LC ₅₀ : 88.75 (24 h), 82.21 (48 h), and 71.74 (72 h)		
			<i>Culex quinquefasciatus</i>			LC ₅₀ : 32.32 (24 h), 26.59 (48 h), and 20.63 (72 h)		
			<i>Anopheles stephensi</i>			LC ₅₀ : 40.13 (24 h), 23.98 (48 h), and 17.26 (72 h)		
	HeE of leaves	Mosquito culture and larvicidal bioassays	<i>Aedes aegypti</i>	Uninformed	Silver Nitrate	LC ₅₀ : 24.41 (24 h), 20.72 (48 h), and 17.03 (72 h)		
			<i>Culex quinquefasciatus</i>			LC ₅₀ : 26.25 (24 h), 20.63 (48 h), and 16.03 (72 h)		
			<i>Anopheles stephensi</i>			LC ₅₀ : 47.48 (24 h), 39.64 (48 h), and 30.23 (72 h)		
	CIE of leaves	Mosquito culture and larvicidal bioassays	<i>Aedes aegypti</i>	Uninformed	Silver nitrate	LC ₅₀ : 31.90 (24 h), 26.24 (48 h), and 18.83 (72 h)		
			<i>Culex quinquefasciatus</i>			LC ₅₀ : 49.19 (24 h), 35.22 (48 h), and 22.47 (72 h)		
			<i>Anopheles stephensi</i>			LC ₅₀ : 45.97 (24 h), 34.16 (48 h), and 26.28 (72 h)		
	AcE of leaves	Mosquito culture and larvicidal bioassays	<i>Aedes aegypti</i>	Uninformed	Silver nitrate	LC ₅₀ : 85.35 (24 h), 81.67 (48 h), and 67.43 (72 h)		
			<i>Culex quinquefasciatus</i>			LC ₅₀ : 39.85 (24 h), 28.38 (48 h), and 20.73 (72 h)		
			<i>Anopheles stephensi</i>			LC ₅₀ : 29.75 (24 h), 23.98 (48 h), and 19.02 (72 h)		
	PEE of leaves	Mosquito culture and larvicidal bioassays	<i>Aedes aegypti</i>	Uninformed	Silver nitrate	LC ₅₀ : 156.87 (24 h), 150.22 (48 h), and 119.38 (72 h)		
			<i>Culex quinquefasciatus</i>			LC ₅₀ : 37.79 (24 h), 30.23 (48 h), and 18.83 (72 h)		
			<i>Anopheles stephensi</i>			LC ₅₀ : 59.0 (24 h), 49.21 (48 h), and 37.93 (72 h)		

(Continues)

TABLE 9 | (Continued)

Species	Extract(s)/Compounds	Assay method	Model	Dose	Positive control	Activity		References	
						Values	Analysis		
Neuroprotective or neurological activity									
<i>Alternanthera philoxeroides</i>	EE of whole plant	Inhibitory assay	MAO-A	Uninformed	Cloglyline	IC ₅₀ : 252.9 ± 0.02 μM	EE and isolated compounds inhibit MAO-A and MAO-B	[38]	
	35	Inhibitory assay	MAO-B	Uninformed	Deprenyl	IC ₅₀ : 90.69 ± 0.02 μM			
	36	Inhibitory assay	MAO-A	Uninformed	Cloglyline	IC ₅₀ : 0.00046 ± 0.04 μM	EE and isolated compounds, except for compound 35, show partial selectivity for MAO-B. Alternatin exhibits partial selectivity by MAO-A		
	79	Inhibitory assay	MAO-B	Uninformed	Deprenyl	IC ₅₀ : 0.00060 ± 0.12 μM			
	5	Inhibitory assay	MAO-A	Uninformed	Cloglyline	IC ₅₀ : 0.00206 ± 0.04 μM			
	41	Inhibitory assay	MAO-B	Uninformed	Deprenyl	IC ₅₀ : 0.00022 ± 0.12 μM			
				MAO-A	Uninformed	Cloglyline	IC ₅₀ : 18.37 ± 1.47 μM		
				MAO-B	Uninformed	Deprenyl	IC ₅₀ : 0.6748 ± 0.46 μM		
				MAO-A	Uninformed	Cloglyline	IC ₅₀ : 0.0544 ± 0.01 μM		
				MAO-B	Uninformed	Deprenyl	IC ₅₀ : 0.1293 ± 0.42 μM		
<i>Alternanthera philoxeroides</i>	EE of whole plant	Inhibitory assay	MAO-A	Uninformed	Cloglyline	IC ₅₀ : 3.051 ± 0.35 μM			
	35	Thioflavin-T assay	MAO-B	100 μg/mL	Deprenyl	IC ₅₀ : 0.5444 ± 0.33 μM			
	36	Thioflavin-T assay	Aβ1-42 solution	100 μM	Cur	%I: 83.25 ± 4.25	Among the isolated compounds, compound 36 exhibits the greatest inhibitory activity against the formation of toxic Aβ plaques in the brain, surpassing that of Cur	[141]	
	41	Thioflavin-T assay	Aβ1-42 solution	100 μM	Cur	%I: 81.96 ± 2.14			
	79	Thioflavin-T assay	Aβ1-42 solution	100 μM	Cur	NDNS			
	5	Thioflavin-T assay	Aβ1-42 solution	100 μM	Cur	NDNS			
			AChE	Uninformed	Tacrine	IC ₅₀ : 2.06 ± 0.016 mg/mL	The SIs of the EE was 1.60, indicating its partial selectivity toward AChE	[141]	
			BChE	Uninformed	—	IC ₅₀ : 3.27 ± 0.011 mg/mL	None of the extracts is capable of inhibiting AChE	[98]	
			AChE	Uninformed	—	NE			
			Ellman's method	Uninformed	—	NE			

(Continues)

TABLE 9 | (Continued)

Species	Extract(s)/Compounds	Assay method	Model	Dose	Positive control	Activity		References	
						Values	Analysis		
<i>Iresine celosia</i>	EE of aerial part	WST-1 assay	Mouse BV2 microglial cells stimulated with/without LPS	1, 10, or 100 µg/mL	Quercetin	No cytotoxic activity was observed against BV2 cells. 100 µg/mL ↓ NO production and PGE ₂ levels		[104]	
			Measurement of NO and PGE ₂	Mouse BV2 microglial cells stimulated with LPS	1, 10, or 100 µg/mL	Quercetin	Significantly ↓ MAPK phosphorylation, without affecting total protein levels of MAPK factors		100 µg/mL significantly ↓ transcriptional activity of NF-κB
		qRT-PCR	Mouse BV2 microglial cells stimulated with LPS	1, 10, or 100 µg/mL	Quercetin	Significantly suppresses the phosphorylation of p65 and its translocation to the nucleus			
			Western blotting	Mouse BV2 microglial cells stimulated with LPS	1, 10, or 100 µg/mL		Can inhibit LPS-induced neuroinflammation without cytotoxicity in BV2 cells, as well as suppress the expression of proinflammatory mediators mediated by the MAPKs/NF-κB signaling pathway		
		Luciferase assay	Mouse BV2 microglial cells stimulated with LPS	100 µg/mL			30 and 100 µM of Iresin (283) significantly ↓ NO production		
			Measurement of NO and PGE ₂	Mouse BV2 microglial cells stimulated with LPS	1, 10, 30, and 100 µM	Quercetin			

(Continues)

TABLE 9 | (Continued)

Species	Extract(s)/Compounds	Assay method	Model	Dose	Positive control	Activity		References	
						Values	Analysis		
<i>Iresine herbstii</i>	AqE of aerial part	5-HT _{1A} serotonergic assay	Cerebral cortex of rats	25, 50, 75, 100, and 125 µg/mL	8-OH-DPAT	%I: 13.51	AqE and ME show no affinity for 5-HT _{2A} receptor, and additionally, the ME did not show affinity against the D2 receptor	[108]	
		5-HT _{2C} serotonergic assay	Frontal cortical regions of rats	25, 50, 75, 100, and 125 µg/mL	Mesulergine	%I: 22.13	AqE and ME have an effect on the CNS similar to that observed with some psychotropic agents		
		D1 dopaminergic assay	Corpora striata	25, 50, 75, 100, and 125 µg/mL	Spiroperidol	%I: 48.32			
		D2 dopaminergic assay	Corpora striata	25, 50, 75, 100, and 125 µg/mL	Spiroperidol	%I: 88.82			
		α ₁ -Adrenergic binding assay	Brain cortex	25, 50, 75, 100, and 125 µg/mL	Prazosin	IC ₅₀ : 32.08 ± 0.52 %I: 13.51			
	ME of aerial part	5-HT _{1A} serotonergic assay	Cerebral cortex of rats	25, 50, 75, 100, and 125 µg/mL	8-OH-DPAT	%I: 22.44			
		5-HT _{2C} serotonergic assay	Frontal cortical regions of rats	25, 50, 75, 100, and 125 µg/mL	Mesulergine	%I: 92.46			
		D1 dopaminergic assay	Corpora striata	25, 50, 75, 100, and 125 µg/mL	Spiroperidol	IC ₅₀ : 34.78 ± 1.80 %I: 90.52			
		α ₁ -Adrenergic binding assay	Brain cortex	25, 50, 75, 100, and 125 µg/mL	Prazosin	IC ₅₀ : 19.63 ± 2.10 %I: 11.76			
	AqE of aerial part	5-HT _{1A} serotonergic assay	Cerebral cortex of rats	7.8–125 µg/mL	—	%I ₁₂₅ µg/mL: 13.51	AqE and ME have no affinity for the 5-HT _{2A} receptor. Additionally, ME did not exhibit affinity for the D2 and α ₂ receptors, while AqE showed no affinity for the α ₁ receptor		[243]
		5-HT _{2C} serotonergic assay	Frontal cortical regions of rats	7.8–125 µg/mL	—	%I ₁₂₅ µg/mL: 22.13			
		D1 dopaminergic assay	Corpora striata	7.8–125 µg/mL	—	%I ₁₂₅ µg/mL: 48.32			
	D2 dopaminergic assay	Corpora striata	7.8–125 µg/mL	—	IC ₅₀ : 2.99 ± 0.02 µg/mL	AqE and ME interact with 5-HT receptors, indicating an effect on the CNS			
	α ₂ -Adrenergic binding assay	Brain cortex	7.8–125 µg/mL	—	%I ₁₂₅ µg/mL: 25.73				
ME of aerial part	5-HT _{1A} serotonergic assay	Cerebral cortex of rats	7.8–125 µg/mL	—	%I ₁₂₅ µg/mL: 22.44				
	5-HT _{2C} serotonergic assay	Frontal cortical regions of rats	7.8–125 µg/mL	—	IC ₅₀ : 60.27 ± 5.59 µg/mL				
	D1 dopaminergic assay	Corpora striata	7.8–125 µg/mL	—	IC ₅₀ : 1.39 ± 1.70 µg/mL				
	α ₁ -Adrenergic binding assay	Brain cortex	7.8–125 µg/mL	—	%I ₁₂₅ µg/mL: 11.76				

(Continues)

TABLE 9 | (Continued)

Species	Extract(s)/Compounds	Assay method	Model	Dose	Positive control	Activity		References
						Values	Analysis	
<i>Puffia glomerata</i>	ME of roots	Sharma and Bhat method	AChE	10 mg/mL	Galantamine	NE	Only the FD of aerial part showed activity	[167]
	ME of aerial part	Sharma and Bhat method	AChE	10 mg/mL	Galantamine	NE		
	FnH of roots	Sharma and Bhat method	AChE	10 mg/mL	Galantamine	NE		
	FnH of aerial part	Sharma and Bhat method	AChE	10 mg/mL	Galantamine	NE		
	FD of roots	Sharma and Bhat method	AChE	10 mg/mL	Galantamine	NE		
	FD of aerial part	Sharma and Bhat method	AChE	10 mg/mL	Galantamine	IC ₅₀ : 2.7 µg/mL		
	FEA of roots	Sharma and Bhat method	AChE	10 mg/mL	Galantamine	NE		
	FEA of aerial part	Sharma and Bhat method	AChE	10 mg/mL	Galantamine	NE		
	FnB of roots	Sharma and Bhat method	AChE	10 mg/mL	Galantamine	NE		
	FnB of aerial part	Sharma and Bhat method	AChE	10 mg/mL	Galantamine	NE		
	AF of roots	Sharma and Bhat method	AChE	10 mg/mL	Galantamine	NE		
	AF of aerial part	Sharma and Bhat method	AChE	10 mg/mL	Galantamine	NE		
	Sun protective effect							
<i>Comptrena globosa</i>	HaE of flowers	Determination of SPF	—	50 µg/mL	—	SPF of about 20		[156]
Treatment of respiratory diseases								
<i>Alternanthera sessilis</i>	EE of whole plant	Assessment of bronchodilator activity	Tracheal tissue of rabbit induced with CCh or K ⁺	Uninformed	Verapamil	EC ₅₀ : 0.22 and 0.18 mg/mL for CCh and K ⁺ induced contraction, respectively	EE and DF decrease the maximum contractile effect similar to verapamil through CCB	[64]
	DF of EE	Assessment of bronchodilator activity	Tracheal tissue of rabbit induced with CCh or K ⁺	Uninformed	Verapamil	EC ₅₀ : 0.04 and 0.03 mg/mL for CCh and K ⁺ induced contraction, respectively	It should be noted that CCBs are beneficial as bronchodilators	
	AF of EE	Assessment of bronchodilator activity	Tracheal tissue of rabbit induced with CCh or K ⁺	Uninformed	Verapamil	NE		

(Continues)

TABLE 9 | (Continued)

Species	Extract(s)/Compounds	Assay method	Model	Dose	Positive control	Activity		References
						Values	Analysis	
Wound-healing activity								
<i>Alternanthera brasiliana</i>	ME of leaves	CM model	Embryonated chicken eggs	200 and 400 µg	—	ME has dose-dependent angiogenic activity, ranging from mild (200 µg) to marked (400 µg)	[244]	
<i>Alternanthera sessilis</i>	EE of stem	Scratch assay	NHDF cells	12.5, 25, and 50 µg/mL	Allantoin	↑ Migration 50 µg/mL: 86%	Dose-dependent activity was observed in all cell lines	[57]
		Scratch assay	HDF-D cells	12.5, 25, and 50 µg/mL	Allantoin	↑ Migration 50 µg/mL: 65%		
<i>Iresine herbstii</i>	EE of leaves	Scratch assay	HaCtT cells	12.5, 25, and 50 µg/mL	Allantoin	↑ Migration 50 µg/mL: 99%	The extracts exhibited moderate migration and filling in the damaged area	[109]
		NF-κB electrophoretic mobility shift assay	Jurkat T cells	100 µg/mL	Parthenolide	%I: <30		
HeE of leaves	NF-κB electrophoretic mobility shift assay	p38α assay	ACC No. 282	100 µg/mL	—	%I: 30.27 ± 0.67	EE inhibits elastase release, while HeE alters elastase activity	HeE has moderate caspase activity
		Elastase assay	PAF-stimulated neutrophils	10, 50, and 100 µg/mL	Resveratrol, GW31616A	Release ₁₀₀ µg/mL: 42.62 ± 1.66	EE did not show a cytotoxic effect, while HeE exhibited cytotoxic effect in a Jurkat T cells	
		Scratch assay	Mouse fibroblasts	10 µg/mL	PDGF-BB	Inhibition ₁₀₀ µg/mL: 13.02 ± 0.92		
		MTT assay	Jurkat T cells	50 and 100 µg/mL	Parthenolide	%St: 34.33 ± 2.92		
						%I ₁₀₀ µg/mL: 7 ± 0.7		
HeE of leaves	NF-κB electrophoretic mobility shift assay	p38α assay	ACC No. 282	100 µg/mL	—	%I: 74.14 ± 6.33	HeE has moderate caspase activity	
		Elastase assay	PAF-stimulated neutrophils	10, 50, and 100 µg/mL	Resveratrol, GW31616A	Release ₁₀₀ µg/mL: 39.22 ± 0.77		
		Scratch assay	Mouse fibroblasts	10 µg/mL	PDGF-BB	Inhibition ₁₀₀ µg/mL: 59.68 ± 0.60		
		Caspase-3-like assay	Jurkat T cells	50 µg/mL	Actinomycin D	%St: 28.26 ± 2.41		
		MTT assay	Jurkat T cells	50 and 100 µg/mL	Parthenolide	Relative fluorescence unit of 1.07		
					%I ₅₀ µg/mL: 12 ± 1.4 and %I ₁₀₀ µg/mL: 61 ± 6.4			

Abbreviations: aPTT, activated partial thromboplastin; CCB, calcium channel blocking; CIE, chloroform extract; DF, dichloromethane fraction; EE, ethanolic extracts; FD, fraction of DCM; FEA, fraction of ethyl acetate; HeE, hexanic extracts; IL-6, interleukin-6; LDH, lactate dehydrogenase; ME, methanolic extracts; NDNS, numerical data not shown; NE, no effect; PBMN, peripheral blood mononuclear cells; PMNLs, polymorphonuclear leucocytes; PTT, prothrombin time; RBCs, red blood cells; ROS, reactive oxygen species; TNF-α, tumor necrosis factor alpha.

TABLE 10 | Pharmacological effects of crude extracts and compounds of Gomphrenoideae subfamily.

Species	Extract (s)/Compounds	Models	Assay method	Dose	Positive control	Effects/Mechanisms	References
Antimicrobial activity							
<i>Gomphrena globosa</i>	20	Male Kunming mice	Murine model of superficial skin infection	30 mg/kg	Ceftriaxone sodium	↓ The number of colonies in the wound Antibacterial efficacy was better than positive control	[136]
Activity related to the sexual system							
<i>Pfaffia glomerata</i>	HaE of roots	C57BL/6J	Histomorphometric studies	600 and 1000 mg/kg	—	Does not act as an endocrine disruptor and has no antiandrogenic activity	[247]
<i>Pfaffia glomerata</i>	HaE of roots	Swiss mice (male)	Histological analysis Volumetric proportions and interstitium analysis Leydig cell morphology Leydig cell viability Hormone assay Collagen and smooth muscle quantification NO assay	100, 200, and 400 mg/kg for 42 days	Sildenafil citrate	400 mg/kg ↑ the weight of the testes and Leydig somatic index 200 mg/kg administered intermittently ↑ the weight of the testes and parenchyma HaE ↑ the proportions of interstitium, Leydig cells, lymphatic vessels, and NO 400 mg/kg of HaE causes DNA damage and cell death in Leydig cells, whereas lower concentrations and sildenafil citrate do not show cytotoxicity 200 and 400 mg/kg ↓ plasma testosterone and ↑ 17β-estradiol levels At 400 mg/kg, the amount of connective tissue in the penis ↓, whereas type I collagen ↑ ↓ The amount of type III collagen and the % of	[113]
<i>Pfaffia glomerata</i>	HaE of roots	SPF ICR mice	Sexual behavior experiment Organ coefficient Measurements of hormones and enzymes Testis histopathological and sperm analysis	150, 750, and 1500 mg/kg for 28 days	Paroxetine	The behavioral study showed that HaE improved sexual performance in mice HaE helps mitigate the damage caused by paroxetine to the testes and has the potential to enhance sexual function HaE concentrations ↑ the levels of T, FSH, and E2, restore NO and cGMP content, and significantly reduced PDE5 activity, with results comparable to the control group. HaE effectively reduced PRX-induced MDA elevation Histologically, testicular lesions were recovered by HaE HaE promoted spermatogenesis	[168]

(Continues)

TABLE 10 | (Continued)

Species	Extract (s)/Compounds		Models	Assay method	Dose	Positive control	Effects/Mechanisms	References
	HaE of roots	Swiss mice (male)						
<i>Pfaffia glomerata</i>	HaE of roots	Swiss mice (male)	Sexual behavior experiment Fertility rates Oxidative stress Mineral quantification in the testis Cell viability Histopathology Sperm evaluation Morphometry	100, 200, and 400 mg/kg for 42 days	Sildenafil citrate	Daily intake of HaE did not affect the BW and caused no morphometric differences in organs such as the uterus, placenta, and ovaries HaE at a concentration of 200 mg/kg ↑ pregnancy rates in females and fertility in males HaE ↑ ROS levels Mn ↑ at concentrations of 200 and 400 mg/kg of HaE All concentrations of HaE caused germ cell damage ↓ Daily sperm production and elongated spermatids	[186]	
Analgesic activity								
<i>Alternanthera brasiliensis</i>	AqE aerial part	Wistar rats (male)	Acetic acid-induced abdominal contractions	25, 50, 100, 200, and 400 mg/kg	Dipyrene	↓ Of contractions for the different []: 90.35%, 91.73%, 95.17%, 94.45%, and 96.55%	[30]	
<i>Alternanthera maritima</i>	EE of aerial parts	Swiss mice	Carrageenan-induced paw edema	30, 100, and 300 mg/kg	—	All [] evaluated had a higher activity than dipyrene EE at doses of 300 and 500 mg/kg prevents mechanical hyperalgesia	[34]	
	72	Swiss mice	Carrageenan-induced paw edema	1, 10, and 20 mg/kg or 3 µg/paw	—	The isolated compound (72) at doses of 0.3, 3, and 300 µg/paw prevents a significant ↓ in sensitivity in rats with carrageenan-induced paw edema Compound 72 inhibited the hyperalgesic effects of TNF and significantly prevented the ↓ in the threshold sensitivity but did not inhibit the hyperalgesic effects of L-DOPA		
		Swiss mice	TNF- or L-DOPA-induced hyperalgesia	3 µg/paw	—			
<i>Alternanthera philoxeroides</i>	ME of whole plant	Swiss albino mice	Acetic acid-induced constriction	50, 100, 200, and 400 mg/kg BW	Aspirin	↓ The number of constrictions in a dose-dependent manner (%I ₅₀ mg/kg: 31 and %I ₄₀₀ g/kg: 44.8)	[39]	

(Continues)

TABLE 10 | (Continued)

Species	Extract (s)/Compounds	Models	Assay method	Dose	Positive control	Effects/Mechanisms	References
<i>Alternanthera sessilis</i>	EE of whole plant	Swiss albino mice	Hot plates test	250 and 500 mg/kg BW	Morphine	Inhibits the number of contortions by 37.28% (250 mg/kg) and 59.52% (500 mg/kg) the number of contortions	[139]
<i>Alternanthera sessilis</i>	ME of aerial parts	Swiss albino mice	Writhing test	250 and 500 mg/kg BW	Diclofenac sodium	Maximum reaction time 6.87 and 7.28 s at doses of 250 and 500 mg/kg EE ↑ pain threshold	[232]
<i>Alternanthera tenella</i> Colla	EE of whole plant	Swiss and C57b16	Abdominal writhing test	50, 100, 200, and 400 mg/kg BW	Aspirin	Dose-dependent activity. ↓ Writhing for the different []: 27.6%, 37.9%, 41.4%, and 44.8%. The last three doses of ME showed greater activity than the control	[67]
		Swiss	Paw edema, mechanical hyperalgesia, and cold allodynia induced by carrageenan (acetone drop test)	30, 100, and 300 mg/kg	PRED	Four hours after carrageenan injection, EE and compound 43 inhibited edema by 54% (100 mg/kg) and 56% (10 mg/kg), respectively Three hours after carrageenan injection, EE and compound 43 inhibited mechanical hyperalgesia by 99% (300 mg/kg) and 100% (10 mg/kg), respectively	
		Swiss	Knee edema and mechanical hyperalgesia induced by zymosan	100 mg/kg	PRED	Three hours after carrageenan injection, EE inhibited the cold response by 82% at 300 mg/kg, but the isolated compound had no effect A total of 4 and 6 h after zymosan injection, EE and compound 43 blocked mechanical hyperalgesia Four hours after zymosan injection, EE and compound 43 inhibited edema by 58% and 72%, respectively	
	43	Swiss and C57b16	Paw edema, mechanical hyperalgesia, and cold allodynia induced (acetone drop test) by carrageenan	0.1, 1, and 10 mg/kg	PRED		

(Continues)

TABLE 10 | (Continued)

Species	Extract (s)/Compounds	Models	Assay method	Dose	Positive control	Effects/Mechanisms	References
<i>Blutaparon portulacoides</i>	EE of stems	Swiss	Knee edema and mechanical hyperalgesia induced by zymosan	1 mg/kg	PRED		
		Swiss mice (male)	Paw edema, mechanical hyperalgesia	30, 100, or 300 mg/kg	Dexamethasone	EE ↓ the sensitivity to mechanical stimuli and reduced carrageenan-induced mechanical hyperalgesia	[71]
<i>Gomphrena celosioides</i>	AqE of leaves	C57BL/6 mice (male)	Mechanical sensitivity and cold sensitivity	30 and 100 mg/kg	Dexamethasone	In mice treated with CFA, EE at a dose of 30 mg/kg inhibited mechanical sensitivity by 60% (6 days), 90% (16 days), and 77% (22 days) and inhibited cold sensitivity in a manner comparable to dexamethasone	
		Swiss albino mice	Hot plate test	100, 200, and 400 mg/kg	Morphine	Reaction time: 18.97 ± 0.47 , 19.32 ± 1.14 , 20.64 ± 0.51 . At 400 mg/kg, activity was significant	[87]
			Acetic acid-induced writhing movement test	100, 200, and 400 mg/kg	Paracetamol	Dose-dependent activity. Number of writhing movements: 35.78 ± 3.2 , 30.16 ± 1.67 , 28.27 ± 2.11	

(Continues)

TABLE 10 | (Continued)

Species	Extract (s)/Compounds	Models	Assay method	Dose	Positive control	Effects/Mechanisms	References
<i>Gomphrena celosioides</i>	EE of aerial part	Swiss mice	Paw edema, mechanical hyperalgesia, and cold allodynia induced (acetone drop test) by carrageenan	300, 700, or 1000 mg/kg	Dexamethasone	All doses ↓ carrageenan-induced edema formation, with a ↑ inhibition of 61% ± 5%, 53% ± 6%, and 68% ± 5%, respectively All doses ↓ hyperalgesia, exhibited ↑ activity at 300 mg/kg with 91% ± 22% Allodynia ↓ at doses of 700 and 1000 mg/kg, with a ↑ inhibition of 58% ± 14%	[78]
		Swiss mice	Model of carrageenan-induced pleurisy	300, 700, or 1000 mg/kg	Dexamethasone	EE significantly ↓ leukocyte migration (58% ± 14%) but did not reduce protein extravasation into the pleural cavity	
		Swiss mice	Leukocyte recruitment and mechanical model of zymosan	300 mg/kg	—	EE ↓ hyperalgesia and leukocyte migration induced with zymosan, with inhibition rates of 52% ± 3% and 81% ± 4%, respectively EE did not significantly alter NO levels EE inhibits cell adhesion to the endothelium (40% ± 7%) and rolling cells (48% ± 6%)	
		Swiss male mice	Zymosan-induced peritonitis	300 mg/kg	Dexamethasone	EE ↓ edema (25% ± 18%), and CFA-induced hyperalgesia	
		Swiss male mice	In situ intravital microscopy analysis	300 mg/kg	Indomethacin		
		C57BL6 mice (male)	Paw edema and mechanical hyperalgesia induced by CFA	100 mg/kg	Dexamethasone		

(Continues)

TABLE 10 | (Continued)

Species	Extract (s)/Compounds	Models	Assay method	Dose	Positive control	Effects/Mechanisms	References
<i>Pfafia glomerata</i>	HaE of roots and rhizomes	Swiss albino mice (male)	Writhing test (acetic acid)	100, 200, and 300 mg/kg	Indomethacin	%I of writhing: 69.1%, 66.4%, and 74.1% for 100, 200, and 300 mg/kg, respectively	[118]
		Wistar rats (male)	Hot plate test	100, 200, and 300 mg/kg	Morphine	Showed no effect in the hot plate test, indicating no analgesic effect on the central nervous system	
<i>Pfafia glomerata</i>	HaE of roots	Swiss mice (female)	Acetic acid-induced constriction	10–300 mg/kg	Indomethacin	Inhibits abdominal constriction by 78% ± 3% at 300 mg/kg and has an ID ₅₀ of 64.6 mg/kg	[231]
		Swiss mice (female)	Glutamate-induced nociception	100–600 mg/kg	Morphine	↓ Glutamate-induced nociception in a dose-dependent manner (ID ₅₀ : 370.8)	
		Swiss mice (female) injected with acetic acid	Involvement of opioid system	300 mg/kg	Morphine	Antinociceptive activity is not ← by naloxone pre-treatment	
Angiogenesis	<i>Alternanthera brasiliana</i>	Swiss mice (female)	Involvement of glutamatergic system was	300 mg/kg	—	Had no effect against nociceptive responses induced by spinal injections of NMDA, AMPA, and kainite but inhibited (32% ± 8%) nociceptive responses induced by spinal injection of <i>trans</i> -ACPD	[195]
						↓ The biting response was induced by TNF-α but did not alter the biting response induced by IL-1β	
	HaE of leaves	Wistar rats (male-trichotomy was performed on the dorsum skin and a dermatological punch of 1.5 cm in diameter)	Histomorphometry and Western blotting	20% HaE of leaves in 2% carbopol gel	—	Favors angiogenesis	

(Continues)

TABLE 10 | (Continued)

Species	Extract (s)/Compounds	Models	Assay method	Dose	Positive control	Effects/Mechanisms	References
Antiangiogenic activity							
<i>Pfaffia paniculata</i>	ME of roots	Adult BALB/c mice (male) with corneal lesion	Histopathological study	250, 500, or 1000 mg/kg	—	1000 mg/kg significantly ↓ the number of new blood vessels formed in mouse cornea	[188]
Anti-arthritic activity							
<i>Alternanthera bettzickiana</i>	EE of aerial parts	Wistar rats with CFA-induced arthritis	Determination of physical parameters Arthritic Index Hematological and biochemical parameters Histopathological analysis Radiographic assessment RT-PCR ELISA	250, 500, and 1000 mg/kg	Diclofenac sodium	%I of edema: 70.56% and 65.81% for 1000 and 500 mg/kg, respectively 1000 and 500 mg/kg reinstated the arthritis index and BW Significant ↓ in CRP, AST, ALP, ALT, RF, urea, creatinine, and BUN levels Improved [] of RBCs, Hb, WBCs, and ESR ↓ Pannus formation, synovial hyperplasia, inflammatory cell infiltration, bone erosion, bone resorption, joint deformation, soft tissues inflammation, and connective tissue alterations ↑ NF-kB, IL-4, IL-10, I-kB expression ↓ COX-2, IL-6, TNF- α , IL-1 β expression, and MDA level	[19]

Restores SOD and CAT values

(Continues)

TABLE 10 | (Continued)

Species	Extract (s)/Compounds	Models	Assay method	Dose	Positive control	Effects/Mechanisms	References
<i>Alternanthera bettzickiana</i>	EE of aerial parts	Wistar rats with formaldehyde-induced arthritis	Hematological and biochemical parameters Enzyme-linked immunosorbent assay Oxidative stress biomarkers	250, 500, 1000 mg/kg	Diclofenac sodium	%I of edema: 72.11%, 65.25%, and 56.62% for 1000, 500, and 250 mg/kg 500 and 1000 mg/kg significantly ↓ ALP, ALT, and AST levels ↓ Creatinine, urea, CRP, and RF levels 500 and 1000 mg/kg: Significant ↓ in TNF-α and IL-6 500 and 1000 mg/kg: ↑ SOD and CAT, and ↓ MDA and NO EE may be an optimal therapy for the treatment of rheumatoid arthritis	[20]
Anticancer activity							
<i>Alternanthera brasiliana</i>	EaE of leaves	EAC bearing Swiss albino mice	Estimation of hematological parameters Biochemical analysis Histopathological study Tumor growth response analysis Determination of %ILS	200 and 400 mg/kg 200 and 400 mg/kg 200 and 400 mg/kg 200 and 400 mg/kg 200 and 400 mg/kg	5-FU 5-FU 5-FU 5-FU 5-FU	↓ BW; doses of 200 and 400 mg/kg ↓ tumor volume, tumor weight, and viable cell count, whereas ↑ the non-viable cell count Significantly ↑ survival rates (%ILS _{200 mg/kg} : 53.33 and %ILS _{400 mg/kg} : 78.37) ← EAC-induced changes in Hb, WBCs, and RBCs ↓ SGPT, SGOT, TGL, and ALP, restoring them to normal levels ↑ GSH, SOD, and CAT levels, while ↓ MDA levels Prevented the development of steatosis and lymphocyte accumulation in the liver, maintaining an almost normal liver histology	[190]

(Continues)

TABLE 10 | (Continued)

Species	Extract (s)/Compounds	Models	Assay method	Dose	Positive control	Effects/Mechanisms	References
<i>Alternanthera sessilis</i>	Paste of leaves	Swiss mice induced with 3,4-benzol[<i>a</i>]pyrene (male)	BW measurement	600 mg/g	Uninformed	Had no effect on mice or rats BW	[228]
		Wistar rats induced with 3'-methyl-4-dimethylaminoazo benzene (male)	Histopathological study			Did not significantly inhibit squamous cell carcinoma of the stomach in mice and did not prevent adenocarcinoma development	
<i>Alternanthera tenella</i> Colla	AqE of aerial parts	Swiss mice (male) injected with EAC cells	BW measurement	600 mg/g	Uninformed		
			Histopathological study				
			Tumor growth	5 or 50 mg/kg	—	↑ Survival time of mice	[66]
			response analysis			50 mg/kg inhibited viable tumor cell count by 59%	
			Determination of %ILS	5 or 50 mg/kg	—	5 mg/kg ↓ BW after 8 days of tumor inoculation	
<i>Gomphrena celosioides</i>	Crude powder	DEN/HCB-induced Albino Wistar rats (male)	Biochemical analysis	200 mg/kg	—	LPO GOT and GPT levels were significantly ↓, indicating antioxidant activity	[133]
	EE of whole plant	DEN/HCB induced Albino Wistar rats (male)	Biochemical analysis	50 mg/kg	—	ALP, ACP, and GGT levels significantly ↓ to near normal values, possibly due to the regenerative capacity of liver cells	
						Crude extract showed remarkable activity on SGOT	
<i>Gomphrena martiana</i>	Mixture of 10, 6, 7, and 17	S180 bearing BALB/c mice and Swiss mice	BW measurement	20 and 40 mg/kg	—	The mixture of flavonoids ↑ the survival of S180-bearing mice by 40%	[100]
			Determination of the %I of tumor ascites			The flavonoid mixture ↓ tumor growth in S180-bearing mice by 21.6% at 40 mg/kg on Day 18	
						The flavonoid mixture at 20 mg/kg did not ↑ the survival in Ehr Ca-bearing mice, with only a 10%–20% survival increase at 40 and 60 mg/kg	
						Tumor inhibition in Ehr Ca-bearing mice was 32% at 40 mg/kg on Day 18	
<i>Pfafia paniculata</i>	Powdered root	Ehr Ca bearing inbred BALB/cICB mice (male)	Ehrlich ascitic tumor growth	200 mg/kg	—	Significantly ↓ the Ehrlich ascitic volume but had no significant effect on total tumor cell count	[224]

(Continues)

TABLE 10 | (Continued)

Species	Extract (s)/Compounds	Models	Assay method	Dose	Positive control	Effects/Mechanisms	References
<i>Pfaffia paniculata</i>	Powdered root	BALB/c mice treated with <i>N</i> -nitrosodiethylamine	Liver macroscopic analysis	0.5%, 2%, or 10% by weight	—	Male mice treated with 10% powder showed a small incidence of macroscopic lesions, while mice treated with 2% did not show any lesions. Female mice treated with 0.5% and 2% showed a ↓ in macroscopic lesions ↓ Mean lesion number, mean area of the preneoplastic lesions, the % of area with lesions, lesions number by cm ² , and total preneoplastic lesions ↓ Adenoma incidence in male mice, and adenomas disappeared in female mice	[226]
<i>Pfaffia paniculata</i>	EE of roots AF of roots	Ehr Ca bearing SWISS mice (male)	Survival time	50, 100, or 200 mg/kg/day	—	BuF 50 and 200 mg/kg ↑ survival, but AF and EE had no effect on survival BuFF had no effect on total ascitic volume, tumor cell count per mL, or total tumor cells collected	[248]
	BuF of roots	Ehr Ca bearing SWISS mice (male)	Survival time	50, 100, or 200 mg/kg/day	—		
<i>Pfaffia paniculata</i>	ME of roots	Ehr Ca bearing BALB/c mice	Ehrlich ascitic tumor growth Macrophage activity	50 or 200 mg/kg/day 100, 250, and 500 mg/kg	—	500 mg/kg ↑ the spreading index of peritoneal macrophages and phagocytosis index Had no effect on H ₂ O ₂ and NO production	[225]
<i>Pfaffia paniculata</i>	Powdered root	BALB/c mice (male) treated with <i>N</i> -nitrosodiethylamine	Histopathological study	0%, 2%, and 10% of weight	—	0% and 10% ↑ relative liver weight Histopathological examination showed diffuse mononuclear inflammatory infiltrates and coagulation necrosis 0% and 10% ↑ cellular proliferation, but 2% ↓ cellular proliferation and PCNA-positive nuclei 2% and 10% ↑ apoptosis Did not alter intercellular hepatocyte communication via gap junctions	[227]
			Immunohistochemical staining Fluorescence microscopy Alkaline comet assay Western blot Real-time PCR				

(Continues)

TABLE 10 | (Continued)

Species	Extract (s)/Compounds	Models	Assay method	Dose	Positive control	Effects/Mechanisms	References
Antidiabetic and antihyperglycemic activity							
<i>Alternanthera philoxeroides</i>	ME of whole plant	Swiss albino mice	OGTT	50, 100, 200, and 400 mg/kg BW	GLB	↓ Serum glucose levels in a dose-dependent manner (% I_{100} mg/kg: 58.6 and % I_{400} mg/kg: 65.6) Doses equal to or greater than 100 mg/kg of ME showed greater activity than GLB	[39]
<i>Alternanthera sessilis</i> (red)	FH of EE of aerial parts	Male Sprague Dawley rats induced with STZ	OGTT	500 mg/kg	GLB	FH and AF did not show significant antihyperglycemic effect	[236]
	AF of EE of aerial parts		OGTT	500 mg/kg	GLB	FEA showed a more significant hypoglycemic effect than GLB	
	FEA of EE of aerial parts	Male Sprague Dawley rats induced with STZ	OGTT	500 mg/kg	GLB	FEA ↓ blood glucose levels in the rats over 15 days but did not affect serum insulin levels	
			Biochemical assay	250 mg/kg	Pioglitazone	FEA ↓ HOMA index and ↑ QUICKI index	
			Liver triglyceride assay	250 mg/kg	Pioglitazone	FEA ↓ triglyceride levels (↓ 42.04%) and free fatty acid levels (↓ 34.38%) in plasma but did not alter the triglyceride content	
			Pancreatic insulin and SOD assay	250 mg/kg	Pioglitazone	FEA ↑ insulin levels and SOD activity in the pancreas	
			Insulin sensitivity indexes	250 mg/kg	Pioglitazone		
<i>Alternanthera sessilis</i>	Green leaf juice	Wistar rats (male)	OGTT	NA	—	Did not reduce starch- or glucose-induced postprandial glycemic load	[211]
			OSTT	NA	—		

(Continues)

TABLE 10 | (Continued)

Species	Extract (s)/Compounds	Models	Assay method	Dose	Positive control	Effects/Mechanisms	References
<i>Alternanthera sessilis</i>	ME of aerial parts	Swiss albino mice (male)	OGTT	50, 100, 200, and 400 mg/kg BW	GLB	Dose-dependent activity. ↓ blood glucose levels by 22.9%, 30.7%, 45.4%, and 46.1%. The highest [] showed activity comparable to that of GLB	[232]
Antihypertensive effect							
<i>Alternanthera sessilis</i>	EE of whole plant	Sprague-Dawley albino rats	Measures of SDB, DBP, MABP	1–10 mg/kg	Verapamil	↓ SBP, DBP, and MABP Dose-dependent hypotensive activity	[64]
<i>Gomphrena celosiotides</i>	EE of aerial parts	Wistar rats (male)—the IKIC method	Acute model of direct blood pressure measurement	30, 100, or 300 mg/kg diluted	—	EE at [] of 100 and 300 mg/kg ↓ MAP in a dose-dependent manner, reducing PAM by 36.7 and 38.2 mm Hg, respectively EE acted as a diuretic	[80]
		Wistar rats (male)—the 2K1C method	Diuretic assessment Blood pressure assessment Urine and serum analysis ACE activity, aldosterone, nitrite, and TBARS Isolation of the mesenteric bed and assessment of vascular reactivity to Phe, ACh, and SNP Organ weighing and histopathology	100 mg/kg	Enalapril	EE ↑ the Na levels in the urine, while K and Cl levels in urine were similar to the control, and serum remained unchanged in all groups EE ↓ MAP in the 2K1C model, but the effect was lower than of enalapril EE inhibited ACE even more than enalapril, as well as ↓ serum aldosterone [] and TBARS, and ↑ serum nitrite The isolated mesenteric beds in the EE group showed ↓ contractility and reduced pressure ↑ after Phe administration, as well as ↑ relaxation after treatment with ACh and SNP The left ventricle was thinner in EE-treated rats than in control, and EE did not affect heart, liver, or kidney weights	

(Continues)

TABLE 10 | (Continued)

Species	Extract (s)/Compounds	Models	Assay method	Dose	Positive control	Effects/Mechanisms	References
Anti-inflammatory activity							
<i>Alternanthera brasiliana</i>	Infusion of aerial part	Wistar rats (male)	Carrageenan-induced pleurisy	200 and 400 mg/kg doses	Indomethacin	400 mg/kg significantly ↓ the number of lymphocytes ↓ Exudate by 19.8% (200 mg/kg) and 23.9% (400 mg/kg) ↓ Polymorphonuclear cells (47.5% and 48.02%) and ↑ mononuclear cells (72.13% and 55.74%)	[30]
<i>Alternanthera brasiliana</i>	EE of leaves	<i>Mus musculus</i> mice	Formalin test	25, 50, and 100 mg/kg	Indomethacin	EE at concentrations of 25, 50, and 100 mg/kg, ↓ the edematogenic process by 35.57%, 64.67%, and 64.17%, respectively	[26]
<i>Alternanthera brasiliana</i>	HaE of leaves	Wistar rats (male-trichotomy was performed on the dorsum skin and a dermatological punch of 1.5 cm in diameter)	Histomorphometry Biochemical analysis (MPO and NAG) Western blotting	20% HaE of leaves in 2% carbopol gel 20% HaE of leaves in 2% carbopol gel 20% HaE of leaves in 2% carbopol gel	—	20% HaE leaf extract in 2% carbopol gel controls the recruitment of inflammatory cells at the wound site, according to histomorphometry and biochemical analysis 20% HaE leaf extract in 2% carbopol gel modulates inflammation by ↑ IL-1 β and ↓ TGF- β 1 levels HaE at 20% exhibited anti-inflammatory activity in the acute phase of inflammation	[195]
<i>Alternanthera maritima</i>	EE of aerial parts	Swiss mice	Carrageenan-induced paw edema	30, 100, and 300 mg/Kg	Dexamethasone	EE inhibits edema formation at 100 and 300 mg/kg (79%), whereas the isolated compound inhibits it at all [] tested, achieving the ↑ inhibition at 1 mg/kg (76%)	[34]
	72	Swiss mice	Carrageenan-induced paw edema	1, 10, and 20 mg/Kg	Dexamethasone	EE ↓ leukocyte counts at 100 and 300 mg/kg, with %I of 65% and 68%, respectively	
	EE of aerial parts	Swiss mice	Carrageenan-induced pleurisy	30, 100, and 300 mg/Kg	Dexamethasone	The isolated compound ↓ leukocyte migration and protein extravasation at all doses, with the ↑ inhibition of leukocyte migration at a dose of 10 mg/kg (77%) and protein extravasation at 20 mg/kg (56%)	
	72	Swiss mice	Carrageenan-Induced Pleurisy	1, 10, and 20 mg/Kg	Dexamethasone		

(Continues)

TABLE 10 | (Continued)

Species	Extract (s)/Compounds	Models	Assay method	Dose	Positive control	Effects/Mechanisms	References
<i>Alternanthera tenella</i> Colla	AqE of whole plant MHW	BALB/c mice (male) induced with carrageenan	Paw thickness measurement	200 or 400 mg/kg	Indomethacin	The extracts inhibit edema formation in a dose-dependent manner	[234]
	AqE of whole plant MCW		Paw thickness measurement	200 or 400 mg/kg	Indomethacin	AqE MCW and MHW showed greater inhibition of edema than indomethacin, with a % I_{400} mg/kg of 61% and 56% at 3 h, respectively	
<i>Alternanthera tenella</i> Colla	EE of whole plant	Swiss mice	Zymosan-induced articular inflammation	100 mg/kg	PRED	Four hours after carrageenan injection, EE and 43 inhibited edema by 54% at 100 and 1 mg/kg, respectively	[67]
			Carrageenan-Induced Pleurisy	100 mg/kg	PRED	Four hours after zymosan injection, EE and 43 inhibited edema by 58% and 72%, respectively	
		C57bl6 mice	MPO and NAG activity assay	100 mg/kg		EE and 43 ↓ the total leukocyte count in synovial fluid by 65% and 61%, respectively	
	43	Swiss mice	Zymosan-induced articular inflammation	1 mg/kg	PRED	EE and 43 blocked leukocyte migration and inhibited edema proteins by 54% and 72%, respectively	
			Carrageenan-induced pleurisy	1 mg/kg	PRED	Twenty-four hours after CFA-injection, EE and 43 inhibited MPO activity by 82.86% and 79.15%, respectively, and also inhibited NAG by 67.87% and 68.56%	
		C57bl6 mice	MPO and NAG activity assay	100 mg/kg			

(Continues)

TABLE 10 | (Continued)

Species	Extract (s)/Compounds	Models	Assay method	Dose	Positive control	Effects/Mechanisms	References
<i>Blutaparon portulacoides</i>	EE of aerial parts	Swiss mice (male)	Venom of <i>Bothriopsis jararacussu</i> induced paw edema	100, 250, or 500 mg/kg	Dexamethasone	EE at 250 and 500 mg/kg inhibits venom-induced edema formation by 28.5% and 39% within 6 h, respectively	[235]
			BthTX-I- and BthTX-II-induced paw edema	500 mg/kg	Dexamethasone	EE also ↓ the edematogenic effect induced by BthTX-I and BthTX-II from 30 min to 6 h (end of experiment)	
			Venom of <i>Bothriopsis jararacussu</i> induced pleurisy	500 mg/kg	Dexamethasone	EE had no effect on leukocyte migration induced by venom or BthTX-II, but it significantly inhibited the leukocyte flux induced by BthTX-I	
			BthTX-I- and BthTX-II-induced pleurisy	500 mg/kg	Dexamethasone		
<i>Blutaparon portulacoides</i>	EE of stems	Swiss mice (female)	Carrageenan-induced pleurisy	30, 100, 300, and 1000 mg/kg	Dexamethasone	Only at 1000 mg/kg was a 55% inhibition of leukocyte invasion in the pleura, and protein exudation was ↓ at doses of 300 and 100 mg/kg, as well as a ↓ in IL-1β levels	[71]
			Carrageenan-induced paw edema	30, 100, or 300 mg/kg	Dexamethasone	EE ↓ edema in a dose- and time-dependent manner, achieving a 67% reduction at 4 h in mice injected with carrageenan, and EE ↓ edema in mice treated with CFA in a manner comparable to that of dexamethasone, reaching an 80% inhibition at Day 22	
			CFA	30 and 100 mg/kg	Dexamethasone		
			BCG-induced pleurisy	30 and 100 mg/kg	Isoniazid		

(Continues)

TABLE 10 | (Continued)

Species	Extract (s)/Compounds	Models	Assay method	Dose	Positive control	Effects/Mechanisms	References
<i>Gomphrena celosioides</i>	AqE of leaves	Adult Sprague–Dawley rats and Swiss albino mice	Carrageenan-induced edema	100, 200, and 400 mg/kg	Indomethacin	Dose-dependent activity %I of edema: 27.97, 39.62, and 39.62 At 100 mg/kg, the effect was not significant	[87]
<i>Gomphrena celosioides</i>	EE of whole plant	Wistar albino rats	Carrageenan induced paw edema	200 mg/kg of BW	Diclofenac	↓ CRP levels, possibly due to the inhibition of inflammatory mediators Inhibition of edema	[77]
<i>Pfafia glomerata</i>	HaE of roots and rhizomes	Wistar rats (male)	Carrageenan induced paw edema Granulomatous tissue assay	100, 200, and 300 mg/kg 100 mg/kg	Dexamethasone Dexamethasone	%I of edema: 46.3, 56.8, and 63.2 for 100, 200, and 300 mg/kg, respectively HaE does not inhibit cell migration ↓ Granulomatous tissue formation by 29%	[118]
<i>Pfafia glomerata</i>	HaE of roots	Swiss mice (male)	Carrageenan induced paw edema	1, 10, 30, 100, or 300 mg/kg	Indomethacin	↓ Carrageenan-induced paw edema in a dose-dependent manner (ID ₅₀ : 60.5 (dose oral) and 20.4 (dose intraperitoneal))	[119]
		Swiss mice (male) with carrageenan-induced edema	Evaluation of the influence of NO synthase and guanylate cyclase inhibition	300 mg/kg	Indomethacin	↓ Edema induced by bradykinin and substance P, highlighting that 300 mg/kg of HaE completely ↓ edema at 120 min. These results suggest that HaE has antinociceptive activity	
		Swiss mice (male)	Bradykinin induced paw edema	1, 10, 30, 100, or 300 mg/kg	Indomethacin	↓ Edema induced by histamine, serotonin, and LPS ↑ NO levels	
		Swiss mice (male)	Substance P induced paw edema	1, 10, 30, 100, or 300 mg/kg	Indomethacin	When the ↑ in NO levels is blocked with L-NAME, a ↓ in anti-edema activity is observed	
		Swiss mice (male)	Serotonin induced paw edema	1, 10, 30, 100, or 300 mg/kg	Indomethacin		
		Swiss mice (male)	Histamine induced paw edema	1, 10, 30, 100, or 300 mg/kg	Indomethacin		
		Swiss mice (male)	LPS induced paw edema	1, 10, 30, 100, or 300 mg/kg	Indomethacin		

(Continues)

TABLE 10 | (Continued)

Species	Extract (s)/Compounds	Models	Assay method	Dose	Positive control	Effects/Mechanisms	References
<i>Pfaffia paniculata</i>	ME of roots	Wistar rats (male)	TNBS induced intestinal inflammation	25, 50, 100, 200, or 400 mg/kg	Prednisolone	No ↓ macroscopic damage score in the preventative protocol, but at 200 mg/kg in the curative protocol, ↓ in gross damage score was observed Doses of 50 and 100 mg/kg ↓ microscopic damage score (↑ mucosal regeneration) ↓ Polymorphonuclear cell infiltration, fewer ulceration sites, ↓ dilated crypts, and depletion of goblet cell 200 mg/kg, ↓ MPO activity was observed, and doses of 50 or 200 mg/kg prevented glutathione depletion in the curative protocol ↓ IL-1β, IFN-γ, and C-reactive protein levels At 200 mg/kg, ↓ TNF-α and IL-6 levels It was not able to prevent TNBS-induced intestinal inflammation but was able to ↓ colonic inflammation	[215]
<i>Pfaffia paniculata</i>	ME of roots	Male Wistar rats (male)	Intestinal inflammation assessment	25, 50, 100, and 200 mg/kg	—	At 200 mg/kg ↓ gross damage score, extent of injury, and MPO activity were observed At 25 mg/kg, ↓ Hsp70; 50 mg/kg, ↓ Mapk3 and ↑ Muc4; 100 mg/kg, ↑ Mapk1, Muc3, Muc4, and ↓ Mapk3; at 200 mg/kg, ↓ Mapk3 No effect was observed on the mRNA levels of heparanase, NF-κB, Mapk6, Mapk9, Mucl, or Muc2 Inflammatory activity was related to the differential modulation of MAPKs and the expression and production of mucin	[125]
<i>Pfaffia townsendii</i>	EE of whole plant 67 106 EE of whole plant 67 106	Swiss mice (male) Swiss mice (female)	Inflammatory mediator's analysis Carrageenan-induced paw edema Carrageenan-induced pleurisy	25, 50, 100, and 200 mg/kg 300 mg/kg 1 mg/kg 1 mg/kg 300 mg/kg 1 mg/kg 1 mg/kg	Dexamethasone Dexamethasone	EE inhibits the formation of edema by 51.00% ± 11.0%, while compound 67 inhibited it by 75.4% ± 4.0% and compound 98 by 73.00% ± 4.0% EE inhibited leukocyte migration to the pleura by 69.2% ± 1.04%, while compounds 67 and 106 by 50.7% ± 1.03% and 59.4% ± 1.25%, respectively EE ↑ plasma leakage, whereas flavonoids ↓ plasma leakage The anti-inflammatory activity of compound 67 was similar to that of dexamethasone	[127]

(Continues)

TABLE 10 | (Continued)

Species	Extract (s)/Compounds	Models	Assay method	Dose	Positive control	Effects/Mechanisms	References
Antimutagenic activity							
<i>Pfaffia glomerata</i>	Commercial root dry extract	Wistar rats (<i>Rattus norvegicus</i>) treated with cyclophosphamide	Chromosomal aberration test	1.5 mg/mL simultaneous or pretreatment or post-treatment	—	Significantly ↓ the % of damage induced by cyclophosphamide; damage was ↓ by 87% for simultaneous treatment, 98% for pretreatment, and 99% for post-treatment	[112]
Antispasmodic activity							
<i>Gomphrena perennis</i>	HaE of aerial parts	Sprague-Dawley rats (female)	Carbachol concentration-response (CCh-CRCs) Calcium concentration-response (Ca ²⁺ -CRCs) Relaxation response concentration (RRC)	0.14–28.1 mg extract/mL	—	HaE demonstrated antispasmodic activity through several mechanisms, highlighting the non-competitive inhibition of Ca ²⁺ influx. Significant values were obtained for the inhibition of CCh-CRCs in a concentration-dependent manner	[140]
Antioxidant activity							
<i>Alternanthera brasiliana</i>	HaE of leaves	Wistar rats (male-trichotomy was performed on the dorsum skin and a dermatological punch of 1.5 cm in diameter)	Biochemical analysis: TBARS and antioxidants—SH groups	20% HaE of leaves in 2% carbopol gel	—	Relevant antioxidant activity was observed on Day 2, probably to control oxidative damage	[195]
<i>Gomphrena celosioides</i>	EE of whole plant	Wistar albino rats	FRAP and TBARS assays	200 mg/kg of BW	Vitamin C	Significantly ↓ serum TBAR levels ↑ Serum levels total antioxidant capacity Significant ↓ in Fe ³⁺ to ion Fe ²⁺ ion activity	[77]

(Continues)

TABLE 10 | (Continued)

Species	Extract (s)/Compounds	Models	Assay method	Dose	Positive control	Effects/Mechanisms	References
<i>Pfaffia glomerata</i>	FD of roots	C57BL/6 mice	Tissue oxidative induction	250, 25, and 2.5 µg/mL	Quercetin	FDs showed inhibitory activity against lipid peroxidation and the formation of ROS. In particular, only the FD of aerial parts, at the highest concentration, showed significant total antioxidant capacity	[167]
	FD of aerial part		Total antioxidant capacity				
			Lipid peroxidation				
			Sulphydryl groups content				
			Reactive oxygen species (ROS)				
Antiviral activity							
<i>Alternanthera philoxeroides</i>	238	BALB/c mice inoculated HSV-2 strain UW 264	Determination of clinical signs and viral shedding	0.3 or 0.6 mg	—	Dose-dependent protection against HSV-2 In the 3rd day of treatment, it ↓ the mean titers of virus shed by 33.33% Significantly suppressed herpetic lesions ↑ Survival by 40 and 60% for doses of 0.3 and 0.6 mg, respectively	[4]
Cardioprotective activity							
<i>Gomphrena celosioides</i>	AqE of stems, flowers, and leaves	Wistar albino rats induced with DOX	Biochemical study RW of the body and heart	200 and 500 mg/kg for 14 days	Resveratrol	AqE and EE ↓ the [] of ALT, AST, CK-MB, cholesterol, and triglycerides in serum AqE and EE ↑ the [] of HDL-C	[76]
	EE of stems, flowers, and leaves.	Wistar albino rats induced with DOX	Biochemical study RW of the body and heart	200 and 500 mg/kg for 14 days	Resveratrol	It ↓ the weight loss of the rat but did not affect the relative weight of the heart	

(Continues)

TABLE 10 | (Continued)

Species	Extract			Assay method	Dose	Positive control	Effects/Mechanisms	References
	(s)/Compounds	Models	Models					
<i>Gomphrena perennis</i>	HaE of aerial parts	Sprague-Dawley rats (female)	Langendorff method with control Krebs solution (Krebs-C), Ischemia/reperfusion15 min prior to I/R (I/R) model	Oral 25 mg HaE/kg/day and HaE at 0.1% v/v were perfused for 15 min prior to I/R	Krebs-C	HaE has a cardioprotective effect due to its action on NO production, attributed to the presence of flavonoids in its composition	[140]	
<i>Blutaparon portulacoides</i>	AqE of whole plant	SHRs and Wistar-Kyoto rats (male)	Electrocardiography Blood pressure Biochemical analysis RW of organs, histopathology, and heart morphometry	30, 100, and 300 mg/kg	HCTZ	AqE prevents changes in the RW of the heart and left ventricle, as well as changes in the levels of MDA and NT AqE has significant diuretic and cardioprotective effects	[155]	
Diuretic activity								
<i>Gomphrena celosioides</i>	EE of aerial parts	Wistar rats (male)	Single-dose model of diuretic assessment Assessment of the involvement of the prostaglandin, bradykinin, and NO pathways Urine and serum analysis Urine	30, 100, and 300 mg/kg 100 mg/kg	HCTZ HCTZ	EE ↑ urine volume, comparable to HCTZ, $DI_{1,000}$ mg/kg: 1.74 ± 0.25 and DI_{300} mg/kg: 1.86 ± 0.28 EE had a higher UNa value than HCTZ EE had no effect on urine K^+ , Ca, and Cl^- [Cl^-], nor on pH, density, serum electrolytes, urea, and creatinine After pretreatment with L-NAME, indomethacin, or HOE-140, EE did not significantly promote diuresis or natriuresis During the 7 days of treatment, an ↑ in UV and UNa and ↓ aldosterone levels were observed	[81]	

(Continues)

TABLE 10 | (Continued)

Species	Extract (s)/Compounds	Models	Assay method	Dose	Positive control	Effects/Mechanisms	References
<i>Gomphrena perennis</i>	HaE of aerial parts	Sprague-Dawley rats (female)	Quantification of Na ⁺ and K ⁺ content urinary volumetric excretion (UVE %)	100 and 400 mg/kg	Amiloride	HaE did not show an ↑ in the total urine volume at the evaluated doses and did not cause a differences in ion excretion in the animal's urine	[140]
<i>Blutaparon portulacoides</i>	AqE of whole plant	SHRs and Wistar-Kyoto rats (male and SHRs)	Biochemical analysis	30, 100, and 300 mg/kg	HCTZ	300 mg/kg of AqE prevents changes in renal sodium and chloride excretion, maintaining urinary volume and electrolyte elimination. AqE does not increase the potassium elimination, preventing the appearance of cramps and arrhythmia 300 mg/kg of AqE has diuretic effects in SHRs	[155]
Gastrointestinal activity							
<i>Alternanthera repens</i>	ME	CDI strain mice (male)	Evaluation of the number of feces	50 and 100 mg/kg	Diphenoxylate	AqE (%I _{100 mg/kg} : 49 ± 6.9) and ME (%I _{50 mg/kg} : 37.9 ± 0.7) significantly ↓ castor oil-induced diarrhea	[197]
	AqE or CIE or HeE or ME	CDI strain mice (male) treated with castor oil or MgSO ₄	Evaluation of the antidiarrheal activity	50 and 100 mg/kg	Diphenoxylate	HeE and CIE did not show antidiarrheal activity ME modifies normal defecation (%I _{100 mg/kg} : 59.6 ± 3.2)	
	ME	CDI strain mice (male) treated with castor oil	Evaluation of the antidiarrheal activity	12.5, 25, 50, and 100 mg/kg	Diphenoxylate	ME has dose-dependent antidiarrheal activity at 12.5, 25, and 50 mg/kg, with highest effect at 50 mg/kg in mice with MgSO ₄ -induced diarrhea (%I:75.9)	
	ME	Wistar rats (male) mice treated with castor oil	Effect on small intestinal transit	12.5, 25, 50, and 100 mg/kg	Diphenoxylate	ME ↓ intestinal transit by 24% at 60 min, but at 90 min, intestinal transit is returned to 100%	

(Continues)

TABLE 10 | (Continued)

Species	Extract (s)/Compounds	Models	Assay method	Dose	Positive control	Effects/Mechanisms	References
<i>Alternanthera repens</i>	AqE of aerial parts EE of aerial parts	Swiss mice (female) Swiss mice (female)	Charcoal meal method Charcoal meal method	1–300 mg/kg 1–300 mg/kg	Atropine Atropine	The extracts ↓ gastrointestinal content and contain metabolites with anti-diarrheal activity	[46]
Gastroprotective activity							
<i>Gomphrena celosoides</i>	ME of leaves	Wistar rats (male) induced with indomethacin	Determination of gastric volumes, pH, acid outputs, ulcer score, and ulcer index Biochemical analysis	200, 500, and 800 mg/kg BW	Cimetidine	↑ pH in a dose-dependent manner, and at 800 mg/kg this ↑ was more significant than that of cimetidine ↓ Acidity, gastric volume, ulcer index, ulcer score, and pepsin activity in a dose-dependent manner, with these effects being more marked at 800 mg/kg of ME than cimetidine ↓ MDA levels and ↑ protein levels ME displays an antiulcerogenic effect related to its gastroprotective activity	[88]
<i>Gomphrena celosoides</i>	ME of leaves	Wistar rats (male) induced with acidified ethanol	Biochemical analysis Histopathological study	200, 400, and 800 mg/kg BW	Cimetidine	ME ↓ the increase in gastric volume and acid output, and ↑ the mucus content ↑ SOD, GSH, and GPX activities ↓ LPO and XO levels ME promotes the restoration of the epithelial layer, lamina propria, and submucosal layer in a dose-dependent manner	[246]
<i>Guilleminea densa</i>	HaE of leaves	Holtzman rats induced with ethanol (male)	Macroscopic analysis Determination of gastric mucus and NP-SG Histopathological study	200, 400, and 600 mg/kg	Ranitidine and sucralfate	Dose-dependent gastroprotective effect (%I of gastric lesions _{400 mg/kg} : 58,78 and (%I of gastric lesions _{600 mg/kg} : 82,72) Significantly ← mucus depletion induced by ethanol at HaE [] of 400 and 600 mg/kg but had no effect on NP-SG levels At 600 mg/kg, it inhibited gastric erosions, ulcers, acute inflammation infiltration, and focal bleeding development	[102]

(Continues)

TABLE 10 | (Continued)

Species	Extract (s)/Compounds	Models	Assay method	Dose	Positive control	Effects/Mechanisms	References
<i>Pfaffia glomerata</i>	AqE of roots and rhizomes	Wistar rats (female) with ulcers induced by restriction or ethanol or indomethacin	Determination of IMD	125, 250, 500, and 1000 mg/kg	Ranitidine	↓ Ethanol-induced gastric lesion in a dose-dependent manner, reducing them by over 90% At 250 and 1000 mg/kg, ↓ stress-induced gastric lesion by 37.8% and 47.8%, respectively The AqE did not show gastric mucosa protective activity against indomethacin-induced ulcers ↑ pH The ↓ in total acidity and gastric volume in rats with a pylorus ligation is associated with an ↑ in NO _x content AqE has no effect on total acidity and gastric secretion volume in rats treated with bethanechol or pentagastrin At 2000 mg/kg, ↓ total acidity by 18.4% and gastric secretion volume by 53.2% in histamine-injected rats	[164]
		Wistar rats (female) with pylorus ligation	Determination of gastric acid secretion	125, 250, 500, and 1000 mg/kg	—		
		Wistar rats (female) with pylorus ligation and administration of bethanechol, histamine or pentagastrin	Determination of gastric acid secretion	125, 250, 500, and 1000 mg/kg	—		
		Wistar rats (female) with pylorus ligation	Determination of nitric oxide production	1500 mg/kg	—		
Hepatic activity							
<i>Pfaffia glomerata</i>	HaE of roots	Swiss mice (male)	Biochemical analysis Liver oxidative stress markers Morphology Histology and histopathology Mineral and hepatic glycogen content	100, 200, and 400 mg/kg	—	The HaE showed effects such as mineral content changes, antioxidant enzymes, and morphological modifications In general, HaE generated oxidative stress severe enough to induce liver damage	[185]

(Continues)

TABLE 10 | (Continued)

Species	Extract (s)/Compounds	Models	Assay method	Dose	Positive control	Effects/Mechanisms	References
Hepatoprotective activity							
<i>Alternanthera brasiliana</i> L.	HaE of leaves	BALB/c mice (male) induced with CCl ₄	Body weight, liver weight, and liver morphology Biochemical analysis (AST, ALT, and ALP) Lipid peroxidation and antioxidant parameters Histopathological study Western blot analysis qRT-PCR analysis ELISA	200 and 400 mg/kg	—	HaE restored the BW ↓ Liver index compared to CCl ₄ alone Restore ALT, AST, and ALP levels Restored liver size to normal, decreased the echogenic pattern, recovered nodular edge appearance, and ↓ the CBD dilation 400 mg/kg of HaE improvement hepatic architecture, showing minimal mononuclear cell infiltration and a ↓ number of mitotic figures HaE significantly ↓ MDA levels Restore GSH, GST, SOD, and vitamin C levels ↓ TNF- α , IL-1 β , and IL-18 levels 400 mg/kg of HaE significantly ↓ phospho-NF- κ B (p65) and NLRP3 protein levels 400 mg/kg of HaE ↓ MMP-2 and MMP-9 levels and restores TIMP-1 ↓ TGF- β , α -SMA, and p-Smad2/3 protein levels HaE leaf extracts may serve as an herbal hepatoprotective agent	[208]
<i>Alternanthera sessilis</i>	ME of whole plant	Wistar rats (male) induced with CCl ₄	Biochemical analysis (TBARS, GSH, CAT) Histopathological study	50, 200, and 250 mg/kg	Silymarin	At 250 mg/kg, ← the ↑ in serum SGPT, SGOT, and ALP levels Generates a ↓ in serum cholesterol and bilirubin levels It ↓ lipid oxidation, ↑ GSH levels, and improves CAT levels At higher doses, ← body degeneration (↓ necrosis and restores cellular integrity)	[51]
<i>Gomphrena celosioides</i>	AqE of stems and leaves	Wistar rats induced with CCl ₄ (PT and TC)	Biochemical analysis (AST, ALT, ALP, BT, and CB) Histopathological study	500 mg/kg BW for 5 days	Silymarin	AqE ↓ AST, ALT, ALP, BT, and CB values, indicating a preventive (PT) and restorative (TC) effect With PT and CT, liver lesions are ↓ severe, with PT showing greater hepatoprotective activity	[90]

(Continues)

TABLE 10 | (Continued)

Species	Extract (s)/Compounds	Models	Assay method	Dose	Positive control	Effects/Mechanisms	References
<i>Gomphrena globosa</i> L.	AqE	C57BL/6 mice (male) with CCl ₄	Biochemical analysis (AST, ALT, ROS, and SOD) Measurement of MPO, TP, MDA, GSH, and GSH-Px Histopathological studies Western blot	100, 200, or 300 mg/kg	Bifendatatum	AqE ↓ serum AST, ALT levels, and hepatic MPO AqE improves hepatic total protein content It ↓ ROS and MDA levels and ↑ GSH, GSH-Px, and SOD activities AqE improves liver injury in a dose-dependent manner It activates Nrf2 protein expression and regulates Keap1 levels It activates GCLC, GCLM, HO-1, and NQO1 protein expression It ↓ PI3K and mTOR phosphorylation, inhibits P62 protein expression, and activate LC3 II protein expression It promotes autophagy AqE alleviates CCl ₄ -induced chronic liver injury in mice by activating antioxidant signaling pathways and promoting autophagy At 5 mg/kg, it ↓ anti-SRBC IgM secreting cells prior to immunization, but 50 mg/kg has no effect on PFC count 50 mg/kg improves the production of IgM and IgG2a antibodies in mice stimulated with LPS It had no effect on the total number of nucleated spleen cells or spleen weight	[249]
Immunomodulatory activity							
<i>Alternanthera tenella</i> Colla	AqE of aerial parts	Swiss mice (male) immunized with sheep RBC	Antibody assays	5 and 50 mg/kg	—		[66]
		LPS stimulated mice (male)	Antibody assays	5 and 50 mg/kg	—		

(Continues)

TABLE 10 | (Continued)

Species	Extract (s)/Compounds	Models	Assay method	Dose	Positive control	Effects/Mechanisms	References
<i>Alternanthera tenella</i> Colla	AqE of whole plant MHW	BALB/c mice immunized with sheep RBC	Measurement of BW and lymphoid organs	50, 100, or 200 mg/kg BW	BALB/c mice (male) only immunized with sheep RBC	The extracts at 50, 100, and 200 mg/kg did not show significant differences in BW and lymphoid organ weight AqE MCW ↑ liver weight by 19.5%	[234]
	AqE of whole plant MCW	BALB/c mice immunized with sheep RBC	Splenic cellularity PFC assay Antibody assays	50, 100, or 200 mg/kg BW	BALB/c mice (male) only immunized with sheep RBC	The extracts did not affect spleen cellularity AqE MHW and AqE MCW maintained cell viability at 88% and 90%, respectively Only AqE MCW at 100 mg/kg significantly ↑ PFC, suggesting the presence of immunomodulators AqE MCW ↑ anti-SRBC IgM and IgG titers, but AqE MHW did not show any significant effect on antibody titers	
Neuropharmacological activity							
<i>Alternanthera brasiliana</i>	Infusion of aerial part	Wistar rats (male)	Open field test	100, 200, and 400 mg/kg	—	There was no effect on latency time in the first rectangle or the number of crossings 100 mg/kg ↑ the number of rearings, while 200 mg/kg ↓ the number of fecal boluses	[30]
				100, 200, and 400 mg/kg	—		

(Continues)

TABLE 10 | (Continued)

Species	Extract (s)/Compounds	Models	Assay method	Dose	Positive control	Effects/Mechanisms	References	
<i>Alternanthera brasiliensis</i>	ME of leaves	Swiss albino mice (male)	Hole board test	100, 300, and 600 mg/kg	Diazepam	ME at 300 and 600 mg/kg significantly ↑ the number of times and duration of the mice that poke their heads [24]		
						Open field test		It ↑ rearing, assisted rearing, and the number of squares traveled, showing comparable or superior activity to diazepam
						Elevated plus maze test		It ↑ in the number of entries into the open arm but ↓ entries into the close arm
						Light/dark exploration test		It ↑ time spent in lighted box, crossing numbers, and transfer latency, while ↓ time spent in the dark box
						Locomotor Activity test		It ↓ locomotor activity in a dose-dependent manner (CNS depressant effect)
								ME has anxiolytic activity
<i>Alternanthera philoxeroides</i>	EE of whole plants	PTZ injected Swiss albino mice (male)	Chemoshock convulsion	100, 300, and 600 mg/kg	Diazepam	It protected mice from PTZ-induced seizures in a dose-dependent manner, achieving maximum protection of 66.66%	[38]	
						Maximal electroshock induced convulsion		ME at 600 mg/kg ↓ the latency of maximal electroshock-induced seizures, but had no effect on seizure incidence
						FST		It ↓ immobility time in FST and TST
						TST		It did not alter locomotor activity in OVX mice
						LAT		It ↓ serum corticosterone levels in a dose-dependent manner
						Corticosterone ELISA		It normalized the expression of CREB and BDNF
	RT-PCR							

(Continues)

TABLE 10 | (Continued)

Species	Extract (s)/Compounds	Models	Assay method	Dose	Positive control	Effects/Mechanisms	References
<i>Alternanthera philoxeroides</i>	EE of whole plant	ICR-OVX mice (female)	NORT	250 and 500 mg/kg/day	17 β -Estradiol	It significantly improved the acquisition and retrieval of reference memory, \downarrow by OVX, in a dose-dependent manner	[141]
			Y-Maze Task	250 and 500 mg/kg/day	17 β -Estradiol	It significantly improves discrimination performance in NORT (enhanced recognition memory)	
			MWMT	250 and 500 mg/kg/day	17 β -Estradiol	It restored spatial working memory deficits induced by OVX	
			Locomotor Activity Test	250 and 500 mg/kg/day	17 β -Estradiol	It significantly \uparrow the % of spontaneous alternation	
			Lipid peroxidation of the brain	250 and 500 mg/kg (mice)	17 β -Estradiol (mice)	It \downarrow IL-1 β , IL-6, and TNF- α mRNA expressions	
			Bradford's method (brain)	250 and 500 mg/kg (mice)	17 β -Estradiol (mice) and BSA (testes)	It normalized the expression of the PI3K and AKT genes	
<i>Alternanthera philoxeroides</i>	EE of whole plant	ICR mice (male)	RT-PCR	250 and 500 mg/kg (mice)	17 β -Estradiol (mice)	Metabolomic analysis showed that 500 mg/kg of EE had better effects against OVX-induced alterations, and the most relevant metabolites in the study were responsible for the galactose metabolic pathway	
			NMR-metabolomic analysis	250 and 500 mg/kg (mice)	17 β -Estradiol (mice)		
			Behavioral assessment	250 and 500 mg/kg/day	Vitamin E	EE contributed to the maintenance of short-term and long-term memory in behavioral tests	[142]
			Biochemical assay Determination of CAT and SOD activities qPCR			The two EE concentrations evaluated were able to restore SOD and CAT levels to healthy conditions EE activity regulates the expression of mTERT, mTRF1, and mTRF2, leading to a delay in telomere shortening	

(Continues)

TABLE 10 | (Continued)

Species	Extract (s)/Compounds	Models	Assay method	Dose	Positive control	Effects/Mechanisms	References
<i>Alternanthera sessilis</i>	EE of whole plant	Swiss Albino mice	Pentobarbital-induced sleeping time	250 and 500 mg/kg	Caffeine	It ↑ the time required for the onset of sleep by 188.70% and 377.49% and ↓ its duration by 12.70% and 23.08%, at doses of 250 and 500 mg/kg, respectively. Locomotion ↑, but after reaching maximum activity, the stimulating effect gradually ↓ with passage of time	[139]
<i>Iresine celosia</i>	EE of aerial parts	ICR mice (male) treated with LPS	Open field test Hole cross test Open field test Pole test	250 and 500 mg/kg 250 and 500 mg/kg 30 or 100 mg/kg	— — —	100 mg/kg significantly ↓ LPS-induced activated microglia and number of S100β-positive cells It ↑ ambulation in open field tests and improved T-turn and T-LA Inhibition of microglia and astrocytes alleviated behavioral dysfunction	[104]
<i>Pfaffia glomerata</i>	EE of roots and rhizomes	Wistar rats (male)	Immunohistochemistry and image analysis Open field test Elevated plus maze test	500 mg/kg 500 mg/kg	Diazepam Diazepam	Rats in the open-field test exhibited behavior similar to those treated with diazepam 500 mg/kg ↓ sleep latency and ↑ sleeping time, but 1000 mg/kg had no effect on latency and sleep duration	[245]
			Step-down inhibitory avoidance task FST	100, 500, 1000, and 1500 mg/kg 500 mg/kg	Diazepam Imipramine hydrochloride	500 mg/kg ↑ latency and a ↓ in the duration of the first convulsion, but 1000 mg/kg had no effect It ↓ entries in enclosed arms 500 and 1000 mg/kg ↓ step-down latency in a []-dependent manner	
		Swiss mice (male)	Pentobarbital-induced sleeping time	500 and 1000 mg/kg	Diazepam	1500 mg/kg showed a tendency to ↑ the memory retention, but this effect was not statistically significant	
			Pentylenetetrazole-induced convulsions	500 and 1000 mg/kg	Diazepam	No antidepressant effect was observed	

(Continues)

TABLE 10 | (Continued)

Species	Extract (s)/Compounds	Models	Assay method	Dose	Positive control	Effects/Mechanisms	References
<i>Puffia glomerata</i>	HaE of roots	Albino mice (male)	Spontaneous movement	10 and 100 mg/kg	—	It causes abdominal contraction when administered intraperitoneally	[116]
			Rota-rod	10 and 100 mg/kg	—	It ↓ motor activity and stereotypy	
			Potentiation of sodium pentobarbital sleeping time	10 and 100 mg/kg	—	At 10 mg/kg, it ↓ scaling behavior and grooming 100, 200, and 1000 mg/kg caused ruffled fur 100 mg/kg ↓ sleep time but did not ← memory retention damage caused by scopolamine	
<i>Puffia glomerata</i>	HF of ME of roots	Albino mice treated with scopolamine	Passive avoidance test	100 mg/kg	—	Old rats treated with HaE performed similarly to young rats in the discrimination test, demonstrating that HaE improved acquisition and retention of determined behavior	
		Young and old Wistar rats (male)	Passive avoidance test	100 mg/kg	—	HaE partially reversed age-associated memory deficit. It ↓ BW	
		Old Wistar rats	Right-left discrimination test	100 mg/kg	—		
<i>Puffia glomerata</i>	HF of ME of roots	C57BL/6J mice (male) with acute stress	Open-field test	3, 10, or 30 mg/kg	—	Avoid ↑ motor function of mice (↓ stress-related behavior)	[114]
			Elevated plus maze test	3, 10, or 30 mg/kg	—	It ↓ depressive-like behaviors	
			FST	3, 10, or 30 mg/kg	—	At 30 mg/kg, it ↓ the time spent in closed arms after Day 2 and gradually ↓ the time spent in the open arms of the maze. At 10 mg/kg, it ↓ immobility time after Day 2 (protective effect in anxiety development)	
			Rotation test	3, 10, or 30 mg/kg	Diazepam	It did not show any effect in the rotation test	
	Biochemical analysis of tissues	3, 10, or 30 mg/kg	—	It prevented the ↓ of SOD and GPx activity in the cortex and striatum, but not in the hippocampus. It restores CAT activity in the striatum, but not in the cortex or hippocampus			

(Continues)

TABLE 10 | (Continued)

Species	Extract (s)/Compounds	Models	Assay method	Dose	Positive control	Effects/Mechanisms	References
Wound-healing activity							
<i>Alternanthera brasiliensis</i>	Ointment of ME of leaves	Sprague Dawley rats (excision wound model)	Wound area contraction measures Histopathological study	5%	Himax	ME ointment completely contracted the excision wound (100%), showing greater activity than Himax Mice treated with ME ointment had a granulation tissue completely filled with epidermal cells covered by a thick layer of keratin ME ointment generated a tensile strength of the healing tissue of 4.861 ± 0.664 , indicating wound-healing activity	[244]
<i>Alternanthera brasiliensis</i>	Ointment of ME of leaves	Sprague Dawley rats (dermal burn wound)	Wound area contraction measures Biochemical estimations Histopathological study	5%	Himax	On Day 8, it ↓ the wound area by 92.13%, showing greater activity than Himax (72%) It ↑ protein and hydroxyproline content It ↑ CAT, GSH, and SOD levels in granulation tissue It ↑ Vitamin C levels ME has good wound-healing activity, as histopathological studies showed collagen fiber deposition and a keratin layer, indicating tissue recovery and regeneration	[250]

(Continues)

TABLE 10 | (Continued)

Species	Extract (s)/Compounds	Models	Assay method	Dose	Positive control	Effects/Mechanisms	References
<i>Alternanthera brasiliensis</i>	Ointment of ME of leaves	Immunocompromised Sprague Dawley rats with HC	Wound area contraction measures Biochemical estimations Histopathological Study	2.5%, 5.0%, and 7.5%	Himax	An ointment with 5% ME achieved 77.10% wound contraction on Day 8, outperforming Himax (60%) It ↑ GSH, CAT, and SOD levels, as well as protein content in granulation tissues At 5%, the highest levels of hydroxyproline and vitamin C were observed, exceeding those of Himax Mice treated with ME showed abundant collagen fibers, fibroblast proliferation, angiogenesis, and development of basement membrane beneath the necrotic debris	[251]
<i>Alternanthera brasiliensis</i>	Ointment of ME of leaves	Aged Sprague Dawley rats (aged wound model)	Wound area contraction measures Biochemical estimations Histopathological Study	5%	—	The % of wound contraction ↑ to 97.62 ± 0.14 on Day 21, indicating wound-healing activity It ↑ the content of collagen, elastin, and hydroxyproline by $16.33\% \pm 0.42\%$, $6.67 \pm 0.42\%$, and 64.67 ± 3.83 (mg/g) on Day 21, respectively Granulation tissues showed abundant collagen fibers and re-epithelialization	[252]
<i>Alternanthera brasiliensis</i>	HaE of leaves	Wistar rats (male-trichotomy was performed on the dorsum skin and a dermatological punch of 1.5 cm in diameter)	Re-epithelialization analysis Histopathological Study	20% HaE of leaves in 2% carbopol gel	—	According to histomorphometry analysis, the extract did not induce a significant fibroblast proliferation According to biochemical studies, the collagen formation ↑ on the 2nd day. Additionally, they observed that it stimulated wound healing, as it gradually reduced collagen III levels, and after Day 21, collagen I increased	[195]

Abbreviations: ACh, acetylcholine; AF, aqueous fraction; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CAT, catalase; CFA, Freund's complete adjuvant; DBP, diastolic blood pressure; EE, ethanolic extracts; ELISA, enzyme-linked immunosorbent assay; FD, fraction of DCM; FEA, fraction of ethyl acetate; FH, fraction of hexane; GLB, glibenclamide; HCTZ, hydrochlorothiazide; MABP, mean arterial blood pressure; MCW, made with cold water; ME, methanolic extracts; MHW, made with hot water; MPO, myeloperoxidase; NA, not applicable; OGTT, oral glucose tolerance test; PFC, plaque forming cells; RBC, red blood cells; ROS, reactive oxygen species; SNP, sodium nitroprusside; SOD, superoxide dismutase.

5.8.3 | Wound-Healing Activity

To date, there are only six articles discussing the wound-healing potential of members of the Gomphrenoideae subfamily. Four of these studies focused on the healing potential of the ME of *A. brasiliana* leaves by the Barua research group. Among the most relevant results obtained by this group is that the ME has a positive effect on wound contraction, fibroblast deposition, and angiogenesis. It also has pro-healing activity in burn wounds, reducing the wound area more efficiently than Himax. Additionally, it increases endogenous antioxidant activity and angiogenesis. Similarly, it was shown that ME maintains its healing potential in wounds of old or immunocompromised mice [202, 220–222]. Additionally, the healing potential of the EE of *A. sessilis* stems was studied in an in vitro model, revealing that the EE can enhance the progression of wound closure in normal and diabetic fibroblast cells, as well as in keratinocytes. This suggests that it has the potential to be used in late healing stages of diabetic patients [57].

6 | Toxicology of Gomphrenoideae

Members of the Gomphrenoideae subfamily are widely used in traditional medicine to treat different ailments. To date, only 37 articles have reported the toxicity of 2.35% of the members of this subfamily (Table 11). It has been reported that the nHE and HE of *A. bettzickiana* possess mutagenic activity and toxicity against the BHK-21 cell line [17]. Additionally, the AuNPs of AqE of leaves of this same plant have shown toxicity against zebrafish embryos at concentrations higher than 25 μM [21]. Regarding *A. brasiliana*, it was found that the ME and EaE of leaves do not present toxicity in mice at the maximum dose evaluated (5 and 2 g/kg, respectively) [24, 185, 202, 220–222]. The HaE of the aerial parts did not present toxicity against murine macrophages at the evaluated concentration (20 $\mu\text{g}/\text{mL}$) [193], but the EE of leaves showed low toxicity against flies [26], and the AqE of leaves showed an LC_{50} of 500 $\mu\text{g}/\text{mL}$ for *Artemia salina* [27]. The ME of *A. philoxeroides* did not show toxicity [39], whereas the AqE and EE extracts of the aerial parts of *A. repens* showed toxicity against mice (LD_{50} : 3.4782 and 4.0639, respectively) [46]. On the contrary, the ME of the aerial parts and the EE of the stem of *A. sessilis* did not show toxicity up to the doses evaluated in an in vivo and in vitro model, respectively [57, 204].

The EE of *B. portulacoides* and the AqE of *G. celosioides* did not show toxicity in rats up to the dose evaluated [71, 87], but the HeE and ME of *G. celosioides* showed weak cytotoxicity against brine shrimp or nauplii, and the AcE and AqE extracts of this same plant showed low toxicity against Vero cells of monkey kidneys [82, 89]. On the other hand, the HE of *G. haageana* and *G. globosa* flowers did not show toxicity against PLP2 cells [73]. Additionally, the HaE of *G. globosa* flowers did not show toxicity against BJ cells but did against HaCat cells [153]. Regarding *P. glomerata* and *P. paniculata*, no toxic effects were observed up to the doses evaluated in rats (3 g/kg) and mice (1 g/kg), respectively [112, 116, 183, 207, 209]. It was also reported that the commercial extract of the root of *P. glomerata* has no cytotoxic effect on the J774 cell line, nor mutagenic effects [234].

It can be concluded that the extracts, fractions, and commercial preparations of the studied members of this subfamily do not present toxicity, or it is very low. Furthermore, toxicological safety evaluations are essential for the application or use of plants and the development of new drugs. Therefore, it is necessary to evaluate the toxicity of the other members of this subfamily.

7 | Relationship Among Traditional Uses, Biological Activity, and Chemical Profile

Different parts or even the whole plant of the members of Gomphrenoideae have been used in traditional medicine to treat bacterial, fungal, and viral infections, parasitic diseases, diabetes, cancer, hypertension, inflammatory diseases, gastrointestinal diseases, and liver damage. They have also been used as antioxidants, analgesics, and diuretics, as well as to treat other pathologies. Therefore, during the last decades, they have been studied at the laboratory level, mainly to verify their antimicrobial, antioxidant, anticancer, antidiabetic, hepatoprotective, gastroprotective, diuretic, and insecticidal properties. An attempt to compare traditional use with results from the laboratory is described as follows:

***Alternanthera bettzickiana*:** Out of the 17 traditional uses, only 4 have been evaluated at the laboratory level, confirming its antimicrobial, antioxidant, and cytotoxic (against the A549 cell line) activities. Additionally, two in vitro studies showed antiarthritic potential. The results obtained to date under laboratory conditions confirm only 23.53% of the traditional uses; therefore, it is necessary to confirm the other traditional uses.

***Alternanthera brasiliana*:** To date, only 10 of the 25 traditional uses of this plant have been evaluated, confirming its anticancer potential against the A549, CaCo-2, HT-29, and Hep-G2 cell lines, as well as its positive effect in mice bearing EAC. In addition, its use in the treatment of infections was confirmed, because it has been reported to have activity against some bacteria and yeasts. Its anti-inflammatory, analgesic, anticonvulsant, anxiolytic, and immunomodulatory activities were also confirmed, as well as its great potential in wound healing.

***Alternanthera flavescens*:** None of its traditional uses have been evaluated under laboratory conditions, but its antioxidant and anticancer activities have been evaluated.

***Alternanthera littoralis* P. Beauv. (*Alternanthera maritima* (Mart.) St. Hil.):** Currently, its two traditional uses have been evaluated under laboratory conditions, confirming that this plant has antifungal activity against yeasts and anti-inflammatory activity. Although its traditional uses do not include antioxidant, antiparasitic, and immunomodulatory activities, these properties were evidenced through pharmacological studies.

***Alternanthera paronychioides*:** Of the seven uses in traditional medicine, only antidiabetic activity has been evaluated under laboratory conditions through in vitro tests, suggesting that this plant has antidiabetic properties as well as antioxidant activity.

***Alternanthera philoxeroides*:** Of the 21 traditional uses, 4 have been evaluated under laboratory conditions, confirming that

TABLE 11 | Cytotoxicity of the Gomphrenoideae subfamily.

Species	Extract(s)/ Compounds	Assay method	Model	Dose	Positive control	Activity	References
<i>Alternanthera bettzickiana</i>	<i>n</i> HE of whole plant	MTT assays	BHK-21	Uninformed	—	IC ₅₀ : 493 µg/mL for HE and IC ₅₀ : 456 µg/mL for <i>n</i> HE.	[17]
		Ames reverse mutation assay	<i>Salmonella typhimurium</i> TA-100 and TA-102	0.015, 0.15, 1.5, 15, and 150 mg/mL	Sodium Azide and H ₂ O ₂	Cytotoxic activity is dependent on concentration. <i>n</i> HE exhibited greater activity than HE Both extracts have dose-dependent mutagenic potential. The enzyme activation system ↑ the mutagenicity in HE, whereas ↓ it in <i>n</i> HE	
<i>Alternanthera bettzickiana</i>	HE of whole plant	MTT assays	BHK-21	Uninformed	—	<i>n</i> HE: MIX ₁₅₀ mg/mL: 33.7 and 45.29 for TA100 and TA102, respectively	
	AuNPs of AqE of leaves	Ames reverse mutation assay	<i>S. typhimurium</i> TA-100 and TA-102	0.015, 0.15, 1.5, 15, and 150 mg/mL	Sodium Azide and H ₂ O ₂	HE: MIX ₁₅ mg/ml: 21.78 TA100 and MIX ₁₅₀ mg/mL: 12.30 for TA102 No toxicity was observed up to 25 µM	[21]
<i>Alternanthera bettzickiana</i>		Toxicity analysis	Zebrafish (<i>Danio rerio</i>) embryo model	12, 25, and 50 µM	—	At 50 µM, it strongly inhibited hatching, affected tail formation, and dark material was observed in the intestinal tract	
	EE of aerial parts	Acute oral toxicity study	Wistar rats	2000 mg/kg	—	No mortality was observed, but slight behavioral changes such as convulsions and tremors occurred, along with ↓ somatomotor activity. It did not affect BW or cause organ injury. No significant changes for hemoglobin, RBCS, ESR, TLC, neutrophils, HCT, MCHC, MCH, MCV, LDL, VLDL, cholesterol, HDL, triglycerides, AST, ALT, proteins, globulin, albumin, and A/G ratio. ↑ platelet count and ↓ alkaline phosphatase and protein levels. It was concluded that the extract was safe	[20]
<i>Alternanthera brasilitiana</i>	ME of leaves	Acute toxicity	Albino mice	2.0 g/kg BW	—	The extract is safe up to 5 g/kg. Showed no changes in motor activity or behavior at a concentration of 2 g/kg	[202]
		Determination of LD ₅₀	Albino mice	Different [] up to 5 g/kg	—		
<i>Alternanthera brasilitiana</i>	HaE of aerial parts	Toxicity test	Murine macrophages	20 µg/mL	—	No apparent cytotoxic effects were observed in murine macrophages	[232]

(Continues)

TABLE II | (Continued)

Species	Extract(s)/ Compounds	Assay method	Model	Dose	Positive control	Activity	References
<i>Alternanthera brasiliiana</i>	ME of leaves	Acute toxicity	Swiss albino mice Sprague Dawley rats	100, 200, 400, 800, 100, and 2000 mg/kg	—	The extract is safe up to 2000 mg/kg	[220]
<i>Alternanthera brasilitiana</i>	ME of leaves	Determination of LD ₅₀	Swiss albino mice Sprague Dawley rats	2.0 g/kg BW 2.0 g/kg BW	—	The extract is safe up to 2000 mg/kg	[221, 222]
<i>Alternanthera brasilitiana</i>	ME of leaves	Acute toxicity	Swiss albino mice Sprague Dawley rats	2.0 g/kg BW 2.0 g/kg BW	—		
<i>Alternanthera brasilitiana</i>	ME of leaves	Determination of LD ₅₀	Swiss albino mice (male)	2000 mg/kg	—	The extract is safe up to 2000 mg/kg, showed no changes in motor activity or behavior	[24]
<i>Alternanthera brasilitiana</i>	ME of leaves	Acute toxicity	Swiss albino mice (male)	2000 mg/kg	—		
<i>Alternanthera brasilitiana</i>	ME of leaves	Gross effect	Swiss albino mice (male)	2000 mg/kg	—		
<i>Alternanthera brasilitiana</i>	EaE of leaves	Acute toxicity	Swiss albino mice	2000 mg/kg	—	LD ₅₀ : >2000 mg/kg. Until the evaluated dose, no gross behavior changes or mortality were observed	[185]
<i>Alternanthera brasilitiana</i>	EaE of leaves	Determination of LD ₅₀	Swiss albino mice	Uninformed	—		
<i>Alternanthera brasilitiana</i>	EE of leaves	Viability of flies	<i>Drosophila melanogaster</i>	10, 20, and 40 µg/mL	—	EE exhibited low toxicity, as mortality significantly differed from the control only after 24 h, without a dose-dependent response. After 48 h, EE killed more than 50% of the flies	[26]
<i>Alternanthera brasilitiana</i>	AqE of leaves	Locomotor assay	<i>Drosophila melanogaster</i>	10, 20, and 40 µg/mL	—		
<i>Alternanthera brasilitiana</i>	AqE of leaves	Determination of LC ₅₀	<i>Artemia salina</i>	[] up to 1000 µg/mL	—	LC ₅₀ : 500 µg/mL	[27]

(Continues)

TABLE 11 | (Continued)

Species	Extract(s)/ Compounds	Assay method	Model	Dose	Positive control	Activity	References
<i>Alternanthera brasiliiana</i>	HaE of leaves	MTT assays	RAW 264.7 and L929	3.9– 500.0 µg/mL	Doxorubicin	IC ₅₀ : 297.5 ± 22.8 µg/mL for RAW 264.7 and IC ₅₀ : 340.7 ± 42.4 µg/mL for L929	[193]
<i>Alternanthera littoralis</i>	EE of aerial parts	Biometric parameters and Reproductive parameters and embryofetal development Micronucleus (MN) levels in peripheral blood Splenic phagocytosis	Swiss mice of both genders	100 and 1000 mg/kg	—	The extract had no effect on weight, number of implantations, live and dead fetuses, resorptions, fetal viability, resorption rate, post-implantation loss rate, placental index, weight adequacy for gestational age, head-to-tail distance, or urogenital distance in males and females Malformations detected: hyperextension of the forelimbs, unilateral hyperflexion of the hindlimb, curly tail, gastroschisis, hydrocephaly, hydronephrosis, femur agenesis, and reduced ossification of skull bones EE did not change the frequency of micronuclei	[253]
<i>Alternanthera philoxeroides</i>	ME of whole plant	Acute toxicity test	Swiss albino mice	100, 200, 300, 600, 800, 1000, 2000, and 3000 mg/kg BW	—	ME not cause changes in behavior or mortality; therefore, it is considered safe up to the evaluated dose	[39]
<i>Alternanthera philoxeroides</i>	ME extract	Swiss albino mice (female)	Body weight and relative organ weight Histopathological analyses Hematological analyses	250, 500, and 1000 mg/kg	—	ME did not cause changes in BW or organ weight or cause architectural or degenerative changes No changes were observed in erythropoiesis, morphology, or osmotic fragility of RBC. No significant changes were observed in leukocyte counts except for neutrophils, which decreased markedly. No changes were observed in platelet count and platelet indices	[132]
<i>Alternanthera repens</i>	AqE of aerial parts	Determination of LD ₅₀	Swiss mice (female)	0.25–8 g/kg	—	LD ₅₀ : 3.4782 and 4.0639 for AqE and EE, respectively. On the basis of LD ₅₀ values, the extracts are slightly toxic	[46]
<i>Alternanthera sessilis</i>	EE of aerial parts	Determination of LD ₅₀	Swiss mice (female)	0.25–8 g/kg	—	—	[204]
<i>Alternanthera sessilis</i>	ME of aerial parts	Acute toxicity test	Swiss albino mice (male)	100, 200, 300, 600, 800, 1000, 2000, and 3000 mg/kg BW	—	Non-toxic up to the evaluated dose	[204]
<i>Alternanthera sessilis</i>	EE of stem	MTT assays	NHDF cells	15.62, 31.25, 62.5, 125, 250, and 500 µg/mL	—	Non-toxic up to the evaluated dose	[56]

(Continues)

TABLE 11 | (Continued)

Species	Extract(s)/ Compounds	Assay method	Model	Dose	Positive control	Activity	References
HDF-D cells							
HaCaT cells							
<i>Alternanthera sessilis</i>	ME of whole plant	Acute toxicity test	Female albino rats	250, 1000, and 2500 mg/kg BW	—	Results not reported	[51]
<i>Alternanthera sessilis</i>	AgNPs of leaves	Toxic effect of AgNPs against non-target organisms	<i>Poecilia reticulata</i>	Uninformed	Silver nitrate	The AgNPs complex was not toxic to <i>Poecilia reticulata</i>	[158]
<i>Blutaparon portulacoides</i>	EE of stems	Acute toxicity test	Female Wistar rats	2000 mg/kg	—	No signs or symptoms of acute and clinical oral pathophysiology were observed with EE use	[71]
<i>Blutaparon portulacoides</i>	AqE of whole plant	Acute toxicity	Female Wistar rats	2000 mg/kg	—	LD ₅₀ : >2000 mg/kg No significant behavioral or physiological changes were induced in female rats	[152]
<i>Gomphrena celosoides</i>	AqE of leaves	Preliminary acute toxicity study	Adult Sprague-Dawley rats	20, 40, 80, 160, 320, and 640 mg/kg	—	Non-toxic up to evaluated dose	[87]
<i>Gomphrena celosoides</i>	HeE of whole plant 449	Brine shrimp toxicity assay	Brine shrimp nauplii	1000, 100, and 10 ppm	Podophylotoxin	LC ₅₀ (µg/mL) of HeE: 52.146 LC ₅₀ (µg/mL) of 449: 110.654 LC ₅₀ (µg/mL) of ME: 77.978	[82]
<i>Gomphrena celosoides</i>	ME of whole plant					The LC ₅₀ values of HeE and ME suggest the presence of cytotoxic and/or insecticidal compounds. The LC ₅₀ indicates weak cytotoxicity	[89]
<i>Gomphrena celosoides</i>	AcE and AqE of flowers, leaves, twigs, and whole plant	MTT assay	Vero monkey kidney cells	Range of 0.03–1 mg/mL	—	All extracts showed low toxicity	[89]

(Continues)

TABLE II | (Continued)

Species	Extract(s)/ Compounds	Assay method	Model	Dose	Positive control	Activity	References
<i>Gomphrena celosoides</i>	EE of aerial parts	Acute oral toxicity	Adult Wistar rats	2000 mg/kg	—	LD ₅₀ : >2000 mg/kg	[254]
		Subacute oral toxicity		75, 150, or 300 mg/kg	—	EE from aerial parts is safe, as no rats exhibited clinical signs of toxicity. Histopathological studies showed no hepatotoxicity, nephrotoxicity, or hematotoxicity	
<i>Gomphrena celosoides</i>	EE of aerial parts	Teratogenesis and genotoxicity	Pregnant mice (<i>Mus musculus</i>)	100, 1000, and 2000 mg/kg	—	Not alter the final weight, weight gain, uterine weight, or net weight gain	[255]
		Biological tests	Pregnant mice (<i>Mus musculus</i>)	100, 1000, and 2000 mg/kg	—	Not affect the numbers of implantations, live fetuses, dead fetuses, or resorptions	
		Biometric parameters	Pregnant mice (<i>Mus musculus</i>)	100, 1000, and 2000 mg/kg	—	Not change fetal weight, placental weight, or the placental index	
		Reproductive performance and embryofetal development	Pregnant mice (<i>Mus musculus</i>)	100, 1000, and 2000 mg/kg	—	The frequency of malformations (external, visceral) did not differ between the EE-treated and control groups	
		Micronucleus in peripheral blood	Pregnant mice (<i>Mus musculus</i>)	100, 1000, and 2000 mg/kg	—	EE ↑ the frequency of abnormal sternum and fibula rotation over the tibia	
		Splenic phagocytosis				EE did not change the frequency of micronuclei	
		SRB assay				These results suggest that daily doses up to 2000 mg/kg are not maternotoxic	
<i>Gomphrena globosa</i> var. <i>albiflora</i> (white amaranth)	HE of flowers		PLP2 cells	Uninformed	—	Non-toxic up to the evaluated dose GI ₅₀ (µg/mL): >400	[73]

(Continues)

TABLE II | (Continued)

Species	Extract(s)/ Compounds	Assay method	Model	Dose	Positive control	Activity	References
<i>Gomphrena haageana</i> K. (red amaranth)	HE of flowers	SRB assay	PLP2 cells	Uninformed	—	Non-toxic up to the evaluated dose GI ₅₀ (µg/mL): >400	[73]
<i>Gomphrena</i> sp. (pink globe amaranth)	HE of flowers	SRB assay	PLP2 cells	Uninformed	—	Non-toxic up to the evaluated dose GI ₅₀ (µg/mL): >400	[73]
<i>Gomphrena globosa</i>	HaE of flowers	Alamar blue and neutral red tests	HaCaT cells and BJ cells	50, 250, and 500 µg/mL	—	It did not affect BJ cell viability but ↓ HaCat cell viability at high concentrations	[153]
<i>Hebanthe eriantha</i>	ME of roots	Determination of LC ₅₀	<i>Artemia salina</i>	Range of 7.81–1000 µg/mL	Potassium dichromate	MEs showed toxicity in <i>A. salina</i> , with lethality ranging from 26.7% to 60% at concentrations of 31.25–1000 µg/mL	[230]
<i>Puffia glomerata</i>	HaE of roots	Acute toxicity test Determination of LD ₅₀	Wistar rats (male)	3 g/kg	—	No behavioral changes or deaths were observed in rats (LD ₅₀ : >3 g/kg)	[116]
<i>Puffia glomerata</i>	AqE of aerial parts	Cytotoxicity assay	J774 cell line	1, 10, and 100 µg/mL	—	Non-toxic up to the evaluated dose	[234]
<i>Puffia glomerata</i>	Commercial root dry extract	Cytotoxic assay	Wistar rats	0.15, 1.5, and 15 mg/mL	—	No cytotoxic effects or mutagenic potentials were observed	[112]
<i>Puffia glomerata</i>	FD of roots	Chromosomal aberration test MTT assay	Wistar rats BMDM (bone marrow-derived macrophage)	0.15, 1.5, and 1.5 mg/mL 250, 25, 2.5, and 0.25 µg/mL	Cyclophosphamide	Cytotoxicity was dose-dependent, with lower cell viability at higher concentrations and higher viability for the concentrations of 2.5 and 0.25 µg/mL, maintaining viability >65%	[162]
<i>Puffia paniculata</i>	FD of aerial part	MTT assay	BMDM (bone marrow-derived macrophage)	250, 25, 2.5, and 0.25 µg/mL	—	—	—
<i>Puffia paniculata</i>	Powdered roots	ALT activity Histopathological study	Inbred BALB/c1C1B mice	200 and 400 mg/kg	—	Histopathological changes were not observed in the liver, kidney, or spleen. No changes in BW and ALT activities were detected	[207]
<i>Puffia paniculata</i>	BuF of roots	BW measurement Biochemical analysis Histopathological study	SWISS mice (male)	200 mg/kg	—	↓ Weight gain on Days 13 and 15. No hepatic or renal toxicity was observed, according to histopathological analysis and levels of ALT, AST, γ-GT, urea, and creatinine	[209]
<i>Puffia paniculata</i>	ME of roots	Histopathological study	Adult BALB/c mice (male)	250, 500, and 1000 mg/kg	—	No histopathological alterations were observed in the liver, kidney, lung, brain, eye, or cerebellum at the studied dose. Only a tendency toward ↓ BW was observed at a [] of 1000 mg/kg	[183]

Abbreviations: AqE, aqueous extract; EaE, ethyl acetate extract; EE, ethanolic extracts; HaE, hydroalcoholic extract; HE, hydromethanolic extract; ME, methanolic extracts; nHE, *n*-hexane extracts.

this plant has antiviral activity (e.g., anti-herpes, anti-measles), potential antidiabetic activity (inhibits α -glycosidase), analgesic, and antidepressant effects. Additionally, this plant has been reported to have antibiotic, antioxidant, cytotoxic (against HeLa cells), anticoagulant, and cardioprotective activities, as well as an antimentia and memory-enhancing effect in mice.

***Alternanthera porrigens* Kuntze:** None of its traditional uses have been confirmed under laboratory conditions.

***Alternanthera pungens* Kunth:** None of its traditional uses have been confirmed under laboratory conditions. However, some articles report that this plant has antitumor activity, but it does not have antifungal activity, nor is it a significant antioxidant.

***Alternanthera repens* (*Alternanthera caracasana*):** Of the nine traditional uses, only its antidiarrheal activity has been evaluated and confirmed under laboratory conditions. It should be noted that this plant has also been reported to have no activity against *C. albicans*.

***Alternanthera sessilis*:** To date, only 11 of the 63 traditional uses have been evaluated under laboratory conditions, confirming that it has antiasthmatic, antidiarrheal, antidiabetic, hypotensive, hepatoprotective, analgesic, wound healing, anti-inflammatory, antioxidant, and antimicrobial (against bacteria) activity. It has also been shown to be cytotoxic against HeLa, Panc-1, MIA, PaCa-2, Capan-1, PC3, L929, and MCF-7 cells and to have antiallergic and CNS-stimulating properties.

***Alternanthera tenella*:** Of the 18 uses in traditional medicine, only the anti-inflammatory, analgesic, and antimicrobial activities have been confirmed by pharmacological studies. Additionally, it has been reported to also have antioxidant, anticancer, and immunomodulatory properties.

***Blutaparon portulacoides*:** Of the two traditional uses, studies confirm its potential to treat vulvovaginitis under laboratory conditions. Additionally, it has also been reported to have antibiotic, antiparasitic, anti-inflammatory, and analgesic properties, as well as diuretic and cardioprotective effects.

***Gomphrena agrestis*:** There are no reports of traditional uses but has been evaluated for antimicrobial, antifungal, and antiparasitic activity.

***Gomphrena arborescens* L.f.:** Under laboratory conditions, none of the traditional uses have been confirmed.

***Gomphrena boliviana*:** Four traditional uses have been reported, of which only antimicrobial activity has been confirmed under laboratory conditions.

***Gomphrena celosioides*:** Of the 22 traditional uses, 9 have been evaluated through pharmacological studies, confirming that *G. celosioides* has the potential to be used in the prevention and treatment of Type 2 diabetes, as well as in the treatment of gastric lesions, to counteract renovascular hypertension, and to treat infections (antibiotic and antifungal activities). It also has hepatoprotective, analgesic, anti-

inflammatory, and immunomodulatory properties. Additionally, it has been reported to have cardioprotective and anticarcinogenic activity.

***Gomphrena elegans*:** Its use in traditional medicine has not been reported, but pharmacological studies have shown that it has cytotoxicity against the HCT-8, SF-295, and MDA-MB-435 cell lines, as well as potential as an insecticide against *Aedes aegypti*.

***Gomphrena globosa*:** To date, only 2 of its 20 traditional uses have been evaluated under laboratory conditions, which report that this plant has antibacterial, antifungal, and antioxidant activities, although these are considered weak. Assays have shown no cytotoxic activity against the MT-1, MT-2, B16F10, HeLa, and MK-1 cell lines, nor any sun protection effect or AChE inhibition. However, it has anti-inflammatory and anti-collagenase properties.

***Gomphrena haageana* K.:** No traditional uses have been reported, but it has been found to have antioxidant and anti-inflammatory properties.

***Gomphrena macrocephala*:** Its two common uses have not been evaluated by pharmacological studies, but two compounds isolated from this plant have been reported to show cytotoxic activity against HSC-2 cells.

***Gomphrena martiana*:** Of the eight traditional uses, only its activity in the treatment of infections has been confirmed by antimicrobial studies, indicating that it has antibacterial and antifungal activity. Additionally, its activity against the KB cell line has been evaluated, showing moderate cytotoxicity against it. It has also been shown to have a beneficial effect on mice bearing S-180 cells or EAC.

***Gomphrena virgata* Mart.:** Its five traditional uses have not yet been confirmed by pharmacological studies, but it has been reported that this plant can inhibit the proliferation of lymphocytes.

***Guilleminea densa*:** Only one of the three traditional uses was evaluated by a pharmacological study, which showed that the plant has a gastroprotective effect, inhibiting gastric lesions and preventing the reduction of mucus induced by toxic agents, confirming its use in the treatment of gastric ulcers.

***Iresine difusa*:** Of the 12 traditional uses, only the anticancer potential has been evaluated under laboratory conditions. It was reported to have cytotoxic activity against the human LNCaP cell line, but not against PC3. Additionally, in vitro and in vivo studies have shown that this plant can be used to treat diseases related to neuroinflammation.

***Iresine herbstii*:** Of the 13 traditional uses, only 2 have been investigated pharmacologically. It was found to have anticancer potential, showing cytotoxic activity against the HeLa cell line. But no significant wound-healing activity. Although its traditional uses do not mention antibiotic, antioxidant, or neurological activity, in vitro studies suggest that this plant has high antibacterial and antioxidant activities as well as has a beneficial effect on the CNS.

Pfaffia glomerata: Of the 22 known traditional uses, only 7 have been evaluated in the laboratory, confirming its anti-inflammatory, analgesic, and stimulant properties. It also reduces stress and depressive behaviors and protects against the development of anxiety but has shown variable antioxidant activity. Other studies indicate that this plant has antiparasitic activity against *Leishmania braziliensis* and *L. amazonensis*, and its fractions have shown activity against *T. cruzi*. Additionally, this plant has demonstrated inhibition of melanogenesis.

Pfaffia paniculata: Of the 13 traditional uses, only its anticancer activity (in vitro and in vivo) and anti-inflammatory properties have been confirmed through pharmacological studies. It was also observed that it did not show antitumor activity in EAC-bearing mice.

Pfaffia townsendii: Of the four traditional uses reported, only the anti-inflammatory activity has been confirmed through an in vivo study. Although its traditional uses do not include antioxidant activity, an in vitro study showed that it has antioxidant potential.

Tidestromia oblongifolia: Its traditional use as an analgesic has not been confirmed by pharmacological studies, highlighting that, to date, no study has been carried out to evaluate its biological potential.

From the above, it can be concluded that only 21.18% of the traditional uses reported for the members of this subfamily have been evaluated under laboratory conditions, whereas 78.2% remain untested. These data are relevant because they suggest a promising field of study, as most studies have shown that the plants of this subfamily indeed have biological activity consistent with their traditional uses. The traditional uses of these plants justify multidisciplinary research, which may include determination of biological activity, identification of chemical profiles, correlation between phytochemical profiles and biological activity, comparative studies of extracts, fractions, isolated compounds, and drug delivery, as well as comparative studies between varieties, plants collected from different locations under varying environmental conditions, and in vitro systems.

8 | Gomphrenoideae Subfamily: Perspectives and Research Directions

Despite significant progress in understanding the biotechnological and chemical potential of the Gomphrenoideae subfamily, many research opportunities remain. These opportunities can be categorized into the following key areas of focus.

8.1 | Evaluation of the Chemical Profile and Activity of Species That Remain Unstudied

Over 80% of species have not yet been studied in terms of their chemical profiles and biological activities, presenting a valuable opportunity to discover new chemical structures and significant biological activities that could be of interest to the pharmaceutical industry.

8.2 | In Vitro Cultures: A Sustainable and Efficient Strategy in Biotechnological Studies

In the sections on pharmacological activity and phytochemical, it is evident that the same species can exhibit multiple chemical profiles, which, in turn, modulate their biological activity. This variation occurs because the phytochemical profile of plants is influenced by various biotic and abiotic factors, including climatic conditions, UV radiation exposure, soil characteristics, nutrient availability, and interactions with other organisms, such as microorganisms.

In this context, a viable alternative is the use of in vitro plant tissue cultures, which allow for the production of genetically identical plants or callus under controlled growth conditions. The use of in vitro cultures not only standardizes growth conditions but also optimizes the production process and helps prevent ecosystem degradation.

8.3 | Co-Cultures of Plants and Endophytic Microorganisms

Endophytic microorganisms play a crucial role in the phytochemistry of plants in natura. In this context, three key theories should be considered: (1) Endophytic microorganisms are responsible for producing certain chemical compounds; (2) microorganisms function as elicitors in the plant and stimulate the production of secondary metabolites; and (3) the interaction between the plant and the microorganism is necessary for the synthesis of specific compounds, which cannot be synthesized in their absence. This could be because endophytes act as stimulants, provide essential precursors for synthesis, or vice versa.

In this context, the use of in vitro plant tissue cultures in co-culture with one or more endophytic microorganisms represents a valuable approach, which also allows for a better understanding of plant-microorganism interactions.

8.4 | Endophytic Microorganisms as a Source of Secondary Metabolites

Endophytic microorganisms are sometimes responsible for producing certain plant secondary metabolites, making them a sustainable alternative that minimizes environmental impact, shortens production times, and allows for process optimization.

Additionally, microorganisms are recognized as a promising source of bioactive molecules due to their metabolic plasticity, which enables them to mimic the metabolism of their host.

9 | Conclusion

The members of the Gomphrenoideae subfamily (Amaranthaceae) have been used in traditional medicine around the world since ancient times. Although some members of this subfamily have been studied at the pharmacological and phytochemical levels, many others remain unstudied, presenting opportunities for research. Additionally, the literature review reveals a direct

relationship between the traditional uses of these plants and the biological activity exhibited by the extracts, fractions, and compounds studied. There is also a correlation between the chemical profile and the types of compounds present and the observed biological activity. Demonstrating the importance of understanding the pharmacological activity of plants to harness this knowledge for the development of new drugs.

Research focused on discovering bioactive compounds can contribute to the development of drugs with fewer side effects and greater effectiveness than current options. Currently, drugs for treating pain, inflammation, cancer, diabetes, microbial infections, and oxidative stress-related conditions are known for their side effects and limited effectiveness. This highlights the need to discover new drugs.

In general, it can be concluded that some phytochemicals found in the subfamily Gomphrenoideae can be used in drug development. Studying the members that have not yet been researched could lead to the discovery of new chemical compounds and the potential development of new drug.

Currently, 512 compounds have been isolated, including 173 phenolic compounds, 95 terpenoids, 87 lipid compounds, 62 alkaloids, and 95 other types of compounds, with phenolic compounds being the most abundant. These different extracts, fractions, and isolated compounds have been associated with various biological activities, such as antioxidant, analgesic, antibacterial, antifungal, antiparasitic, anticancer, antitumor, anti-inflammatory, antidiabetic, antiarthritis, cardioprotective, healing, diuretic, gastroprotective, hepatoprotective, radioprotective, and hypertension and blood pressure management. The most extensively studied biological activities to date are anticancer, antimicrobial, and antioxidant activities. In conclusion, these plants represent a promising source of bioactive molecules with low or no toxicity.

Author Contributions

Dayanna Isabel Araque Gelves: bibliographic survey, writing and revision of text, design of graphical abstract, design of chemical structures and tables. **Giulia Cristina Andreoli de Souza:** bibliographic survey, writing and revision of text, design of graphical abstract, design of chemical structures and tables. **Alvaro Jose Hernandez Tasco:** bibliographic survey, writing and revision of text, design of graphical abstract, design of chemical structures and tables. **Marcos Jose Salvador:** bibliographic survey, writing and revision of text, design of graphical abstract, design of chemical structures and tables.

Acknowledgments

We would like to thank all the institutions that allowed this work to be carried out. This work was only possible due to the support of the Coordination for the Improvement of Higher Education Personnel-Brazil (CAPES) Process no. 88887.513201/2020-00 and Financing Code 001. It also had the support of the São Paulo State Research Support Foundation (FAPESP, Processes no. 06/06079-4, 15/03726-8, 21/09693-5, and 2017/03598-5), from the National Council for Scientific and Technological Development (CNPq, Process no. 306603/2022-5, and 427859/2018-2), and from the Fund for Support to Teaching, Research, and Extension-UNICAMP (FAEPEX-UNICAMP) for financial support and scholarships.

The Article Processing Charge for the publication of this research was funded by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) (ROR identifier: 00x0ma614).

Conflicts of Interest

The authors declare no conflicts of interest.

Data Availability Statement

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

References

1. G. Kadereit, T. Borsch, K. Weising, and H. Freitag, "Phylogeny of Amaranthaceae and Chenopodiaceae and the Evolution of C4 Photosynthesis," *International Journal of Plant Sciences* 164, no. 6 (2003): 959–986, <https://doi.org/10.1086/378649>.
2. E. O. Ferreira, M. J. Salvador, E. M. F. Pral, S. C. Alfieri, I. Y. Ito, and D. A. Dias, "A New Heptasubstituted (E)-Aurone Glucoside and Other Aromatic Compounds of *Gomphrena agrestis* With Biological Activity," *Zeitschrift Fur Naturforschung—Section C Journal of Biosciences* 59 (2004): 499–505, <https://doi.org/10.1515/znc-2004-7-808>.
3. M. Ilyas, A. Tarnam, and N. Begum, "Biological Potential and Phytopharmacological Screening of *Gomphrena* Species," *International Journal of Pharma Research & Review* 3 (2014): 58–66, <https://doi.org/10.5829/idosi.gjp.2013.7.4.76167>.
4. A. Mroczek, "Phytochemistry and Bioactivity of Triterpene Saponins From Amaranthaceae Family," *Phytochemistry* 14 (2015): 577–605, <https://doi.org/10.1007/s11101-015-9394-4>.
5. G. E. Burrows and R. J. Tylr "Amaranthaceae Juss.," *Toxic Plants of North America*, 2nd ed. 28–34 (Wiley-blackwell, 2013), <https://doi.org/10.1002/9781118413425.ch5>.
6. M. A. Eshete, Z. Asfaw, and E. Kelbessa, "A Review on Taxonomic and Use Diversity of the Family Amaranthaceae in Ethiopia," *Journal of Medicinal Plants Studies* 4 (2016): 185–194.
7. M. W. Chase, M. J. M. Christenhusz, M. F. Fay, et al., "An Update of the Angiosperm Phylogeny Group Classification for the Orders and Families of Flowering Plants: APG IV," *Botanical Journal of the Linnean Society* 181, no. 1 (2016): 1–20, <https://doi.org/10.1111/boj.12385>.
8. H. H. F. Koolen, E. M. F. Pral, S. C. Alfieri, et al., "Antiprotozoal and Antioxidant Alkaloids From *Alternanthera littoralis*," *Phytochemistry* 134 (2017): 106–113, <https://doi.org/10.1016/j.phytochem.2016.11.008>.
9. N. T. H. Yen and L. P. T. Quoc, "Optimization of Ultrasound-Assisted Extraction of Bioactive Compounds From *Gomphrena celosioides* Mart. Using Response Surface Methodology," *Bulletin of the Chemical Society of Ethiopia* 11 (2020): 237–248, <https://doi.org/10.4314/bcse.v34i2.3>.
10. S. Arora and S. Tandon, "Achyranthes Aspera Root Extracts Induce Human Colon Cancer Cell (COLO-205) Death by Triggering the Mitochondrial Apoptosis Pathway and S Phase Cell Cycle Arrest," *Scientific World Journal* (2014): 1–15, <https://doi.org/10.1155/2014/129697>.
11. P. Charan Behera and M. Ghosh, "Evaluation of Antioxidant, Antimicrobial, and Antiuro lithiatic Potential of Different Solvent Extracts of *Aerva lanata* Linn Flowers," *Pharmacognosy Magazine* 14 (2018): 53–57, <https://doi.org/10.4103/pm.pm>.
12. M. Khalid, M. Bilal, D. Hassani, H. M. N. Iqbal, and D. Huang, "Antimicrobial, Antioxidant, Cytotoxicity and LC-MS Analyses of *Aerva javanica*: An Ethnomedicinally Important Plant," *Journal of Biological Regulators and Homeostatic Agents* 31 (2017): 963–969.
13. D. Kumarasamyraja, N. S. Jeganathan, and R. Manavalan, "A Review on Medicinal Plants With Potential Wound Healing Activity," *Pharmacy & Pharmacology International Journal* 2 (2012): 101–107.
14. B. A. Lone, M. Z. Chishti, F. A. Bhat, H. Tak, S. A. Bandh, and A. Khan, "Evaluation of Anthelmintic Antimicrobial and Antioxidant Activity of

- Chenopodium album*,” *Tropical Animal Health and Production* 49 (2017): 1597–1605, <https://doi.org/10.1007/s11250-017-1364-y>.
15. V. Sachithanandam, P. Lalitha, A. Parthiban, T. Mageswaran, K. Manmadhan, and R. Sridhar, “A Review on Antidiabetic Properties of Indian Mangrove Plants with Reference to Island Ecosystem,” *Evidence-Based Complementary and Alternative Medicine* 2019 (2019): 4305148, <https://doi.org/10.1155/2019/4305148>.
 16. Z. Kazmi, N. Safdar, and A. Yasmin, “Biological Screening of Three Selected Folklore Medicinal Plants From Pakistan,” *Pakistan Journal of Pharmaceutical Sciences* 32 (2019): 1477–1484.
 17. M. F. Akhtar, A. Sharif, M. Saleem, et al., “Genotoxic and Cytotoxic Potential of *Alternanthera bettzickiana*, an Important Ethno-Medicinal Plant,” *Cellular and Molecular Biology* 63 (2017): 109–114, <https://doi.org/10.14715/cmb/2017.63.8.23>.
 18. J. M. Kitadi, P. P. Mazasa, D. S. Tshibangu, et al., “Ethnopharmacological Survey and Antisickling Activity of Plants Used in the Management of Sickle Cell Disease in Kikwit City, DR Congo,” *Evidence-Based Complementary and Alternative Medicine* 2020 (2020): 1346493, <https://doi.org/10.1155/2020/1346493>.
 19. M. Manan, U. Saleem, M. Sajid, et al., “Antiartihritic Potential of Comprehensively Standardized Extract of *Alternanthera bettzickiana*: In Vitro and In Vivo Studies,” *ACS Omega* 5 (2020): 19478–19496, <https://doi.org/10.1021/acsomega.0c01670>.
 20. M. Manan, U. Saleem, B. Ahmad, N. Aslam, A. Anwar, and A. Zafar, “Anti-Arthritic and Toxicological Evaluation of Ethanolic Extract of *Alternanthera bettzickiana* in Rats,” *Frontiers in Pharmacology* 13 (2022): 1–13, <https://doi.org/10.3389/fphar.2022.1002037>.
 21. M. Nagalingam, V. N. Kalpana, V. D. Rajeswari, and A. Panneerselvam, “Biosynthesis, Characterization, and Evaluation of Bioactivities of Leaf Extract-Mediated Biocompatible Gold Nanoparticles From *Alternanthera bettzickiana*,” *Biotechnology Reports* 19 (2018): 1–12, <https://doi.org/10.1016/j.btre.2018.e00268>.
 22. J. M. T. de Alencar Filho, H. A. P. Teixeira, P. A. Sampaio, et al., “Phytochemical Analysis in *Alternanthera brasiliana* by LC–MS/MS and GC–MS,” *Natural Product Research* 34 (2020): 429–433, <https://doi.org/10.1080/14786419.2018.1533827>.
 23. N. Andrezza, C. de Lourenco, C. Siqueira, et al., “Photodynamic Inactivation of Yeast and Bacteria by Extracts of *Alternanthera brasiliana*,” *Current Drug Targets* 14 (2013): 1015–1022, <https://doi.org/10.2174/1389450111314090010>.
 24. C. C. Barua, S. A. Begum, A. G. Barua, R. S. Borah, and M. Lahkar, “Anxiolytic and Anticonvulsant Activity of Methanol Extract of Leaves of *Alternanthera brasiliana* (L.) Kuntze (Amaranthaceae) in Laboratory Animals,” *Indian Journal of Experimental Biology* 51 (2013): 450–457.
 25. I. G. C. Bieski, M. Leonti, J. T. Arnason, et al., “Ethnobotanical Study of Medicinal Plants by Population of Valley of Jurueña Region, Legal Amazon, Mato Grosso, Brazil,” *Journal of Ethnopharmacology* 173 (2015): 383–423, <https://doi.org/10.1016/j.jep.2015.07.025>.
 26. H. D. M. Coutinho, C. D. de Moraes Oliveira-Tintino, S. R. Tintino, et al., “Toxicity Against *Drosophila melanogaster* and Antiedematogenic and Antimicrobial Activities of *Alternanthera brasiliana* (L.) Kuntze (Amaranthaceae),” *Environmental Science and Pollution Research* 25 (2018): 10353–10361, <https://doi.org/10.1007/s11356-017-9366-x>.
 27. A. D. de Araújo, M. de Barros Pimentel C. da Silva Santos, et al., “Aqueous Extract of Fresh Leaves from *Alternanthera brasiliana* (L.) Kuntze: Chemical Evaluation and Antimycobacterial and Anticandidal Activities,” *Advances in Traditional Medicine* 21 (2020): 767–777, <https://doi.org/10.1007/s13596-020-00509-8>.
 28. L. Deladino, I. Alvarez, B. De Ancos, C. Sánchez-Moreno, A. D. Molina-García, and A. Schneider Teixeira, “Betalains and Phenolic Compounds of Leaves and Stems of *Alternanthera brasiliana* and *Alternanthera tenella*,” *Food Research International* 97 (2017): 240–249, <https://doi.org/10.1016/j.foodres.2017.04.017>.
 29. M. G. Miguel, “Betalains in Some Species of the Amaranthaceae Family: A Review,” *Antioxidants* 7, no. 4 (2018): 1–33, <https://doi.org/10.3390/antiox7040053>.
 30. E. L. Pelisoli Formagio, M. T. Mendel, R. Fracasso, et al., “Evaluation of the Pharmacological Activity of the *Alternanthera brasiliana* Aqueous Extract,” *Pharmaceutical Biology* 50 (2012): 1442–1447, <https://doi.org/10.3109/13880209.2012.688058>.
 31. J. Tauchen, L. Huml, L. Bortl, et al., “Screening of Medicinal Plants Traditionally Used in Peruvian Amazon for In Vitro Antioxidant and Anticancer Potential,” *Natural Product Research* 33 (2019): 2718–2721, <https://doi.org/10.1080/14786419.2018.1462180>.
 32. M. A. Trapp, M. Kai, A. Mithöfer, and E. Rodrigues-Filho, “Antibiotic Oxylinpins from *Alternanthera brasiliana* and Its Endophytic Bacteria,” *Phytochemistry* 110 (2015): 72–82, <https://doi.org/10.1016/j.phytochem.2014.11.005>.
 33. M. Canales-Martínez, T. Hernández-Delgado, C. Flores-Ortiz, A. Durán-Díaz, A. M. García-Bores, and G. Avila-Acevedo, “Antimicrobial Activity of *Alternanthera caracasana*,” *Pharmaceutical Biology* 43 (2005): 305–307, <https://doi.org/10.1080/13880200590951685>.
 34. D. F. de Santana Aquino, A. C. Piccinelli, F. L. P. Soares, A. C. Arena, M. J. Salvador, and C. A. L. Kassuya, “Anti-Hyperalgesic and Anti-Inflammatory Activity of *Alternanthera maritima* Extract and 2'-O- α -l-Rhamnopyranosylvitexin in Mice,” *Inflammation* 38 (2015): 2057–2066, <https://doi.org/10.1007/s10753-015-0187-0>.
 35. C. H. Wu, H. T. Hsieh, J. A. Lin, and G. C. Yen, “*Alternanthera paronychioides* Protects Pancreatic β -Cells From Glucotoxicity by Its Antioxidant, Antiapoptotic and Insulin Secretagogue Actions,” *Food Chemistry* 139 (2013): 362–370, <https://doi.org/10.1016/j.foodchem.2013.01.026>.
 36. J. B. Fang, W. Jia, W. Y. Gao, et al., “Antitumor Constituents From *Alternanthera philoxeroides*,” *Journal of Asian Natural Products Research* 9 (2007): 511–515, <https://doi.org/10.1080/10286020600782231>.
 37. J. B. Fang, Z. Yao, J. C. Chen, Y. W. Liu, Y. Takaishi, and H. Q. Duan, “Cytotoxic Triterpene Saponins From *Alternanthera philoxeroides*,” *Journal of Asian Natural Products Research* 11 (2009): 261–266, <https://doi.org/10.1080/10286020802684656>.
 38. C. Khamphukdee, O. Monthakantirat, Y. Chulikhit, et al., “Chemical Constituents and Antidepressant-Like Effects in Ovariectomized Mice of the Ethanolic Extract of *Alternanthera philoxeroides*,” *Molecules (Basel, Switzerland)* 23 (2018): 1–18, <https://doi.org/10.3390/molecules23092202>.
 39. F. Khatun, F. Zaman, T. Mosaib, et al., “Evaluation of Antinociceptive and Antihyperglycemic Activities in Methanol Extracts of Whole Plants of *Alternanthera philoxeroides* (Mart.) Griseb. (Amaranthaceae) in Mice,” *Pakistan Journal of Pharmaceutical Sciences* 25 (2012): 583–587.
 40. B. Li, Q. L. Guo, Y. Tian, et al., “New Anti-HBV C-Boivinopyranosyl Flavones From: *Alternanthera philoxeroides*,” *Molecules (Basel, Switzerland)* 21 (2016): 6–10, <https://doi.org/10.3390/molecules21030336>.
 41. A. Rattanathongkom, J. B. Lee, K. Hayashi, B. O. Sripaidkulchai, T. Kanchanapoom, and T. Hayashi, “Evaluation of Chikusetsusaponin IVa Isolated From *Alternanthera philoxeroides* for Its Potency Against Viral Replication,” *Planta Medica* 75 (2009): 829–835, <https://doi.org/10.1055/s-0029-1185436>.
 42. X. Zhang, P. Li, S. Guo, S. Wang, and D. Liu, “Quantitation of β -Carboline and Quercetin in Alligator Weed (*Alternanthera philoxeroides* (Mart.) Griseb.) by LC–MS/MS and Evaluation of Cardioprotective Effects of the Methanol Extracts,” *Drug Discoveries & Therapeutics* 12 (2018): 341–346, <https://doi.org/10.5582/ddt.2018.01070>.
 43. R. W. Bussmann and A. Glenn, “Medicinal Plants Used in Northern Peru for Reproductive Problems and Female Health,” *Journal of Ethnobiology and Ethnomedicine* 6 (2010): 1–12, <https://doi.org/10.1186/1746-4269-6-30>.
 44. M. O. Faruque, G. Feng, M. N. A. Khan, et al., “Qualitative and Quantitative Ethnobotanical Study of the Pangkhua Community in Bilaichari

- Upazilla, Rangamati District, Bangladesh,” *Journal of Ethnobiology and Ethnomedicine* 15 (2019): 1–29, <https://doi.org/10.1186/s13002-019-0287-2>.
45. S. S. Semenya, M. J. Potgieter, and L. J. C. Erasmus, “Exotic and Indigenous Problem Plants Species Used, by the Bapedi, to Treat Sexually Transmitted Infections in Limpopo Province, South Africa,” *African Health Sciences* 13 (2013): 320–326, <https://doi.org/10.4314/ahs.v13i2.17>.
46. A. Astudillo-Vázquez, H. Dávalos Valle, L. De Jesús, G. Herrera, and A. Navarrete, “Investigation of *Alternanthera repens* and *Bidens odorata* on Gastrointestinal Disease,” *Fitoterapia* 79 (2008): 577–580, <https://doi.org/10.1016/j.fitote.2008.07.001>.
47. M. E. Garín-Aguilar, D. Benavides-Catalán, D. Segura Cobos, G. Ramírez Sotelo, A. B. Piña Guzmán, and G. Valencia-Del Toro, “Spasmodic Effect of *Alternanthera repens* on Isolated Rat Ileum,” *Pharmaceutical Biology* 52 (2014): 479–485, <https://doi.org/10.3109/13880209.2013.844716>.
48. M. Ahmad, M. P. Z. Khan, A. Mukhtar, M. Zafar, S. Sultana, and S. Jahan, “Ethnopharmacological Survey on Medicinal Plants Used in Herbal Drinks Among the Traditional Communities of Pakistan,” *Journal of Ethnopharmacology* 184 (2016): 154–186, <https://doi.org/10.1016/j.jep.2016.02.039>.
49. S. Aryal, M. K. Baniya, K. Danekhu, P. Kunwar, R. Gurung, and N. Koirala, “Total Phenolic Content, Flavonoid Content and Antioxidant Potential of Wild Vegetables From Western Nepal,” *Plants* 8 (2019): 96, <https://doi.org/10.3390/plants8040096>.
50. M. F. Bachok, B. M. Yusof, A. Ismail, and A. A. Hamid, “Effectiveness of Traditional Malaysian Vegetables (Ulam) in Modulating Blood Glucose Levels,” *Asia Pacific Journal of Clinical Nutrition* 23 (2014): 369–376, <https://doi.org/10.6133/apjcn.2014.23.3.01>.
51. B. Bhuyan, K. Baishya, and P. Rajak, “Effects of *Alternanthera sessilis* on Liver Function in Carbon Tetra Chloride Induced Hepatotoxicity in Wistar Rat Model,” *Indian Journal of Clinical Biochemistry* 33 (2018): 190–195, <https://doi.org/10.1007/s12291-017-0666-1>.
52. L. Hong, Z. Guo, K. Huang, et al., “Ethnobotanical Study on Medicinal Plants Used by Maonan People in China,” *Journal of Ethnobiology and Ethnomedicine* 11 (2015): 32, <https://doi.org/10.1186/s13002-015-0019-1>.
53. A. I. Hossain, M. Faisal, S. Rahman, R. Jahan, and M. Rahmatullah, “A Preliminary Evaluation of Antihyperglycemic and Analgesic Activity of *Alternanthera sessilis* Aerial Parts,” *BMC Complementary and Alternative Medicine* 14 (2014): 1–5, <https://doi.org/10.1186/1472-6882-14-169>.
54. C. S. Hwong, K. H. Leong, A. Abdul Aziz, S. Mat Junit, S. Mohd Noor, and K. W. Kong, “*Alternanthera sessilis*: Uncovering the Nutritional and Medicinal Values of an Edible Weed,” *Journal of Ethnopharmacology* 298 (2022): 115608, <https://doi.org/10.1016/j.jep.2022.115608>.
55. U. H. A. Mohd Hazli, A. Abdul-Aziz, S. Mat-Junit, C. F. Chee, and K. W. Kong, “Solid-Liquid Extraction of Bioactive Compounds With Antioxidant Potential From *Alternanthera sessilis* (red) and Identification of the Polyphenols Using UHPLC-QqQ-MS/MS,” *Food Research International* 115 (2019): 241–250, <https://doi.org/10.1016/j.foodres.2018.08.094>.
56. K. Muniandy, S. Gothai, K. M. H. Badran, S. S. Kumar, N. M. Esa, and P. Arulselvan, “Suppression of Proinflammatory Cytokines and Mediators in LPS-Induced RAW 264.7 Macrophages by Stem Extract of *Alternanthera sessilis* via the Inhibition of the NF- κ B Pathway,” *Journal of Immunology Research* 4 (2018a): 1–12, <https://doi.org/10.1155/2018/3430684>.
57. K. Muniandy, S. Gothai, W. S. Tan, et al., “In Vitro Wound Healing Potential of Stem Extract of *Alternanthera sessilis*,” *Evidence-Based Complementary and Alternative Medicine* (2018b): 1–13, <https://doi.org/10.1155/2018/3142073>.
58. O. Neamsuvan and P. Bunmee, “A Survey of Herbal Weeds for Treating Skin Disorders From Southern Thailand: Songkhla and Krabi Province,” *Journal of Ethnopharmacology* 193 (2016): 574–585, <https://doi.org/10.1016/j.jep.2016.09.048>.
59. O. Neamsuvan and T. Ruangrit, “A Survey of Herbal Weeds That Are Used to Treat Gastrointestinal Disorders From Southern Thailand: Krabi and Songkhla Provinces,” *Journal of Ethnopharmacology* 196 (2017): 84–93, <https://doi.org/10.1016/j.jep.2016.11.033>.
60. K. L. Niraimathi, V. Sudha, R. Lavanya, and P. Brindha, “Biosynthesis of Silver Nanoparticles Using *Alternanthera sessilis* (Linn.) Extract and Their Antimicrobial, Antioxidant Activities,” *Colloids Surfaces B Biointerfaces* 102 (2013): 288–291, <https://doi.org/10.1016/j.colsurfb.2012.08.041>.
61. A. Qayum, R. Arya, and A. M. Lynn, “Ethnobotanical Perspective of Antimalarial Plants: Traditional Knowledge Based Study,” *BMC Research Notes* 9 (2016): 1–20, <https://doi.org/10.1186/s13104-015-1827-z>.
62. L. Qian, W. Su, Y. Wang, M. Dang, W. Zhang, and C. Wang, “Synthesis and Characterization of Gold Nanoparticles From Aqueous Leaf Extract of *Alternanthera sessilis* and Its Anticancer Activity on Cervical Cancer Cells (HeLa),” *Artificial Cells Nanomedicine, and Biotechnology* 47 (2019): 1173–1180, <https://doi.org/10.1080/21691401.2018.1549064>.
63. C. Y. Ragasa, N. Tremor, and J. A. Rideout, “Ionone Derivatives From *Alternanthera sessilis*,” *Journal of Asian Natural Products Research* 4 (2002): 109–115, <https://doi.org/10.1080/10286020290027380>.
64. F. Saqib and K. H. Janbaz, “Rationalizing Ethnopharmacological Uses of *Alternanthera sessilis*: A Folk Medicinal Plant of Pakistan to Manage Diarrhea, Asthma and Hypertension,” *Journal of Ethnopharmacology* 182 (2016): 110–121, <https://doi.org/10.1016/j.jep.2016.02.017>.
65. A. Shehzad, A. Qayyum, R. Rehman, F. Nadeem, and M. R. Shehzad, “A Review of Bioactivity Guided Medicinal Uses and Therapeutic Potentials of Noxious Weed (*Alternanthera sessilis*),” *International Journal of Chemical and Biochemical Sciences* 14 (2018): 95–103.
66. R. N. M. Guerra, H. A. W. Pereira, L. M. S. Silveira, and R. S. G. Olea, “Immunomodulatory Properties of *Alternanthera tenella* Colla Aqueous Extracts in Mice,” *Brazilian Journal of Medical and Biological Research* 36 (2003): 1215–1219, <https://doi.org/10.1590/S0100-879X2003000900011>.
67. R. M. Kassuya, E. dos Santos, F. H. Bosso, et al., “Anti-Inflammatory Properties of Ethanolic Extract and 2”-O- β -d-Glucopyranosyl-Vitexin Obtained From *Alternanthera tenella* Colla Whole Plant,” *Inflammation* 44, no. 4 (2021): 1–13, <https://doi.org/10.1007/s10753-021-01438-7>.
68. P. K. A. Magalhães, E. N. Araujo, A. M. Santos, et al., “Ethnobotanical and Ethnopharmacological Study of Medicinal Plants Used by a Traditional Community in Brazil’s Northeastern,” *Brazilian Journal of Biology* 82 (2021): e237642, <https://doi.org/10.1590/1519-6984.237642>.
69. A. T. Nunes, R. F. Paivade Lucena, M. V. Ferreira dos Santos, and U. P. Albuquerque, “Local Knowledge About Fodder Plants in the Semi-Arid Region of Northeastern Brazil,” *Journal of Ethnobiology and Ethnomedicine* 11 (2015): 1–12, <https://doi.org/10.1186/1746-4269-11-12>.
70. P. Sathishkumar, K. Vennila, R. Jayakumar, A. R. M. Yusoff, T. Hadibarata, and T. Palvannan, “Phyto-Synthesis of Silver Nanoparticles Using *Alternanthera tenella* Leaf Extract: An Effective Inhibitor for the Migration of Human Breast Adenocarcinoma (MCF-7) Cells,” *Bioprocess and Biosystems Engineering* 39 (2016): 651–659, <https://doi.org/10.1007/s00449-016-1546-4>.
71. R. M. Kassuya, J. A. S. Radai, L. F. B. Macorini, et al., “*Blutaparon portulacoides* Ethanolic Extract Reduced IL-1 β and Inflammatory Parameters Induced by the Mycobacterium Complex and Carrageenan in Mice,” *Inflammopharmacology* 29 (2021): 439–450, <https://doi.org/10.1007/s10787-020-00752-0>.
72. P. Wang, S. Li, S. Ownby, et al., “Ecdysteroids and a Sucrose Phenylpropanoid Ester From *Froelichia floridana*,” *Phytochemistry* 70 (2009): 430–436, <https://doi.org/10.1016/j.phytochem.2009.01.017>.
73. Â. Liberal, R. C. Calhelha, C. Pereira, et al., “A Comparison of the Bioactivity and Phytochemical Profile of Three Different Cultivars of Globe Amaranth: Red, White, and Pink,” *Food & Function* 7 (2016): 679–688, <https://doi.org/10.1039/c5fo01342a>.
74. A. S. Botsaris, “Plants Used Traditionally to Treat Malaria in Brazil: The Archives of Flora Medicinal,” *Journal of Ethnobiology and Ethnomedicine* 3 (2007): 18, <https://doi.org/10.1186/1746-4269-3-18>.

75. A. B. Pomilio, C. A. Buschi, C. N. Tomes, and A. A. Viale, "Antimicrobial Constituents of *Gomphrena martiana* and *Gomphrena boliviana*," *Journal of Ethnopharmacology* 36 (1992): 155–161, [https://doi.org/10.1016/0378-8741\(92\)90016-K](https://doi.org/10.1016/0378-8741(92)90016-K).
76. B. Abou, F. Houphouet, B. Alexis, D. Nazaire, D. Prisca, and G. Goueh, "Effects of Aqueous and Ethanol Extracts of *Entandrophragma angolense*, *Cola nitida* and *Gomphrena celosioides* Against Doxorubicin-Induced Cardiotoxicity in Rats," *Journal of Advances in Medical and Pharmaceutical Sciences* 10 (2016): 1–13, <https://doi.org/10.9734/jamps/2016/29269>.
77. M. F. Adeoti, K. Gogahy, P. A. Bidie, and G. François, "Anti-Inflammatory and Antioxidant Effects of Ethanol Extract of *Gomphrena celosioides* (Amaranthaceae) in Wistar Rats," *Journal of Pharmaceutical, Chemical and Biological Sciences* 4 (2017): 503–511.
78. L. F. Benitez Macorini, J. A. S. Radai, R. S. Maris, et al., "Antiarthritic and Antihyperalgesic Properties of Ethanol Extract From *Gomphrena celosioides* Mart. (Amaranthaceae) Aerial Parts," *Evidence-Based Complementary and Alternative Medicine* 2020 (2020): 1–11, <https://doi.org/10.1155/2020/4170589>.
79. F. Chassagne, E. Deharo, H. Punley, and G. Bourdy, "Treatment and Management of Liver Diseases by Khmer Traditional Healers Practicing in Phnom Penh Area, Cambodia," *Journal of Ethnopharmacology* 202 (2017): 38–53, <https://doi.org/10.1016/j.jep.2017.03.002>.
80. P. C. de Paula Vasconcelos, C. A. S. Tirloni, R. A. C. Palozzi, et al., "Diuretic Herb *Gomphrena celosioides* Mart. (Amaranthaceae) Promotes Sustained Arterial Pressure Reduction and Protection From Cardiac Remodeling on Rats With Renovascular Hypertension," *Journal of Ethnopharmacology* 224 (2018): 126–133, <https://doi.org/10.1016/j.jep.2018.05.036>.
81. P. C. de Paula Vasconcelos, D. Ramos Spessottoa, J. Vasconcelos Marinho, M. J. Salvador, G. Junior Arquimedes, and C. A. Leide Kassuya, "Mechanisms Underlying the Diuretic Effect of *Gomphrena celosioides* Mart. (Amaranthaceae)," *Journal of Ethnopharmacology* 202 (2017): 85–91, <https://doi.org/10.1016/j.jep.2017.03.007>.
82. O. O. Dosumu, P. A. Idowu, P. A. Onocha, and O. Ekundayo, "Isolation of 3-(4-Hydroxyphenyl) Methylpropenoate and Bioactivity Evaluation of *Gomphrena celosioides* Extracts," *EXCLI Journal* 9 (2010): 173–180.
83. O. Dosumu, P. Onocha, O. Ekundayo, and M. Ali, "Isolation of Aurantiamides from *Gomphrena celosioides* C. Mart.," *Iranian Journal of Pharmaceutical Research* 13 (2014): 143–147.
84. L. V. Duc, D. Le Hong, and G. D. Hoang, "Hypoglycemic Activity of Isolated Compounds From *Gomphrena celosioides* Mart.," *Pharmaceutical Chemistry Journal* 54 (2020): 484–489, <https://doi.org/10.1007/s11094-020-02226-7>.
85. C. V. Ilodibia, M. U. Chukwuma, and C. U. Umenwa, "Assessment of Phytochemical and Antibacterial Activities of the Leaf and Stem Extracts of *Gomphrena celosioides* Mart. (Amaranthaceae)," *Trends in Medical Research* 15 (2020): 1–6, <https://doi.org/10.3923/tmr.2020.1.6>.
86. M. S. Kpodar, S. D. Karou, G. Katawa, et al., "An Ethnobotanical Study of Plants Used to Treat Liver Diseases in the Maritime Region of Togo," *Journal of Ethnopharmacology* 181 (2016): 263–273, <https://doi.org/10.1016/j.jep.2015.12.051>.
87. G. M. Oladele, M. O. Abatan, J. O. Olukunle, and B. S. Okediran, "Anti-Inflammatory and Analgesic Effects of Aqueous Leaf Extracts of *Gomphrena celosioides* and *Momordica Charantia*," *Journal of Natural Sciences Engineering and Technology* 8 (2009): 1–8, <https://doi.org/10.51406/jnset.v8i2.996>.
88. I. J. Oluwabunmi and T. Abiola, "Gastroprotective Effect of Methanolic Extract of *Gomphrena celosioides* on Indomethacin Induced Gastric Ulcer in Wistar Albino Rats," *International Journal of Applied and Basic Medical Research* 5 (2015): 41–45, <https://doi.org/10.4103/2229-516X.149238>.
89. A. G. Omokhua-Uyi and J. Van Staden, "Extracts of *Gomphrena celosioides* Mart as Potential Treatment for Urinary Tract Infections Against Antibiotic Resistant β -Lactamase Producing Uropathogens," *South African Journal of Botany* 132 (2020): 502–510, <https://doi.org/10.1016/j.sajb.2020.06.002>.
90. M. M. Sangare, J. R. Klotoe, V. Dougnon, et al., "Evaluation of the Hepatoprotective Activity of *Gomphrena celosioides* (Amaranthaceae) on Wistar Rats Intoxicated With Tetrachloride Carbon," *International Journal of Current Research* 4 (2012): 67–72.
91. A. K. Tiwari, S. R. Geed, R. S. Singh, and B. N. Rai, "Extraction of Essential Oil From *Gomphrena celosioides* by Green Separation Technology," *International Journal of Basic and Applied Biology* 2 (2014): 18–22.
92. D. T. Trang, B. H. Tai, P. H. Yen, D. T. H. Yen, N. X. Nhiem, and P. V. Kiem, "Study on Water Soluble Constituents From *Gomphrena celosioides*," *Vietnam Journal of Chemistry* 57 (2019): 229–233, <https://doi.org/10.1002/vjch.201900011>.
93. Y. N. Clement, Y. S. Baksh-Comeau, and C. E. Seaforth, "An Ethnobotanical Survey of Medicinal Plants in Trinidad," *Journal of Ethnobiology and Ethnomedicine* 11 (2015): 1–28, <https://doi.org/10.1186/s13002-015-0052-0>.
94. F. Ferreres, A. Gil-Izquierdo, P. Valentão, and P. B. Andrade, "Structural Characterization of Phenolics and Betacyanins in *Gomphrena globosa* by High-Performance Liquid Chromatography-Diode Array Detection/Electrospray Ionization Multi-Stage Mass Spectrometry," *Rapid Communications in Mass Spectrometry* 25 (2011): 3441–3446, <https://doi.org/10.1002/rcm.5248>.
95. C. A. Lans, "Ethnomedicines Used in Trinidad and Tobago for Urinary Problems and Diabetes Mellitus," *Journal of Ethnobiology and Ethnomedicine* 2 (2006): 1–11, <https://doi.org/10.1186/1746-4269-2-45>.
96. C. L. Roriz, L. Barros, M. A. Prieto, et al., "Enhancing the Antimicrobial and Antifungal Activities of a Coloring Extract Agent Rich in Betacyanins Obtained From: *Gomphrena globosa* L. Flowers," *Royal Society of Chemistry* 9 (2018): 6205–6217, <https://doi.org/10.1039/c8fo01829d>.
97. C. L. Roriz, L. Barros, A. M. Carvalho, and I. C. F. R. Ferreira, "HPLC-Profiles of Tocopherols, Sugars, and Organic Acids in Three Medicinal Plants Consumed as Infusions," *International Journal of Food Science* 2014 (2014): 241481, <https://doi.org/10.1155/2014/241481>.
98. L. R. Silva, P. Valentão, J. Faria, et al., "Phytochemical Investigations and Biological Potential Screening With Cellular and Non-Cellular Models of Globe Amaranth, (*Gomphrena globosa* L) Inflorescences," *Food Chemistry* 135 (2012): 756–763, <https://doi.org/10.1016/j.foodchem.2012.05.015>.
99. M. Kuroda, T. Aoshima, M. Haraguchi, M. C. M. Young, H. Sakagami, and Y. Mimaki, "Oleanane and Taraxerane Glycosides From the Roots of *Gomphrena macrocephala*," *Journal of Natural Products* 69 (2006): 1606–1610, <https://doi.org/10.1177/1934578x0600100601>.
100. A. B. Pomilio, G. A. Ruty Solá, A. M. S. Mayer, and L. S. Rumi, "Antitumor and Cytotoxic Screen of 5,6,7-Trisubstituted Flavones From *Gomphrena martiana*," *Journal of Ethnopharmacology* 44 (1994): 25–33, [https://doi.org/10.1016/0378-8741\(94\)90095-7](https://doi.org/10.1016/0378-8741(94)90095-7).
101. B. M. Marinho, D. N. Fernandes, M. Z. Chicoti, et al., "Phytochemical Profile and Antiproliferative Activity of Human Lymphocytes of *Gomphrena virgata* Mart. (Amaranthaceae)," *Natural Product Research* 36 (2022): 1641–1647, <https://doi.org/10.1080/14786419.2021.1895151>.
102. P. M. Palomino, H. G. O. Gustavo, B. C. Elsa, J. T. Bertha, and P. P. Christian, "Evaluación Gastroprotectora Del Extracto Hidroalcohólico De Hojas De *Guilleminea densa* (Hum. Bonpl. ex Willd.) Moq.(Sanguinaria) En Ulceras Inducidas Con Etanol," *Revista De La Academia Peruana De Salud* 17 (2010): 55–60.
103. J. A. Barajas-Ramírez, A. H. Cabrera-Ramírez, and V. G. Aguilar-Raymundo, "Antioxidant Activity, Total Phenolic, Tannin, and Flavonoid Content of Five Plants Used in Traditional Medicine in Penjamo, Guanajuato," *Chemistry & Biodiversity* 20 (2023): e202200834, <https://doi.org/10.1002/cbdv.202200834>.

104. N. Kim, C. C. Martínez, D. S. Jang, J. K. Lee, and M. S. Oh, "Anti-Neuroinflammatory Effect of *Iresine celosia* on Lipopolysaccharide-Stimulated Microglial Cells and Mouse," *Biomedicine & Pharmacotherapy* 111 (2019): 1359–1366, <https://doi.org/10.1016/j.biopha.2019.01.017>.
105. M. Y. Rios and L. Á. Berber, "1H and 13C Assignments of Three New Drimenes From *Iresine diffusa* Humb. & Bonpl. Ex Willd.," *Magnetic Resonance in Chemistry* 43 (2005): 339–342, <https://doi.org/10.1002/mrc.1550>.
106. E. F. Anderson, "Ethnobotany of Hill Tribes of northern Thailand. I. Medicinal Plants of Akha," *Economic Botany* 40 (1986): 38–53, <https://doi.org/10.1007/BF02858945>.
107. C. Dipankar, S. Murugan, and P. Uma Devi, "Review on Medicinal and Pharmacological Properties of *Iresine herbstii*, *Chrozophora Rottleri* and *Ecolobium Linneanum*," *African Journal of Traditional, Complementary and Alternative Medicines* 8 (2011): 124–129, <https://doi.org/10.4314/ajtcam.v8i5S.6>.
108. C. Nencini, F. Cavallo, G. Bruni, et al., "Affinity of *Iresine herbstii* and *Brugmansia arborea* Extracts on Different Cerebral Receptors," *Journal of Ethnopharmacology* 105 (2006): 352–357, <https://doi.org/10.1016/j.jep.2005.11.022>.
109. C. Schmidt, M. Fronza, M. Goettert, et al., "Biological Studies on Brazilian Plants Used in Wound Healing," *Journal of Ethnopharmacology* 122 (2009): 523–532, <https://doi.org/10.1016/j.jep.2009.01.022>.
110. A. Spórna-Kucab, N. Wróbel, A. Kumorkiewicz-Jamro, and S. Wybraniec, "Separation of Betacyanins From *Iresine herbstii* Hook. Ex Lindl. Leaves by High-Speed Countercurrent Chromatography in a Polar Solvent System," *Journal of Chromatography A* 1626 (2020): 461370, <https://doi.org/10.1016/j.chroma.2020.461370>.
111. M. Valentová, R. Marek, E. Švajdlenka, R. Kubínová, and V. Suchý, "A New Isoflavanone From *Iresine herbstii*," *Fitoterapia* 82 (2011): 272–275, <https://doi.org/10.1016/j.fitote.2010.10.010>.
112. I. V. Almeida, E. Düsman, G. I. Mattge, F. Toledo, A. F. Reusing, and V. E. P. Vicentini, "In Vivo Antimutagenic Activity of the Medicinal Plants *Pfaffia glomerata* (Brazilian Ginseng) and *Ginkgo biloba*," *Genetics and Molecular Research* 16 (2017): 1–11, <https://doi.org/10.4238/gmr16039785>.
113. F. C. R. Dias, M. de Lucca Moreira Gomes, F. C. S. A. de Melo, et al., "*Pfaffia glomerata* Hydroalcoholic Extract Stimulates Penile Tissue in Adult Swiss Mice," *Journal of Ethnopharmacology* 261 (2020): 113182, <https://doi.org/10.1016/j.jep.2020.113182>.
114. R. R. Franco, L. de Almeida Takata, K. Chagas, et al., "A 20-Hydroxyecdysone-Enriched Fraction From *Pfaffia glomerata* (Spreng.) Pedersen Roots Alleviates Stress, Anxiety, and Depression in Mice," *Journal of Ethnopharmacology* 267 (2021): 113599, <https://doi.org/10.1016/j.jep.2020.113599>.
115. Y. Z. Han, Y. Zhou, Z. T. Zhang, S. Y. Niu, X. H. Liu, and X. Y. Jia, "Three New Noroleanane-Type Triterpenes From the Roots of *Pfaffia glomerata*," *Journal of Asian Natural Products Research* 20 (2018): 460–466, <https://doi.org/10.1080/10286020.2017.1343820>.
116. L. C. Marques, S. M. P. Galvão, E. Espínola, et al., "Psychopharmacological Assessment of *Pfaffia glomerata* Roots (Extract BNT-08) in Rodents," *Phytotherapy Research* 18 (2004): 566–572, <https://doi.org/10.1002/ptr.1500>.
117. A. G. Neto, A. A. Da Silva Filho, J. M. L. C. Costa, et al., "Evaluation of the Trypanocidal and Leishmanicidal in Vitro Activity of the Crude Hydroalcoholic Extract of *Pfaffia glomerata* (Amaranthaceae) Roots," *Phytomedicine* 11 (2004): 662–665, <https://doi.org/10.1016/j.phymed.2003.06.005>.
118. A. G. Neto, J. M. L. C. Costa, C. C. Belati, et al., "Analgesic and Anti-Inflammatory Activity of a Crude Root Extract of *Pfaffia glomerata* (Spreng) Pedersen," *Journal of Ethnopharmacology* 96 (2005): 87–91, <https://doi.org/10.1016/j.jep.2004.08.035>.
119. C. G. L. Teixeira, A. Piccoli, P. Costa, L. Soares, and J. E. da Silva-Santos, "Involvement of the Nitric Oxide/Soluble Guanylate Cyclase Pathway in the Anti-Oedematogenic Action of *Pfaffia glomerata* (Spreng) Pedersen in Mice," *Journal of Pharmacy and Pharmacology* 58 (2006): 667–675, <https://doi.org/10.1211/jpp.58.5.0012>.
120. C. A. R. A. Costa, A. E. V. Quaglio, and L. C. Di Stasi, "*Pfaffia paniculata* (Brazilian Ginseng) Extract Modulates Mapk and Mucin Pathways in Intestinal Inflammation," *Journal of Ethnopharmacology* 213 (2018): 21–25, <https://doi.org/10.1016/j.jep.2017.10.009>.
121. T. C. Da Silva, B. Cogliati, A. O. Latorre, et al., "Pfaffosidic Fraction From *Hebanthe paniculata* Induces Cell Cycle Arrest and Caspase-3-Induced Apoptosis in HepG2 Cells," *Evidence-Based Complementary and Alternative Medicine* 2015 (2015): 835796, <https://doi.org/10.1155/2015/835796>.
122. G. M. Figueira, M. M. Bajay, C. M. S. Silva, M. I. Zucchi, M. Monteiro, and M. V. N. Rodrigues, "Development and Characterization of Microsatellite Markers for *Hebanthe eriantha* (Amaranthaceae)," *American Journal of Botany* 98 (2011): 282–283, <https://doi.org/10.3732/ajb.1100180>.
123. J. Li, A. N. Jadhav, and I. A. Khan, "Triterpenoids From Brazilian Ginseng, *Pfaffia paniculata*," *Planta Medica* 76 (2010): 635–639, <https://doi.org/10.1055/s-0029-1240631>.
124. M. K. Nagamine, T. C. da Silva, P. Matsuzaki, et al., "Cytotoxic Effects of Butanolic Extract From *Pfaffia paniculata* (Brazilian Ginseng) on Cultured Human Breast Cancer Cell Line MCF-7," *Experimental and Toxicologic Pathology* 61 (2009): 75–82, <https://doi.org/10.1016/j.etp.2008.01.017>.
125. N. Nishimoto, S. Nakai, N. Takagi, et al., "Pfaffosides and Nortriterpenoid Saponins From *Pfaffia paniculata*," *Phytochemistry* 23 (1984): 139–142, [https://doi.org/10.1016/0031-9422\(84\)83094-0](https://doi.org/10.1016/0031-9422(84)83094-0).
126. M. V. N. Rodrigues, K. de Paula Souza, V. L. G. Rehder, et al., "Development of an Analytical Method for the Quantification of Pfaffic Acid in Brazilian Ginseng (*Hebanthe eriantha*)," *Journal of Pharmaceutical and Biomedical Analysis* 77 (2013): 76–82, <https://doi.org/10.1016/j.jpba.2013.01.010>.
127. W. R. Corrêa, A. F. Serain, L. Aranha Netto, et al., "Anti-Inflammatory and Antioxidant Properties of the Extract, Tiliroside, and Patuletin 3-O-β-D-Glucopyranoside From *Pfaffia townsendii* (Amaranthaceae)," *Evidence-Based Complementary and Alternative Medicine* 2018 (2018): 6057579, <https://doi.org/10.1155/2018/6057579>.
128. S. Chaudhary, V. Thomas, L. Todaro, O. LeGendre, S. Pecic, and W. W. Harding, "New Drimane Sesquiterpenoids From *Tidestromia oblongifolia*," *National Institutes of Health* 23 (2008): 1–7.
129. P. Mishra, A. Sha, P. Bhakat, S. Mondal, and A. K. Mohapatra, "Antibacterial Activity Assessment of Petroleum Ether and Methanolic Extracts of *Achyranthes aspera* Linn (Amaranthaceae)," *Journal of Applied and Natural Science* 12 (2020): 354–364, <https://doi.org/10.31018/jans.v12i3.2319>.
130. S. F. H. Naqvi and M. Husnain, "Betalains: Potential Drugs With Versatile Phytochemistry," *Critical ReviewsTM in Eukaryotic Gene Expression* 30 (2020): 169–189, <https://doi.org/10.1615/CritRevEukaryotGeneExpr.2020030231>.
131. T. Abu-Izneid, A. Rauf, M. A. Shariati, et al., "Sesquiterpenes and Their Derivatives-Natural Anticancer Compounds: An Update," *Pharmacological Research* 161 (2020): 1–20, <https://doi.org/10.1016/j.phrs.2020.105165>.
132. S. S. Khandker, M. Alam, F. Uddin, et al., "Subchronic Toxicity Study of Alternanthera philoxeroides in Swiss Albino Mice Having Antioxidant and Anticoagulant Activities," *Journal of Toxicology* 2022 (2022): 8152820, <https://doi.org/10.1155/2022/8152820>.
133. H. Mondal, S. Saha, K. Awang, et al., "Central-Stimulating and Analgesic Activity of the Ethanolic Extract of *Alternanthera sessilis* in Mice," *BMC Complementary Medicine and Therapies* 14 (2014): 398, <https://doi.org/10.1186/1472-6882-14-398>.
134. A. M. Bonilla Bonilla, T. C. Gaviñán Buñay, M. Bayley, et al., "Antispasmodic, Cardioprotective and Blood-Pressure Lowering Properties of *Gomphrena perennis* L. and Its Mechanisms of Action," *Journal*

- of *Traditional and Complementary Medicine* 14, no. 2 (2024): 182–190, <https://doi.org/10.1016/j.jtcme.2023.10.005>.
135. C. Khamphukdee, O. Monthakantirat, Y. Chulikhit, et al., “Antidementia Effects of Alternanthera philoxeroides in Ovariectomized Mice Supported by NMR-based Metabolomic Analysis,” *Molecules* 26 (2021): 2789, <https://doi.org/10.3390/molecules26092789>.
136. P. Aon-im, O. Monthakantirat, S. Daodee, et al., “Evaluation of the Impact of Alternanthera philoxeroides (Mart.) Griseb. Extract on Memory Impairment in D-Galactose-Induced Brain Aging in Mice Through Its Effects on Antioxidant Enzymes, Neuroinflammation, and Telomere Shortening,” *Molecules (Basel, Switzerland)* 29, no. 2 (2024): 503, <https://doi.org/10.3390/molecules29020503>.
137. T. Iwashina, “Flavonoid Properties in Plant Families Synthesizing Betalain Pigments (Review),” *Natural Product Communications* 10 (2015): 1103–1114, <https://doi.org/10.1177/1934578X1501000675>.
138. A. Gasparetto, T. F. Lapinski, S. R. Zamuner, et al., “Extracts From Alternanthera maritima as Natural Photosensitizers in Photodynamic Antimicrobial Chemotherapy (PACT),” *Journal of Photochemistry and Photobiology B: Biology* 99 (2010): 15–20, <https://doi.org/10.1016/j.jphotobiol.2010.01.009>.
139. G. A. Melo, I. N. Abreu, M. B. de Oliveira, et al., “A Metabolomic Study of Gomphrena agrastis in Brazilian Cerrado Suggests Drought-Adaptive Strategies on Metabolism,” *Scientific Reports* 11 (2021): 1–13, <https://doi.org/10.1038/s41598-021-92449-9>.
140. C. S. Hwang, K. H. Leong, A. A. Aziz, and K. W. Kong, “Separation of Antioxidant-Rich Alternanthera sessilis Red Extracts by Sephadex LH-20 and Identification of Polyphenols Using HPLC-QToF-MS/MS,” *Chemistry and Biodiversity* 20, no. 7 (2023): e202300215, <https://doi.org/10.1002/cbdv.202300215>.
141. A. Bhattacharjee, T. Ghosh, R. Sil, and A. Datta, “Isolation and Characterisation of Methanol-Soluble Fraction of Alternanthera philoxeroides (Mart.)—Evaluation of Their Antioxidant, α -Glucosidase Inhibitory and Antimicrobial Activity in In Vitro Systems,” *Natural Product Research* 28 (2014): 2199–2202, <https://doi.org/10.1080/14786419.2014.930857>.
142. M. J. Salvador, P. S. Pereira, S. C. França, R. C. Candido, I. Y. Ito, and D. A. Dias, “Bioactive Chemical Constituents and Comparative Antimicrobial Activity of Callus Culture and Adult Plant Extracts From Alternanthera tenella,” *Zeitschrift Fur Naturforschung—Section C Journal of Biosciences* 64 (2009): 373–381, <https://doi.org/10.1515/znc-2009-5-612>.
143. M. J. Salvador, E. O. Ferreira, and S. U. Mertens-Talcott, “Isolation and HPLC Quantitative Analysis of Antioxidant Flavonoids From Alternanthera tenella Colla,” *Zeitschrift Fur Naturforschung—Section C Journal of Biosciences* 61 (2006): 19–25, <https://doi.org/10.1515/znc-2006-1-204>.
144. X. J. Xu, Z. J. Wang, X. J. Qin et al., “Phytochemical and Antibacterial Constituents of Edible Globe Amaranth Flower Against Pseudomonas aeruginosa,” *Chemistry & Biodiversity* 19 (2022): e202200139, <https://doi.org/10.1002/cbdv.202200139>.
145. J. G. Souza, R. R. Tomei, A. Kanashiro, and L. M. Kabeya, “Ethanol Crude Extract and Flavonoids Isolated From Alternanthera Maritima: Neutrophil Chemiluminescence Inhibition and Free Radical Scavenging Activity,” *Zeitschrift Fur Naturforschung—Section C Journal of Biosciences* 62 (2007): 339–347, <https://doi.org/10.1515/znc-2007-5-604>.
146. P. Goswami and R. Srivastava, “Isolation and Characterization of Quercetin From Amaranthaceae Family Plants,” *International Journal of Ayurveda and Pharma Research* 8 (2017): 70–76, <https://doi.org/10.7897/2277-4343.084218>.
147. B. Klejduš, J. Vacek, L. Benešová, J. Kopecký, O. Lapčík, and V. Kubáň, “Rapid-Resolution HPLC With Spectrometric Detection for the Determination and Identification of Isoflavones in Soy Preparations and Plant Extracts,” *Analytical and Bioanalytical Chemistry* 389 (2007): 2277–2285, <https://doi.org/10.1007/s00216-007-1606-3>.
148. E. O. Ferreira and D. A. Dias, “A Methylenedioxyflavonol From Aerial Parts of *Blutaparon portulacoides*,” *Phytochemistry* 53 (2000): 145–147, [https://doi.org/10.1016/S0031-9422\(99\)00390-8](https://doi.org/10.1016/S0031-9422(99)00390-8).
149. N. N. Mohd Razali, S. S. Teh, S. H. Mah, et al., “Protective Effects of Alternanthera sessilis Ethanolic Extract Against TNF- α or H₂O₂-Induced Endothelial Activation in Human Aortic Endothelial Cells,” *Evidence-Based Complementary and Alternative Medicine* 2022 (2022): 8738435, <https://doi.org/10.1155/2022/8738435>.
150. C. L. Roriz, L. Barros, A. M. Carvalho, C. Santos-Buelga, and I. C. F. R. Ferreira, “Scientific Validation of Synergistic Antioxidant Effects in Commercialised Mixtures of Cymbopogon Citratus and Pterospartum Tridentatum or Gomphrena globosa for Infusions Preparation,” *Food Chemistry* 185 (2015): 16–24, <https://doi.org/10.1016/j.foodchem.2015.03.136>.
151. M. J. Salvador, E. O. Ferreira, E. M. F. Pral, et al., “Bioactivity of Crude Extracts and Some Constituents of *Blutaparon portulacoides* (Amaranthaceae),” *Phytomedicine* 9 (2002): 566–571, <https://doi.org/10.1078/09447110260573227>.
152. P. R. Terço Leite, B. R. Lorençone, K. G. T. Moreno, et al., “The NO-cGMP-K⁺ Channel Pathway Participates in Diuretic and Cardioprotective Effects of *Blutaparon portulacoides* in Spontaneously Hypertensive Rats,” *Planta Medica* 88 (2022): 1152–1162, <https://doi.org/10.1055/a-1690-3566>.
153. T. Bujak, M. Zagórska-dziok, A. Ziemlewska, Z. Nizioł-Łukaszewska, T. Wasilewski, and Z. Hordyjewicz-Baran, “Antioxidant and Cytoprotective Properties of Plant Extract From Dry Flowers as Functional Dyes for Cosmetic Products,” *Molecules (Basel, Switzerland)* 26 (2021): 1–25, <https://doi.org/10.3390/molecules260928>.
154. D. F. Felipe, L. Z. S. Brambilla, C. Porto, E. J. Pilau, and D. A. G. Cortez, “Phytochemical Analysis of *Pfaffia glomerata* Inflorescences by LC-ESI-MS/MS,” *Molecules (Basel, Switzerland)* 19 (2014): 15720–15734, <https://doi.org/10.3390/molecules191015720>.
155. D. B. De Oliveira, A. P. De Almeida, G. L. D. B. A. Simoes, C. Auvin, C. R. Kaiser, and S. S. Costa, “First Isolation of a Symmetrical Glycosylated Methylene Bisflavonoid,” *Planta Medica* 69 (2003): 382–384, <https://doi.org/10.1055/s-2003-38885>.
156. M. T. Suleiman, “Estudo fitoquímico e atividades biológicas de *Gomphrena elegans* Mart. (amaranthaceae),” Thesis (doctorate), São Paulo State University, Araraquara Chemistry Institute, (2010): 246, <http://hdl.handle.net/11449/105817>.
157. R. M. X. de Moura, P. S. Pereira, A. H. Januário, S. de Castro França, and D. A. Dias, “Antimicrobial Screening and Quantitative Determination of Benzoic Acid Derivative of *Gomphrena celosioides* by TLC-Densitometry,” *Chemical and Pharmaceutical Bulletin* 52 (2004): 1342–1344, <https://doi.org/10.1248/cpb.52.1342>.
158. D. Kumar, B. Singh, G. Kumar, et al., “Phyto-Fabrication and Characterization of Alternanthera sessilis Leaf Extract-Mediated Silver Nanoparticles and Evaluation of Larvicidal Potential,” *Biomass Conversion and Biorefinery* 15 (2023): 2329–2344, <https://doi.org/10.1007/s13399-023-04948-6>.
159. C. S. Freitas, C. H. Baggio, J. E. Da Silva-Santos, et al., “Involvement of Nitric Oxide in the Gastroprotective Effects of an Aqueous Extract of *Pfaffia glomerata* (Spreng) Pedersen, Amaranthaceae, in Rats,” *Life Sciences* 74 (2004): 1167–1179, <https://doi.org/10.1016/j.lfs.2003.08.003>.
160. L. Lian, Y. Feng, Y. W. Li, et al., “Two New Triterpenes From the Roots of *Pfaffia glomerata*,” *Journal of Asian Natural Products Research* 21 (2019): 442–448, <https://doi.org/10.1080/10286020.2018.1446949>.
161. S. Nakamura, G. Chen, S. Nakashima, H. Matsuda, Y. Pei, and M. Yoshikawa, “Brazilian Natural Medicines. IV. New Noroleanane-Type Triterpene and Ecdysterone-Type Sterol Glycosides and Melanogenesis Inhibitors From the Roots of *Pfaffia glomerata*,” *Chemical and Pharmaceutical Bulletin* 58 (2010): 690–695, <https://doi.org/10.1248/cpb.58.690>.
162. R. R. Franco, R. M. Franco, A. B. Justino, et al., “Phytochemical Composition of Aerial Parts and Roots of *Pfaffia glomerata* (Spreng.)

- Pedersen and Anticholinesterase, Antioxidant, and Antiglycation Activities," *Protoplasma* 261, no. 4 (2024): 609–624, <https://doi.org/10.1007/s00709-023-01916-9>.
163. Q. Huang, H. Wu, and X. Qin, "Extract of *Pfaffia glomerata* Ameliorates Paroxetine-Induced Sexual Dysfunction in Male Mice and the Characterization of Its Phytoconstituents by UPLC-MS," *Foods* 12, no. 17 (2023): 3236, <https://doi.org/10.3390/foods12173236>.
164. S. Nakai, N. Takagi, H. Miichi, et al., "Pfaffosides, Nortriterpenoid Saponins, From *Pfaffia paniculata*," *Phytochemistry* 23 (1984): 1703–1705, [https://doi.org/10.1016/S0031-9422\(00\)83473-1](https://doi.org/10.1016/S0031-9422(00)83473-1).
165. C. Killian, S. L. Johnson, H. Ma, et al., "Celosiadines A and B, Unusual Guanidine Alkaloids From *Iresine diffusa*," *Natural Product Research* 36 (2021): 356–360, <https://doi.org/10.1080/14786419.2020.1784174>.
166. Y. Cai, M. Sun, and H. Corke, "Identification and Distribution of Simple and Acylated Betacyanins in the Amaranthaceae," *Journal of Agricultural and Food Chemistry* 49 (2001): 1971–1978, <https://doi.org/10.1021/jf000963h>.
167. F. Kugler, F. C. Stintzing, and R. Carle, "Characterisation of Betalain Patterns of Differently Coloured Inflorescences From *Gomphrena globosa* L. and *Bougainvillea* Sp. by HPLC-DAD-ESI-MSn," *Analytical and Bioanalytical Chemistry* 387 (2007): 637–648, <https://doi.org/10.1007/s00216-006-0897-0>.
168. A. Spórna-Kucab, J. Jagodzińska, and S. Wybraniec, "Separation of Betacyanins From Purple Flowers of *Gomphrena globosa* L. by Ion-Pair High-Speed Counter-Current Chromatography," *Journal of Chromatography A* 1489 (2017): 51–57, <https://doi.org/10.1016/j.chroma.2017.01.064>.
169. G. Jerz, N. Gebers, D. Szot, M. Szaleniec, P. Winterhalter, and S. Wybraniec, "Separation of Amaranthine-Type Betacyanins by Ion-Pair High-Speed Countercurrent Chromatography," *Journal of Chromatography A* 1344 (2014): 42–50, <https://doi.org/10.1016/j.chroma.2014.03.085>.
170. A. Spórna-Kucab, E. Hołda, and S. Wybraniec, "High-Speed Counter-Current Chromatography in Separation of Betacyanins From Flowers of Red *Gomphrena globosa* L. Cultivars," *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences* 1033–1034 (2016): 421–427, <https://doi.org/10.1016/j.jchromb.2016.09.005>.
171. A. Spórna-Kucab, A. Milo, A. Kumorkiewicz, and S. Wybraniec, "Studies on Polar High-Speed Counter-Current Chromatographic Systems in Separation of Amaranthine-Type Betacyanins From *Celosia* Species," *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences* 1073 (2018): 96–103, <https://doi.org/10.1016/j.jchromb.2017.11.028>.
172. C. L. Roriz, L. Barros, M. A. Prieto, P. Morales, and I. C. F. R. Ferreira, "Floral Parts of *Gomphrena globosa* L. as a Novel Alternative Source of Betacyanins: Optimization of the Extraction Using Response Surface Methodology," *Food Chemistry* 229 (2017): 223–234, <https://doi.org/10.1016/j.foodchem.2017.02.073>.
173. A. Spórna-Kucab, K. Bernaś, A. Grzegorzczak, A. Malm, K. Skalicka-Woźniak, and S. Wybraniec, "Liquid Chromatographic Techniques in Betacyanin Isomers Separation From *Gomphrena globosa* L. flowers for the Determination of Their Antimicrobial Activities," *Journal of Pharmaceutical and Biomedical Analysis* 161 (2018): 83–93, <https://doi.org/10.1016/j.jpba.2018.08.025>.
174. C. L. Roriz, S. A. Heleno, M. Carrocho, et al., "Betacyanins From *Gomphrena globosa* L. Flowers: Incorporation in Cookies as Natural Colouring Agents," *Food Chemistry* (2020): 329, <https://doi.org/10.1016/j.foodchem.2020.127178>.
175. N. Drobnicka, K. Sutor, A. Kumorkiewicz-Jamro, et al., "Phytochemical Molecules From the Decarboxylation of Gomphrenins in Violet *Gomphrena globosa* L.—Floral Infusions From Functional Food," *International Journal of Molecular Sciences* 21 (2020): 1–19, <https://doi.org/10.3390/ijms21228834>.
176. Y. Z. Cai, J. Xing, M. Sun, and H. Corke, "Rapid Identification of Betacyanins From *Amaranthus tricolor*, *Gomphrena globosa*, and *Hylcoereus polyrhizus* by Matrix-Assisted Laser Desorption/Ionization Quadrupole Ion Trap Time-of-Flight Mass Spectrometry (MALDI-QIT-TOF MS)," *Journal of Agricultural and Food Chemistry* 54 (2006): 6520–6526, <https://doi.org/10.1021/jf0609983>.
177. M. L. A. E. Silva, A. C. Pereira, D. S. Ferreira, et al., "In Vitro Activities of *Pfaffia glomerata* Root Extract, Its Hydrolyzed Fractions and Pfaffic Acid Against *Trypanosoma Cruzi* Trypomastigotes," *Chemistry & Biodiversity* 14 (2017): e1600175, <https://doi.org/10.1002/cbdv.201600175>.
178. N. V. Quang, N. T. M. Phuong, D. V. Luong, N. T. T. Huyen, D. T. T. Xuan, and T. T. T. Thuy, "Xanthine Oxidase and Nitric Oxide Inhibitory Activities of Compounds Isolated From *Gomphrena celosioides*," *Vietnam Journal of Chemistry* 62 (2024): 110–116, <https://doi.org/10.1002/vjch.202300269>.
179. L. D. Z. da Silva Souza, S. R. A. V. da Fonseca, A. Ferrari, and D. F. Felipe, "β-Ecdysone Content and Antioxidant Capacity in Different Organs of Brazilian Ginsen," *Ciência Rural* (2021): 51, <https://doi.org/10.1590/0103-8478cr20200618>.
180. F. C. R. Dias, S. L. P. Matta, G. D. A. Lima, et al., "*Pfaffia glomerata* Polyploid Accession Compromises Male Fertility and Fetal Development," *Journal of Ethnopharmacology* (2023): 314, <https://doi.org/10.1016/j.jep.2023.116680>.
181. F. C. R. Dias, M. C. Cupertino, P. G. Silva, et al., "Exposure to *Pfaffia glomerata* Causes Oxidative Stress and Triggers Hepatic Changes," *Brazilian Journal of Biology* (2023): 83, <https://doi.org/10.1590/1519-6984.271425>.
182. S. D. Sarker, V. Sik, H. H. Rees, and L. Dinan, "2-Dehydro-3-Epi-20-Hydroxyecdysone From *Froelichia florida*," *Phytochemistry* 49 (1998): 2311–2314, [https://doi.org/10.1016/S0031-9422\(98\)00447-6](https://doi.org/10.1016/S0031-9422(98)00447-6).
183. C. S. Carneiro, F. A. Costa-Pinto, A. P. da Silva, et al., "*Pfaffia paniculata* (Brazilian ginseng) Methanolic Extract Reduces Angiogenesis in Mice," *Experimental and Toxicologic Pathology* 58 (2007): 427–431, <https://doi.org/10.1016/j.etp.2006.11.005>.
184. J. M. Firdhouse and P. Lalitha, "Apoptotic Efficacy of Biogenic Silver Nanoparticles on Human Breast Cancer MCF-7 Cell Lines," *Progress in Biomaterials* 4 (2015): 113–121, <https://doi.org/10.1007/s40204-015-0042-2>.
185. P. K. Samudrala, B. B. Augustine, and E. R. Kasala, "Evaluation of Antitumor Activity and Antioxidant Status of *Alternanthera brasiliana* Against Ehrlich Ascites Carcinoma in Swiss Albino Mice," *Pharmacognosy Research* 7 (2015): 66–73, <https://doi.org/10.4103/0974-8490.147211>.
186. E. O. Joaquim, A. H. Hayashi, L. M. B. Torres, et al., "Chemical Structure and Localization of LEVAN, the Predominant Fructan Type in Underground Systems of *Gomphrena marginata* (Amaranthaceae)," *Frontiers in Plant Science* 9 (2018): 1–10, <https://doi.org/10.3389/fpls.2018.0174>.
187. E. V. Creus, "Compuestos Fenólicos," *Offarm: farmacia y sociedad* 23 (2004): 80–84.
188. A. Meena and V. Elango, "Antioxidant/Antidegradative Effects of *Trichopus zeylanicus* Gaertn and *Gomphrena celosioides* on Den/Hcb Induced Male Albino Rats," *Journal of Medical Science And Clinical Research* 1, no. 5 (2013): 252–266.
189. W. S. Pereira, G. P. da Silva, M. V. Vigliano, et al., "Anti-Arthritic Properties of Crude Extract From *Chenopodium ambrosioides* L. Leaves," *Journal of Pharmacy and Pharmacology* 70 (2018): 1078–1091, <https://doi.org/10.1111/jphp.12926>.
190. X. Xiao, X. Wang, X. Gui, L. Chen, and B. Huang, "Natural Flavonoids as Promising Analgesic Candidates: A Systematic Review," *Chemistry & Biodiversity* 13 (2016): 1427–1440, <https://doi.org/10.1002/cbdv.201600060>.
191. A. G. Guimarães, J. S. S. Quintans, and L. J. Quintans-Júnior, "Monoterpenes With Analgesic Activity—A Systematic Review," *Phytotherapy Research* 27 (2013): 1–15, <https://doi.org/10.1002/ptr.4686>.
192. E. S. da Penha, R. Lacerda-Santos, M. G. F. Carvalho, and P. T. Oliveira, "Effect of *Chenopodium Ambrosioides* on the Healing Process of the In Vivo Bone Tissue," *Microscopy Research and Technique* 80 (2017): 1167–1173, <https://doi.org/10.1002/jemt.22913>.

193. R. Marchete, S. Oliveira, L. Bagne, et al., "Anti-Inflammatory and Antioxidant Properties of Alternanthera brasiliana Improve Cutaneous Wound Healing in Rats," *Inflammopharmacology* 29 (2021): 1443–1458, <https://doi.org/10.1007/s10787-021-00862-3>.
194. M. Ghonime, M. Emara, R. Shawky, H. Soliman, R. El-Domany, and A. Abdelaziz, "Immunomodulation of RAW 264.7 Murine Macrophage Functions and Antioxidant Activities of 11 Plant Extracts," *Cellular & Molecular Immunology* 44 (2015): 237–252, <https://doi.org/10.3109/08820139.2014.988720>.
195. A. K. Tiwari, A. L. Jyothi, and V. B. Tejeswini, "Mitigation of Starch and Glucose - Induced Postprandial Glycemic Excursion in Rats by Antioxidant - Rich Green - Leafy Vegetables ' Juice," *Pharmacognosy Magazine* 9, no. s1 (2013): S66–S73, <https://doi.org/10.4103/0973-1296.117872>.
196. T. T. Chai, C. S. Khoo, C. S. Tee, and F. C. Wong, "Alpha-Glucosidase Inhibitory and Antioxidant Potential of Antidiabetic Herb Alternanthera sessilis: Comparative Analyses of Leaf and Callus Solvent Fractions," *Pharmacognosy Magazine* 12 (2016): 253–258, <https://doi.org/10.4103/0973-1296.192202>.
197. S. K. Ballas, "Hydration of Sickle Erythrocytes Using a Herbal Extract (Pfaffia paniculata) In Vitro," *British Journal of Haematology* 111 (2000): 359–362, <https://doi.org/10.1046/j.1365-2141.2000.02276.x>.
198. A. Mozar, K. Charlot, B. Sandor, et al., "Pfaffia paniculata Extract Improves Red Blood Cell Deformability in Sickle Cell Patients," *Clinical Hemorheology and Microcirculation* 62 (2016): 327–333, <https://doi.org/10.3233/CH-151972>.
199. S. Rayees, A. Kumar, S. Rasool, et al., "Ethanollic Extract of Alternanthera sessilis (AS-1) Inhibits IgE-Mediated Allergic Response in RBL-2H3 Cells," *Immunological Investigations* 42 (2013): 470–480, <https://doi.org/10.3109/08820139.2013.789909>.
200. V. L. G. Moraes, L. F. M. Santos, S. B. Castro, et al., "Inhibition of Lymphocyte Activation by Extracts and Fractions of Kalanchoe, Alternanthera, Paullinia and Mikania Species," *Phytomedicine* 1 (1994): 199–204, [https://doi.org/10.1016/S0944-7113\(11\)80065-6](https://doi.org/10.1016/S0944-7113(11)80065-6).
201. A. Capasso and V. Feo, "In Vitro Binding Receptors Study by Valeriana Adscendens, Iresine herbstii and Brugmansia Arborea Extracts," *Journal of Medicinal Chemistry* 3 (2007): 599–604, <https://doi.org/10.2174/157340607782360290>.
202. C. C. Barua, A. Talukdar, S. A. Begum, et al., "Wound Healing Activity of Methanolic Extract of Leaves of Alternanthera brasiliana Kuntz Using In Vivo and In Vitro Model," *Indian Journal of Experimental Biology* 47 (2009): 1001–1005.
203. S. A. Auharek, C. A. Carollo, R. J. Oliveira, et al., "Evaluation of the Testis Function of Mice Exposed in Utero and During Lactation to Pfaffia glomerata (Brazilian Ginseng)," *Andrologia* 51 (2019): 1–8, <https://doi.org/10.1111/and.13328>.
204. A. I. Hossain, M. Faisal, S. Rahman, R. Jahan, and M. Rahmatullah, "A Preliminary Evaluation of Antihyperglycemic and Analgesic Activity of Alternanthera sessilis Aerial Parts," *BMC Complementary Medicine and Therapies* 14 (2014): 1–5, <https://doi.org/10.1186/1472-6882-14-169>.
205. C. S. Freitas, C. H. Baggio, A. Twardowschy, et al., "Involvement of Glutamate and Cytokine Pathways on Antinociceptive Effect of Pfaffia glomerata in Mice," *Journal of Ethnopharmacology* 122 (2009): 468–472, <https://doi.org/10.1016/j.jep.2009.01.033>.
206. K. Aruna and V. M. Sivaramkrishnan, "Anticarcinogenic Effects of Some Indian Plant Products," *Food and Chemical Toxicology* 30 (1992): 953–956, [https://doi.org/10.1016/0278-6915\(92\)90180-S](https://doi.org/10.1016/0278-6915(92)90180-S).
207. P. Matsuzaki, G. Akisue, S. C. Salgado Oloris, S. L. Górnaiak, and M. L. Zaidan Dagli, "Effect of Pfaffia paniculata (Brazilian Ginseng) on the Ehrlich Tumor in Its Ascitic Form," *Life Sciences* 74 (2003): 573–579, <https://doi.org/10.1016/j.lfs.2003.05.010>.
208. T. C. Da Silva, A. P. Da Silva, G. Akisue, et al., "Inhibitory Effects of Pfaffia paniculata (Brazilian Ginseng) on Preneoplastic and Neoplastic Lesions in a Mouse Hepatocarcinogenesis Model," *Cancer Letters* 226 (2005): 107–113, <https://doi.org/10.1016/j.canlet.2004.12.004>.
209. P. Matsuzaki, M. Haraguchi, G. Akisue, et al., "Antineoplastic Effects of Butanolic Residue of Pfaffia paniculata," *Cancer Letters* 238 (2006): 85–89, <https://doi.org/10.1016/j.canlet.2005.06.020>.
210. K. C. Pinello, E. D. S. M. Fonseca, G. Akisue, et al., "Effects of Pfaffia paniculata (Brazilian Ginseng) Extract on Macrophage Activity," *Life Sciences* 78 (2006): 1287–1292, <https://doi.org/10.1016/j.lfs.2005.06.040>.
211. T. C. Da Silva, B. Cogliati, A. P. da Silva, et al., "Pfaffia paniculata (Brazilian Ginseng) Roots Decrease Proliferation and Increase Apoptosis but Do Not Affect Cell Communication in Murine Hepatocarcinogenesis," *Experimental and Toxicologic Pathology* 62 (2010): 145–155, <https://doi.org/10.1016/j.etp.2009.03.003>.
212. K. K. Tan and K. H. Kim, "Alternanthera sessilis Red Ethyl Acetate Fraction Exhibits Antidiabetic Potential on Obese Type 2 Diabetic Rats," *Evidence-Based Complementary and Alternative Medicine* 2013 (2013): 845172, <https://doi.org/10.1155/2013/845172>.
213. C. D. A. Biella, M. J. Salvador, D. A. Dias, M. Dias-Baruffi, and L. S. Pereira-Crott, "Evaluation of Immunomodulatory and Anti-Inflammatory Effects and Phytochemical Screening of Alternanthera tenella Colla (Amaranthaceae) Aqueous Extracts," *Memórias do Instituto Oswaldo Cruz* 103 (2008): 569–577, <https://doi.org/10.1590/S0074-02762008000600010>.
214. I. C. Pereira, A. M. Barbosa, M. J. Salvador, et al., "Anti-Inflammatory Activity of Blutaparon portulacoides Ethanolic Extract Against the Inflammatory Reaction Induced by Bothrops jararacussu Venom and Isolated Myotoxins BthTX-I and II," *Journal of Venomous Animals and Toxins Including Tropical Diseases* 15 (2009): 527–545, <https://doi.org/10.1590/S1678-91992009000300013>.
215. C. A. R. A. Costa, A. Tanimoto, A. E. V. Quaglio, L. D. Almeida, J. A. Severi, and L. C. Di Stasi, "Anti-Inflammatory Effects of Brazilian Ginseng (Pfaffia paniculata) on TNBS-Induced Intestinal Inflammation: Experimental Evidence," *International Immunopharmacology* 28 (2015): 459–469, <https://doi.org/10.1016/j.intimp.2015.07.002>.
216. M. A. Zavala, S. Pérez, C. Pérez, R. Vargas, and R. Pérex, "Antidiarrhoeal Activity of Waltheria americana, Commelina coelestis and Alternanthera repens," *Journal of Ethnopharmacology* 61 (1998): 41–47, [https://doi.org/10.1016/S0378-8741\(98\)00014-2](https://doi.org/10.1016/S0378-8741(98)00014-2).
217. A. Fafioye and O. Omotayo, "Protective Role of Methanolic Extract of Gomphrena celosioides Leaves on Acidified Ethanol-Induced Gastric Ulcer in Male Wistar Rats," *International Journal of Women in Technical Education and Employment* 1 (2020): 90–99.
218. Y. Wei, W. Tan, H. Qin, et al., "Gomphrena globosa L. Extract Alleviates Carbon Tetrachloride-Induced Liver Injury in Mice by Activating Antioxidant Signaling Pathways and Promoting Autophagy," *Molecular Biology Reports* 50 (2023): 97–106, <https://doi.org/10.1007/s11033-022-07942-9>.
219. F. De-Paris, G. Neves, J. B. Salgueiro, J. Quevedo, I. Izquierdo, and S. M. K. Rates, "Psychopharmacological Screening of Pfaffia glomerata Spreng. (Amaranthaceae) In Rodents," *Journal of Ethnopharmacology* 73 (2000): 261–269, [https://doi.org/10.1016/S0378-8741\(00\)00329-9](https://doi.org/10.1016/S0378-8741(00)00329-9).
220. C. C. Barua, A. Talukdar, S. A. Begum, et al., "Effect of Alternanthera brasiliana (L) Kuntze on Healing of Dermal Burn Wound," *Indian Journal of Experimental Biology* 50 (2012): 56–60.
221. C. Barua, A. Choudhury, S. Begum, et al., "Influence of Alternanthera brasiliana (L.) Kuntze on Altered Antioxidant Enzyme Profile During Cutaneous Wound Healing in Immunocompromised Rats," *ISRN Pharmacology* 2012 (2012): 948792, <https://doi.org/10.5402/2012/948792>.
222. C. C. Barua, S. Begum, D. Sarma, D. Pathak, and R. Borah, "Healing Efficacy of Methanol Extract of Leaves of Alternanthera brasiliana Kuntze in Aged Wound Model," *Journal of Basic and Clinical Pharmacy* 3 (2012): 341, <https://doi.org/10.4103/0976-0105.105336>.
223. A. Mondal and T. Kumar, "Antibacterial Activity of a Novel Fatty Acid (14E, 18E, 22E, 26E)-Methyl Nonacosate-14, 18, 22, 26 Tetraenoate

- Isolated From *Amaranthus spinosus*,” *Pharmaceutical Biology* 54 (2016): 2364–2367, <https://doi.org/10.3109/13880209.2016.1155628>.
224. J. W. Almeida Bezerra, A. Rodrigues Costa, M. A. de Freitas, et al., “Chemical Composition, Antimicrobial, Modulator and Antioxidant Activity of Essential Oil of *Dysphania ambrosioides* (L.) Mosyakin & Clements,” *Comparative Immunology, Microbiology and Infectious Diseases* 65 (2019): 58–64, <https://doi.org/10.1016/j.cimid.2019.04.010>.
225. D. A. Kumar, V. Palanichamy, and S. M. Roopan, “Green Synthesis of Silver Nanoparticles Using *Alternanthera dentata* Leaf Extract at Room Temperature and Their Antimicrobial Activity,” *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy* 127 (2014): 168–171, <https://doi.org/10.1016/j.saa.2014.02.058>.
226. M. O. Ullah, M. Haque, K. F. Urmi, A. H. Zulfiker, E. S. Anita, and K. Hamid, “Anti-Bacterial Activity and Brine Shrimp Lethality Bioassay of Methanolic Extracts of Fourteen Different Edible Vegetables From Bangladesh,” *Asian Pacific Journal of Tropical Biomedicine* 3 (2013): 1–7, [https://doi.org/10.1016/S2221-1691\(13\)60015-5](https://doi.org/10.1016/S2221-1691(13)60015-5).
227. N. Kabeerdass, K. Murugesan, N. Arumugam, et al., “Biomedical and Textile Applications of *Alternanthera sessilis* Leaf Extract Mediated Synthesis of Colloidal Silver Nanoparticle,” *Nanomaterials* 12 (2022): 1–12, <https://doi.org/10.3390/nano12162759>.
228. G. Venkatraman, P. S. Mohan, M. M. Mashghan, et al., “Phyto-Fabricated ZnO Nanoparticles for Anticancer, Photo-Antimicrobial Effect on Carbenem-Resistant/Sensitive *Pseudomonas aeruginosa* and Removal of Tetracycline,” *Bioprocess and Biosystems Engineering* 47 (2024): 1163–1182, <https://doi.org/10.1007/s00449-024-02984-8>.
229. M. E. Abalaka, S. Y. Daniyan, S. O. Adeyemo, and D. Damisa, “The Antibacterial Efficacy of Gold Nanoparticles Derived From *Gomphrena celosioides* and *Prunus amygdalus* (Almond) Leaves on Selected Bacterial Pathogens,” *International Journal of Innovative Research and Scientific Studies* 8 (2014): 5–8.
230. S. Rahamouz-Haghighi and A. Sharafi, “Antiproliferative Assay of Suma or Brazilian Ginseng (*Hebanthe eriantha*) Methanolic Extract on HCT116 and 4T1 Cancer Cell Lines, In Vitro Toxicity on *Artemia salina* Larvae, and Antibacterial Activity,” *Natural Product Research* 38, no. 11 (2024): 1850–1854, <https://doi.org/10.1080/14786419.2023.2225688>.
231. C. Dipankar and S. Murugan, “The Green Synthesis, Characterization and Evaluation of the Biological Activities of Silver Nanoparticles Synthesized From *Iresine herbstii* Leaf Aqueous Extracts,” *Colloids Surfaces B Biointerfaces* 98 (2012): 112–119, <https://doi.org/10.1016/j.colsurfb.2012.04.006>.
232. S. Johann, P. S. Cisalpino, G. A. Watanabe, et al., “Antifungal Activity of Extracts of Some Plants Used in Brazilian Traditional Medicine Against the Pathogenic Fungus *Paracoccidioides brasiliensis*,” *Pharmaceutical Biology* 48 (2010): 388–396, <https://doi.org/10.3109/13880200903150385>.
233. N. Domingues, L. P. de Ramos, et al., “Antimicrobial Action of Four Herbal Plants Over Mixed-Species Biofilms of *Candida albicans* With Four Different Microorganisms,” *Australian Endodontic Journal* 49 (2022): 262–271, <https://doi.org/10.1111/aej.12681>.
234. A. C. De Queiroz, T. De Lima Matos Freire Dias, C. B. B. Da Matta, et al., “Alexandre-Moreira, M.S. Antileishmanial Activity of Medicinal Plants Used in Endemic Areas in Northeastern Brazil,” *Evidence-Based Complementary and Alternative Medicine* 2014 (2014): 478290, <https://doi.org/10.1155/2014/478290>.
235. D. F. Pereira, R. B. Zanon, M. Dos Santos, A. A. Boligon, and M. L. Athayde, “Antioxidant Activities and Triterpenoids Isolated From *Alternanthera brasiliana* (L.) Kuntze Leaves,” *Natural Product Research* 27 (2013): 1660–1663, <https://doi.org/10.1080/14786419.2012.750313>.
236. V. M. Paliwal, S. Kundu, U. Kulhari, et al., “*Alternanthera brasiliana* L. Extract Alleviates Carbon Tetrachloride-Induced Liver Injury and Fibrotic Changes in Mice: Role of Matrix Metalloproteinases and TGF- β /Smad Axis,” *Journal of Ethnopharmacology* 303 (2023): 115992, <https://doi.org/10.1016/j.jep.2022.115992>.
237. A. B. Tukun, N. Shaheen, C. P. Banu, M. Mohiduzzaman, S. Islam, and M. Begum, “Antioxidant Capacity and Total Phenolic Contents in Hydrophilic Extracts of Selected Bangladeshi Medicinal Plants,” *Asian Pacific Journal of Tropical Medicine* 7 (2014): S568–S573, [https://doi.org/10.1016/S1995-7645\(14\)60291-1](https://doi.org/10.1016/S1995-7645(14)60291-1).
238. B. Rainatou, B. K. W. L. M. Esther, K. Boukaré, C. Souleymane, K. Moumouni, and O. Noufou, “Phytochemical Study and In Vitro Biological Activities of *Hibiscus panduriformis* Burm. F. (Malvaceae), *Alternanthera pungens* Kunth (Amaranthaceae), and *Wissadula Rostrata* (Schumach.) Hook. F. (Malvaceae),” *BioMed Research International* 2023 (2023): 8289750, <https://doi.org/10.1155/2023/8289750>.
239. B. Promraksa, J. Phetcharaburanin, N. Namwat, A. Techasen, P. Boonsiri, and W. Loilome, “Evaluation of Anticancer Potential of Thai Medicinal Herb Extracts Against Cholangiocarcinoma Cell Lines,” *PLoS ONE* 14 (2019): 1–16, <https://doi.org/10.1371/journal.pone.0216721>.
240. A. C. Sabbione, F. O. Ogutu, A. Scilingo, M. Zhang, M. C. Añón, and T. H. Mu, “Antiproliferative Effect of Amaranth Proteins and Peptides on HT-29 Human Colon Tumor Cell Line,” *Plant Foods for Human Nutrition* 74 (2019): 107–114, <https://doi.org/10.1007/s1130-018-0708-8>.
241. T. S. Mahmoud, M. R. Marques, C. do Ó Pessoa, et al., “In Vitro Cytotoxic Activity of Brazilian Middle West Plant Extracts,” *Revista Brasileira De Farmacognosia* 21 (2011): 456–464, <https://doi.org/10.1590/S0102-695X2011005000061>.
242. A. S. Sowemimo, M. van de Venter, L. Baatjies, and T. Koekemoer, “Cytotoxic Activity of Selected Nigerian Plants,” *African Journal of Traditional, Complementary and Alternative Medicines* 6 (2009): 526–528, <https://doi.org/10.4314/ajcam.v6i4.57186>.
243. D. Nakano, K. Ishitsuka, M. Kamikawa, et al., “Screening of Promising Chemotherapeutic Candidates From Plants Against Human Adult T-Cell Leukemia/Lymphoma (III),” *Journal of Natural Medicines* 67 (2013): 894–903, <https://doi.org/10.1007/s11418-013-0747-2>.
244. S. George, S. V. Bhalerao, E. A. Lidstone, et al., “Cytotoxicity Screening of Bangladeshi Medicinal Plant Extracts on Pancreatic Cancer Cells,” *BMC Complementary Medicine and Therapies* 10 (2010): 1–11, <https://doi.org/10.1186/1472-6882-10-52>.
245. M. J. Firdhouse and P. Lalitha, “Biosynthesis of Silver Nanoparticles Using the Extract of *Alternanthera sessilis*-Antiproliferative Effect Against Prostate Cancer Cells,” *Cancer Nanotechnology* 4 (2013): 137–143, <https://doi.org/10.1007/s12645-013-0045-4>.
246. M. J. Firdhouse and P. Lalitha, “Facile Synthesis of Anisotropic Gold Nanoparticles and Its Synergistic Effect on Breast Cancer Cell Lines,” *IET Nanobiotechnology* 14 (2020): 224–229, <https://doi.org/10.1049/iet-nbt.2019.0279>.
247. J. Kinjo, D. Nakano, T. Fujioka, and H. Okabe, “Screening of Promising Chemotherapeutic Candidates From Plants Extracts,” *Journal of Natural Medicines* 70 (2016): 335–360, <https://doi.org/10.1007/s11418-016-0992-2>.
248. R. N. Almeida, R. N. Almeida, D. S. Navarro, and J. M. Barbosa-Filho, “Plants With Central Analgesic Activity,” *Phytomedicine* 8 (2001): 310–322, <https://doi.org/10.1078/0944-7113-00050>.
249. R. G. Brito, A. A. S. Araújo, J. S. S. Quintans, K. A. Sluka, and L. J. Quintans, “Enhanced Analgesic Activity by Cyclodextrins—A Systematic Review and Meta-Analysis,” *Expert Opinion on Drug Delivery* 12 (2015): 1–12, <https://doi.org/10.1517/17425247.2015.1046835>.
250. J. H. Seo, M. H. Jin, and Y. H. Chang, “Anti-Inflammatory Effect of *Salsola komarovii* Extract With Dissociated Glucocorticoid Activity,” *BMC Complementary Medicine and Therapies* 20 (2020): 1–9, <https://doi.org/10.1186/s12906-020-02979-4>.
251. S. Aneja, M. Vats, S. Aggarwal, and S. Sardana, “Phytochemistry and Hepatoprotective Activity of Aqueous Extract of *Amaranthus tricolor* Linn. Roots,” *Journal of Ayurveda and Integrative Medicine* 4 (2013): 211–215, <https://doi.org/10.4103/0975-9476.123693>.
252. E. Bourogaa, R. M. Jarraya, R. Nciri, M. Damak, and A. Elfeki, “Protective Effects of Aqueous Extract of *Hammada scoparia* Against

Hepatotoxicity Induced by Ethanol in the Rat,” *Toxicology and Industrial Health* 30 (2012): 1–10, <https://doi.org/10.1177/0748233712452602>.

253. G. C. D. Rezende, R. C. R. Noronha, H. C. Ortiz, et al., “Absence of Maternal-Fetal Adverse Effects of *Alternanthera littoralis* P. Beauv. Following Treatment During Pregnancy in Mice,” *Journal of Toxicology and Environmental Health, Part A* 86, no. 16 (2023): 543–556, <https://doi.org/10.1080/15287394.2023.2223624>.

254. L. F. B. Macorini, R. S. Maris, T. C. Teixeira, et al., “Preclinical Safety Evaluation of the Ethanolic Extract From the Aerial Parts of *Gomphrena celosioides* Mart. in Rodents,” *Regulatory Toxicology and Pharmacology* 133 (2022): 133, <https://doi.org/10.1016/j.yrtph.2022.105217>.

255. F. R. Salustriano, A. C. D. Monreal, S. C. das Neves, et al., “The Ethanolic Extract of *Gomphrena celosioides* Mart. Does Not Alter Reproductive Performance or Embryo-Fetal Development, Nor Does It Cause Chromosomal Damage,” *Pharmaceutics* 14 (2022): 1–15, <https://doi.org/10.3390/pharmaceutics14112369>.

Supporting Information

Additional supporting information can be found online in the Supporting Information section.